sentances,predictions
A family history of amyloidosis was present in every affected individual.,"[{'A': 'O'}, {'family': 'O'}, {'history': 'O'}, {'of': 'O'}, {'amyloidosis': 'I-Entity'}, {'was': 'O'}, {'present': 'O'}, {'in': 'O'}, {'every': 'O'}, {'affected': 'O'}, {'individual.': 'O'}]"
No improvement in renal tubular dysfunction (in the form of a reduction in the alkali dose) after immunomodulating therapy was observed over a mean follow-up of 2.8 years.,"[{'No': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'(in': 'O'}, {'the': 'O'}, {'form': 'O'}, {'of': 'O'}, {'a': 'O'}, {'reduction': 'O'}, {'in': 'O'}, {'the': 'O'}, {'alkali': 'I-Entity'}, {'dose)': 'O'}, {'after': 'O'}, {'immunomodulating': 'O'}, {'therapy': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'over': 'O'}, {'a': 'O'}, {'mean': 'O'}, {'follow-up': 'O'}, {'of': 'O'}, {'2.8': 'O'}, {'years.': 'O'}]"
The plasma McIgM level decreased after chemotherapy (P=0.002).,"[{'The': 'O'}, {'plasma': 'O'}, {'McIgM': 'O'}, {'level': 'O'}, {'decreased': 'O'}, {'after': 'O'}, {'chemotherapy': 'O'}, {'(P=0.002).': 'O'}]"
"We describe a case of a 43-year-old woman who presented with symptoms including movement disorder, sensory neurogenic bladder, sensory loss and neuropathic pain, migraine like headaches, musculoskeletal pain, Raynaud's phenomenon and dysautonomia.","[{'We': 'O'}, {'describe': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'43-year-old': 'O'}, {'woman': 'O'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'symptoms': 'O'}, {'including': 'O'}, {'movement': 'B-Entity'}, {'disorder,': 'I-Entity'}, {'sensory': 'O'}, {'neurogenic': 'B-Entity'}, {'bladder,': 'I-Entity'}, {'sensory': 'B-Entity'}, {'loss': 'I-Entity'}, {'and': 'O'}, {'neuropathic': 'B-Entity'}, {'pain,': 'I-Entity'}, {'migraine': 'I-Entity'}, {'like': 'O'}, {'headaches,': 'I-Entity'}, {'musculoskeletal': 'B-Entity'}, {'pain,': 'I-Entity'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon': 'I-Entity'}, {'and': 'O'}, {'dysautonomia.': 'I-Entity'}]"
"Ten SS patients with proximal neuropathic pain were evaluated by this MRN protocol, as well as by punch skin biopsies evaluating for intraepidermal nerve fiber density (IENFD) of unmyelinated nerves.","[{'Ten': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'proximal': 'O'}, {'neuropathic': 'B-Entity'}, {'pain': 'I-Entity'}, {'were': 'O'}, {'evaluated': 'O'}, {'by': 'O'}, {'this': 'O'}, {'MRN': 'O'}, {'protocol,': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'by': 'O'}, {'punch': 'O'}, {'skin': 'O'}, {'biopsies': 'O'}, {'evaluating': 'O'}, {'for': 'O'}, {'intraepidermal': 'O'}, {'nerve': 'O'}, {'fiber': 'O'}, {'density': 'O'}, {'(IENFD)': 'O'}, {'of': 'O'}, {'unmyelinated': 'O'}, {'nerves.': 'O'}]"
"The patient complained of ocular discomfort, oral dryness and continuous nasal bleeding in 2007.","[{'The': 'O'}, {'patient': 'O'}, {'complained': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'discomfort,': 'I-Entity'}, {'oral': 'B-Entity'}, {'dryness': 'I-Entity'}, {'and': 'O'}, {'continuous': 'O'}, {'nasal': 'B-Entity'}, {'bleeding': 'I-Entity'}, {'in': 'O'}, {'2007.': 'O'}]"
"In addition, our study reveals that the coexistence of SS and systemic scleroderma decreases the incidence of FS value ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢1 compared to pSS.Turkey.Turkey.Turkey.10.4103/IJPM.IJPM_416_17.","[{'In': 'O'}, {'addition,': 'O'}, {'our': 'O'}, {'study': 'O'}, {'reveals': 'O'}, {'that': 'O'}, {'the': 'O'}, {'coexistence': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'scleroderma': 'I-Entity'}, {'decreases': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'FS': 'O'}, {'value': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢1': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'pSS.Turkey.Turkey.Turkey.10.4103/IJPM.IJPM_416_17.': 'O'}]"
"Primary outcome measures included ocular dryness, oral dryness, tear production, and salivary function.","[{'Primary': 'O'}, {'outcome': 'O'}, {'measures': 'O'}, {'included': 'O'}, {'ocular': 'B-Entity'}, {'dryness,': 'I-Entity'}, {'oral': 'B-Entity'}, {'dryness,': 'I-Entity'}, {'tear': 'O'}, {'production,': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'function.': 'O'}]"
"In some cases, the level of ocular discomfort was so severe it prevented sleep, which in turn impacted on general fatigue levels.","[{'In': 'O'}, {'some': 'O'}, {'cases,': 'O'}, {'the': 'O'}, {'level': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'discomfort': 'I-Entity'}, {'was': 'O'}, {'so': 'O'}, {'severe': 'O'}, {'it': 'O'}, {'prevented': 'O'}, {'sleep,': 'O'}, {'which': 'O'}, {'in': 'O'}, {'turn': 'O'}, {'impacted': 'O'}, {'on': 'O'}, {'general': 'O'}, {'fatigue': 'I-Entity'}, {'levels.': 'O'}]"
"We evaluated the Schirmer test value, tear breakup time (tBUT), and fluorescein and Rose Bengal (RB) staining scores at baseline, 3 months, 6 months, 1 year, and >1 year after treatment.","[{'We': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'Schirmer': 'O'}, {'test': 'O'}, {'value,': 'O'}, {'tear': 'O'}, {'breakup': 'O'}, {'time': 'O'}, {'(tBUT),': 'O'}, {'and': 'O'}, {'fluorescein': 'I-Entity'}, {'and': 'O'}, {'Rose': 'I-Entity'}, {'Bengal': 'I-Entity'}, {'(RB)': 'O'}, {'staining': 'O'}, {'scores': 'O'}, {'at': 'O'}, {'baseline,': 'O'}, {'3': 'O'}, {'months,': 'O'}, {'6': 'O'}, {'months,': 'O'}, {'1': 'O'}, {'year,': 'O'}, {'and': 'O'}, {'>1': 'O'}, {'year': 'O'}, {'after': 'O'}, {'treatment.': 'O'}]"
To evaluate lower tear meniscus and corneal sub-basal nerve plexus in primary Sjogrens syndrome (pSS) and Sicca syndrome patients.,"[{'To': 'O'}, {'evaluate': 'O'}, {'lower': 'O'}, {'tear': 'O'}, {'meniscus': 'O'}, {'and': 'O'}, {'corneal': 'O'}, {'sub-basal': 'O'}, {'nerve': 'O'}, {'plexus': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'and': 'O'}, {'Sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patients.': 'O'}]"
"We identified 17,072 patients with pSS and 68,270 controls.","[{'We': 'O'}, {'identified': 'O'}, {'17,072': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'68,270': 'O'}, {'controls.': 'O'}]"
"Although anterior inferior cerebellar artery compression has been well documented in the literature, compression caused by the posterior inferior cerebellar artery is rare.","[{'Although': 'O'}, {'anterior': 'O'}, {'inferior': 'B-Entity'}, {'cerebellar': 'I-Entity'}, {'artery': 'I-Entity'}, {'compression': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'well': 'O'}, {'documented': 'O'}, {'in': 'O'}, {'the': 'O'}, {'literature,': 'O'}, {'compression': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'the': 'O'}, {'posterior': 'O'}, {'inferior': 'O'}, {'cerebellar': 'I-Entity'}, {'artery': 'O'}, {'is': 'O'}, {'rare.': 'O'}]"
Eight of 128 consecutive patients with optic neuritis resulted from varied causes fulfilled the diagnostic criteria for the primary SS.,"[{'Eight': 'O'}, {'of': 'O'}, {'128': 'O'}, {'consecutive': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'optic': 'B-Entity'}, {'neuritis': 'I-Entity'}, {'resulted': 'O'}, {'from': 'O'}, {'varied': 'O'}, {'causes': 'O'}, {'fulfilled': 'O'}, {'the': 'O'}, {'diagnostic': 'O'}, {'criteria': 'O'}, {'for': 'O'}, {'the': 'O'}, {'primary': 'O'}, {'SS.': 'I-Entity'}]"
"Histopathologic examination showed moderate or severe lymphocytic infiltration and tissue destruction in all cases, similar to that in the SS-A- and/or SS-B-positive groups.","[{'Histopathologic': 'O'}, {'examination': 'O'}, {'showed': 'O'}, {'moderate': 'O'}, {'or': 'O'}, {'severe': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'tissue': 'O'}, {'destruction': 'I-Entity'}, {'in': 'O'}, {'all': 'O'}, {'cases,': 'O'}, {'similar': 'O'}, {'to': 'O'}, {'that': 'O'}, {'in': 'O'}, {'the': 'O'}, {'SS-A-': 'I-Entity'}, {'and/or': 'O'}, {'SS-B-positive': 'I-Entity'}, {'groups.': 'O'}]"
"The overall incidence density of asthma was 1.62-fold higher in the primary SS group than in the non-SS group (9.86 vs. 6.10 per 1000 person-years), with a multivariable Cox proportional hazards model measured adjusted HR of 1.38 [95% confidence interval (CI)‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢1.21-1.58].","[{'The': 'O'}, {'overall': 'O'}, {'incidence': 'O'}, {'density': 'O'}, {'of': 'O'}, {'asthma': 'I-Entity'}, {'was': 'O'}, {'1.62-fold': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'the': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'group': 'O'}, {'than': 'O'}, {'in': 'O'}, {'the': 'O'}, {'non-SS': 'O'}, {'group': 'O'}, {'(9.86': 'O'}, {'vs.': 'O'}, {'6.10': 'O'}, {'per': 'O'}, {'1000': 'O'}, {'person-years),': 'O'}, {'with': 'O'}, {'a': 'O'}, {'multivariable': 'O'}, {'Cox': 'O'}, {'proportional': 'O'}, {'hazards': 'O'}, {'model': 'O'}, {'measured': 'O'}, {'adjusted': 'O'}, {'HR': 'O'}, {'of': 'O'}, {'1.38': 'O'}, {'[95%': 'O'}]"
It was indicated that MSUS is useful for pSS-C. ACPA-positive pSS-C patients have arthritis and subclinical arthritis more frequently than ACPA-negative patients.Dec 20.Sjogren's syndrome.,"[{'It': 'O'}, {'was': 'O'}, {'indicated': 'O'}, {'that': 'O'}, {'MSUS': 'O'}, {'is': 'O'}, {'useful': 'O'}, {'for': 'O'}, {'pSS-C.': 'B-Entity'}, {'ACPA-positive': 'I-Entity'}, {'pSS-C': 'B-Entity'}, {'patients': 'O'}, {'have': 'O'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {'subclinical': 'O'}, {'arthritis': 'I-Entity'}, {'more': 'O'}, {'frequently': 'O'}, {'than': 'O'}, {'ACPA-negative': 'I-Entity'}, {'patients.Dec': 'O'}, {""20.Sjogren's"": 'O'}, {'syndrome.': 'I-Entity'}]"
"It is essential to eliminate other autoimmune diseases, as well as non-autoimmune causes of sicca syndrome, such as menopause, endocrine diseases, anticholinergic effects of drugs, and fibromyalgia, to delineate pSS patients who are at risk of systemic complications.","[{'It': 'O'}, {'is': 'O'}, {'essential': 'O'}, {'to': 'O'}, {'eliminate': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'non-autoimmune': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'sicca': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'menopause,': 'O'}, {'endocrine': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'anticholinergic': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'drugs,': 'O'}, {'and': 'O'}, {'fibromyalgia,': 'I-Entity'}, {'to': 'O'}, {'delineate': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'who': 'O'}]"
"In recent years, several studies have explored the efficacy and safety of biologic agents in pSS and after the failure of tumor necrosis factor inhibitors, the attention has been focused on compounds directly targeting B or T lymphocytes.","[{'In': 'O'}, {'recent': 'O'}, {'years,': 'O'}, {'several': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'explored': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'biologic': 'O'}, {'agents': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'and': 'O'}, {'after': 'O'}, {'the': 'O'}, {'failure': 'O'}, {'of': 'O'}, {'tumor': 'O'}, {'necrosis': 'O'}, {'factor': 'O'}, {'inhibitors,': 'O'}, {'the': 'O'}, {'attention': 'O'}, {'has': 'O'}, {'been': 'O'}, {'focused': 'O'}, {'on': 'O'}, {'compounds': 'O'}, {'directly': 'O'}, {'targeting': 'O'}, {'B': 'O'}, {'or': 'O'}, {'T': 'O'}, {'lymphocytes.': 'O'}]"
To evaluate the effects of non-pharmacological interventions for primary SS (pSS) on outcomes falling within the World Health Organization International Classification of Functioning Disability and Health domains.,"[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'non-pharmacological': 'O'}, {'interventions': 'O'}, {'for': 'O'}, {'primary': 'B-Entity'}, {'SS': 'I-Entity'}, {'(pSS)': 'O'}, {'on': 'O'}, {'outcomes': 'O'}, {'falling': 'O'}, {'within': 'O'}, {'the': 'O'}, {'World': 'O'}, {'Health': 'O'}, {'Organization': 'O'}, {'International': 'O'}, {'Classification': 'O'}, {'of': 'O'}, {'Functioning': 'O'}, {'Disability': 'O'}, {'and': 'O'}, {'Health': 'O'}, {'domains.': 'O'}]"
The studies were eligible for inclusion if they reported specific Standardized Incidence Ratio (SIR) with 95% CI.,"[{'The': 'O'}, {'studies': 'O'}, {'were': 'O'}, {'eligible': 'O'}, {'for': 'O'}, {'inclusion': 'O'}, {'if': 'O'}, {'they': 'O'}, {'reported': 'O'}, {'specific': 'O'}, {'Standardized': 'O'}, {'Incidence': 'O'}, {'Ratio': 'O'}, {'(SIR)': 'O'}, {'with': 'O'}, {'95%': 'O'}, {'CI.': 'O'}]"
"The main diagnosis of the patients was chronic recurrent parotitis, with the exception of 1 patient, who presented with salivary stones.","[{'The': 'O'}, {'main': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'was': 'O'}, {'chronic': 'O'}, {'recurrent': 'O'}, {'parotitis,': 'I-Entity'}, {'with': 'O'}, {'the': 'O'}, {'exception': 'O'}, {'of': 'O'}, {'1': 'O'}, {'patient,': 'O'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'salivary': 'B-Entity'}, {'stones.': 'I-Entity'}]"
"Expert commentary: The authors provide their perspective on the role of IFNs in pSS and how this knowledge could be used to improve pSS diagnosis, provide new treatment targets, to monitor clinical trials and to stratify pSS patients in order to move toward precision medicine.Netherlands.Netherlands.10.1080/1744666X.2018.1519396.","[{'Expert': 'O'}, {'commentary:': 'O'}, {'The': 'O'}, {'authors': 'O'}, {'provide': 'O'}, {'their': 'O'}, {'perspective': 'O'}, {'on': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'IFNs': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'how': 'O'}, {'this': 'O'}, {'knowledge': 'O'}, {'could': 'O'}, {'be': 'O'}, {'used': 'O'}, {'to': 'O'}, {'improve': 'O'}, {'pSS': 'I-Entity'}, {'diagnosis,': 'O'}, {'provide': 'O'}, {'new': 'O'}, {'treatment': 'O'}, {'targets,': 'O'}, {'to': 'O'}, {'monitor': 'O'}, {'clinical': 'O'}, {'trials': 'O'}, {'and': 'O'}, {'to': 'O'}, {'stratify': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'in': 'O'}, {'order': 'O'}, {'to': 'O'}, {'move': 'O'}, {'toward': 'O'}, {'precision': 'O'}, {'medicine.Netherlands.Netherlands.10.1080/1744666X.2018.1519396.': 'O'}]"
One of the secondary causes of hypoKPP is distal renal tubular acidosis (dRTA).,"[{'One': 'O'}, {'of': 'O'}, {'the': 'O'}, {'secondary': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'hypoKPP': 'I-Entity'}, {'is': 'O'}, {'distal': 'B-Entity'}, {'renal': 'I-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(dRTA).': 'O'}]"
"In 2 patients, corneal perforation was observed as a complication of corneal infection and in one patient as a late complication of a severe chemical burn.","[{'In': 'O'}, {'2': 'O'}, {'patients,': 'O'}, {'corneal': 'B-Entity'}, {'perforation': 'I-Entity'}, {'was': 'O'}, {'observed': 'O'}, {'as': 'O'}, {'a': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'corneal': 'B-Entity'}, {'infection': 'I-Entity'}, {'and': 'O'}, {'in': 'O'}, {'one': 'O'}, {'patient': 'O'}, {'as': 'O'}, {'a': 'O'}, {'late': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'a': 'O'}, {'severe': 'O'}, {'chemical': 'O'}, {'burn.': 'I-Entity'}]"
Sjogren syndrome was identified by the present-on-admission diagnosis code 710.2.,"[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'identified': 'O'}, {'by': 'O'}, {'the': 'O'}, {'present-on-admission': 'O'}, {'diagnosis': 'O'}, {'code': 'O'}, {'710.2.': 'O'}]"
"Autoimmune diseases do not impair fertility, and women with autoimmune diseases who become pregnant are likely to experience more complicated pregnancies than are women without the disease.","[{'Autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'do': 'O'}, {'not': 'O'}, {'impair': 'O'}, {'fertility,': 'O'}, {'and': 'O'}, {'women': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'who': 'O'}, {'become': 'O'}, {'pregnant': 'O'}, {'are': 'O'}, {'likely': 'O'}, {'to': 'O'}, {'experience': 'O'}, {'more': 'O'}, {'complicated': 'O'}, {'pregnancies': 'O'}, {'than': 'O'}, {'are': 'O'}, {'women': 'O'}, {'without': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
There are many different causes of pulmonary hypertension and the pathogenesis of the disease is still being elucidated.,"[{'There': 'O'}, {'are': 'O'}, {'many': 'O'}, {'different': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'pulmonary': 'B-Entity'}, {'hypertension': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'is': 'O'}, {'still': 'O'}, {'being': 'O'}, {'elucidated.': 'O'}]"
One patient (group A) developed peripheral ulcerative keratitis (PUK) with exacerbation of disease activity (DAS-28‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢6.9) that improved by taking corticosteroids.,"[{'One': 'O'}, {'patient': 'O'}, {'(group': 'O'}, {'A)': 'O'}, {'developed': 'O'}, {'peripheral': 'B-Entity'}, {'ulcerative': 'B-Entity'}, {'keratitis': 'I-Entity'}, {'(PUK)': 'O'}, {'with': 'O'}, {'exacerbation': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'(DAS-28‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢6.9)': 'O'}]"
"However, SS patients have been reported who have similar patterns of proximal neuropathic pain, despite having normal skin biopsy studies.","[{'However,': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'have': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'who': 'O'}, {'have': 'O'}, {'similar': 'O'}, {'patterns': 'O'}, {'of': 'O'}, {'proximal': 'O'}, {'neuropathic': 'B-Entity'}, {'pain,': 'I-Entity'}, {'despite': 'O'}, {'having': 'O'}, {'normal': 'O'}, {'skin': 'O'}, {'biopsy': 'O'}, {'studies.': 'O'}]"
Long-lived plasma cells (PC) can produce autoantibodies for prolonged period of times without being affected by immunosuppressive therapies.,"[{'Long-lived': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'(PC)': 'O'}, {'can': 'O'}, {'produce': 'O'}, {'autoantibodies': 'O'}, {'for': 'O'}, {'prolonged': 'O'}, {'period': 'O'}, {'of': 'O'}, {'times': 'O'}, {'without': 'O'}, {'being': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'immunosuppressive': 'O'}, {'therapies.': 'O'}]"
"This study investigated whether PSS increased the risk of ischemic stroke in a large, nationwide cohort.","[{'This': 'O'}, {'study': 'O'}, {'investigated': 'O'}, {'whether': 'O'}, {'PSS': 'I-Entity'}, {'increased': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'ischemic': 'B-Entity'}, {'stroke': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'large,': 'O'}, {'nationwide': 'O'}, {'cohort.': 'O'}]"
Sicca syndrome was occurred in 8 patients.,"[{'Sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'occurred': 'O'}, {'in': 'O'}, {'8': 'O'}, {'patients.': 'O'}]"
SFN can be diagnosed by punch skin biopsy results that identify decreased intra-epidermal nerve-fiber density (IENFD) of unmyelinated nerves.,"[{'SFN': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'diagnosed': 'O'}, {'by': 'O'}, {'punch': 'O'}, {'skin': 'O'}, {'biopsy': 'O'}, {'results': 'O'}, {'that': 'O'}, {'identify': 'O'}, {'decreased': 'O'}, {'intra-epidermal': 'O'}, {'nerve-fiber': 'O'}, {'density': 'O'}, {'(IENFD)': 'O'}, {'of': 'O'}, {'unmyelinated': 'O'}, {'nerves.': 'O'}]"
This difference was independent of tissue destruction.,"[{'This': 'O'}, {'difference': 'O'}, {'was': 'O'}, {'independent': 'O'}, {'of': 'O'}, {'tissue': 'O'}, {'destruction.': 'O'}]"
"AS eye drops improve symptoms and confocal microscopy findings in SS-related dry eyes.Delinassios), All rights reserved.Specialties and Public Health, University of Brescia, Brescia, Italy.Specialties and Public Health, University of Brescia, Brescia, Italy.Specialties and Public Health, University of Brescia, Brescia, Italy.Liverpool University Hospital, Liverpool, U.K. vito.romano@gmail.com.Campobasso, Italy.Campobasso, Italy.","[{'AS': 'O'}, {'eye': 'O'}, {'drops': 'O'}, {'improve': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'confocal': 'O'}, {'microscopy': 'O'}, {'findings': 'O'}, {'in': 'O'}, {'SS-related': 'I-Entity'}, {'dry': 'B-Entity'}, {'eyes.Delinassios),': 'I-Entity'}, {'All': 'O'}, {'rights': 'O'}, {'reserved.Specialties': 'O'}, {'and': 'O'}, {'Public': 'O'}, {'Health,': 'O'}, {'University': 'O'}, {'of': 'O'}, {'Brescia,': 'O'}, {'Brescia,': 'O'}, {'Italy.Specialties': 'O'}, {'and': 'O'}, {'Public': 'O'}, {'Health,': 'O'}, {'University': 'O'}, {'of': 'O'}, {'Brescia,': 'O'}, {'Brescia,': 'O'}]"
Clinical ambiguity easily leads to misdiagnosis and delayed initial treatment.,"[{'Clinical': 'O'}, {'ambiguity': 'O'}, {'easily': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'misdiagnosis': 'O'}, {'and': 'O'}, {'delayed': 'O'}, {'initial': 'O'}, {'treatment.': 'O'}]"
"Peripheral blood and salivary-gland B-cell subset distribution is altered, leading to the constitution of ectopic germinal centers where auto-reactive clones may escape tolerance checkpoints.","[{'Peripheral': 'O'}, {'blood': 'O'}, {'and': 'O'}, {'salivary-gland': 'O'}, {'B-cell': 'O'}, {'subset': 'O'}, {'distribution': 'O'}, {'is': 'O'}, {'altered,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'the': 'O'}, {'constitution': 'O'}, {'of': 'O'}, {'ectopic': 'O'}, {'germinal': 'O'}, {'centers': 'O'}, {'where': 'O'}, {'auto-reactive': 'O'}, {'clones': 'O'}, {'may': 'O'}, {'escape': 'O'}, {'tolerance': 'O'}, {'checkpoints.': 'O'}]"
"Many other skin lesions, although not specific, require further investigation to look for a possible underlying inflammatory rheumatic disease: non-pruritic urticarial lesions in anti-C1q-associated urticarial vasculitis, Still's disease or hereditary auto-inflammatory syndromes, transient macular purpura of vasculitis in Sjogrens syndrome, Beh‚Äö√†√∂‚àö√ºet's disease, or RA, Raynaud's phenomenon in SSc and mixed connective tissue disease, erythema nodosum or other panniculitis in RA, Beh‚Äö√†√∂‚àö√ºet's disease and SLE, pustular eruptions in Beh‚Äö√†√∂‚àö√ºet's disease, psoriasis, and hereditary auto-inflammatory syndromes.","[{'Many': 'O'}, {'other': 'O'}, {'skin': 'O'}, {'lesions,': 'O'}, {'although': 'O'}, {'not': 'O'}, {'specific,': 'O'}, {'require': 'O'}, {'further': 'O'}, {'investigation': 'O'}, {'to': 'O'}, {'look': 'O'}, {'for': 'O'}, {'a': 'O'}, {'possible': 'O'}, {'underlying': 'O'}, {'inflammatory': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'disease:': 'I-Entity'}, {'non-pruritic': 'O'}, {'urticarial': 'B-Entity'}, {'lesions': 'I-Entity'}, {'in': 'O'}, {'anti-C1q-associated': 'O'}, {'urticarial': 'B-Entity'}, {'vasculitis,': 'I-Entity'}, {""Still's"": 'B-Entity'}, {'disease': 'I-Entity'}, {'or': 'O'}, {'hereditary': 'O'}, {'auto-inflammatory': 'B-Entity'}, {'syndromes,': 'I-Entity'}]"
"Since then, the disease has been reported as affecting virtually every organ system and has been identified in the biliary tree, salivary and lacrimal glands, periorbital tissues, lungs, lymph nodes, thyroid gland, kidneys, prostate gland, testicles, breasts, and pituitary gland.","[{'Since': 'O'}, {'then,': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'has': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'as': 'O'}, {'affecting': 'O'}, {'virtually': 'O'}, {'every': 'O'}, {'organ': 'O'}, {'system': 'O'}, {'and': 'O'}, {'has': 'O'}, {'been': 'O'}, {'identified': 'O'}, {'in': 'O'}, {'the': 'O'}, {'biliary': 'O'}, {'tree,': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands,': 'O'}, {'periorbital': 'O'}, {'tissues,': 'O'}, {'lungs,': 'O'}, {'lymph': 'O'}, {'nodes,': 'O'}, {'thyroid': 'O'}, {'gland,': 'O'}, {'kidneys,': 'O'}, {'prostate': 'O'}, {'gland,': 'O'}, {'testicles,': 'O'}]"
The presence of SS-B antibodies significantly affected disease activity.,"[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'SS-B': 'B-Entity'}, {'antibodies': 'O'}, {'significantly': 'O'}, {'affected': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
Patients with common variable immunodeficiency (CVID) have a higher incidence of rheumatologic disorders.,"[{'Patients': 'O'}, {'with': 'O'}, {'common': 'B-Entity'}, {'variable': 'I-Entity'}, {'immunodeficiency': 'I-Entity'}, {'(CVID)': 'O'}, {'have': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'rheumatologic': 'B-Entity'}, {'disorders.': 'I-Entity'}]"
"In patients diagnosed with both distal RTA and vitamin D deficiency, clinicians should consider autoimmune diseases such as pSS, as a possible underlying etiology.","[{'In': 'O'}, {'patients': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'both': 'O'}, {'distal': 'O'}, {'RTA': 'I-Entity'}, {'and': 'O'}, {'vitamin': 'B-Entity'}, {'D': 'I-Entity'}, {'deficiency,': 'I-Entity'}, {'clinicians': 'O'}, {'should': 'O'}, {'consider': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'pSS,': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'possible': 'O'}, {'underlying': 'O'}, {'etiology.': 'O'}]"
We highlight the principles and the necessary information required for a diagnosis of classic distal renal tubular acidosis.,"[{'We': 'O'}, {'highlight': 'O'}, {'the': 'O'}, {'principles': 'O'}, {'and': 'O'}, {'the': 'O'}, {'necessary': 'O'}, {'information': 'O'}, {'required': 'O'}, {'for': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'classic': 'O'}, {'distal': 'O'}, {'renal': 'I-Entity'}, {'tubular': 'I-Entity'}, {'acidosis.': 'I-Entity'}]"
"Pulmonary manifestations are frequent in primary Sjogren syndrome but often not clinically significant; the most common are xerotrachea, interstitial lung diseases, and small airway obstruction.","[{'Pulmonary': 'O'}, {'manifestations': 'O'}, {'are': 'O'}, {'frequent': 'O'}, {'in': 'O'}, {'primary': 'O'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'but': 'O'}, {'often': 'O'}, {'not': 'O'}, {'clinically': 'O'}, {'significant;': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'are': 'O'}, {'xerotrachea,': 'I-Entity'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'and': 'O'}, {'small': 'B-Entity'}, {'airway': 'I-Entity'}, {'obstruction.': 'I-Entity'}]"
Patient was classified as having stage IV disseminated disease and a standard chemotherapy protocol was administered; the treatment was well tolerated and resulted in complete remission.,"[{'Patient': 'O'}, {'was': 'O'}, {'classified': 'O'}, {'as': 'O'}, {'having': 'O'}, {'stage': 'O'}, {'IV': 'O'}, {'disseminated': 'O'}, {'disease': 'O'}, {'and': 'O'}, {'a': 'O'}, {'standard': 'O'}, {'chemotherapy': 'O'}, {'protocol': 'O'}, {'was': 'O'}, {'administered;': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'was': 'O'}, {'well': 'O'}, {'tolerated': 'O'}, {'and': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'complete': 'O'}, {'remission.': 'O'}]"
Reliability was examined by asking patients to complete the questionnaire twice 1-2 weeks apart.,"[{'Reliability': 'O'}, {'was': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'asking': 'O'}, {'patients': 'O'}, {'to': 'O'}, {'complete': 'O'}, {'the': 'O'}, {'questionnaire': 'O'}, {'twice': 'O'}, {'1-2': 'O'}, {'weeks': 'O'}, {'apart.': 'O'}]"
"Circulating TNC levels were significantly raised in patients with RA, as well as patients with systemic lupus erythematosus, idiopathic inflammatory myositis, psoriatic arthritis and ankylosing spondylitis, whilst patients with Sjogren's syndrome displayed levels similar to healthy controls.","[{'Circulating': 'O'}, {'TNC': 'I-Entity'}, {'levels': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'raised': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'RA,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'idiopathic': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'myositis,': 'I-Entity'}, {'psoriatic': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {'ankylosing': 'B-Entity'}, {'spondylitis,': 'I-Entity'}, {'whilst': 'O'}, {'patients': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}]"
"Acoustic radiation force impulses sonoelastography can assist diagnosis of SS, and is a non-invasive and fast method of detecting pathological changes to the parotid and submandibular glands.Australia, Ltd.Cl‚Äö√†√∂‚Äö√¢‚Ä†nico Universitario Virgen de la Arrixaca, Murcia, Spain.Murcia, Spain.","[{'Acoustic': 'O'}, {'radiation': 'O'}, {'force': 'O'}, {'impulses': 'O'}, {'sonoelastography': 'O'}, {'can': 'O'}, {'assist': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'is': 'O'}, {'a': 'O'}, {'non-invasive': 'O'}, {'and': 'O'}, {'fast': 'O'}, {'method': 'O'}, {'of': 'O'}, {'detecting': 'O'}, {'pathological': 'O'}, {'changes': 'O'}, {'to': 'O'}, {'the': 'O'}, {'parotid': 'O'}, {'and': 'O'}, {'submandibular': 'O'}, {'glands.Australia,': 'O'}, {'Ltd.Cl‚Äö√†√∂‚Äö√¢‚Ä†nico': 'O'}]"
"We believe that all patients with diagnosis of undifferentiated connective tissue disease, especially those with a systemic sclerosis-like presentation, should be investigated for celiac disease, even in absence of gastrointestinal symptoms.","[{'We': 'O'}, {'believe': 'O'}, {'that': 'O'}, {'all': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'undifferentiated': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease,': 'I-Entity'}, {'especially': 'O'}, {'those': 'O'}, {'with': 'O'}, {'a': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis-like': 'I-Entity'}, {'presentation,': 'O'}, {'should': 'O'}, {'be': 'O'}, {'investigated': 'O'}, {'for': 'O'}, {'celiac': 'B-Entity'}, {'disease,': 'I-Entity'}, {'even': 'O'}, {'in': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'gastrointestinal': 'B-Entity'}, {'symptoms.': 'O'}]"
To evaluate the efficacy of rituximab in central nervous system (CNS) manifestations of patients with primary Sjogrens syndrome (pSS).,"[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'rituximab': 'I-Entity'}, {'in': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'(CNS)': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"However, important issues have emerged in these patients wherein life-long conventional right ventricular apical pacing may produce left ventricular dysfunction (pacing-induced cardiomyopathy) necessitating a priori alternate site pacing or subsequent upgrading to biventricular pacing.","[{'However,': 'O'}, {'important': 'O'}, {'issues': 'O'}, {'have': 'O'}, {'emerged': 'O'}, {'in': 'O'}, {'these': 'O'}, {'patients': 'O'}, {'wherein': 'O'}, {'life-long': 'O'}, {'conventional': 'O'}, {'right': 'O'}, {'ventricular': 'O'}, {'apical': 'O'}, {'pacing': 'O'}, {'may': 'O'}, {'produce': 'O'}, {'left': 'B-Entity'}, {'ventricular': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'(pacing-induced': 'O'}, {'cardiomyopathy)': 'I-Entity'}, {'necessitating': 'O'}, {'a': 'O'}, {'priori': 'O'}, {'alternate': 'O'}, {'site': 'O'}, {'pacing': 'O'}, {'or': 'O'}, {'subsequent': 'O'}, {'upgrading': 'O'}, {'to': 'O'}, {'biventricular': 'O'}, {'pacing.': 'O'}]"
"In multivariate analysis, dryness, limb pain and fatigue, but not mental fatigue, were significantly associated with PGA; weights derived from the regression were identical for these three domains.","[{'In': 'O'}, {'multivariate': 'O'}, {'analysis,': 'O'}, {'dryness,': 'I-Entity'}, {'limb': 'B-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'fatigue,': 'I-Entity'}, {'but': 'O'}, {'not': 'O'}, {'mental': 'O'}, {'fatigue,': 'I-Entity'}, {'were': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'PGA;': 'I-Entity'}, {'weights': 'O'}, {'derived': 'O'}, {'from': 'O'}, {'the': 'O'}, {'regression': 'O'}, {'were': 'O'}, {'identical': 'O'}, {'for': 'O'}, {'these': 'O'}, {'three': 'O'}, {'domains.': 'O'}]"
"To determine the prevalence of sicca symptoms, dry eye, and secondary Sjogrens syndrome and to evaluate the severity of dry eye in patients with mixed connective tissue disease.","[{'To': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'sicca': 'B-Entity'}, {'symptoms,': 'O'}, {'dry': 'B-Entity'}, {'eye,': 'I-Entity'}, {'and': 'O'}, {'secondary': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'severity': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'mixed': 'B-Entity'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"In this Review, we analyse the evidence regarding the efficacy of the therapeutic agents currently available to treat the manifestations of SS.","[{'In': 'O'}, {'this': 'O'}, {'Review,': 'O'}, {'we': 'O'}, {'analyse': 'O'}, {'the': 'O'}, {'evidence': 'O'}, {'regarding': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'the': 'O'}, {'therapeutic': 'O'}, {'agents': 'O'}, {'currently': 'O'}, {'available': 'O'}, {'to': 'O'}, {'treat': 'O'}, {'the': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'SS.': 'I-Entity'}]"
"comprehensive, accessible, efficient) and the advantages of ultrasound (US) use (patient-friendly, convenient, cost-effective, and does not require exposure to radiation or magnetic fields), there seems to be a 'gap' in the actual clinical practice.","[{'comprehensive,': 'O'}, {'accessible,': 'O'}, {'efficient)': 'O'}, {'and': 'O'}, {'the': 'O'}, {'advantages': 'O'}, {'of': 'O'}, {'ultrasound': 'O'}, {'(US)': 'O'}, {'use': 'O'}, {'(patient-friendly,': 'O'}, {'convenient,': 'O'}, {'cost-effective,': 'O'}, {'and': 'O'}, {'does': 'O'}, {'not': 'O'}, {'require': 'O'}, {'exposure': 'O'}, {'to': 'O'}, {'radiation': 'O'}, {'or': 'O'}, {'magnetic': 'O'}, {'fields),': 'O'}, {'there': 'O'}, {'seems': 'O'}, {'to': 'O'}, {'be': 'O'}, {'a': 'O'}, {""'gap'"": 'O'}, {'in': 'O'}, {'the': 'O'}, {'actual': 'O'}, {'clinical': 'O'}, {'practice.': 'O'}]"
"In this review we will go through the more recent evidence on UCTD and we will discuss in what extent the availability of new criteria for the CTDs could interfere with the ""UCTD concept"".","[{'In': 'O'}, {'this': 'O'}, {'review': 'O'}, {'we': 'O'}, {'will': 'O'}, {'go': 'O'}, {'through': 'O'}, {'the': 'O'}, {'more': 'O'}, {'recent': 'O'}, {'evidence': 'O'}, {'on': 'O'}, {'UCTD': 'I-Entity'}, {'and': 'O'}, {'we': 'O'}, {'will': 'O'}, {'discuss': 'O'}, {'in': 'O'}, {'what': 'O'}, {'extent': 'O'}, {'the': 'O'}, {'availability': 'O'}, {'of': 'O'}, {'new': 'O'}, {'criteria': 'O'}, {'for': 'O'}, {'the': 'O'}, {'CTDs': 'I-Entity'}, {'could': 'O'}, {'interfere': 'O'}, {'with': 'O'}, {'the': 'O'}, {'""UCTD': 'O'}, {'concept"".': 'O'}]"
Biopsies of apparently healthy skin can contribute to the diagnosis of an internal disorder in a patient or in the detection of a potential disease carrier.,"[{'Biopsies': 'O'}, {'of': 'O'}, {'apparently': 'O'}, {'healthy': 'O'}, {'skin': 'O'}, {'can': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'an': 'O'}, {'internal': 'B-Entity'}, {'disorder': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'or': 'O'}, {'in': 'O'}, {'the': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'a': 'O'}, {'potential': 'O'}, {'disease': 'O'}, {'carrier.': 'O'}]"
Primary SS related optic neuritis is less common and easily misdiagnosed.,"[{'Primary': 'O'}, {'SS': 'I-Entity'}, {'related': 'O'}, {'optic': 'B-Entity'}, {'neuritis': 'I-Entity'}, {'is': 'O'}, {'less': 'O'}, {'common': 'O'}, {'and': 'O'}, {'easily': 'O'}, {'misdiagnosed.': 'O'}]"
Primary Sjogrens syndrome (pSS) is a solitary poorly understood autoimmune inflammatory disease by involvement of the salivary and lacrimal glands resulting in dry mouth and dry eyes.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'solitary': 'O'}, {'poorly': 'O'}, {'understood': 'O'}, {'autoimmune': 'B-Entity'}, {'inflammatory': 'O'}, {'disease': 'O'}, {'by': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eyes.': 'I-Entity'}]"
"Parotitis is a common condition seen in the pediatric population, usually as an isolated occurrence associated with viral or bacterial infection.","[{'Parotitis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'condition': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pediatric': 'O'}, {'population,': 'O'}, {'usually': 'O'}, {'as': 'O'}, {'an': 'O'}, {'isolated': 'O'}, {'occurrence': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'viral': 'B-Entity'}, {'or': 'O'}, {'bacterial': 'I-Entity'}, {'infection.': 'I-Entity'}]"
A significant difference was observed in the Beck Depression Inventory scores between patients with and without cough.,"[{'A': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'the': 'O'}, {'Beck': 'O'}, {'Depression': 'I-Entity'}, {'Inventory': 'O'}, {'scores': 'O'}, {'between': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'and': 'O'}, {'without': 'O'}, {'cough.': 'I-Entity'}]"
"In addition, the dry eye severity was graded.","[{'In': 'O'}, {'addition,': 'O'}, {'the': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'severity': 'O'}, {'was': 'O'}, {'graded.': 'O'}]"
The relationship between infection and autoimmunity has been increasingly defined over the last 20 years.,"[{'The': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'infection': 'I-Entity'}, {'and': 'O'}, {'autoimmunity': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'increasingly': 'O'}, {'defined': 'O'}, {'over': 'O'}, {'the': 'O'}, {'last': 'O'}, {'20': 'O'}, {'years.': 'O'}]"
Etiologies of dry eye syndrome were dominated by Sjogren syndrome (32¬¨¬®‚Äö√Ñ‚Ä†%) and severe ocular surface conditions (48¬¨¬®‚Äö√Ñ‚Ä†%).,"[{'Etiologies': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'were': 'O'}, {'dominated': 'O'}, {'by': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(32¬¨¬®‚Äö√Ñ‚Ä†%)': 'O'}, {'and': 'O'}, {'severe': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'conditions': 'I-Entity'}, {'(48¬¨¬®‚Äö√Ñ‚Ä†%).': 'O'}]"
Clinicians should consider EGID as a possible diagnosis and perform gastrointestinal tract biopsies in patients with CTD presenting with gastrointestinal symptoms and unexplained eosinophilia.,"[{'Clinicians': 'O'}, {'should': 'O'}, {'consider': 'O'}, {'EGID': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'possible': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'perform': 'O'}, {'gastrointestinal': 'O'}, {'tract': 'O'}, {'biopsies': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'CTD': 'I-Entity'}, {'presenting': 'O'}, {'with': 'O'}, {'gastrointestinal': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'and': 'O'}, {'unexplained': 'O'}, {'eosinophilia.': 'I-Entity'}]"
"Profound loss in joint position is associated with sensory ataxia, and reflects degeneration of large-sized dorsal root ganglia.","[{'Profound': 'O'}, {'loss': 'B-Entity'}, {'in': 'I-Entity'}, {'joint': 'I-Entity'}, {'position': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'sensory': 'B-Entity'}, {'ataxia,': 'I-Entity'}, {'and': 'O'}, {'reflects': 'O'}, {'degeneration': 'O'}, {'of': 'O'}, {'large-sized': 'O'}, {'dorsal': 'O'}, {'root': 'O'}, {'ganglia.': 'O'}]"
"Awareness must therefore be raised among clinicians of the somatosensory and autonomic symptoms that can reveal small fiber neuropathy, appropriate diagnostic investigations, most common causes, and best treatment options for each patient profile.","[{'Awareness': 'O'}, {'must': 'O'}, {'therefore': 'O'}, {'be': 'O'}, {'raised': 'O'}, {'among': 'O'}, {'clinicians': 'O'}, {'of': 'O'}, {'the': 'O'}, {'somatosensory': 'O'}, {'and': 'O'}, {'autonomic': 'O'}, {'symptoms': 'O'}, {'that': 'O'}, {'can': 'O'}, {'reveal': 'O'}, {'small': 'O'}, {'fiber': 'O'}, {'neuropathy,': 'I-Entity'}, {'appropriate': 'O'}, {'diagnostic': 'O'}, {'investigations,': 'O'}, {'most': 'O'}, {'common': 'O'}, {'causes,': 'O'}, {'and': 'O'}, {'best': 'O'}, {'treatment': 'O'}, {'options': 'O'}, {'for': 'O'}, {'each': 'O'}, {'patient': 'O'}, {'profile.': 'O'}]"
The clinical progress of the patient and autopsy findings suggested that complement activation might have been associated with the pathology.2018 Dec 18.,"[{'The': 'O'}, {'clinical': 'O'}, {'progress': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'and': 'O'}, {'autopsy': 'O'}, {'findings': 'O'}, {'suggested': 'O'}, {'that': 'O'}, {'complement': 'O'}, {'activation': 'O'}, {'might': 'O'}, {'have': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'pathology.2018': 'O'}, {'Dec': 'O'}, {'18.': 'O'}]"
Therapy- and complication-related lung changes would pose difficulty in diagnosing and classifying an ILD.,"[{'Therapy-': 'O'}, {'and': 'O'}, {'complication-related': 'O'}, {'lung': 'O'}, {'changes': 'O'}, {'would': 'O'}, {'pose': 'O'}, {'difficulty': 'O'}, {'in': 'O'}, {'diagnosing': 'O'}, {'and': 'O'}, {'classifying': 'O'}, {'an': 'O'}, {'ILD.': 'I-Entity'}]"
"Increased age associated with higher incidence of xerostomia, and females had a higher incidence of sialadenitis.","[{'Increased': 'O'}, {'age': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'higher': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'xerostomia,': 'I-Entity'}, {'and': 'O'}, {'females': 'O'}, {'had': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'sialadenitis.': 'I-Entity'}]"
Thirty-three consecutive patients undergoing 36 sialendoscopy procedures performed at a tertiary medical center from July 2008 to July 2010 were included.,"[{'Thirty-three': 'O'}, {'consecutive': 'O'}, {'patients': 'O'}, {'undergoing': 'O'}, {'36': 'O'}, {'sialendoscopy': 'O'}, {'procedures': 'O'}, {'performed': 'O'}, {'at': 'O'}, {'a': 'O'}, {'tertiary': 'O'}, {'medical': 'O'}, {'center': 'O'}, {'from': 'O'}, {'July': 'O'}, {'2008': 'O'}, {'to': 'O'}, {'July': 'O'}, {'2010': 'O'}, {'were': 'O'}, {'included.': 'O'}]"
"Primary biliary cirrhosis is a chronic cholestatic liver disease characterised by destruction of small intrahepatic bile ducts, leading to fibrosis and potential cirrhosis through resulting complications.","[{'Primary': 'B-Entity'}, {'biliary': 'I-Entity'}, {'cirrhosis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'cholestatic': 'B-Entity'}, {'liver': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterised': 'O'}, {'by': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'small': 'O'}, {'intrahepatic': 'O'}, {'bile': 'O'}, {'ducts,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'fibrosis': 'I-Entity'}, {'and': 'O'}, {'potential': 'O'}, {'cirrhosis': 'I-Entity'}, {'through': 'O'}, {'resulting': 'O'}, {'complications.': 'O'}]"
"Renal involvement of pSS is mostly due to TIN with marked T, B and especially plasma cell infiltration.","[{'Renal': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'is': 'O'}, {'mostly': 'O'}, {'due': 'O'}, {'to': 'O'}, {'TIN': 'I-Entity'}, {'with': 'O'}, {'marked': 'O'}, {'T,': 'O'}, {'B': 'O'}, {'and': 'O'}, {'especially': 'O'}, {'plasma': 'O'}, {'cell': 'O'}, {'infiltration.': 'O'}]"
"Her dyspnea symptom was much improved with endothelin receptor antagonist and azathioprine.Medicine, Cardiovascular Research Institute, Busan Paik Hospital, Busan, Korea.31.risk of congenital heart block.","[{'Her': 'O'}, {'dyspnea': 'I-Entity'}, {'symptom': 'O'}, {'was': 'O'}, {'much': 'O'}, {'improved': 'O'}, {'with': 'O'}, {'endothelin': 'O'}, {'receptor': 'O'}, {'antagonist': 'O'}, {'and': 'O'}, {'azathioprine.Medicine,': 'I-Entity'}, {'Cardiovascular': 'O'}, {'Research': 'O'}, {'Institute,': 'O'}, {'Busan': 'O'}, {'Paik': 'O'}, {'Hospital,': 'O'}, {'Busan,': 'O'}, {'Korea.31.risk': 'O'}, {'of': 'O'}, {'congenital': 'B-Entity'}, {'heart': 'I-Entity'}, {'block.': 'I-Entity'}]"
We abstracted data relating to anti-NR2A/B antibodies from the identified studies.,"[{'We': 'O'}, {'abstracted': 'O'}, {'data': 'O'}, {'relating': 'O'}, {'to': 'O'}, {'anti-NR2A/B': 'O'}, {'antibodies': 'O'}, {'from': 'O'}, {'the': 'O'}, {'identified': 'O'}, {'studies.': 'O'}]"
"In 75 established pSS patients, mean disease duration 12.4¬¨¬®¬¨¬±7.2 years, the hyperechoic bands of parotid gland (PG) and submandibular gland (SMG) were significantly associated with sialometry (p<0.001) and VAS oral dryness (PG p=0.002, SMG p<0.001).","[{'In': 'O'}, {'75': 'O'}, {'established': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'mean': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'12.4¬¨¬®¬¨¬±7.2': 'O'}, {'years,': 'O'}, {'the': 'O'}, {'hyperechoic': 'O'}, {'bands': 'O'}, {'of': 'O'}, {'parotid': 'O'}, {'gland': 'O'}, {'(PG)': 'O'}, {'and': 'O'}, {'submandibular': 'O'}, {'gland': 'O'}, {'(SMG)': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'sialometry': 'O'}, {'(p<0.001)': 'O'}]"
Histopathologic changes were examined by light microscopy according to Chisholm's classification.,"[{'Histopathologic': 'O'}, {'changes': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'light': 'O'}, {'microscopy': 'O'}, {'according': 'O'}, {'to': 'O'}, {""Chisholm's"": 'O'}, {'classification.': 'O'}]"
Primary Sjogrens syndrome (pSS) is a common chronic autoimmune disease that primarily affects the salivary and lacrimal glands.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'chronic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'primarily': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands.': 'O'}]"
Three (27.3%) patients died: 2 due to transformation from mucosa-associated lymphoid tissue to diffuse large B-cell.,"[{'Three': 'O'}, {'(27.3%)': 'O'}, {'patients': 'O'}, {'died:': 'O'}, {'2': 'O'}, {'due': 'O'}, {'to': 'O'}, {'transformation': 'O'}, {'from': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'O'}, {'tissue': 'O'}, {'to': 'O'}, {'diffuse': 'O'}, {'large': 'O'}, {'B-cell.': 'O'}]"
"Although Sjogrens syndrome has been known to complicate with white matter lesions, encephalopathy, or stroke, reports of cerebral venous sinus thrombosis due to Sjogrens syndrome with atypical antibodies are rare.","[{'Although': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'known': 'O'}, {'to': 'O'}, {'complicate': 'O'}, {'with': 'O'}, {'white': 'B-Entity'}, {'matter': 'I-Entity'}, {'lesions,': 'I-Entity'}, {'encephalopathy,': 'I-Entity'}, {'or': 'O'}, {'stroke,': 'I-Entity'}, {'reports': 'O'}, {'of': 'O'}, {'cerebral': 'B-Entity'}, {'venous': 'I-Entity'}, {'sinus': 'I-Entity'}, {'thrombosis': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'with': 'O'}, {'atypical': 'O'}, {'antibodies': 'O'}, {'are': 'O'}, {'rare.': 'O'}]"
"The differential diagnosis extends to thyroid eye disease; blepharitis; Sjogrens syndrome; Churg-Strauss vasculitis; Wegener's granulomatosis; Gleich syndrome; orbital and ocular lymphoid hyperplasia or adnexal lymphoma; idiopathic orbital inflammatory disease/idiopathic sclerosing orbital inflammation; rarely, orbital parasitosis; and IgG4-related diseases.","[{'The': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'extends': 'O'}, {'to': 'O'}, {'thyroid': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease;': 'I-Entity'}, {'blepharitis;': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome;': 'I-Entity'}, {'Churg-Strauss': 'B-Entity'}, {'vasculitis;': 'I-Entity'}, {""Wegener's"": 'B-Entity'}, {'granulomatosis;': 'I-Entity'}, {'Gleich': 'B-Entity'}, {'syndrome;': 'I-Entity'}, {'orbital': 'B-Entity'}, {'and': 'I-Entity'}, {'ocular': 'I-Entity'}, {'lymphoid': 'I-Entity'}, {'hyperplasia': 'I-Entity'}, {'or': 'O'}, {'adnexal': 'I-Entity'}]"
"Whereas our review of the literature revealed that ubiquitous patterns of clinical injury were frequently associated with magnetic resonance imaging (MRI) findings suggestive of a widespread vasculopathy, our patients did not have such neuroimaging findings.","[{'Whereas': 'O'}, {'our': 'O'}, {'review': 'O'}, {'of': 'O'}, {'the': 'O'}, {'literature': 'O'}, {'revealed': 'O'}, {'that': 'O'}, {'ubiquitous': 'O'}, {'patterns': 'O'}, {'of': 'O'}, {'clinical': 'O'}, {'injury': 'I-Entity'}, {'were': 'O'}, {'frequently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'magnetic': 'O'}, {'resonance': 'O'}, {'imaging': 'O'}, {'(MRI)': 'O'}, {'findings': 'O'}, {'suggestive': 'O'}, {'of': 'O'}, {'a': 'O'}, {'widespread': 'O'}, {'vasculopathy,': 'I-Entity'}, {'our': 'O'}, {'patients': 'O'}, {'did': 'O'}, {'not': 'O'}, {'have': 'O'}, {'such': 'O'}, {'neuroimaging': 'O'}, {'findings.': 'O'}]"
Few studies have evaluated the association between Sjogren's syndrome (SS) and respiratory failure (RF).,"[{'Few': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'association': 'O'}, {'between': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'respiratory': 'B-Entity'}, {'failure': 'I-Entity'}, {'(RF).': 'O'}]"
"We utilized the nonobese diabetic (NOD) mice, a model of SS-like disease as well as lower-lip biopsy samples of subjects without or with a diagnosis of SS in association with immunostaining studies.","[{'We': 'O'}, {'utilized': 'O'}, {'the': 'O'}, {'nonobese': 'O'}, {'diabetic': 'I-Entity'}, {'(NOD)': 'O'}, {'mice,': 'O'}, {'a': 'O'}, {'model': 'O'}, {'of': 'O'}, {'SS-like': 'I-Entity'}, {'disease': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'lower-lip': 'O'}, {'biopsy': 'O'}, {'samples': 'O'}, {'of': 'O'}, {'subjects': 'O'}, {'without': 'O'}, {'or': 'O'}, {'with': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'association': 'O'}, {'with': 'O'}, {'immunostaining': 'O'}, {'studies.': 'O'}]"
"To facilitate the detection of treatment efficacy in clinical trials and to help in determining which subgroups of patients would have benefits from intensive therapies, a better definition of activity scores and the availability of new prognostic markers are urgent.","[{'To': 'O'}, {'facilitate': 'O'}, {'the': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'efficacy': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'trials': 'O'}, {'and': 'O'}, {'to': 'O'}, {'help': 'O'}, {'in': 'O'}, {'determining': 'O'}, {'which': 'O'}, {'subgroups': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'would': 'O'}, {'have': 'O'}, {'benefits': 'O'}, {'from': 'O'}, {'intensive': 'O'}, {'therapies,': 'O'}, {'a': 'O'}, {'better': 'O'}, {'definition': 'O'}, {'of': 'O'}, {'activity': 'O'}, {'scores': 'O'}, {'and': 'O'}, {'the': 'O'}, {'availability': 'O'}, {'of': 'O'}, {'new': 'O'}, {'prognostic': 'O'}, {'markers': 'O'}, {'are': 'O'}, {'urgent.': 'O'}]"
A further comparison of patients with mixed connective tissue disease with or without Sjogrens syndrome revealed that the former presented significantly lower frequencies of polyarthritis and cutaneous involvement than did the patients without Sjogrens syndrome.,"[{'A': 'O'}, {'further': 'O'}, {'comparison': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'mixed': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'with': 'O'}, {'or': 'O'}, {'without': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'revealed': 'O'}, {'that': 'O'}, {'the': 'O'}, {'former': 'O'}, {'presented': 'O'}, {'significantly': 'O'}, {'lower': 'O'}, {'frequencies': 'O'}, {'of': 'O'}, {'polyarthritis': 'I-Entity'}, {'and': 'O'}, {'cutaneous': 'O'}, {'involvement': 'O'}, {'than': 'O'}, {'did': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"While many of the potential disorders that may mimic MS in routine clinical practice are either extremely rare, or associated with specific and characteristic distinguishing diagnostic features, some inflammatory demyelinating disorders of the CNS may be particularly challenging to distinguish from MS, especially during initial presentation.","[{'While': 'O'}, {'many': 'O'}, {'of': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'disorders': 'O'}, {'that': 'O'}, {'may': 'O'}, {'mimic': 'O'}, {'MS': 'I-Entity'}, {'in': 'O'}, {'routine': 'O'}, {'clinical': 'O'}, {'practice': 'O'}, {'are': 'O'}, {'either': 'O'}, {'extremely': 'O'}, {'rare,': 'O'}, {'or': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'specific': 'O'}, {'and': 'O'}, {'characteristic': 'O'}, {'distinguishing': 'O'}, {'diagnostic': 'O'}, {'features,': 'O'}, {'some': 'O'}, {'inflammatory': 'B-Entity'}, {'demyelinating': 'B-Entity'}, {'disorders': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'O'}, {'CNS': 'O'}, {'may': 'O'}, {'be': 'O'}, {'particularly': 'O'}, {'challenging': 'O'}, {'to': 'O'}, {'distinguish': 'O'}, {'from': 'O'}, {'MS,': 'I-Entity'}, {'especially': 'O'}, {'during': 'O'}, {'initial': 'O'}, {'presentation.': 'O'}]"
"A wide variety of neurological complications are characteristic features of Sjogren's syndrome, of which peripheral neuropathy is a major neurological manifestation.","[{'A': 'O'}, {'wide': 'O'}, {'variety': 'O'}, {'of': 'O'}, {'neurological': 'O'}, {'complications': 'O'}, {'are': 'O'}, {'characteristic': 'O'}, {'features': 'O'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'of': 'O'}, {'which': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'major': 'O'}, {'neurological': 'O'}, {'manifestation.': 'O'}]"
FGN responds poorly to immunosuppressive therapy and has a poor prognosis.,"[{'FGN': 'I-Entity'}, {'responds': 'O'}, {'poorly': 'O'}, {'to': 'O'}, {'immunosuppressive': 'O'}, {'therapy': 'O'}, {'and': 'O'}, {'has': 'O'}, {'a': 'O'}, {'poor': 'O'}, {'prognosis.': 'O'}]"
"A similar situation occurred in the SF-36, where all domains demonstrated improvement except for the emotional aspect (p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.710): FC, physical aspects limitation, general health status, vitality, social aspects, and mental health (all p <¬¨¬®‚Äö√Ñ‚Ä†0.01).","[{'A': 'O'}, {'similar': 'O'}, {'situation': 'O'}, {'occurred': 'O'}, {'in': 'O'}, {'the': 'O'}, {'SF-36,': 'O'}, {'where': 'O'}, {'all': 'O'}, {'domains': 'O'}, {'demonstrated': 'O'}, {'improvement': 'O'}, {'except': 'O'}, {'for': 'O'}, {'the': 'O'}, {'emotional': 'O'}, {'aspect': 'O'}, {'(p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.710):': 'O'}, {'FC,': 'O'}, {'physical': 'O'}, {'aspects': 'O'}, {'limitation,': 'O'}, {'general': 'O'}, {'health': 'O'}, {'status,': 'O'}]"
"Of these, the authors excluded patients with diabetes, hypertension, advanced liver cirrhosis at initial diagnosis of PBC (Child-Turcotte-Pugh classification score of ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢7) and other liver diseases (ie, alcoholic liver disease, alpha-antitrypsin deficiency, viral hepatitis, and primary sclerosing cholangitis), and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis.","[{'Of': 'O'}, {'these,': 'O'}, {'the': 'O'}, {'authors': 'O'}, {'excluded': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'diabetes,': 'I-Entity'}, {'hypertension,': 'I-Entity'}, {'advanced': 'O'}, {'liver': 'B-Entity'}, {'cirrhosis': 'I-Entity'}, {'at': 'O'}, {'initial': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'PBC': 'I-Entity'}, {'(Child-Turcotte-Pugh': 'O'}, {'classification': 'O'}, {'score': 'O'}, {'of': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢7)': 'O'}, {'and': 'O'}]"
"Systemic involvement in SS is well known, however, obvious cardiac manifestations, particularly significant valve disorders, are extremely rare and only three cases of significant valve disease associated with SS that required surgical intervention have been previously described.","[{'Systemic': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'is': 'O'}, {'well': 'O'}, {'known,': 'O'}, {'however,': 'O'}, {'obvious': 'O'}, {'cardiac': 'O'}, {'manifestations,': 'O'}, {'particularly': 'O'}, {'significant': 'O'}, {'valve': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'are': 'O'}, {'extremely': 'O'}, {'rare': 'O'}, {'and': 'O'}, {'only': 'O'}, {'three': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'significant': 'O'}, {'valve': 'B-Entity'}, {'disease': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'that': 'O'}, {'required': 'O'}, {'surgical': 'O'}, {'intervention': 'O'}, {'have': 'O'}, {'been': 'O'}, {'previously': 'O'}, {'described.': 'O'}]"
MATERIALS & We studied fifty patients with primary Sjogrens syndrome for peripheral nervous system involvement.,"[{'MATERIALS': 'O'}, {'&': 'O'}, {'We': 'O'}, {'studied': 'O'}, {'fifty': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'for': 'O'}, {'peripheral': 'B-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'involvement.': 'O'}]"
Further studies are warranted in order to explore underlying pathophysiologic pathways that might explain fatigue in the setting of primary SS.,"[{'Further': 'O'}, {'studies': 'O'}, {'are': 'O'}, {'warranted': 'O'}, {'in': 'O'}, {'order': 'O'}, {'to': 'O'}, {'explore': 'O'}, {'underlying': 'O'}, {'pathophysiologic': 'O'}, {'pathways': 'O'}, {'that': 'O'}, {'might': 'O'}, {'explain': 'O'}, {'fatigue': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'setting': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'SS.': 'I-Entity'}]"
Immunomodulating drugs are commonly used in treating patients with autoimmune diseases but with very different outcomes.,"[{'Immunomodulating': 'O'}, {'drugs': 'O'}, {'are': 'O'}, {'commonly': 'O'}, {'used': 'O'}, {'in': 'O'}, {'treating': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'but': 'O'}, {'with': 'O'}, {'very': 'O'}, {'different': 'O'}, {'outcomes.': 'O'}]"
"The Schirmer-1 test and BUT values of patients in advanced stage of primary SS decreased significantly, whereas the Rose bengal and OSDI values increased significantly when compared with the values of patients in early stage of primary SS and with those of normal individuals (P<0.05 and P<0.001, respectively).","[{'The': 'O'}, {'Schirmer-1': 'O'}, {'test': 'O'}, {'and': 'O'}, {'BUT': 'O'}, {'values': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'in': 'O'}, {'advanced': 'O'}, {'stage': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'decreased': 'O'}, {'significantly,': 'O'}, {'whereas': 'O'}, {'the': 'O'}, {'Rose': 'B-Entity'}, {'bengal': 'I-Entity'}, {'and': 'O'}, {'OSDI': 'I-Entity'}, {'values': 'O'}, {'increased': 'O'}, {'significantly': 'O'}, {'when': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'the': 'O'}, {'values': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'in': 'O'}, {'early': 'O'}, {'stage': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'with': 'O'}, {'those': 'O'}, {'of': 'O'}, {'normal': 'O'}, {'individuals': 'O'}, {'(P<0.05': 'O'}, {'and': 'O'}, {'P<0.001,': 'O'}]"
A three-step process followed by a Delphi exercise with closed voting was applied.,"[{'A': 'O'}, {'three-step': 'O'}, {'process': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'a': 'O'}, {'Delphi': 'O'}, {'exercise': 'O'}, {'with': 'O'}, {'closed': 'O'}, {'voting': 'O'}, {'was': 'O'}, {'applied.': 'O'}]"
"Connective tissue diseases encompass a wide range of heterogeneous disorders characterised by immune-mediated chronic inflammation often leading to tissue damage, collagen deposition and possible loss of function of the target organ.","[{'Connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'encompass': 'O'}, {'a': 'O'}, {'wide': 'O'}, {'range': 'O'}, {'of': 'O'}, {'heterogeneous': 'O'}, {'disorders': 'O'}, {'characterised': 'O'}, {'by': 'O'}, {'immune-mediated': 'O'}, {'chronic': 'O'}, {'inflammation': 'I-Entity'}, {'often': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'tissue': 'B-Entity'}, {'damage,': 'I-Entity'}, {'collagen': 'O'}, {'deposition': 'O'}, {'and': 'O'}, {'possible': 'O'}, {'loss': 'O'}, {'of': 'O'}, {'function': 'O'}, {'of': 'O'}, {'the': 'O'}, {'target': 'O'}, {'organ.': 'O'}]"
"Primary Sjogrens syndrome (pSS) is an important cause of renal tubular dysfunction in adults, mainly due to acquired type 1 distal renal tubular acidosis (RTA 1) and concentration defects (CD).","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'important': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'in': 'O'}, {'adults,': 'O'}, {'mainly': 'O'}, {'due': 'O'}, {'to': 'O'}, {'acquired': 'O'}, {'type': 'O'}, {'1': 'O'}, {'distal': 'O'}, {'renal': 'O'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(RTA': 'O'}, {'1)': 'O'}, {'and': 'O'}, {'concentration': 'O'}, {'defects': 'O'}, {'(CD).': 'O'}]"
PATIENTS AND A 69-year-old woman treated for mucosa-associated lymphoid tissue (MALT) gastric lymphoma was referred for a bullous eruption.,"[{'PATIENTS': 'O'}, {'AND': 'O'}, {'A': 'O'}, {'69-year-old': 'O'}, {'woman': 'O'}, {'treated': 'O'}, {'for': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'I-Entity'}, {'tissue': 'I-Entity'}, {'(MALT)': 'O'}, {'gastric': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'was': 'O'}, {'referred': 'O'}, {'for': 'O'}, {'a': 'O'}, {'bullous': 'O'}, {'eruption.': 'I-Entity'}]"
"However, physiological changes that occur during aging might also lead to a diminished glandular function.","[{'However,': 'O'}, {'physiological': 'O'}, {'changes': 'O'}, {'that': 'O'}, {'occur': 'O'}, {'during': 'O'}, {'aging': 'O'}, {'might': 'O'}, {'also': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'a': 'O'}, {'diminished': 'O'}, {'glandular': 'O'}, {'function.': 'O'}]"
Five of 8 patients were treated for systemic immunological diseases.,"[{'Five': 'O'}, {'of': 'O'}, {'8': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'treated': 'O'}, {'for': 'O'}, {'systemic': 'B-Entity'}, {'immunological': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"To assess pSS activity, the EULAR Sjogrens Syndrome Disease Activity Index (ESSDAI) and EULAR Sjogrens Syndrome Patient Reported Index (ESSPRI) were used.","[{'To': 'O'}, {'assess': 'O'}, {'pSS': 'O'}, {'activity,': 'O'}, {'the': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'(ESSDAI)': 'O'}, {'and': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Patient': 'O'}, {'Reported': 'O'}, {'Index': 'O'}, {'(ESSPRI)': 'O'}, {'were': 'O'}, {'used.': 'O'}]"
"Chinese herbal medicine for nourishing yin, supplementing qi, and activating blood can alleviate the disease activity of pSS by regulating the immune balance of Th1/Th2.China.","[{'Chinese': 'O'}, {'herbal': 'O'}, {'medicine': 'O'}, {'for': 'O'}, {'nourishing': 'O'}, {'yin,': 'I-Entity'}, {'supplementing': 'O'}, {'qi,': 'O'}, {'and': 'O'}, {'activating': 'O'}, {'blood': 'O'}, {'can': 'O'}, {'alleviate': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'by': 'O'}, {'regulating': 'O'}, {'the': 'O'}, {'immune': 'O'}, {'balance': 'O'}, {'of': 'O'}, {'Th1/Th2.China.': 'O'}]"
Patients with Sjogren's syndrome may be Epstein-Barr virus carriers.Management of Sjogren Syndrome-Associated Dry Eye.,"[{'Patients': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'Epstein-Barr': 'B-Entity'}, {'virus': 'O'}, {'carriers.Management': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'Syndrome-Associated': 'I-Entity'}, {'Dry': 'B-Entity'}, {'Eye.': 'I-Entity'}]"
"Though largely associated with systemic sclerosis, it is being increasingly recognized in other rheumatic diseases.","[{'Though': 'O'}, {'largely': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'it': 'O'}, {'is': 'O'}, {'being': 'O'}, {'increasingly': 'O'}, {'recognized': 'O'}, {'in': 'O'}, {'other': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
We obtained similar results with B-cell lymphomas associated with SS.,"[{'We': 'O'}, {'obtained': 'O'}, {'similar': 'O'}, {'results': 'O'}, {'with': 'O'}, {'B-cell': 'B-Entity'}, {'lymphomas': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'SS.': 'I-Entity'}]"
"The diagnosis of SFN can be confirmed by the evidence of decreased intra-epidermal nerve fibre density after a skin punch biopsy or the presence of abnormal nonconventional neurophysiological tests exploring the A-delta and C small nerve fibres (laser-evoked potentials, quantitative sensory tests, cutaneous sympathic reflex, autonomic function tests).","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SFN': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'confirmed': 'O'}, {'by': 'O'}, {'the': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'decreased': 'O'}, {'intra-epidermal': 'O'}, {'nerve': 'O'}, {'fibre': 'O'}, {'density': 'O'}, {'after': 'O'}, {'a': 'O'}, {'skin': 'O'}, {'punch': 'O'}, {'biopsy': 'O'}, {'or': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'abnormal': 'O'}, {'nonconventional': 'O'}, {'neurophysiological': 'O'}, {'tests': 'O'}, {'exploring': 'O'}, {'the': 'O'}, {'A-delta': 'O'}, {'and': 'O'}, {'C': 'O'}, {'small': 'O'}, {'nerve': 'O'}, {'fibres': 'O'}, {'(laser-evoked': 'O'}, {'potentials,': 'O'}]"
"Interestingly, neither transgenic TCR‚âà√≠‚Äö√¢¬ß nor TCRmini mice develop diabetes, which we show is due to lack of insulin B:9-23 specific T cells in the periphery.","[{'Interestingly,': 'O'}, {'neither': 'O'}, {'transgenic': 'O'}, {'TCR‚âà√≠‚Äö√¢¬ß': 'O'}, {'nor': 'O'}, {'TCRmini': 'O'}, {'mice': 'O'}, {'develop': 'O'}, {'diabetes,': 'I-Entity'}, {'which': 'O'}, {'we': 'O'}, {'show': 'O'}, {'is': 'O'}, {'due': 'O'}, {'to': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'insulin': 'I-Entity'}, {'B:9-23': 'O'}, {'specific': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'the': 'O'}, {'periphery.': 'O'}]"
"Using Spdef(-/-) mice, we determined that Spdef is required for conjunctival goblet cell differentiation and that Spdef(-/-) mice, which lack conjunctival goblet cells, have significantly increased corneal surface fluorescein staining and tear volume, a phenotype consistent with dry eye.","[{'Using': 'O'}, {'Spdef(-/-)': 'O'}, {'mice,': 'O'}, {'we': 'O'}, {'determined': 'O'}, {'that': 'O'}, {'Spdef': 'O'}, {'is': 'O'}, {'required': 'O'}, {'for': 'O'}, {'conjunctival': 'O'}, {'goblet': 'O'}, {'cell': 'O'}, {'differentiation': 'O'}, {'and': 'O'}, {'that': 'O'}, {'Spdef(-/-)': 'O'}, {'mice,': 'O'}, {'which': 'O'}, {'lack': 'O'}, {'conjunctival': 'O'}, {'goblet': 'O'}, {'cells,': 'O'}, {'have': 'O'}, {'significantly': 'O'}, {'increased': 'O'}, {'corneal': 'O'}, {'surface': 'O'}, {'fluorescein': 'I-Entity'}]"
The treatment recommended substitution of tears in order to protect the eye and the occasional use of preparations moisturizing mucous membrane of the nose and mouth.,"[{'The': 'O'}, {'treatment': 'O'}, {'recommended': 'O'}, {'substitution': 'O'}, {'of': 'O'}, {'tears': 'O'}, {'in': 'O'}, {'order': 'O'}, {'to': 'O'}, {'protect': 'O'}, {'the': 'O'}, {'eye': 'O'}, {'and': 'O'}, {'the': 'O'}, {'occasional': 'O'}, {'use': 'O'}, {'of': 'O'}, {'preparations': 'O'}, {'moisturizing': 'O'}, {'mucous': 'O'}, {'membrane': 'O'}, {'of': 'O'}, {'the': 'O'}, {'nose': 'O'}, {'and': 'O'}, {'mouth.': 'O'}]"
"Emergent pericardiocentesis and enhanced immunosuppression can effectively control this life-threatening complication.Hospital, No.","[{'Emergent': 'O'}, {'pericardiocentesis': 'O'}, {'and': 'O'}, {'enhanced': 'O'}, {'immunosuppression': 'O'}, {'can': 'O'}, {'effectively': 'O'}, {'control': 'O'}, {'this': 'O'}, {'life-threatening': 'O'}, {'complication.Hospital,': 'O'}, {'No.': 'O'}]"
"Moreover, subjects' satisfaction and the proportion of the subjects who identified their allocation will also be measured and analyzed.","[{'Moreover,': 'O'}, {""subjects'"": 'O'}, {'satisfaction': 'O'}, {'and': 'O'}, {'the': 'O'}, {'proportion': 'O'}, {'of': 'O'}, {'the': 'O'}, {'subjects': 'O'}, {'who': 'O'}, {'identified': 'O'}, {'their': 'O'}, {'allocation': 'O'}, {'will': 'O'}, {'also': 'O'}, {'be': 'O'}, {'measured': 'O'}, {'and': 'O'}, {'analyzed.': 'O'}]"
"Several studies have shown a negative association between smoking and primary Sjogrens syndrome (pSS), and smoking may interfere with the immune response.","[{'Several': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'shown': 'O'}, {'a': 'O'}, {'negative': 'O'}, {'association': 'O'}, {'between': 'O'}, {'smoking': 'I-Entity'}, {'and': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'and': 'O'}, {'smoking': 'I-Entity'}, {'may': 'O'}, {'interfere': 'O'}, {'with': 'O'}, {'the': 'O'}, {'immune': 'O'}, {'response.': 'O'}]"
This case reminds clinicians that chronic MTX use is associated with LPDs and can ultimately lead to hypercalcaemia.,"[{'This': 'O'}, {'case': 'O'}, {'reminds': 'O'}, {'clinicians': 'O'}, {'that': 'O'}, {'chronic': 'O'}, {'MTX': 'I-Entity'}, {'use': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'LPDs': 'I-Entity'}, {'and': 'O'}, {'can': 'O'}, {'ultimately': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'hypercalcaemia.': 'I-Entity'}]"
"Primary Sjogrens syndrome (pSS) is a chronic autoimmune disease characterized by dry eyes, dry mouth, and other clinical manifestations.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'dry': 'B-Entity'}, {'eyes,': 'I-Entity'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'and': 'O'}, {'other': 'O'}, {'clinical': 'O'}, {'manifestations.': 'O'}]"
This study demonstrated that presence of the anti-Ro antibody was not associated with increased mortality in patients with autoimmune rheumatic disease.,"[{'This': 'O'}, {'study': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'the': 'O'}, {'anti-Ro': 'O'}, {'antibody': 'O'}, {'was': 'O'}, {'not': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'mortality': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"In order to assess a potential autonomic neuropathy, ""Deep Breathing Test"" (E/I 1.02), ""Lying to Standing Test"" (R/R' 0.95), and ""Orthostatic Hypotension Tests"" (T 120s Systolic reduction >20 mmHg and Diastolic reduction >10 mmHg) were performed, all of which were abnormal.","[{'In': 'O'}, {'order': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'a': 'O'}, {'potential': 'O'}, {'autonomic': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'""Deep': 'O'}, {'Breathing': 'O'}, {'Test""': 'O'}, {'(E/I': 'O'}, {'1.02),': 'O'}, {'""Lying': 'O'}, {'to': 'O'}, {'Standing': 'O'}, {'Test""': 'O'}, {""(R/R'"": 'O'}, {'0.95),': 'O'}, {'and': 'O'}, {'""Orthostatic': 'O'}, {'Hypotension': 'I-Entity'}, {'Tests""': 'O'}, {'(T': 'O'}, {'120s': 'O'}]"
"Gitelman syndrome (GS) is an autosomal recessive, salt-losing renal tubulopathy caused by mutations in the SLC12A3 gene; however, it can also be acquired in patients with autoimmune disease, especially in those with Sjogrens syndrome.","[{'Gitelman': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(GS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autosomal': 'O'}, {'recessive,': 'O'}, {'salt-losing': 'B-Entity'}, {'renal': 'B-Entity'}, {'tubulopathy': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'mutations': 'O'}, {'in': 'O'}, {'the': 'O'}, {'SLC12A3': 'O'}, {'gene;': 'O'}, {'however,': 'O'}, {'it': 'O'}, {'can': 'O'}, {'also': 'O'}, {'be': 'O'}, {'acquired': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'especially': 'O'}, {'in': 'O'}, {'those': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Systemic disease-modifying therapies were used mostly in patients who had another concurrent autoimmune disease, suggesting a lack of treatment options for SS.","[{'Systemic': 'O'}, {'disease-modifying': 'O'}, {'therapies': 'O'}, {'were': 'O'}, {'used': 'O'}, {'mostly': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'had': 'O'}, {'another': 'O'}, {'concurrent': 'O'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'suggesting': 'O'}, {'a': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'options': 'O'}, {'for': 'O'}, {'SS.': 'I-Entity'}]"
"To study the safety and clinical efficacy of rituximab therapy for primary Sjogrens syndrome, as well as to investigate its mechanisms.","[{'To': 'O'}, {'study': 'O'}, {'the': 'O'}, {'safety': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'rituximab': 'I-Entity'}, {'therapy': 'O'}, {'for': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'its': 'O'}, {'mechanisms.': 'O'}]"
"HLH usually presents with persistent fever, pancytopenia, and organomegaly and is associated with very high levels of serum ferritin.","[{'HLH': 'I-Entity'}, {'usually': 'O'}, {'presents': 'O'}, {'with': 'O'}, {'persistent': 'O'}, {'fever,': 'I-Entity'}, {'pancytopenia,': 'I-Entity'}, {'and': 'O'}, {'organomegaly': 'I-Entity'}, {'and': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'very': 'O'}, {'high': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'ferritin.': 'O'}]"
Five women with acute and/or chronic optic neuropathy who were diagnosed as primary Sjogrens syndrome were retrospectively evaluated.,"[{'Five': 'O'}, {'women': 'O'}, {'with': 'O'}, {'acute': 'O'}, {'and/or': 'O'}, {'chronic': 'O'}, {'optic': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'who': 'O'}, {'were': 'O'}, {'diagnosed': 'O'}, {'as': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'were': 'O'}, {'retrospectively': 'O'}, {'evaluated.': 'O'}]"
"In contrast, EGCG-fed mice exhibited normal levels of PCNA and peroxiredoxin 6, comparable to healthy untreated BALB/c mice.","[{'In': 'O'}, {'contrast,': 'O'}, {'EGCG-fed': 'I-Entity'}, {'mice': 'O'}, {'exhibited': 'O'}, {'normal': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'PCNA': 'O'}, {'and': 'O'}, {'peroxiredoxin': 'O'}, {'6,': 'O'}, {'comparable': 'O'}, {'to': 'O'}, {'healthy': 'O'}, {'untreated': 'O'}, {'BALB/c': 'O'}, {'mice.': 'O'}]"
Childhood-onset SS is an heterogeneous disease in its presentation and outcome.,"[{'Childhood-onset': 'O'}, {'SS': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'heterogeneous': 'O'}, {'disease': 'O'}, {'in': 'O'}, {'its': 'O'}, {'presentation': 'O'}, {'and': 'O'}, {'outcome.': 'O'}]"
"In patients with pSS and anti-Ro52 antibodies, a clinical screening and pulmonary functional tests with DLCO is necessary during the follow-up and should comprise chest HRCT if there is a decline in the DLCO or clinical symptoms or inspiratory crackles.63100, Clermont-Ferrand, France.Av.","[{'In': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'anti-Ro52': 'O'}, {'antibodies,': 'O'}, {'a': 'O'}, {'clinical': 'O'}, {'screening': 'O'}, {'and': 'O'}, {'pulmonary': 'O'}, {'functional': 'O'}, {'tests': 'O'}, {'with': 'O'}, {'DLCO': 'O'}, {'is': 'O'}, {'necessary': 'O'}, {'during': 'O'}, {'the': 'O'}, {'follow-up': 'O'}, {'and': 'O'}, {'should': 'O'}, {'comprise': 'O'}, {'chest': 'O'}, {'HRCT': 'O'}, {'if': 'O'}, {'there': 'O'}, {'is': 'O'}, {'a': 'O'}, {'decline': 'O'}, {'in': 'O'}, {'the': 'O'}, {'DLCO': 'O'}, {'or': 'O'}, {'clinical': 'O'}, {'symptoms': 'O'}, {'or': 'O'}, {'inspiratory': 'O'}, {'crackles.63100,': 'O'}, {'Clermont-Ferrand,': 'O'}]"
"The positive rate of serum GPI in the patients with RA was 55.4%, contrasting to other autoimmune diseases (14.3%) and healthy controls (7.78%)(P<0.001).","[{'The': 'O'}, {'positive': 'O'}, {'rate': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'GPI': 'O'}, {'in': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'RA': 'I-Entity'}, {'was': 'O'}, {'55.4%,': 'O'}, {'contrasting': 'O'}, {'to': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(14.3%)': 'O'}, {'and': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'(7.78%)(P<0.001).': 'O'}]"
"Moreover, 434 samples from controls (150 healthy blood donors, 150 chronic fatigue syndrome, and 134 diseased controls) and 252 samples (obtained at diagnosis) from patients with systemic rheumatic diseases were screened for antinuclear antibodies (1:80) on HEp-2 cells using NOVA View, and likelihood ratios were calculated for fluorescence intensity result intervals.","[{'Moreover,': 'O'}, {'434': 'O'}, {'samples': 'O'}, {'from': 'O'}, {'controls': 'O'}, {'(150': 'O'}, {'healthy': 'O'}, {'blood': 'O'}, {'donors,': 'O'}, {'150': 'O'}, {'chronic': 'B-Entity'}, {'fatigue': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'134': 'O'}, {'diseased': 'O'}, {'controls)': 'O'}, {'and': 'O'}, {'252': 'O'}, {'samples': 'O'}, {'(obtained': 'O'}, {'at': 'O'}, {'diagnosis)': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'were': 'O'}, {'screened': 'O'}, {'for': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'(1:80)': 'O'}, {'on': 'O'}, {'HEp-2': 'O'}, {'cells': 'O'}, {'using': 'O'}, {'NOVA': 'O'}]"
"More importantly, NODscid mice exhibited normal LG ECM structures, indicating the lymphocytes seen in the LGs of NOD mice are responsible for the degradation of the LG ECM.","[{'More': 'O'}, {'importantly,': 'O'}, {'NODscid': 'O'}, {'mice': 'O'}, {'exhibited': 'O'}, {'normal': 'O'}, {'LG': 'O'}, {'ECM': 'O'}, {'structures,': 'O'}, {'indicating': 'O'}, {'the': 'O'}, {'lymphocytes': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'the': 'O'}, {'LGs': 'O'}, {'of': 'O'}, {'NOD': 'O'}, {'mice': 'O'}, {'are': 'O'}, {'responsible': 'O'}, {'for': 'O'}, {'the': 'O'}, {'degradation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'LG': 'O'}, {'ECM.': 'O'}]"
"A total of 1463 studies were identified, from which 17 full text articles were screened and 5 studies were included in the review; a total of 130 participants were randomized.","[{'A': 'O'}, {'total': 'O'}, {'of': 'O'}, {'1463': 'O'}, {'studies': 'O'}, {'were': 'O'}, {'identified,': 'O'}, {'from': 'O'}, {'which': 'O'}, {'17': 'O'}, {'full': 'O'}, {'text': 'O'}, {'articles': 'O'}, {'were': 'O'}, {'screened': 'O'}, {'and': 'O'}, {'5': 'O'}, {'studies': 'O'}, {'were': 'O'}, {'included': 'O'}, {'in': 'O'}, {'the': 'O'}, {'review;': 'O'}, {'a': 'O'}, {'total': 'O'}, {'of': 'O'}, {'130': 'O'}, {'participants': 'O'}, {'were': 'O'}, {'randomized.': 'O'}]"
Primary Sjogren syndrome (SS) is an autoimmune disease mainly affecting the exocrine glands causing a sicca syndrome.,"[{'Primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'mainly': 'O'}, {'affecting': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'causing': 'O'}, {'a': 'O'}, {'sicca': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Neurological examination disclosed bilateral temporal pallor of the optic disc, atrophy and fasciculation of the right side of the tongue, dysesthesia in four limbs, mild motor weakness of both lower limbs, hyperreflexia in the right leg, pathological reflexes in bilateral lower limbs, and spastic bladder.","[{'Neurological': 'O'}, {'examination': 'O'}, {'disclosed': 'O'}, {'bilateral': 'O'}, {'temporal': 'B-Entity'}, {'pallor': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'optic': 'I-Entity'}, {'disc,': 'I-Entity'}, {'atrophy': 'I-Entity'}, {'and': 'O'}, {'fasciculation': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'right': 'O'}, {'side': 'O'}, {'of': 'O'}, {'the': 'O'}, {'tongue,': 'O'}, {'dysesthesia': 'I-Entity'}, {'in': 'O'}, {'four': 'O'}, {'limbs,': 'O'}, {'mild': 'O'}, {'motor': 'B-Entity'}, {'weakness': 'I-Entity'}, {'of': 'O'}, {'both': 'O'}, {'lower': 'O'}, {'limbs,': 'O'}, {'hyperreflexia': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'right': 'O'}, {'leg,': 'O'}, {'pathological': 'B-Entity'}, {'reflexes': 'O'}]"
Diagnosis of pSS requires an invasive tissue biopsy and a delay in diagnosis of pSS has been frequently reported.,"[{'Diagnosis': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'requires': 'O'}, {'an': 'O'}, {'invasive': 'O'}, {'tissue': 'O'}, {'biopsy': 'O'}, {'and': 'O'}, {'a': 'O'}, {'delay': 'O'}, {'in': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'frequently': 'O'}, {'reported.': 'O'}]"
"Shrinking lung syndrome (SLS) is an uncommon feature of systemic lupus erythematosus (SLE) characterized by dyspnea, pleuritic chest pain, diaphragmatic elevation, restrictive ventilatory defect and reduced respiratory muscle strength as measured by volitional tests.","[{'Shrinking': 'B-Entity'}, {'lung': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SLS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'uncommon': 'O'}, {'feature': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'dyspnea,': 'I-Entity'}, {'pleuritic': 'B-Entity'}, {'chest': 'B-Entity'}, {'pain,': 'I-Entity'}, {'diaphragmatic': 'O'}, {'elevation,': 'I-Entity'}, {'restrictive': 'B-Entity'}, {'ventilatory': 'I-Entity'}, {'defect': 'I-Entity'}, {'and': 'O'}, {'reduced': 'O'}, {'respiratory': 'O'}, {'muscle': 'O'}, {'strength': 'O'}, {'as': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'volitional': 'O'}]"
"IgG4-related disease (IgG4-RD) is a recently recognized fibro-inflammatory disorder, which may affect many organs, and often comes to clinical attention due to tumor-like organ swelling or is identified incidentally by specific biopsy findings.","[{'IgG4-related': 'B-Entity'}, {'disease': 'I-Entity'}, {'(IgG4-RD)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'recently': 'O'}, {'recognized': 'O'}, {'fibro-inflammatory': 'B-Entity'}, {'disorder,': 'I-Entity'}, {'which': 'O'}, {'may': 'O'}, {'affect': 'O'}, {'many': 'O'}, {'organs,': 'O'}, {'and': 'O'}, {'often': 'O'}, {'comes': 'O'}, {'to': 'O'}, {'clinical': 'O'}, {'attention': 'O'}, {'due': 'O'}, {'to': 'O'}, {'tumor-like': 'I-Entity'}, {'organ': 'B-Entity'}, {'swelling': 'I-Entity'}, {'or': 'O'}, {'is': 'O'}, {'identified': 'O'}, {'incidentally': 'O'}, {'by': 'O'}, {'specific': 'O'}, {'biopsy': 'O'}, {'findings.': 'O'}]"
"In addition, only patients affected by pSS without HT had evidence of cryoglobulins, cutaneous vasculitis with palpable purpura, peripheral neuropathy, and development of lymphoma, although all these manifestations were observed in a 4.1-8.2 % of the cases, without reaching statistical significance.","[{'In': 'O'}, {'addition,': 'O'}, {'only': 'O'}, {'patients': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'pSS': 'O'}, {'without': 'O'}, {'HT': 'I-Entity'}, {'had': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'cryoglobulins,': 'O'}, {'cutaneous': 'B-Entity'}, {'vasculitis': 'I-Entity'}, {'with': 'O'}, {'palpable': 'O'}, {'purpura,': 'I-Entity'}, {'peripheral': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'and': 'O'}, {'development': 'O'}, {'of': 'O'}, {'lymphoma,': 'I-Entity'}, {'although': 'O'}, {'all': 'O'}, {'these': 'O'}, {'manifestations': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'a': 'O'}, {'4.1-8.2': 'O'}]"
"Herein we review the evidence regarding the association of these antibodies with HLA background, demographic, clinical, glandular dysfunction, other serologic features and response to treatment in patients with pSS.Nutrici‚Äö√†√∂‚Äö√¢‚Ä¢n SZ, Vasco de Quiroga 15.","[{'Herein': 'O'}, {'we': 'O'}, {'review': 'O'}, {'the': 'O'}, {'evidence': 'O'}, {'regarding': 'O'}, {'the': 'O'}, {'association': 'O'}, {'of': 'O'}, {'these': 'O'}, {'antibodies': 'O'}, {'with': 'O'}, {'HLA': 'O'}, {'background,': 'O'}, {'demographic,': 'O'}, {'clinical,': 'O'}, {'glandular': 'B-Entity'}, {'dysfunction,': 'I-Entity'}, {'other': 'O'}, {'serologic': 'O'}, {'features': 'O'}, {'and': 'O'}, {'response': 'O'}, {'to': 'O'}, {'treatment': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.Nutrici‚Äö√†√∂‚Äö√¢‚Ä¢n': 'I-Entity'}]"
"The most common reasons for referrals included positive review of systems (60%), severe dry eye symptoms (51%) or ocular signs (47%), or dry eye that is refractory to treatment (42%).","[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'reasons': 'O'}, {'for': 'O'}, {'referrals': 'O'}, {'included': 'O'}, {'positive': 'O'}, {'review': 'O'}, {'of': 'O'}, {'systems': 'O'}, {'(60%),': 'O'}, {'severe': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'symptoms': 'O'}, {'(51%)': 'O'}, {'or': 'O'}, {'ocular': 'O'}, {'signs': 'O'}, {'(47%),': 'O'}, {'or': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'that': 'O'}, {'is': 'O'}, {'refractory': 'O'}, {'to': 'O'}, {'treatment': 'O'}, {'(42%).': 'O'}]"
A growing body of evidence presents a link between chronic inflammatory rheumatic diseases and atherosclerosis.,"[{'A': 'O'}, {'growing': 'O'}, {'body': 'O'}, {'of': 'O'}, {'evidence': 'O'}, {'presents': 'O'}, {'a': 'O'}, {'link': 'O'}, {'between': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'and': 'O'}, {'atherosclerosis.': 'I-Entity'}]"
"Aromatase inhibitors (AIs) are widely prescribed for post-menopausal hormone receptor-positive breast cancer; however, musculoskeletal symptoms limit their tolerability.","[{'Aromatase': 'O'}, {'inhibitors': 'O'}, {'(AIs)': 'O'}, {'are': 'O'}, {'widely': 'O'}, {'prescribed': 'O'}, {'for': 'O'}, {'post-menopausal': 'O'}, {'hormone': 'O'}, {'receptor-positive': 'O'}, {'breast': 'B-Entity'}, {'cancer;': 'I-Entity'}, {'however,': 'O'}, {'musculoskeletal': 'B-Entity'}, {'symptoms': 'O'}, {'limit': 'O'}, {'their': 'O'}, {'tolerability.': 'O'}]"
Rose bengal staining of the ocular surface is an important observation in the detection of SS and the differentiation of pSS and KCS.barbaracafferyeyes@yahoo.ca2010 Jan 27.,"[{'Rose': 'B-Entity'}, {'bengal': 'I-Entity'}, {'staining': 'O'}, {'of': 'O'}, {'the': 'O'}, {'ocular': 'O'}, {'surface': 'O'}, {'is': 'O'}, {'an': 'O'}, {'important': 'O'}, {'observation': 'O'}, {'in': 'O'}, {'the': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'differentiation': 'O'}, {'of': 'O'}, {'pSS': 'O'}, {'and': 'O'}, {'KCS.barbaracafferyeyes@yahoo.ca2010': 'I-Entity'}, {'Jan': 'O'}, {'27.': 'O'}]"
The WHO reports that one of the major chronic conditions affecting the elderly worldwide is musculoskeletal disorders that are associated with long-term pain and disability.,"[{'The': 'O'}, {'WHO': 'O'}, {'reports': 'O'}, {'that': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'major': 'O'}, {'chronic': 'O'}, {'conditions': 'O'}, {'affecting': 'O'}, {'the': 'O'}, {'elderly': 'O'}, {'worldwide': 'O'}, {'is': 'O'}, {'musculoskeletal': 'B-Entity'}, {'disorders': 'I-Entity'}, {'that': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'long-term': 'O'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'disability.': 'I-Entity'}]"
"Early recognition of disease can prevent end-organ damage and, as more cases are diagnosed, its relationship to SS may be elucidated leading to further advances in treatment and surveillance.Floor, Dayton, OH 45409.Force, 4881 Sugar Maple Drive, WPAFB, OH 45433.","[{'Early': 'O'}, {'recognition': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'can': 'O'}, {'prevent': 'O'}, {'end-organ': 'B-Entity'}, {'damage': 'I-Entity'}, {'and,': 'O'}, {'as': 'O'}, {'more': 'O'}, {'cases': 'O'}, {'are': 'O'}, {'diagnosed,': 'O'}, {'its': 'O'}, {'relationship': 'O'}, {'to': 'O'}, {'SS': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'elucidated': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'further': 'O'}, {'advances': 'O'}, {'in': 'O'}, {'treatment': 'O'}, {'and': 'O'}, {'surveillance.Floor,': 'O'}, {'Dayton,': 'O'}, {'OH': 'O'}, {'45409.Force,': 'O'}, {'4881': 'O'}, {'Sugar': 'O'}, {'Maple': 'O'}, {'Drive,': 'O'}, {'WPAFB,': 'O'}, {'OH': 'O'}, {'45433.': 'O'}]"
"Steroid pulse therapy was performed, and after three cycles, the ileus symptoms disappeared, and the disturbed visual acuity OU returned to normal.","[{'Steroid': 'I-Entity'}, {'pulse': 'O'}, {'therapy': 'O'}, {'was': 'O'}, {'performed,': 'O'}, {'and': 'O'}, {'after': 'O'}, {'three': 'O'}, {'cycles,': 'O'}, {'the': 'O'}, {'ileus': 'I-Entity'}, {'symptoms': 'O'}, {'disappeared,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'disturbed': 'B-Entity'}, {'visual': 'I-Entity'}, {'acuity': 'I-Entity'}, {'OU': 'O'}, {'returned': 'O'}, {'to': 'O'}, {'normal.': 'O'}]"
"Medium term complications (n=164): 16 patients: 9.75%, 95% CI: 5.9-15.6 (pain 7.32%, inflammation 3.66%, sensitivity disorders 3.05%, granuloma 1.22%,).","[{'Medium': 'O'}, {'term': 'O'}, {'complications': 'O'}, {'(n=164):': 'O'}, {'16': 'O'}, {'patients:': 'O'}, {'9.75%,': 'O'}, {'95%': 'O'}, {'CI:': 'O'}, {'5.9-15.6': 'O'}, {'(pain': 'O'}, {'7.32%,': 'O'}, {'inflammation': 'I-Entity'}, {'3.66%,': 'O'}, {'sensitivity': 'B-Entity'}, {'disorders': 'I-Entity'}, {'3.05%,': 'O'}, {'granuloma': 'I-Entity'}, {'1.22%,).': 'O'}]"
"The histopathologic findings of the 60 patients showed that 37 (61.7%) had identifiable types of lacrimal inflammation including 10 with Sjogren's syndrome, seven with sarcoidal reaction, six with feature of granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), five with lymphoma, two with sclerosing inflammation, two with IgG4-related dacryoadenitis, and one patient each with infectious dacryoadenitis, myoepithelial carcinoma, xanthogranuloma, eosinophilic angiocentric fibrosis, and eosinophilic allergic granulomatous nodule.","[{'The': 'O'}, {'histopathologic': 'O'}, {'findings': 'O'}, {'of': 'O'}, {'the': 'O'}, {'60': 'O'}, {'patients': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'37': 'O'}, {'(61.7%)': 'O'}, {'had': 'O'}, {'identifiable': 'O'}, {'types': 'O'}, {'of': 'O'}, {'lacrimal': 'B-Entity'}, {'inflammation': 'I-Entity'}, {'including': 'O'}, {'10': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'seven': 'O'}, {'with': 'O'}, {'sarcoidal': 'B-Entity'}, {'reaction,': 'I-Entity'}, {'six': 'O'}, {'with': 'O'}, {'feature': 'O'}, {'of': 'O'}, {'granulomatosis': 'B-Entity'}, {'with': 'O'}, {'polyangiitis': 'I-Entity'}]"
Twenty-five patients with PSS who underwent renal biopsies from two renal units in Scotland between 1978 and 2013 were identified from renal biopsy database.,"[{'Twenty-five': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'PSS': 'I-Entity'}, {'who': 'O'}, {'underwent': 'O'}, {'renal': 'O'}, {'biopsies': 'O'}, {'from': 'O'}, {'two': 'O'}, {'renal': 'O'}, {'units': 'O'}, {'in': 'O'}, {'Scotland': 'O'}, {'between': 'O'}, {'1978': 'O'}, {'and': 'O'}, {'2013': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'from': 'O'}, {'renal': 'O'}, {'biopsy': 'O'}, {'database.': 'O'}]"
These results remained after 3 different sensitivity analyses.,"[{'These': 'O'}, {'results': 'O'}, {'remained': 'O'}, {'after': 'O'}, {'3': 'O'}, {'different': 'O'}, {'sensitivity': 'O'}, {'analyses.': 'O'}]"
"In recent years, Burn Center has evolved to become a ""wound intensive care unit"" treating disease processes other than those due to thermal injury.","[{'In': 'O'}, {'recent': 'O'}, {'years,': 'O'}, {'Burn': 'O'}, {'Center': 'O'}, {'has': 'O'}, {'evolved': 'O'}, {'to': 'O'}, {'become': 'O'}, {'a': 'O'}, {'""wound': 'O'}, {'intensive': 'O'}, {'care': 'O'}, {'unit""': 'O'}, {'treating': 'O'}, {'disease': 'O'}, {'processes': 'O'}, {'other': 'O'}, {'than': 'O'}, {'those': 'O'}, {'due': 'O'}, {'to': 'O'}, {'thermal': 'B-Entity'}, {'injury.': 'I-Entity'}]"
"Distinct microRNA expression patterns are associated with salivary gland inflammation and dysfunction in patients with SS, and microRNA represent a novel group of potential biomarkers.20892, USA.cirrhosis overlap syndrome and Sjogren syndrome: A case report.","[{'Distinct': 'O'}, {'microRNA': 'O'}, {'expression': 'O'}, {'patterns': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'dysfunction': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'microRNA': 'O'}, {'represent': 'O'}, {'a': 'O'}, {'novel': 'O'}, {'group': 'O'}, {'of': 'O'}, {'potential': 'O'}, {'biomarkers.20892,': 'O'}, {'USA.cirrhosis': 'O'}, {'overlap': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'Sjogren': 'I-Entity'}, {'syndrome:': 'I-Entity'}, {'A': 'O'}, {'case': 'O'}, {'report.': 'O'}]"
"Accordingly, Sema5A stimulation caused significant up-regulation of T-bet and retinoic acid receptor-related orphan nuclear receptor ‚âà√≠‚Äö√¢‚Ä¢t levels in T cells.","[{'Accordingly,': 'O'}, {'Sema5A': 'I-Entity'}, {'stimulation': 'O'}, {'caused': 'O'}, {'significant': 'O'}, {'up-regulation': 'O'}, {'of': 'O'}, {'T-bet': 'O'}, {'and': 'O'}, {'retinoic': 'B-Entity'}, {'acid': 'I-Entity'}, {'receptor-related': 'O'}, {'orphan': 'O'}, {'nuclear': 'O'}, {'receptor': 'O'}, {'‚âà√≠‚Äö√¢‚Ä¢t': 'O'}, {'levels': 'O'}, {'in': 'O'}, {'T': 'O'}, {'cells.': 'O'}]"
The diagnosis relies on renal biopsy findings of haphazardly arranged fibrils in all glomerular compartments and distinction from other forms of fibrillary glomerulopathies such as renal amyloidosis and immunotactoid glomerulopathy.,"[{'The': 'O'}, {'diagnosis': 'O'}, {'relies': 'O'}, {'on': 'O'}, {'renal': 'O'}, {'biopsy': 'O'}, {'findings': 'O'}, {'of': 'O'}, {'haphazardly': 'O'}, {'arranged': 'O'}, {'fibrils': 'O'}, {'in': 'O'}, {'all': 'O'}, {'glomerular': 'O'}, {'compartments': 'O'}, {'and': 'O'}, {'distinction': 'O'}, {'from': 'O'}, {'other': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'fibrillary': 'B-Entity'}, {'glomerulopathies': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'renal': 'B-Entity'}, {'amyloidosis': 'I-Entity'}, {'and': 'O'}, {'immunotactoid': 'B-Entity'}, {'glomerulopathy.': 'I-Entity'}]"
"In primary SS, functional impairment was significantly associated with physical fatigue (P < 0.0001, R(2) = 0.3), pain (P < 0.0001, R(2) = 0.3), depression (P < 0.0001, R(2) = 0.3), total symptom burden (P < 0.0001, R(2) = 0.3), systemic disease activity (P = 0.002, R(2) = 0.15), quality of life (P < 0.0001, R(2) = 0.3), dryness (P = 0.002, R(2) = 0.12), daytime somnolence (P = 0.02, R(2) = 0.08), anxiety score (P = 0.03, R(2) = 0.07), and CRP level (P = 0.04, R(2) = 0.06).","[{'In': 'O'}, {'primary': 'O'}, {'SS,': 'I-Entity'}, {'functional': 'O'}, {'impairment': 'I-Entity'}, {'was': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'physical': 'O'}, {'fatigue': 'I-Entity'}, {'(P': 'O'}, {'<': 'O'}, {'0.0001,': 'O'}, {'R(2)': 'O'}, {'=': 'O'}, {'0.3),': 'O'}, {'pain': 'I-Entity'}, {'(P': 'O'}, {'<': 'O'}, {'0.0001,': 'O'}, {'R(2)': 'O'}, {'=': 'O'}, {'0.3),': 'O'}, {'depression': 'I-Entity'}, {'(P': 'O'}, {'<': 'O'}, {'0.0001,': 'O'}, {'R(2)': 'O'}]"
"Depending on the underlying disease, various thoracic compartments can be involved but interstitial lung disease is a major contributor to morbidity and mortality.","[{'Depending': 'O'}, {'on': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'disease,': 'O'}, {'various': 'O'}, {'thoracic': 'O'}, {'compartments': 'O'}, {'can': 'O'}, {'be': 'O'}, {'involved': 'O'}, {'but': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'major': 'O'}, {'contributor': 'O'}, {'to': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality.': 'O'}]"
"Therefore, biomarkers that have both high sensitivity and high specificity for diagnosis, reflect disease activity and predict drug response are necessary.","[{'Therefore,': 'O'}, {'biomarkers': 'O'}, {'that': 'O'}, {'have': 'O'}, {'both': 'O'}, {'high': 'O'}, {'sensitivity': 'O'}, {'and': 'O'}, {'high': 'O'}, {'specificity': 'O'}, {'for': 'O'}, {'diagnosis,': 'O'}, {'reflect': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'predict': 'O'}, {'drug': 'O'}, {'response': 'O'}, {'are': 'O'}, {'necessary.': 'O'}]"
The use of composite measures might increase our ability to diagnose and evaluate disease activity and cumulative irreversible organ injury in this disease.,"[{'The': 'O'}, {'use': 'O'}, {'of': 'O'}, {'composite': 'O'}, {'measures': 'O'}, {'might': 'O'}, {'increase': 'O'}, {'our': 'O'}, {'ability': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'and': 'O'}, {'evaluate': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'cumulative': 'O'}, {'irreversible': 'O'}, {'organ': 'B-Entity'}, {'injury': 'I-Entity'}, {'in': 'O'}, {'this': 'O'}, {'disease.': 'O'}]"
Plaque formation and high IMT levels were detected by ultrasound in 41(69.5%) out of the 59 pSS patients.,"[{'Plaque': 'I-Entity'}, {'formation': 'O'}, {'and': 'O'}, {'high': 'O'}, {'IMT': 'O'}, {'levels': 'O'}, {'were': 'O'}, {'detected': 'O'}, {'by': 'O'}, {'ultrasound': 'O'}, {'in': 'O'}, {'41(69.5%)': 'O'}, {'out': 'O'}, {'of': 'O'}, {'the': 'O'}, {'59': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"These cases led to the question of whether there are other such cases, and thus, an exhaustive literature search was conducted.","[{'These': 'O'}, {'cases': 'O'}, {'led': 'O'}, {'to': 'O'}, {'the': 'O'}, {'question': 'O'}, {'of': 'O'}, {'whether': 'O'}, {'there': 'O'}, {'are': 'O'}, {'other': 'O'}, {'such': 'O'}, {'cases,': 'O'}, {'and': 'O'}, {'thus,': 'O'}, {'an': 'O'}, {'exhaustive': 'O'}, {'literature': 'O'}, {'search': 'O'}, {'was': 'O'}, {'conducted.': 'O'}]"
"In this study, our aim is to determine if there is any differences in AS and left ventricular function between patients diagnosed as SS and healthy control groups.","[{'In': 'O'}, {'this': 'O'}, {'study,': 'O'}, {'our': 'O'}, {'aim': 'O'}, {'is': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'if': 'O'}, {'there': 'O'}, {'is': 'O'}, {'any': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'AS': 'I-Entity'}, {'and': 'O'}, {'left': 'O'}, {'ventricular': 'O'}, {'function': 'O'}, {'between': 'O'}, {'patients': 'O'}, {'diagnosed': 'O'}, {'as': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'healthy': 'O'}, {'control': 'O'}, {'groups.': 'O'}]"
"First, it must be demonstrated that a potential IgG4-RD case has involvement of at least one of 11 possible organs in a manner consistent with IgG4-RD.","[{'First,': 'O'}, {'it': 'O'}, {'must': 'O'}, {'be': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'a': 'O'}, {'potential': 'O'}, {'IgG4-RD': 'B-Entity'}, {'case': 'O'}, {'has': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'at': 'O'}, {'least': 'O'}, {'one': 'O'}, {'of': 'O'}, {'11': 'O'}, {'possible': 'O'}, {'organs': 'O'}, {'in': 'O'}, {'a': 'O'}, {'manner': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'IgG4-RD.': 'B-Entity'}]"
The mean ages were 60.7 years in RA cases and 64.6 years in non-RA controls.,"[{'The': 'O'}, {'mean': 'O'}, {'ages': 'O'}, {'were': 'O'}, {'60.7': 'O'}, {'years': 'O'}, {'in': 'O'}, {'RA': 'I-Entity'}, {'cases': 'O'}, {'and': 'O'}, {'64.6': 'O'}, {'years': 'O'}, {'in': 'O'}, {'non-RA': 'O'}, {'controls.': 'O'}]"
Serum and urine calcium concentration should be measured in addition to routine laboratory test.epub@benthamscience.net.Shanghai.,"[{'Serum': 'O'}, {'and': 'O'}, {'urine': 'O'}, {'calcium': 'I-Entity'}, {'concentration': 'O'}, {'should': 'O'}, {'be': 'O'}, {'measured': 'O'}, {'in': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'routine': 'O'}, {'laboratory': 'O'}, {'test.epub@benthamscience.net.Shanghai.': 'O'}]"
"Thus, localized anti-IL17 therapy may be effective in preventing glandular dysfunction.Nguyen@pathology.ufl.edubut only inefficiently promotes ectopic B-cell differentiation.","[{'Thus,': 'O'}, {'localized': 'O'}, {'anti-IL17': 'O'}, {'therapy': 'O'}, {'may': 'O'}, {'be': 'O'}, {'effective': 'O'}, {'in': 'O'}, {'preventing': 'O'}, {'glandular': 'B-Entity'}, {'dysfunction.Nguyen@pathology.ufl.edubut': 'I-Entity'}, {'only': 'O'}, {'inefficiently': 'O'}, {'promotes': 'O'}, {'ectopic': 'O'}, {'B-cell': 'O'}, {'differentiation.': 'O'}]"
"In multivariate analysis, sensorimotor neuropathy was associated with the presence of B-NHL (odds ratio [OR], 39.0; p < 0.001), whereas nonataxic sensory neuropathy was associated with the presence of CNS involvement (OR, 17.0; p = 0.025) and ANA (OR, 0.07; p < 0.001).","[{'In': 'O'}, {'multivariate': 'O'}, {'analysis,': 'O'}, {'sensorimotor': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'B-NHL': 'B-Entity'}, {'(odds': 'O'}, {'ratio': 'O'}, {'[OR],': 'O'}, {'39.0;': 'O'}, {'p': 'O'}, {'<': 'O'}, {'0.001),': 'O'}, {'whereas': 'O'}, {'nonataxic': 'O'}, {'sensory': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'CNS': 'O'}, {'involvement': 'O'}, {'(OR,': 'O'}, {'17.0;': 'O'}]"
"The diagnosis of bronchiolitis should be suspected in any atypical form of asthma, or recurrent ""bronchitis"", and it is essential to look for extrarespiratory symptoms and auto-antibodies to establish the diagnose of systemic disease.","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'bronchiolitis': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'suspected': 'O'}, {'in': 'O'}, {'any': 'O'}, {'atypical': 'O'}, {'form': 'O'}, {'of': 'O'}, {'asthma,': 'I-Entity'}, {'or': 'O'}, {'recurrent': 'O'}, {'""bronchitis"",': 'O'}, {'and': 'O'}, {'it': 'O'}, {'is': 'O'}, {'essential': 'O'}, {'to': 'O'}, {'look': 'O'}, {'for': 'O'}, {'extrarespiratory': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'auto-antibodies': 'O'}, {'to': 'O'}, {'establish': 'O'}, {'the': 'O'}, {'diagnose': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'disease.': 'O'}]"
"Among the 30 patients recruited, 28 were evaluated at week 28 as already reported.","[{'Among': 'O'}, {'the': 'O'}, {'30': 'O'}, {'patients': 'O'}, {'recruited,': 'O'}, {'28': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'at': 'O'}, {'week': 'O'}, {'28': 'O'}, {'as': 'O'}, {'already': 'O'}, {'reported.': 'O'}]"
"On the basis of the renal biopsy showing nonspecific chronic interstitial nephritis, renal tubular atrophy, and interstitial enlargement, tubulointerstitial nephritis associated with SS was diagnosed.Japan.","[{'On': 'O'}, {'the': 'O'}, {'basis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'renal': 'O'}, {'biopsy': 'O'}, {'showing': 'O'}, {'nonspecific': 'O'}, {'chronic': 'O'}, {'interstitial': 'B-Entity'}, {'nephritis,': 'I-Entity'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'atrophy,': 'I-Entity'}, {'and': 'O'}, {'interstitial': 'B-Entity'}, {'enlargement,': 'I-Entity'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'was': 'O'}, {'diagnosed.Japan.': 'O'}]"
"Antibodies to EBV (anti-VCA IgG/IgM, anti-EBNA-1 IgG, anti-EA-D IgG) were determined by ELISA.","[{'Antibodies': 'O'}, {'to': 'O'}, {'EBV': 'O'}, {'(anti-VCA': 'O'}, {'IgG/IgM,': 'O'}, {'anti-EBNA-1': 'O'}, {'IgG,': 'O'}, {'anti-EA-D': 'O'}, {'IgG)': 'O'}, {'were': 'O'}, {'determined': 'O'}, {'by': 'O'}, {'ELISA.': 'O'}]"
The main clinical manifestation is renal tubular acidosis.,"[{'The': 'O'}, {'main': 'O'}, {'clinical': 'O'}, {'manifestation': 'O'}, {'is': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis.': 'I-Entity'}]"
An unexpected finding was that higher tear osmolarity was associated with lower symptom severity.,"[{'An': 'O'}, {'unexpected': 'O'}, {'finding': 'O'}, {'was': 'O'}, {'that': 'O'}, {'higher': 'O'}, {'tear': 'O'}, {'osmolarity': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'lower': 'O'}, {'symptom': 'O'}, {'severity.': 'O'}]"
An association of non-length-dependent pattern and dysautonomia seems to predict the absence of LFN in SS and encourages the search for SFN.,"[{'An': 'O'}, {'association': 'O'}, {'of': 'O'}, {'non-length-dependent': 'O'}, {'pattern': 'O'}, {'and': 'O'}, {'dysautonomia': 'I-Entity'}, {'seems': 'O'}, {'to': 'O'}, {'predict': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'LFN': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'encourages': 'O'}, {'the': 'O'}, {'search': 'O'}, {'for': 'O'}, {'SFN.': 'I-Entity'}]"
"We speculate that increased (18)F-fluorodeoxyglucose uptake with cholesterol granuloma occurs through cellular infiltration and macrophage proliferation, resulting in the activation of glycolysis-like tuberculosis.of Medical Science, Otsu, Shiga, Japan.experience.","[{'We': 'O'}, {'speculate': 'O'}, {'that': 'O'}, {'increased': 'O'}, {'(18)F-fluorodeoxyglucose': 'O'}, {'uptake': 'O'}, {'with': 'O'}, {'cholesterol': 'I-Entity'}, {'granuloma': 'O'}, {'occurs': 'O'}, {'through': 'O'}, {'cellular': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'macrophage': 'O'}, {'proliferation,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'the': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'glycolysis-like': 'O'}, {'tuberculosis.of': 'O'}, {'Medical': 'O'}, {'Science,': 'O'}, {'Otsu,': 'O'}]"
IN Cryoglobulinemia and SSA/SSB positivity are associated with systemic activity after diagnosis in pSS.,"[{'IN': 'B-Entity'}, {'Cryoglobulinemia': 'I-Entity'}, {'and': 'O'}, {'SSA/SSB': 'O'}, {'positivity': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'activity': 'O'}, {'after': 'O'}, {'diagnosis': 'O'}, {'in': 'O'}, {'pSS.': 'O'}]"
All participants stated that an ideal medication would address the cause of pSS and not just treat symptoms.,"[{'All': 'O'}, {'participants': 'O'}, {'stated': 'O'}, {'that': 'O'}, {'an': 'O'}, {'ideal': 'O'}, {'medication': 'O'}, {'would': 'O'}, {'address': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'not': 'O'}, {'just': 'O'}, {'treat': 'O'}, {'symptoms.': 'O'}]"
This retrospective study included 38 dry eye patients (11 with SS and 27 with non-SS) who were treated with 3% diquafosol due to lack of response to artificial tear treatment for more than 3 months.,"[{'This': 'O'}, {'retrospective': 'O'}, {'study': 'O'}, {'included': 'O'}, {'38': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients': 'O'}, {'(11': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'27': 'O'}, {'with': 'O'}, {'non-SS)': 'O'}, {'who': 'O'}, {'were': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'3%': 'O'}, {'diquafosol': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'response': 'O'}, {'to': 'O'}, {'artificial': 'O'}, {'tear': 'O'}, {'treatment': 'O'}, {'for': 'O'}, {'more': 'O'}, {'than': 'O'}, {'3': 'O'}, {'months.': 'O'}]"
Fistulas between systemic and pulmonary arteries are associated with various underlying etiologies and cause pulmonary hypertension (PH).,"[{'Fistulas': 'O'}, {'between': 'O'}, {'systemic': 'O'}, {'and': 'O'}, {'pulmonary': 'O'}, {'arteries': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'various': 'O'}, {'underlying': 'O'}, {'etiologies': 'O'}, {'and': 'O'}, {'cause': 'O'}, {'pulmonary': 'B-Entity'}, {'hypertension': 'I-Entity'}, {'(PH).': 'O'}]"
The most common sources of error are false-negative results due to loss of cryoprecipitate during transport and storage.,"[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'sources': 'O'}, {'of': 'O'}, {'error': 'O'}, {'are': 'O'}, {'false-negative': 'O'}, {'results': 'O'}, {'due': 'O'}, {'to': 'O'}, {'loss': 'O'}, {'of': 'O'}, {'cryoprecipitate': 'O'}, {'during': 'O'}, {'transport': 'O'}, {'and': 'O'}, {'storage.': 'O'}]"
"Magnetic resonance image features of heterogeneity and smaller volume in the submandibular gland are reliable for predicting hyposalivation related to the progression of Sjogrens syndrome.reserved.Sendai, Japan.Sendai, Japan.Sendai, Japan.Sendai, Japan.Sendai, Japan.Sendai, Japan.review.","[{'Magnetic': 'O'}, {'resonance': 'O'}, {'image': 'O'}, {'features': 'O'}, {'of': 'O'}, {'heterogeneity': 'O'}, {'and': 'O'}, {'smaller': 'O'}, {'volume': 'O'}, {'in': 'O'}, {'the': 'O'}, {'submandibular': 'O'}, {'gland': 'O'}, {'are': 'O'}, {'reliable': 'O'}, {'for': 'O'}, {'predicting': 'O'}, {'hyposalivation': 'I-Entity'}, {'related': 'O'}, {'to': 'O'}, {'the': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.reserved.Sendai,': 'I-Entity'}, {'Japan.Sendai,': 'O'}, {'Japan.Sendai,': 'O'}, {'Japan.Sendai,': 'O'}]"
"A 37-year-old woman was admitted with complaints of dry mouth, dry eyes, and progressive muscle weakness for 17 months.","[{'A': 'O'}, {'37-year-old': 'O'}, {'woman': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'with': 'O'}, {'complaints': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'dry': 'B-Entity'}, {'eyes,': 'I-Entity'}, {'and': 'O'}, {'progressive': 'O'}, {'muscle': 'B-Entity'}, {'weakness': 'I-Entity'}, {'for': 'O'}, {'17': 'O'}, {'months.': 'O'}]"
"Importantly, the decrease in circulating TFH cells was associated with lower systemic disease activity over time, as measured by the European League Against Rheumatism Sjogrens Syndrome Disease Activity Index scores and serum IgG levels.","[{'Importantly,': 'O'}, {'the': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'circulating': 'O'}, {'TFH': 'O'}, {'cells': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'lower': 'O'}, {'systemic': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'over': 'O'}, {'time,': 'O'}, {'as': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'the': 'O'}, {'European': 'O'}, {'League': 'O'}, {'Against': 'I-Entity'}, {'Rheumatism': 'I-Entity'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'scores': 'O'}, {'and': 'O'}, {'serum': 'O'}, {'IgG': 'O'}, {'levels.': 'O'}]"
Optic neuritis is a common feature of inflammatory diseases of the central nervous system such as multiple sclerosis and neuromyelitis optica.,"[{'Optic': 'B-Entity'}, {'neuritis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'feature': 'O'}, {'of': 'O'}, {'inflammatory': 'B-Entity'}, {'diseases': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'and': 'O'}, {'neuromyelitis': 'B-Entity'}, {'optica.': 'I-Entity'}]"
"However, not negligible doses of ionizing radiation limit the use of HRCT, especially for serial follow-up in younger female patients.","[{'However,': 'O'}, {'not': 'O'}, {'negligible': 'O'}, {'doses': 'O'}, {'of': 'O'}, {'ionizing': 'O'}, {'radiation': 'O'}, {'limit': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'HRCT,': 'O'}, {'especially': 'O'}, {'for': 'O'}, {'serial': 'O'}, {'follow-up': 'O'}, {'in': 'O'}, {'younger': 'O'}, {'female': 'O'}, {'patients.': 'O'}]"
The incidence and severity of sialoadenitis was significantly higher in the alum-treated mice.,"[{'The': 'O'}, {'incidence': 'O'}, {'and': 'O'}, {'severity': 'O'}, {'of': 'O'}, {'sialoadenitis': 'I-Entity'}, {'was': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'the': 'O'}, {'alum-treated': 'I-Entity'}, {'mice.': 'O'}]"
"In contrast, a greater variety of yeast species was identified on samples of the control group.","[{'In': 'O'}, {'contrast,': 'O'}, {'a': 'O'}, {'greater': 'O'}, {'variety': 'O'}, {'of': 'O'}, {'yeast': 'O'}, {'species': 'O'}, {'was': 'O'}, {'identified': 'O'}, {'on': 'O'}, {'samples': 'O'}, {'of': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group.': 'O'}]"
"In pSS, the pattern of joint involvement by US is polyarticular, bilateral, and symmetrical.","[{'In': 'O'}, {'pSS,': 'O'}, {'the': 'O'}, {'pattern': 'O'}, {'of': 'O'}, {'joint': 'O'}, {'involvement': 'O'}, {'by': 'O'}, {'US': 'O'}, {'is': 'O'}, {'polyarticular,': 'O'}, {'bilateral,': 'O'}, {'and': 'O'}, {'symmetrical.': 'O'}]"
"Primary Sjogren syndrome (pSS) is a common autoimmune condition which primarily affects epithelial tissue, often including the kidney causing either tubulointerstitial nephritis (TIN) or more rarely, an immune complex related glomerulonephritis.","[{'Primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'autoimmune': 'O'}, {'condition': 'O'}, {'which': 'O'}, {'primarily': 'O'}, {'affects': 'O'}, {'epithelial': 'O'}, {'tissue,': 'O'}, {'often': 'O'}, {'including': 'O'}, {'the': 'O'}, {'kidney': 'O'}, {'causing': 'O'}, {'either': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'(TIN)': 'O'}, {'or': 'O'}, {'more': 'O'}, {'rarely,': 'O'}, {'an': 'O'}, {'immune': 'O'}, {'complex': 'O'}, {'related': 'O'}, {'glomerulonephritis.': 'I-Entity'}]"
"During a median follow-up of 9.5¬¨¬®‚Äö√Ñ‚Ä†years, the overall hazard ratio (HR) was 1.6 (95% CI 1.2-2.1) for myocardial infarction, 1.2 (95% CI 0.9-1.7) for cerebral infarction and 2.1 (95% CI 1.6-2.9) for venous thromboembolism.","[{'During': 'O'}, {'a': 'O'}, {'median': 'O'}, {'follow-up': 'O'}, {'of': 'O'}, {'9.5¬¨¬®‚Äö√Ñ‚Ä†years,': 'O'}, {'the': 'O'}, {'overall': 'O'}, {'hazard': 'O'}, {'ratio': 'O'}, {'(HR)': 'O'}, {'was': 'O'}, {'1.6': 'O'}, {'(95%': 'O'}, {'CI': 'O'}, {'1.2-2.1)': 'O'}, {'for': 'O'}, {'myocardial': 'B-Entity'}, {'infarction,': 'I-Entity'}, {'1.2': 'O'}, {'(95%': 'O'}]"
"Pediatric patients with SS report fewer sicca symptoms; therefore, many are under-diagnosed and cannot access appropriate medical management.","[{'Pediatric': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'report': 'O'}, {'fewer': 'O'}, {'sicca': 'I-Entity'}, {'symptoms;': 'O'}, {'therefore,': 'O'}, {'many': 'O'}, {'are': 'O'}, {'under-diagnosed': 'O'}, {'and': 'O'}, {'cannot': 'O'}, {'access': 'O'}, {'appropriate': 'O'}, {'medical': 'O'}, {'management.': 'O'}]"
"The most current etiology is multiple sclerosis (MS) but, when MRI and Cerebrospinal fluid (CSF) analyses are normal, ON is usually considered as ""idiopathic"" with a suspected viral etiology.","[{'The': 'O'}, {'most': 'O'}, {'current': 'O'}, {'etiology': 'O'}, {'is': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(MS)': 'O'}, {'but,': 'O'}, {'when': 'O'}, {'MRI': 'O'}, {'and': 'O'}, {'Cerebrospinal': 'O'}, {'fluid': 'O'}, {'(CSF)': 'O'}, {'analyses': 'O'}, {'are': 'O'}, {'normal,': 'O'}, {'ON': 'I-Entity'}, {'is': 'O'}, {'usually': 'O'}, {'considered': 'O'}, {'as': 'O'}, {'""idiopathic""': 'O'}, {'with': 'O'}, {'a': 'O'}, {'suspected': 'O'}, {'viral': 'O'}, {'etiology.': 'O'}]"
IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ.,"[{'IgG4-related': 'B-Entity'}, {'disease': 'I-Entity'}, {'(IgG4-RD)': 'O'}, {'can': 'O'}, {'cause': 'O'}, {'fibroinflammatory': 'B-Entity'}, {'lesions': 'O'}, {'in': 'O'}, {'nearly': 'O'}, {'any': 'O'}, {'organ.': 'O'}]"
"This review discusses the utility of biologic therapies in PSS, potential challenges for their use, the available data on rituximab and the potential role for other biologic therapies currently in development, or in clinical trials, in other autoimmune conditions.6JD, UK.","[{'This': 'O'}, {'review': 'O'}, {'discusses': 'O'}, {'the': 'O'}, {'utility': 'O'}, {'of': 'O'}, {'biologic': 'O'}, {'therapies': 'O'}, {'in': 'O'}, {'PSS,': 'I-Entity'}, {'potential': 'O'}, {'challenges': 'O'}, {'for': 'O'}, {'their': 'O'}, {'use,': 'O'}, {'the': 'O'}, {'available': 'O'}, {'data': 'O'}, {'on': 'O'}, {'rituximab': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'role': 'O'}, {'for': 'O'}, {'other': 'O'}, {'biologic': 'O'}, {'therapies': 'O'}, {'currently': 'O'}, {'in': 'O'}, {'development,': 'O'}, {'or': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'trials,': 'O'}, {'in': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'conditions.6JD,': 'O'}]"
"This is even more true in the case of patients who are positive for antinuclear antibodies (ANAs) because, although sensitive, ANA positivity is not specific for SLE or connective tissue diseases, and can also be found in 10-15% of FM patients.","[{'This': 'O'}, {'is': 'O'}, {'even': 'O'}, {'more': 'O'}, {'true': 'O'}, {'in': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'are': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'(ANAs)': 'O'}, {'because,': 'O'}, {'although': 'O'}, {'sensitive,': 'O'}, {'ANA': 'O'}, {'positivity': 'O'}, {'is': 'O'}, {'not': 'O'}, {'specific': 'O'}, {'for': 'O'}, {'SLE': 'I-Entity'}, {'or': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'and': 'O'}, {'can': 'O'}, {'also': 'O'}, {'be': 'O'}, {'found': 'O'}, {'in': 'O'}, {'10-15%': 'O'}, {'of': 'O'}, {'FM': 'I-Entity'}, {'patients.': 'O'}]"
"However, the ESSDAI seemed to detect changes in activity more accurately than other disease activity indexes.","[{'However,': 'O'}, {'the': 'O'}, {'ESSDAI': 'O'}, {'seemed': 'O'}, {'to': 'O'}, {'detect': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'activity': 'O'}, {'more': 'O'}, {'accurately': 'O'}, {'than': 'O'}, {'other': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'indexes.': 'O'}]"
"Studied variables were neurological findings, associated autoimmune diseases, biological profiles, nerve conduction and sensory/motor amplitudes study, treatments received, and outcomes.","[{'Studied': 'O'}, {'variables': 'O'}, {'were': 'O'}, {'neurological': 'O'}, {'findings,': 'O'}, {'associated': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'biological': 'O'}, {'profiles,': 'O'}, {'nerve': 'O'}, {'conduction': 'O'}, {'and': 'O'}, {'sensory/motor': 'O'}, {'amplitudes': 'O'}, {'study,': 'O'}, {'treatments': 'O'}, {'received,': 'O'}, {'and': 'O'}, {'outcomes.': 'O'}]"
"The reactivity of antibodies expressed by CD19+CD10-CD27-IgM+CD21(-/low) cells isolated from the blood of patients with SS was tested using a¬¨¬®‚Äö√Ñ‚Ä†polymerase chain reaction-based approach that allows us to clone and express, in vitro, recombinant antibodies produced by single B cells.","[{'The': 'O'}, {'reactivity': 'O'}, {'of': 'O'}, {'antibodies': 'O'}, {'expressed': 'O'}, {'by': 'O'}, {'CD19+CD10-CD27-IgM+CD21(-/low)': 'O'}, {'cells': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {'the': 'O'}, {'blood': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'was': 'O'}, {'tested': 'O'}, {'using': 'O'}, {'a¬¨¬®‚Äö√Ñ‚Ä†polymerase': 'O'}, {'chain': 'O'}, {'reaction-based': 'O'}, {'approach': 'O'}, {'that': 'O'}, {'allows': 'O'}, {'us': 'O'}]"
"Primary Sjogrens syndrome (pSS) is an autoimmune disease characterized by inflammation in exocrine glands, resulting in reduced secretion of tears and saliva, manifesting as xerophthalmia and xerostomia, respectively.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'reduced': 'O'}, {'secretion': 'O'}, {'of': 'O'}, {'tears': 'O'}, {'and': 'O'}, {'saliva,': 'O'}, {'manifesting': 'O'}, {'as': 'O'}, {'xerophthalmia': 'I-Entity'}, {'and': 'O'}, {'xerostomia,': 'I-Entity'}, {'respectively.': 'O'}]"
"However, no studies have specifically evaluated the association between irregular menstrual cycles and pSS.","[{'However,': 'O'}, {'no': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'specifically': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'association': 'O'}, {'between': 'O'}, {'irregular': 'O'}, {'menstrual': 'I-Entity'}, {'cycles': 'O'}, {'and': 'O'}, {'pSS.': 'O'}]"
"At present, sialendoscopic surgery have limitation in the treatment of Stensen's duct stenosis and may similarly have limitation in the treatment of Sjogrens syndrome and recurrent parotitis.Shinjuku-ku, Tokyo 162-8666, Japan.","[{'At': 'O'}, {'present,': 'O'}, {'sialendoscopic': 'O'}, {'surgery': 'O'}, {'have': 'O'}, {'limitation': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {""Stensen's"": 'B-Entity'}, {'duct': 'I-Entity'}, {'stenosis': 'I-Entity'}, {'and': 'O'}, {'may': 'O'}, {'similarly': 'O'}, {'have': 'O'}, {'limitation': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'recurrent': 'O'}, {'parotitis.Shinjuku-ku,': 'I-Entity'}, {'Tokyo': 'O'}, {'162-8666,': 'O'}, {'Japan.': 'O'}]"
"The number of patients with Sjogren's syndrome, thyroid disease, autoimmune hepatitis, and idiopathic thrombocytopenia were 4, 1, 1, and 1, respectively.","[{'The': 'O'}, {'number': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'thyroid': 'B-Entity'}, {'disease,': 'I-Entity'}, {'autoimmune': 'B-Entity'}, {'hepatitis,': 'I-Entity'}, {'and': 'O'}, {'idiopathic': 'B-Entity'}, {'thrombocytopenia': 'I-Entity'}, {'were': 'O'}, {'4,': 'O'}, {'1,': 'O'}, {'1,': 'O'}, {'and': 'O'}, {'1,': 'O'}, {'respectively.': 'O'}]"
Experts identified 12 organ-specific 'domains' contributing to disease activity.,"[{'Experts': 'O'}, {'identified': 'O'}, {'12': 'O'}, {'organ-specific': 'O'}, {""'domains'"": 'O'}, {'contributing': 'O'}, {'to': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
"Rapamycin or PEG-DSPE eye drops (vehicle) were administered in a well-established Sjogrens syndrome disease model, the male nonobese diabetic (NOD) mice, twice daily for 12 weeks starting at 8 weeks of age.","[{'Rapamycin': 'I-Entity'}, {'or': 'O'}, {'PEG-DSPE': 'O'}, {'eye': 'O'}, {'drops': 'O'}, {'(vehicle)': 'O'}, {'were': 'O'}, {'administered': 'O'}, {'in': 'O'}, {'a': 'O'}, {'well-established': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'disease': 'I-Entity'}, {'model,': 'O'}, {'the': 'O'}, {'male': 'O'}, {'nonobese': 'O'}, {'diabetic': 'I-Entity'}, {'(NOD)': 'O'}, {'mice,': 'O'}, {'twice': 'O'}, {'daily': 'O'}, {'for': 'O'}, {'12': 'O'}, {'weeks': 'O'}, {'starting': 'O'}, {'at': 'O'}, {'8': 'O'}, {'weeks': 'O'}, {'of': 'O'}, {'age.': 'O'}]"
"In view of the high costs of the therapy, intravenous immunoglobulins are mostly applied in emergency situations, as salvage therapy when other standard therapies have failed or when severe infections are a¬¨¬®‚Äö√Ñ‚Ä†contraindication to the administration of immunosuppressants.Carl-Neuberg-Str.¬¨¬®‚Äö√Ñ‚Ä†1, 30625, Hannover, Deutschland.","[{'In': 'O'}, {'view': 'O'}, {'of': 'O'}, {'the': 'O'}, {'high': 'O'}, {'costs': 'O'}, {'of': 'O'}, {'the': 'O'}, {'therapy,': 'O'}, {'intravenous': 'O'}, {'immunoglobulins': 'O'}, {'are': 'O'}, {'mostly': 'O'}, {'applied': 'O'}, {'in': 'O'}, {'emergency': 'O'}, {'situations,': 'O'}, {'as': 'O'}, {'salvage': 'O'}, {'therapy': 'O'}, {'when': 'O'}, {'other': 'O'}, {'standard': 'O'}, {'therapies': 'O'}, {'have': 'O'}, {'failed': 'O'}, {'or': 'O'}, {'when': 'O'}, {'severe': 'O'}, {'infections': 'I-Entity'}, {'are': 'O'}, {'a¬¨¬®‚Äö√Ñ‚Ä†contraindication': 'O'}]"
"On physical examination, she had dry eye and mouth, but was otherwise normal.","[{'On': 'O'}, {'physical': 'O'}, {'examination,': 'O'}, {'she': 'O'}, {'had': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth,': 'I-Entity'}, {'but': 'O'}, {'was': 'O'}, {'otherwise': 'O'}, {'normal.': 'O'}]"
"It is very likely therefore, that we will soon have efficient therapies, which will be able to stop the disease progression in an early stage of pSS.Firmen Abbvie, Biogen, BMS, Celgene, Chugai, GSK, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi und UCB erhalten hat.2018 Dec 3.","[{'It': 'O'}, {'is': 'O'}, {'very': 'O'}, {'likely': 'O'}, {'therefore,': 'O'}, {'that': 'O'}, {'we': 'O'}, {'will': 'O'}, {'soon': 'O'}, {'have': 'O'}, {'efficient': 'O'}, {'therapies,': 'O'}, {'which': 'O'}, {'will': 'O'}, {'be': 'O'}, {'able': 'O'}, {'to': 'O'}, {'stop': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'progression': 'O'}, {'in': 'O'}, {'an': 'O'}, {'early': 'O'}, {'stage': 'O'}, {'of': 'O'}, {'pSS.Firmen': 'I-Entity'}, {'Abbvie,': 'O'}, {'Biogen,': 'O'}, {'BMS,': 'O'}, {'Celgene,': 'O'}, {'Chugai,': 'O'}, {'GSK,': 'O'}, {'Janssen,': 'O'}, {'Lilly,': 'O'}]"
"The purpose of this study was to examine the relationship between tear osmolarity, the Schirmer test I, and dry eye symptoms in SS.","[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'examine': 'O'}, {'the': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'tear': 'O'}, {'osmolarity,': 'O'}, {'the': 'O'}, {'Schirmer': 'O'}, {'test': 'O'}, {'I,': 'O'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'symptoms': 'I-Entity'}, {'in': 'O'}, {'SS.': 'I-Entity'}]"
"To assess whether there are shared exposures associated with Sjogren's syndrome (SS), dry eye syndrome (DES), and B-cell non-Hodgkin lymphoma (B-NHL), in order to determine whether they are etiologically related.","[{'To': 'O'}, {'assess': 'O'}, {'whether': 'O'}, {'there': 'O'}, {'are': 'O'}, {'shared': 'O'}, {'exposures': 'O'}, {'associated': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(DES),': 'O'}, {'and': 'O'}, {'B-cell': 'B-Entity'}, {'non-Hodgkin': 'I-Entity'}, {'lymphoma': 'I-Entity'}, {'(B-NHL),': 'O'}, {'in': 'O'}, {'order': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'they': 'O'}, {'are': 'O'}, {'etiologically': 'O'}, {'related.': 'O'}]"
Prompt recognition of extrahepatic disease can lead to improved patient outcomes and quality of life.,"[{'Prompt': 'O'}, {'recognition': 'O'}, {'of': 'O'}, {'extrahepatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'improved': 'O'}, {'patient': 'O'}, {'outcomes': 'O'}, {'and': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life.': 'O'}]"
"In pSS patients, high FURIN protein levels were significantly associated with elevated IFN-‚âà√≠‚Äö√¢‚Ä¢ levels in the plasma as well as a longer duration of sicca symptoms in the eyes.","[{'In': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'high': 'O'}, {'FURIN': 'O'}, {'protein': 'O'}, {'levels': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'elevated': 'O'}, {'IFN-‚âà√≠‚Äö√¢‚Ä¢': 'O'}, {'levels': 'O'}, {'in': 'O'}, {'the': 'O'}, {'plasma': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'a': 'O'}, {'longer': 'O'}, {'duration': 'O'}, {'of': 'O'}, {'sicca': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'eyes.': 'O'}]"
"Five patients had an indolent course in spite of limited therapeutic intervention while, in the patient who died, the cause of death was related to the spread of the lymphoma and was not due to the pulmonary lesions.","[{'Five': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'an': 'O'}, {'indolent': 'O'}, {'course': 'O'}, {'in': 'O'}, {'spite': 'O'}, {'of': 'O'}, {'limited': 'O'}, {'therapeutic': 'O'}, {'intervention': 'O'}, {'while,': 'O'}, {'in': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'who': 'O'}, {'died,': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'death': 'I-Entity'}, {'was': 'O'}, {'related': 'O'}, {'to': 'O'}, {'the': 'O'}, {'spread': 'O'}, {'of': 'O'}, {'the': 'O'}, {'lymphoma': 'I-Entity'}, {'and': 'O'}, {'was': 'O'}, {'not': 'O'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'pulmonary': 'O'}, {'lesions.': 'O'}]"
"Sjogren syndrome (SS) is one of the most common autoimmune disorders that classically affects exocrine glands, resulting in keratoconjunctivitis sicca and xerostomia, and frequently is associated with other systemic symptoms.","[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders': 'I-Entity'}, {'that': 'O'}, {'classically': 'O'}, {'affects': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'keratoconjunctivitis': 'B-Entity'}, {'sicca': 'I-Entity'}, {'and': 'O'}, {'xerostomia,': 'I-Entity'}, {'and': 'O'}, {'frequently': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'other': 'O'}, {'systemic': 'O'}, {'symptoms.': 'O'}]"
"A positive impact of 30 weeks of HCQ treatment only on uSFRs of SS patients was revealed.Bornova/Izmir, Turkey.10.1016/j.tripleo.2010.02.032.Sjogrens syndrome-related keratopathy: a case report.","[{'A': 'O'}, {'positive': 'O'}, {'impact': 'O'}, {'of': 'O'}, {'30': 'O'}, {'weeks': 'O'}, {'of': 'O'}, {'HCQ': 'I-Entity'}, {'treatment': 'O'}, {'only': 'O'}, {'on': 'O'}, {'uSFRs': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'was': 'O'}, {'revealed.Bornova/Izmir,': 'O'}, {'Turkey.10.1016/j.tripleo.2010.02.032.Sjogrens': 'O'}, {'syndrome-related': 'I-Entity'}, {'keratopathy:': 'I-Entity'}, {'a': 'O'}, {'case': 'O'}]"
"In contrast to SS, the reduced sweating function seen in atopic dermatitis (AD) is restricted only to axon reflex-induced indirect sweating, which is usually restored to normal levels after improvement of the dermatitis.","[{'In': 'O'}, {'contrast': 'O'}, {'to': 'O'}, {'SS,': 'I-Entity'}, {'the': 'O'}, {'reduced': 'O'}, {'sweating': 'O'}, {'function': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'atopic': 'B-Entity'}, {'dermatitis': 'I-Entity'}, {'(AD)': 'O'}, {'is': 'O'}, {'restricted': 'O'}, {'only': 'O'}, {'to': 'O'}, {'axon': 'O'}, {'reflex-induced': 'O'}, {'indirect': 'O'}, {'sweating,': 'O'}, {'which': 'O'}, {'is': 'O'}, {'usually': 'O'}, {'restored': 'O'}, {'to': 'O'}, {'normal': 'O'}, {'levels': 'O'}, {'after': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'the': 'O'}, {'dermatitis.': 'I-Entity'}]"
"Patients with SLE and associated SS treated with epratuzumab showed improvement in SLE disease activity, which was associated with bioactivity, such as decreases in B cell number and IgM level.behalf of American College of Rheumatology.Institut de Biologie Mol‚Äö√†√∂¬¨¬©culaire et Cellulaire, Immunopathologie et Chimie Th‚Äö√†√∂¬¨¬©rapeutique, Laboratory of Excellence MEDALIS, Strasbourg University Hospital, Strasbourg, France.Kremlin-Bic‚Äö√†√∂‚Äö√ë¬¢tre, France.University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.12.patients with certain salivary gland diseases.","[{'Patients': 'O'}, {'with': 'O'}, {'SLE': 'I-Entity'}, {'and': 'O'}, {'associated': 'O'}, {'SS': 'I-Entity'}, {'treated': 'O'}, {'with': 'O'}, {'epratuzumab': 'I-Entity'}, {'showed': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'SLE': 'I-Entity'}, {'disease': 'O'}, {'activity,': 'O'}, {'which': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'bioactivity,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'decreases': 'O'}, {'in': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'number': 'O'}, {'and': 'O'}, {'IgM': 'O'}, {'level.behalf': 'O'}, {'of': 'O'}, {'American': 'O'}, {'College': 'O'}, {'of': 'O'}, {'Rheumatology.Institut': 'O'}, {'de': 'O'}, {'Biologie': 'O'}, {'Mol‚Äö√†√∂¬¨¬©culaire': 'O'}]"
"The development of the EULAR-SS disease activity index represents a step forward in the evaluation of systemic Sjogrens, and three multicenter studies including more than 2500 European patients have confirmed that primary Sjogrens syndrome is, undeniably, a systemic autoimmune disease.","[{'The': 'O'}, {'development': 'O'}, {'of': 'O'}, {'the': 'O'}, {'EULAR-SS': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'index': 'O'}, {'represents': 'O'}, {'a': 'O'}, {'step': 'O'}, {'forward': 'O'}, {'in': 'O'}, {'the': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'Sjogrens,': 'I-Entity'}, {'and': 'O'}, {'three': 'O'}, {'multicenter': 'O'}, {'studies': 'O'}, {'including': 'O'}, {'more': 'O'}, {'than': 'O'}, {'2500': 'O'}, {'European': 'O'}, {'patients': 'O'}, {'have': 'O'}, {'confirmed': 'O'}, {'that': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is,': 'O'}, {'undeniably,': 'O'}, {'a': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"However, B-cell depleting therapy using anti-CD20 antibodies such as rituximab, which is a chimeric mAb, has shown promise in the field, while anti-CD22 mAb seems to be less active.","[{'However,': 'O'}, {'B-cell': 'O'}, {'depleting': 'O'}, {'therapy': 'O'}, {'using': 'O'}, {'anti-CD20': 'O'}, {'antibodies': 'O'}, {'such': 'O'}, {'as': 'O'}, {'rituximab,': 'I-Entity'}, {'which': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chimeric': 'O'}, {'mAb,': 'O'}, {'has': 'O'}, {'shown': 'O'}, {'promise': 'O'}, {'in': 'O'}, {'the': 'O'}, {'field,': 'O'}, {'while': 'O'}, {'anti-CD22': 'O'}, {'mAb': 'O'}, {'seems': 'O'}, {'to': 'O'}, {'be': 'O'}, {'less': 'O'}, {'active.': 'O'}]"
"Here, we report Sjogren syndrome cases showing multifocal nodular AL amyloidosis and the followed benign course.","[{'Here,': 'O'}, {'we': 'O'}, {'report': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'cases': 'O'}, {'showing': 'O'}, {'multifocal': 'O'}, {'nodular': 'O'}, {'AL': 'B-Entity'}, {'amyloidosis': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'followed': 'O'}, {'benign': 'O'}, {'course.': 'O'}]"
"In contrast, myelopathies are the most common cause of increased bladder sensation without DO (25.0-40.0% in spinal forms of systemic lupus erythematosus, Sjogren's syndrome, etc.).","[{'In': 'O'}, {'contrast,': 'O'}, {'myelopathies': 'I-Entity'}, {'are': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'increased': 'B-Entity'}, {'bladder': 'I-Entity'}, {'sensation': 'I-Entity'}, {'without': 'O'}, {'DO': 'I-Entity'}, {'(25.0-40.0%': 'O'}, {'in': 'O'}, {'spinal': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'etc.).': 'O'}]"
Relationships between nerve morphology and tear lacritin were examined by Spearman correlation.,"[{'Relationships': 'O'}, {'between': 'O'}, {'nerve': 'O'}, {'morphology': 'O'}, {'and': 'O'}, {'tear': 'O'}, {'lacritin': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'Spearman': 'O'}, {'correlation.': 'O'}]"
"Prednisone or immunosuppressants are associated with decreased vaccine serological response, whereas hydroxicloroquine seems to improve vaccine immunogenicity.","[{'Prednisone': 'I-Entity'}, {'or': 'O'}, {'immunosuppressants': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'decreased': 'O'}, {'vaccine': 'O'}, {'serological': 'O'}, {'response,': 'O'}, {'whereas': 'O'}, {'hydroxicloroquine': 'I-Entity'}, {'seems': 'O'}, {'to': 'O'}, {'improve': 'O'}, {'vaccine': 'O'}, {'immunogenicity.': 'O'}]"
"Detailed ophthalmologic, neurologic and rheumatologic examination were performed on all participants.","[{'Detailed': 'O'}, {'ophthalmologic,': 'O'}, {'neurologic': 'O'}, {'and': 'O'}, {'rheumatologic': 'I-Entity'}, {'examination': 'O'}, {'were': 'O'}, {'performed': 'O'}, {'on': 'O'}, {'all': 'O'}, {'participants.': 'O'}]"
Methods Forty pSS patients with fluid depletion and distribution obstacles syndrome (FDDOS) were randomly assigned to the experimen- tal group and the control group according to 1:1 proportion.,"[{'Methods': 'O'}, {'Forty': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'fluid': 'B-Entity'}, {'depletion': 'I-Entity'}, {'and': 'O'}, {'distribution': 'B-Entity'}, {'obstacles': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(FDDOS)': 'O'}, {'were': 'O'}, {'randomly': 'O'}, {'assigned': 'O'}, {'to': 'O'}, {'the': 'O'}, {'experimen-': 'O'}, {'tal': 'I-Entity'}, {'group': 'O'}, {'and': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group': 'O'}, {'according': 'O'}, {'to': 'O'}, {'1:1': 'O'}, {'proportion.': 'O'}]"
To evaluate in a cohort of 100 consecutive patients affected by primary Sjogren's syndrome (pSS) the incidence of Hashimoto thyroiditis (HT) and to compare the clinical features and the laboratory parameters of patients affected by pSS with and without concomitant HT.,"[{'To': 'O'}, {'evaluate': 'O'}, {'in': 'O'}, {'a': 'O'}, {'cohort': 'O'}, {'of': 'O'}, {'100': 'O'}, {'consecutive': 'O'}, {'patients': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'Hashimoto': 'B-Entity'}, {'thyroiditis': 'I-Entity'}, {'(HT)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'compare': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'and': 'O'}, {'the': 'O'}, {'laboratory': 'O'}, {'parameters': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'pSS': 'I-Entity'}, {'with': 'O'}, {'and': 'O'}, {'without': 'O'}, {'concomitant': 'O'}, {'HT.': 'I-Entity'}]"
"Among molecules that can be targeted to achieve B-cell depletion, CD20 and CD22 are surface antigens expressed specifically by B lymphocytes; and the cytokine B-cell-activating factor belonging to the TNF family (BAFF) is a TNF receptor ligand involved in B-cell differentiation, survival, and activation.","[{'Among': 'O'}, {'molecules': 'O'}, {'that': 'O'}, {'can': 'O'}, {'be': 'O'}, {'targeted': 'O'}, {'to': 'O'}, {'achieve': 'O'}, {'B-cell': 'O'}, {'depletion,': 'O'}, {'CD20': 'O'}, {'and': 'O'}, {'CD22': 'O'}, {'are': 'O'}, {'surface': 'O'}, {'antigens': 'O'}, {'expressed': 'O'}, {'specifically': 'O'}, {'by': 'O'}, {'B': 'O'}, {'lymphocytes;': 'O'}, {'and': 'O'}, {'the': 'O'}, {'cytokine': 'O'}, {'B-cell-activating': 'O'}, {'factor': 'O'}, {'belonging': 'O'}, {'to': 'O'}, {'the': 'O'}, {'TNF': 'O'}, {'family': 'O'}, {'(BAFF)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'TNF': 'I-Entity'}, {'receptor': 'O'}, {'ligand': 'O'}]"
A gastroendoscopy showed an advanced gastric cancer and a CT scan demonstrated diffuse interstitial infiltrative shadows in both lungs.,"[{'A': 'O'}, {'gastroendoscopy': 'O'}, {'showed': 'O'}, {'an': 'O'}, {'advanced': 'O'}, {'gastric': 'B-Entity'}, {'cancer': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'CT': 'O'}, {'scan': 'O'}, {'demonstrated': 'O'}, {'diffuse': 'O'}, {'interstitial': 'O'}, {'infiltrative': 'O'}, {'shadows': 'O'}, {'in': 'O'}, {'both': 'O'}, {'lungs.': 'O'}]"
"Such an experience is consistent with the available evidence-based data for hydroxypropyl cellulose ophthalmic inserts and supports their use in clinical practice for the treatment of moderate-to-severe dry eye disease.Academic Health Center, Cincinnati, OH, USA.","[{'Such': 'O'}, {'an': 'O'}, {'experience': 'O'}, {'is': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'the': 'O'}, {'available': 'O'}, {'evidence-based': 'O'}, {'data': 'O'}, {'for': 'O'}, {'hydroxypropyl': 'B-Entity'}, {'cellulose': 'I-Entity'}, {'ophthalmic': 'O'}, {'inserts': 'O'}, {'and': 'O'}, {'supports': 'O'}, {'their': 'O'}, {'use': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'practice': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'moderate-to-severe': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease.Academic': 'I-Entity'}, {'Health': 'O'}, {'Center,': 'O'}, {'Cincinnati,': 'O'}, {'OH,': 'O'}, {'USA.': 'O'}]"
"She also reported dry eyes, dry mouth, as well as pain in her shoulders and thighs.","[{'She': 'O'}, {'also': 'O'}, {'reported': 'O'}, {'dry': 'B-Entity'}, {'eyes,': 'I-Entity'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'pain': 'I-Entity'}, {'in': 'O'}, {'her': 'O'}, {'shoulders': 'O'}, {'and': 'O'}, {'thighs.': 'O'}]"
Sjogrens syndrome (SS) is an autoimmune rheumatic disease that is characterised by decreased exocrine gland function and frequent ocular symptoms associated with eye dryness.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'is': 'O'}, {'characterised': 'O'}, {'by': 'O'}, {'decreased': 'O'}, {'exocrine': 'O'}, {'gland': 'O'}, {'function': 'O'}, {'and': 'O'}, {'frequent': 'O'}, {'ocular': 'O'}, {'symptoms': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'eye': 'B-Entity'}, {'dryness.': 'I-Entity'}]"
"Upper and lower gastrointestinal endoscopy showed abnormal findings in only 40% and 30% of cases, respectively.","[{'Upper': 'O'}, {'and': 'O'}, {'lower': 'O'}, {'gastrointestinal': 'O'}, {'endoscopy': 'O'}, {'showed': 'O'}, {'abnormal': 'O'}, {'findings': 'O'}, {'in': 'O'}, {'only': 'O'}, {'40%': 'O'}, {'and': 'O'}, {'30%': 'O'}, {'of': 'O'}, {'cases,': 'O'}, {'respectively.': 'O'}]"
"Results Compared to controls, pSS patients had significantly increased ReHo values in the right cerebrum, left limbic lobe, right middle temporal gyrus, and the inferior parietal lobe.","[{'Results': 'O'}, {'Compared': 'O'}, {'to': 'O'}, {'controls,': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'had': 'O'}, {'significantly': 'O'}, {'increased': 'O'}, {'ReHo': 'O'}, {'values': 'O'}, {'in': 'O'}, {'the': 'O'}, {'right': 'O'}, {'cerebrum,': 'O'}, {'left': 'O'}, {'limbic': 'O'}, {'lobe,': 'O'}, {'right': 'O'}, {'middle': 'O'}, {'temporal': 'O'}, {'gyrus,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'inferior': 'O'}, {'parietal': 'O'}, {'lobe.': 'O'}]"
"Anti-Ro52 was significantly associated with liver and muscle involvements, while anti-Ro60 was inversely associated with liver involvement in Korean patients with pSS.Heuksuk-dong, Dongjak-gu, 156-755 Seoul, South Korea.","[{'Anti-Ro52': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'liver': 'O'}, {'and': 'O'}, {'muscle': 'I-Entity'}, {'involvements,': 'O'}, {'while': 'O'}, {'anti-Ro60': 'O'}, {'was': 'O'}, {'inversely': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'liver': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'Korean': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.Heuksuk-dong,': 'O'}, {'Dongjak-gu,': 'O'}, {'156-755': 'O'}, {'Seoul,': 'O'}, {'South': 'O'}, {'Korea.': 'O'}]"
"To investigate the relationships between self-reported cognitive abilities, psychological symptoms and neuropsychological outcomes in PSS.","[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'relationships': 'O'}, {'between': 'O'}, {'self-reported': 'O'}, {'cognitive': 'O'}, {'abilities,': 'O'}, {'psychological': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'neuropsychological': 'O'}, {'outcomes': 'O'}, {'in': 'O'}, {'PSS.': 'I-Entity'}]"
We conducted this study to characterize the relationship between primary Sjogren syndrome (pSS)-associated peripheral neuropathy (PN) and markers of B-cell monoclonal proliferation and chronic activation.,"[{'We': 'O'}, {'conducted': 'O'}, {'this': 'O'}, {'study': 'O'}, {'to': 'O'}, {'characterize': 'O'}, {'the': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)-associated': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'(PN)': 'O'}, {'and': 'O'}, {'markers': 'O'}, {'of': 'O'}, {'B-cell': 'O'}, {'monoclonal': 'O'}, {'proliferation': 'O'}, {'and': 'O'}, {'chronic': 'O'}, {'activation.': 'O'}]"
"Particularly in the elderly, the occurrence of sicca symptoms may be considered as age-related and medication-related.Lublinie, Lublin, Polska.Lublinie, Lublin, Polska.Lublinie, Lublin, Polska.","[{'Particularly': 'O'}, {'in': 'O'}, {'the': 'O'}, {'elderly,': 'O'}, {'the': 'O'}, {'occurrence': 'O'}, {'of': 'O'}, {'sicca': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'as': 'O'}, {'age-related': 'O'}, {'and': 'O'}, {'medication-related.Lublinie,': 'O'}, {'Lublin,': 'O'}, {'Polska.Lublinie,': 'O'}, {'Lublin,': 'O'}, {'Polska.Lublinie,': 'O'}, {'Lublin,': 'O'}, {'Polska.': 'O'}]"
"Rarely, extraglandular sites such as skin, lung, kidneys, and nervous system may be involved.","[{'Rarely,': 'O'}, {'extraglandular': 'O'}, {'sites': 'O'}, {'such': 'O'}, {'as': 'O'}, {'skin,': 'O'}, {'lung,': 'O'}, {'kidneys,': 'O'}, {'and': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'may': 'O'}, {'be': 'O'}, {'involved.': 'O'}]"
"The patient was treated with oral and intravenous potassium chloride, along with intravenous sodium bicarbonate.","[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'oral': 'O'}, {'and': 'O'}, {'intravenous': 'O'}, {'potassium': 'B-Entity'}, {'chloride,': 'I-Entity'}, {'along': 'O'}, {'with': 'O'}, {'intravenous': 'O'}, {'sodium': 'B-Entity'}, {'bicarbonate.': 'I-Entity'}]"
"However, a marked decrease in the interfollicular CD4:CD8 ratio was observed in all HIV+ CLH cases, which was statistically significant when compared with the HIV- cases (P = .02) and cases of LESA of Sjogren syndrome (P = .03).","[{'However,': 'O'}, {'a': 'O'}, {'marked': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'the': 'O'}, {'interfollicular': 'O'}, {'CD4:CD8': 'O'}, {'ratio': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'all': 'O'}, {'HIV+': 'O'}, {'CLH': 'I-Entity'}, {'cases,': 'O'}, {'which': 'O'}, {'was': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'when': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'the': 'O'}, {'HIV-': 'O'}, {'cases': 'O'}, {'(P': 'O'}, {'=': 'O'}, {'.02)': 'O'}, {'and': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'LESA': 'I-Entity'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(P': 'O'}, {'=': 'O'}, {'.03).': 'O'}]"
The authors' recent study demonstrated that the presence of serum IgG autoantibodies against modified C-reactive protein (mCRP) was closely associated with the intensity of tubulointerstitial lesions in lupus nephritis.,"[{'The': 'O'}, {""authors'"": 'O'}, {'recent': 'O'}, {'study': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'IgG': 'O'}, {'autoantibodies': 'O'}, {'against': 'O'}, {'modified': 'O'}, {'C-reactive': 'O'}, {'protein': 'O'}, {'(mCRP)': 'O'}, {'was': 'O'}, {'closely': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'intensity': 'O'}, {'of': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'lesions': 'O'}, {'in': 'O'}, {'lupus': 'B-Entity'}, {'nephritis.': 'I-Entity'}]"
"On the other hand, certain autoimmune diseases, such as Sjogren's syndrome versus SLE, share similar symptoms and autoantibodies, which also causes difficulties in diagnosis.","[{'On': 'O'}, {'the': 'O'}, {'other': 'O'}, {'hand,': 'O'}, {'certain': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'versus': 'O'}, {'SLE,': 'I-Entity'}, {'share': 'O'}, {'similar': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'autoantibodies,': 'O'}, {'which': 'O'}, {'also': 'O'}, {'causes': 'O'}, {'difficulties': 'O'}, {'in': 'O'}, {'diagnosis.': 'O'}]"
"The prevalence of peripheral neuropathy in patients with Sjogren syndrome remains unclear owing to conflicting results in the published series, with numbers ranging from 2% to over 60% of Sjogren syndrome patients.","[{'The': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'remains': 'O'}, {'unclear': 'O'}, {'owing': 'O'}, {'to': 'O'}, {'conflicting': 'O'}, {'results': 'O'}, {'in': 'O'}, {'the': 'O'}, {'published': 'O'}, {'series,': 'O'}, {'with': 'O'}, {'numbers': 'O'}, {'ranging': 'O'}, {'from': 'O'}, {'2%': 'O'}, {'to': 'O'}, {'over': 'O'}, {'60%': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patients.': 'O'}]"
"Sonographic fetal thymus size was retrospectively evaluated in 190 healthy pregnant women, and 84 pregnancies of mothers suffering from systemic lupus erythematosus, antiphospholipid syndrome (APS), or Sjogrens syndrome between 19 and 37 weeks of gestation.","[{'Sonographic': 'O'}, {'fetal': 'O'}, {'thymus': 'O'}, {'size': 'O'}, {'was': 'O'}, {'retrospectively': 'O'}, {'evaluated': 'O'}, {'in': 'O'}, {'190': 'O'}, {'healthy': 'O'}, {'pregnant': 'O'}, {'women,': 'O'}, {'and': 'O'}, {'84': 'O'}, {'pregnancies': 'O'}, {'of': 'O'}, {'mothers': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'antiphospholipid': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(APS),': 'O'}, {'or': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'between': 'O'}, {'19': 'O'}, {'and': 'O'}, {'37': 'O'}, {'weeks': 'O'}, {'of': 'O'}, {'gestation.': 'O'}]"
We report on a¬¨¬®‚Äö√Ñ‚Ä†case of Acanthamoeba keratitis (AK)-related reactive ischemic posterior segment inflammation following intraocular surgery in a¬¨¬®‚Äö√Ñ‚Ä†patient with primary Sjogrens syndrome (PSS).,"[{'We': 'O'}, {'report': 'O'}, {'on': 'O'}, {'a¬¨¬®‚Äö√Ñ‚Ä†case': 'O'}, {'of': 'O'}, {'Acanthamoeba': 'B-Entity'}, {'keratitis': 'I-Entity'}, {'(AK)-related': 'O'}, {'reactive': 'O'}, {'ischemic': 'B-Entity'}, {'posterior': 'O'}, {'segment': 'O'}, {'inflammation': 'I-Entity'}, {'following': 'O'}, {'intraocular': 'O'}, {'surgery': 'O'}, {'in': 'O'}, {'a¬¨¬®‚Äö√Ñ‚Ä†patient': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}]"
64% of patients had abdominal pain or gastric heaviness.,"[{'64%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'abdominal': 'B-Entity'}, {'pain': 'I-Entity'}, {'or': 'O'}, {'gastric': 'B-Entity'}, {'heaviness.': 'I-Entity'}]"
Plasma hyperviscosity is a rare complication of both monoclonal and polyclonal disorders associated with elevation of immunoglobulins.,"[{'Plasma': 'O'}, {'hyperviscosity': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'both': 'O'}, {'monoclonal': 'O'}, {'and': 'O'}, {'polyclonal': 'O'}, {'disorders': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'elevation': 'O'}, {'of': 'O'}, {'immunoglobulins.': 'O'}]"
Salivary gland screening during thyroid ultrasonography revealed abnormal findings including Sjogrens syndrome and IgG4-related sialadenitis in about 4% of the patients.,"[{'Salivary': 'O'}, {'gland': 'O'}, {'screening': 'O'}, {'during': 'O'}, {'thyroid': 'O'}, {'ultrasonography': 'O'}, {'revealed': 'O'}, {'abnormal': 'O'}, {'findings': 'O'}, {'including': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'IgG4-related': 'O'}, {'sialadenitis': 'I-Entity'}, {'in': 'O'}, {'about': 'O'}, {'4%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients.': 'O'}]"
"In Han nationality of Shanxi province, HLA-DQA1*0501 and HLA-DQB1*0201 alleles probably are susceptible genes of pSS, while HLA-DQA1*0301/2 allele probably is a protective gene of pSS.zxyon2000@yahoo.com.cnimmunologypain and swelling: a case report.","[{'In': 'O'}, {'Han': 'O'}, {'nationality': 'O'}, {'of': 'O'}, {'Shanxi': 'O'}, {'province,': 'O'}, {'HLA-DQA1*0501': 'O'}, {'and': 'O'}, {'HLA-DQB1*0201': 'O'}, {'alleles': 'O'}, {'probably': 'O'}, {'are': 'O'}, {'susceptible': 'O'}, {'genes': 'O'}, {'of': 'O'}, {'pSS,': 'O'}, {'while': 'O'}, {'HLA-DQA1*0301/2': 'O'}, {'allele': 'O'}, {'probably': 'O'}, {'is': 'O'}, {'a': 'O'}, {'protective': 'O'}, {'gene': 'O'}, {'of': 'O'}, {'pSS.zxyon2000@yahoo.com.cnimmunologypain': 'I-Entity'}]"
SS typically presents as dry eyes (xerophthalmia) and dry mouth (xerostomia).,"[{'SS': 'I-Entity'}, {'typically': 'O'}, {'presents': 'O'}, {'as': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'(xerophthalmia)': 'O'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'(xerostomia).': 'O'}]"
"To assess the risk of incident cardiovascular disease in patients with primary Sjogrens syndrome, overall and stratified by Ro/SSA and La/SSB autoantibody status.","[{'To': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'incident': 'O'}, {'cardiovascular': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'overall': 'O'}, {'and': 'O'}, {'stratified': 'O'}, {'by': 'O'}, {'Ro/SSA': 'I-Entity'}, {'and': 'O'}, {'La/SSB': 'I-Entity'}, {'autoantibody': 'O'}, {'status.': 'O'}]"
The diagnosis of rheumatic conditions was the responsibility of the treating physician.,"[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'rheumatic': 'B-Entity'}, {'conditions': 'I-Entity'}, {'was': 'O'}, {'the': 'O'}, {'responsibility': 'O'}, {'of': 'O'}, {'the': 'O'}, {'treating': 'O'}, {'physician.': 'O'}]"
"This article examines the differences and interaction between sex and gender, and how they affect women's oral and general health.","[{'This': 'O'}, {'article': 'O'}, {'examines': 'O'}, {'the': 'O'}, {'differences': 'O'}, {'and': 'O'}, {'interaction': 'O'}, {'between': 'O'}, {'sex': 'O'}, {'and': 'O'}, {'gender,': 'O'}, {'and': 'O'}, {'how': 'O'}, {'they': 'O'}, {'affect': 'O'}, {""women's"": 'O'}, {'oral': 'O'}, {'and': 'O'}, {'general': 'O'}, {'health.': 'O'}]"
"Herein, we investigated the occurrence of aberrant DNA build-up in various biologic compartments of SS patients and its correlation with the activity of NLRP3 and AIM2 inflammasomes.","[{'Herein,': 'O'}, {'we': 'O'}, {'investigated': 'O'}, {'the': 'O'}, {'occurrence': 'O'}, {'of': 'O'}, {'aberrant': 'O'}, {'DNA': 'O'}, {'build-up': 'O'}, {'in': 'O'}, {'various': 'O'}, {'biologic': 'O'}, {'compartments': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'its': 'O'}, {'correlation': 'O'}, {'with': 'O'}, {'the': 'O'}, {'activity': 'O'}, {'of': 'O'}, {'NLRP3': 'O'}, {'and': 'O'}, {'AIM2': 'O'}, {'inflammasomes.': 'O'}]"
We analysed four cases in which neurological manifestations were the first symptoms of Sjogrens syndrome.,"[{'We': 'O'}, {'analysed': 'O'}, {'four': 'O'}, {'cases': 'O'}, {'in': 'O'}, {'which': 'O'}, {'neurological': 'O'}, {'manifestations': 'O'}, {'were': 'O'}, {'the': 'O'}, {'first': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"We investigated sub-clinical cardiovascular involvement in primary Sjogrens syndrome (pSS) patients by means of ADMA, coronary flow reserve (CFR), intima media thickness (cIMT), pulse wave velocity (PWV) and myocardial deformation.","[{'We': 'O'}, {'investigated': 'O'}, {'sub-clinical': 'O'}, {'cardiovascular': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'patients': 'O'}, {'by': 'O'}, {'means': 'O'}, {'of': 'O'}, {'ADMA,': 'I-Entity'}, {'coronary': 'O'}, {'flow': 'O'}, {'reserve': 'O'}, {'(CFR),': 'O'}, {'intima': 'O'}, {'media': 'O'}, {'thickness': 'O'}, {'(cIMT),': 'O'}, {'pulse': 'O'}, {'wave': 'O'}, {'velocity': 'O'}, {'(PWV)': 'O'}, {'and': 'O'}, {'myocardial': 'B-Entity'}, {'deformation.': 'I-Entity'}]"
"METHODS AND Here, we report a 47-year-old Chinese woman who lost vision in the right eye for 7 days.","[{'METHODS': 'O'}, {'AND': 'O'}, {'Here,': 'O'}, {'we': 'O'}, {'report': 'O'}, {'a': 'O'}, {'47-year-old': 'O'}, {'Chinese': 'O'}, {'woman': 'O'}, {'who': 'O'}, {'lost': 'B-Entity'}, {'vision': 'I-Entity'}, {'in': 'I-Entity'}, {'the': 'I-Entity'}, {'right': 'I-Entity'}, {'eye': 'I-Entity'}, {'for': 'O'}, {'7': 'O'}, {'days.': 'O'}]"
Thrombospondin-1-deficient (TSP-1(-/-)) mice are used as an animal model of Sjogrens Syndrome because they exhibit many of the symptoms associated with the autoimmune type of dry eye found in primary Sjogrens Syndrome.,"[{'Thrombospondin-1-deficient': 'O'}, {'(TSP-1(-/-))': 'O'}, {'mice': 'O'}, {'are': 'O'}, {'used': 'O'}, {'as': 'O'}, {'an': 'O'}, {'animal': 'O'}, {'model': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'because': 'O'}, {'they': 'O'}, {'exhibit': 'O'}, {'many': 'O'}, {'of': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'autoimmune': 'B-Entity'}, {'type': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'found': 'O'}, {'in': 'O'}, {'primary': 'O'}, {'Sjogrens': 'I-Entity'}]"
"To investigate if PSS was an independent factor in determining the risk of developing ischemic stroke, a Cox regression model was used with adjustment for age, gender, and comorbid disorders.","[{'To': 'O'}, {'investigate': 'O'}, {'if': 'O'}, {'PSS': 'O'}, {'was': 'O'}, {'an': 'O'}, {'independent': 'O'}, {'factor': 'O'}, {'in': 'O'}, {'determining': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'developing': 'O'}, {'ischemic': 'B-Entity'}, {'stroke,': 'I-Entity'}, {'a': 'O'}, {'Cox': 'O'}, {'regression': 'O'}, {'model': 'O'}, {'was': 'O'}, {'used': 'O'}, {'with': 'O'}, {'adjustment': 'O'}, {'for': 'O'}, {'age,': 'O'}, {'gender,': 'O'}, {'and': 'O'}, {'comorbid': 'O'}, {'disorders.': 'O'}]"
"In the majority (86.1%) of the 44 RA-sicca cases, periductal infiltrates were observed in LMSG biopsies.","[{'In': 'O'}, {'the': 'O'}, {'majority': 'O'}, {'(86.1%)': 'O'}, {'of': 'O'}, {'the': 'O'}, {'44': 'O'}, {'RA-sicca': 'I-Entity'}, {'cases,': 'O'}, {'periductal': 'O'}, {'infiltrates': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'LMSG': 'O'}, {'biopsies.': 'O'}]"
"The subsequent structural damage of the arterial wall may be responsible for the increase in resistances in small cerebral arteries and sustained hypoperfusion.Sciences and Biotechnologies, Sapienza University of Rome, Viale dell'Universit‚Äö√†√∂‚Äö√Ñ‚Ä† 30, 00185, Rome, Italy, manuelamorreale@yahoo.it.the Italian Society of Clinical Neurophysiology14.pilot study of correlation with high-resolution chest tomography.","[{'The': 'O'}, {'subsequent': 'O'}, {'structural': 'O'}, {'damage': 'O'}, {'of': 'O'}, {'the': 'O'}, {'arterial': 'O'}, {'wall': 'O'}, {'may': 'O'}, {'be': 'O'}, {'responsible': 'O'}, {'for': 'O'}, {'the': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'resistances': 'O'}, {'in': 'O'}, {'small': 'O'}, {'cerebral': 'O'}, {'arteries': 'O'}, {'and': 'O'}, {'sustained': 'O'}, {'hypoperfusion.Sciences': 'I-Entity'}, {'and': 'O'}, {'Biotechnologies,': 'O'}, {'Sapienza': 'O'}, {'University': 'O'}, {'of': 'O'}, {'Rome,': 'O'}, {'Viale': 'O'}, {""dell'Universit‚Äö√†√∂‚Äö√Ñ‚Ä†"": 'O'}]"
"IgG4-related disease (IgG4-RD) is a set of diseases that can affect multiple organs, produce an immune-mediated fibroinflammatory response, and lead to tissue destruction and organ failure.","[{'IgG4-related': 'B-Entity'}, {'disease': 'I-Entity'}, {'(IgG4-RD)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'set': 'O'}, {'of': 'O'}, {'diseases': 'O'}, {'that': 'O'}, {'can': 'O'}, {'affect': 'O'}, {'multiple': 'O'}, {'organs,': 'O'}, {'produce': 'O'}, {'an': 'O'}, {'immune-mediated': 'O'}, {'fibroinflammatory': 'O'}, {'response,': 'O'}, {'and': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'tissue': 'B-Entity'}, {'destruction': 'I-Entity'}, {'and': 'O'}, {'organ': 'B-Entity'}, {'failure.': 'I-Entity'}]"
"These results show that C4d can be an appropriate marker of antibody response and complement activation in pSS patients with Abs, and possibly may show the more severe condition-exhaustion of C4.","[{'These': 'O'}, {'results': 'O'}, {'show': 'O'}, {'that': 'O'}, {'C4d': 'O'}, {'can': 'O'}, {'be': 'O'}, {'an': 'O'}, {'appropriate': 'O'}, {'marker': 'O'}, {'of': 'O'}, {'antibody': 'O'}, {'response': 'O'}, {'and': 'O'}, {'complement': 'O'}, {'activation': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'Abs,': 'O'}, {'and': 'O'}, {'possibly': 'O'}, {'may': 'O'}, {'show': 'O'}, {'the': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'condition-exhaustion': 'O'}, {'of': 'O'}, {'C4.': 'O'}]"
The remaining two cases involved abdominal periaortitis including one associated with retrosperitoneal fibrosis and tuberculosis and the other with spondylarthropathy.,"[{'The': 'O'}, {'remaining': 'O'}, {'two': 'O'}, {'cases': 'O'}, {'involved': 'O'}, {'abdominal': 'B-Entity'}, {'periaortitis': 'I-Entity'}, {'including': 'O'}, {'one': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'retrosperitoneal': 'B-Entity'}, {'fibrosis': 'I-Entity'}, {'and': 'O'}, {'tuberculosis': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'other': 'O'}, {'with': 'O'}, {'spondylarthropathy.': 'I-Entity'}]"
"Data on disease activity, duration, damage scores, inflammatory and serologic markers, treatment and clinical and ultrasound parameters (derived from the assessment of 902 joints) were analysed and correlated using descriptive statistics, correlation tests and regression models.","[{'Data': 'O'}, {'on': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'duration,': 'O'}, {'damage': 'O'}, {'scores,': 'O'}, {'inflammatory': 'O'}, {'and': 'O'}, {'serologic': 'O'}, {'markers,': 'O'}, {'treatment': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'ultrasound': 'O'}, {'parameters': 'O'}, {'(derived': 'O'}, {'from': 'O'}, {'the': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'902': 'O'}, {'joints)': 'O'}, {'were': 'O'}, {'analysed': 'O'}, {'and': 'O'}, {'correlated': 'O'}, {'using': 'O'}, {'descriptive': 'O'}, {'statistics,': 'O'}, {'correlation': 'O'}, {'tests': 'O'}, {'and': 'O'}, {'regression': 'O'}, {'models.': 'O'}]"
"Current therapeutic options for the treatment of pSS are mainly empirical, often translated by other autoimmune diseases, and recent systematic reviews have highlighted the lack of evidence-based recommendations for most of the drugs commonly employed in the spectrum of extraglandular involvement.","[{'Current': 'O'}, {'therapeutic': 'O'}, {'options': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'pSS': 'O'}, {'are': 'O'}, {'mainly': 'O'}, {'empirical,': 'O'}, {'often': 'O'}, {'translated': 'O'}, {'by': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'and': 'O'}, {'recent': 'O'}, {'systematic': 'O'}, {'reviews': 'O'}, {'have': 'O'}, {'highlighted': 'O'}, {'the': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'evidence-based': 'O'}, {'recommendations': 'O'}, {'for': 'O'}, {'most': 'O'}, {'of': 'O'}, {'the': 'O'}, {'drugs': 'O'}, {'commonly': 'O'}, {'employed': 'O'}, {'in': 'O'}, {'the': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'extraglandular': 'O'}, {'involvement.': 'O'}]"
"Post diagnosis of SS, claims for myocardial infarction and coronary artery bypass graft doubled.","[{'Post': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS,': 'I-Entity'}, {'claims': 'O'}, {'for': 'O'}, {'myocardial': 'B-Entity'}, {'infarction': 'I-Entity'}, {'and': 'O'}, {'coronary': 'O'}, {'artery': 'O'}, {'bypass': 'O'}, {'graft': 'O'}, {'doubled.': 'O'}]"
"Syndrome includes affection of glands in gastrointestinal system, respiratory apparatus, skin, and vaginal mucosa.","[{'Syndrome': 'O'}, {'includes': 'O'}, {'affection': 'O'}, {'of': 'I-Entity'}, {'glands': 'I-Entity'}, {'in': 'I-Entity'}, {'gastrointestinal': 'I-Entity'}, {'system,': 'I-Entity'}, {'respiratory': 'I-Entity'}, {'apparatus,': 'I-Entity'}, {'skin,': 'O'}, {'and': 'O'}, {'vaginal': 'O'}, {'mucosa.': 'O'}]"
To examine amount of CD4+CXCR5+Tfh cells and B cells subsets in salivary gland and peripheral blood from patients with primary Sjogren's syndrome (pSS) and to analyze whether the frequency of CD4+CXCR5+Tfh cells is associated with pSS pathologic process.,"[{'To': 'O'}, {'examine': 'O'}, {'amount': 'O'}, {'of': 'O'}, {'CD4+CXCR5+Tfh': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'subsets': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'and': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'analyze': 'O'}, {'whether': 'O'}, {'the': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'CD4+CXCR5+Tfh': 'O'}]"
A higher rate of pulmonary complications and trends towards longer disease duration and higher age indicated a selection of more complicated cases referred from outside our primary area.,"[{'A': 'O'}, {'higher': 'O'}, {'rate': 'O'}, {'of': 'O'}, {'pulmonary': 'B-Entity'}, {'complications': 'I-Entity'}, {'and': 'O'}, {'trends': 'O'}, {'towards': 'O'}, {'longer': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'and': 'O'}, {'higher': 'O'}, {'age': 'O'}, {'indicated': 'O'}, {'a': 'O'}, {'selection': 'O'}, {'of': 'O'}, {'more': 'O'}, {'complicated': 'O'}, {'cases': 'O'}, {'referred': 'O'}, {'from': 'O'}, {'outside': 'O'}, {'our': 'O'}, {'primary': 'O'}, {'area.': 'O'}]"
The evaluation of these symptoms requires measures of ocular and oral dryness.,"[{'The': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'these': 'O'}, {'symptoms': 'O'}, {'requires': 'O'}, {'measures': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'oral': 'I-Entity'}, {'dryness.': 'I-Entity'}]"
The evaluation of these symptoms requires measures of ocular and oral dryness.,"[{'The': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'these': 'O'}, {'symptoms': 'O'}, {'requires': 'O'}, {'measures': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'oral': 'I-Entity'}, {'dryness.': 'I-Entity'}]"
The objective of this study was to determine whether tendon pain in pSS is related to involvement of the tendons and entheses.,"[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'tendon': 'B-Entity'}, {'pain': 'I-Entity'}, {'in': 'O'}, {'pSS': 'O'}, {'is': 'O'}, {'related': 'O'}, {'to': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'the': 'O'}, {'tendons': 'O'}, {'and': 'O'}, {'entheses.': 'O'}]"
"In this study, we included patients who experienced musculoskeletal pain for 3 months or longer (CP) and with a DN4 score‚Äö√Ñ√∂‚àö√ë‚àö¬¢‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢‚Äö√Ñ√∂‚àö√ë‚àö¬¢4 (NP).","[{'In': 'O'}, {'this': 'O'}, {'study,': 'O'}, {'we': 'O'}, {'included': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'experienced': 'O'}, {'musculoskeletal': 'B-Entity'}, {'pain': 'I-Entity'}, {'for': 'O'}, {'3': 'O'}, {'months': 'O'}, {'or': 'O'}, {'longer': 'O'}, {'(CP)': 'O'}, {'and': 'O'}, {'with': 'O'}, {'a': 'O'}, {'DN4': 'O'}, {'score‚Äö√Ñ√∂‚àö√ë‚àö¬¢‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢‚Äö√Ñ√∂‚àö√ë‚àö¬¢4': 'O'}]"
"The diagnosis of AOSD was stated and because of persistent fever and polyarthralgias, after exclusion of active infection, steroids were started (prednisone 1 mg/kg) associated with colchicine, which allowed clinical remission and C-reactive protein significant decrease.","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'AOSD': 'I-Entity'}, {'was': 'O'}, {'stated': 'O'}, {'and': 'O'}, {'because': 'O'}, {'of': 'O'}, {'persistent': 'O'}, {'fever': 'I-Entity'}, {'and': 'O'}, {'polyarthralgias,': 'I-Entity'}, {'after': 'O'}, {'exclusion': 'O'}, {'of': 'O'}, {'active': 'O'}, {'infection,': 'I-Entity'}, {'steroids': 'I-Entity'}, {'were': 'O'}, {'started': 'O'}, {'(prednisone': 'O'}, {'1': 'O'}, {'mg/kg)': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'colchicine,': 'I-Entity'}, {'which': 'O'}, {'allowed': 'O'}, {'clinical': 'O'}, {'remission': 'O'}, {'and': 'O'}, {'C-reactive': 'O'}, {'protein': 'O'}, {'significant': 'O'}, {'decrease.': 'O'}]"
"Nevertheless, it can be difficult to diagnose pSS as the symptoms are frequently unspecific and diagnostic markers are lacking in many patients.","[{'Nevertheless,': 'O'}, {'it': 'O'}, {'can': 'O'}, {'be': 'O'}, {'difficult': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'pSS': 'I-Entity'}, {'as': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'are': 'O'}, {'frequently': 'O'}, {'unspecific': 'O'}, {'and': 'O'}, {'diagnostic': 'O'}, {'markers': 'O'}, {'are': 'O'}, {'lacking': 'O'}, {'in': 'O'}, {'many': 'O'}, {'patients.': 'O'}]"
"We previously reported that lacrimal glands (LGs) of male non-obese diabetic (NOD) mice, an established mouse model of autoimmune inflammatory LG disease that displays many features of human LGs in patients afflicted with Sjogrens syndrome (SjS), exhibit significant degradation of extracellular matrix (ECM) structures as well as increased expression of matrix metalloproteinases (MMPs).","[{'We': 'O'}, {'previously': 'O'}, {'reported': 'O'}, {'that': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'(LGs)': 'O'}, {'of': 'O'}, {'male': 'O'}, {'non-obese': 'O'}, {'diabetic': 'I-Entity'}, {'(NOD)': 'O'}, {'mice,': 'O'}, {'an': 'O'}, {'established': 'O'}, {'mouse': 'O'}, {'model': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'inflammatory': 'O'}, {'LG': 'B-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'displays': 'O'}, {'many': 'O'}, {'features': 'O'}, {'of': 'O'}, {'human': 'O'}, {'LGs': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'afflicted': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}]"
"The girl has stable renal function and no residual nervous system damage in the next 1.5‚Äö√Ñ√∂‚àö√ë‚àö¬¢years, but she underwent low dose prednisone therapy because of persistent renal glucosuria.","[{'The': 'O'}, {'girl': 'O'}, {'has': 'O'}, {'stable': 'O'}, {'renal': 'O'}, {'function': 'O'}, {'and': 'O'}, {'no': 'O'}, {'residual': 'O'}, {'nervous': 'B-Entity'}, {'system': 'I-Entity'}, {'damage': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'next': 'O'}, {'1.5‚Äö√Ñ√∂‚àö√ë‚àö¬¢years,': 'O'}, {'but': 'O'}, {'she': 'O'}, {'underwent': 'O'}, {'low': 'O'}, {'dose': 'O'}, {'prednisone': 'I-Entity'}, {'therapy': 'O'}, {'because': 'O'}, {'of': 'O'}, {'persistent': 'O'}, {'renal': 'O'}, {'glucosuria.': 'I-Entity'}]"
"Sjogrens syndrome (SS) has been associated with bronchial hyperresponsiveness and asthma; however, no population-based cohort study has been performed.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'has': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'bronchial': 'B-Entity'}, {'hyperresponsiveness': 'I-Entity'}, {'and': 'O'}, {'asthma;': 'I-Entity'}, {'however,': 'O'}, {'no': 'O'}, {'population-based': 'O'}, {'cohort': 'O'}, {'study': 'O'}, {'has': 'O'}, {'been': 'O'}, {'performed.': 'O'}]"
"Our case report is about a patient who presented with generalized weakness and hypokalemia, which upon further workup turned out to be RTA.","[{'Our': 'O'}, {'case': 'O'}, {'report': 'O'}, {'is': 'O'}, {'about': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'generalized': 'O'}, {'weakness': 'I-Entity'}, {'and': 'O'}, {'hypokalemia,': 'I-Entity'}, {'which': 'O'}, {'upon': 'O'}, {'further': 'O'}, {'workup': 'O'}, {'turned': 'O'}, {'out': 'O'}, {'to': 'O'}, {'be': 'O'}, {'RTA.': 'I-Entity'}]"
"The burden of pregnancy complications associated with well defined, already established systemic rheumatic diseases preexisting pregnancy such as rheumatoid arthritis, systemic lupus erythematosus or scleroderma is well known.","[{'The': 'O'}, {'burden': 'O'}, {'of': 'O'}, {'pregnancy': 'O'}, {'complications': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'well': 'O'}, {'defined,': 'O'}, {'already': 'O'}, {'established': 'O'}, {'systemic': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'preexisting': 'O'}, {'pregnancy': 'O'}, {'such': 'O'}, {'as': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'or': 'O'}, {'scleroderma': 'I-Entity'}, {'is': 'O'}, {'well': 'O'}, {'known.': 'O'}]"
"Imagine a time where your health status could be available to you without the pain, discomfort and inconvenience of a physical examination.","[{'Imagine': 'O'}, {'a': 'O'}, {'time': 'O'}, {'where': 'O'}, {'your': 'O'}, {'health': 'O'}, {'status': 'O'}, {'could': 'O'}, {'be': 'O'}, {'available': 'O'}, {'to': 'O'}, {'you': 'O'}, {'without': 'O'}, {'the': 'O'}, {'pain,': 'I-Entity'}, {'discomfort': 'I-Entity'}, {'and': 'O'}, {'inconvenience': 'O'}, {'of': 'O'}, {'a': 'O'}, {'physical': 'O'}, {'examination.': 'O'}]"
"Clinical stages and individualized treatment for pSS patients with lung cancer should be carefully determined.Academy of Medical Science & Peking Union Medical College Beijing, China.of Medical Science & Peking Union Medical College Beijing, China.Academy of Medical Science & Peking Union Medical College Beijing, China.Academy of Medical Science & Peking Union Medical College Beijing, China.Academy of Medical Science & Peking Union Medical College Beijing, China.Academy of Medical Science & Peking Union Medical College Beijing, China.Academy of Medical Science & Peking Union Medical College Beijing, China.","[{'Clinical': 'O'}, {'stages': 'O'}, {'and': 'O'}, {'individualized': 'O'}, {'treatment': 'O'}, {'for': 'O'}, {'pSS': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'lung': 'B-Entity'}, {'cancer': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'carefully': 'O'}, {'determined.Academy': 'O'}, {'of': 'O'}, {'Medical': 'O'}, {'Science': 'O'}, {'&': 'O'}, {'Peking': 'O'}, {'Union': 'O'}, {'Medical': 'O'}, {'College': 'O'}, {'Beijing,': 'O'}, {'China.of': 'O'}, {'Medical': 'O'}, {'Science': 'O'}, {'&': 'O'}, {'Peking': 'O'}, {'Union': 'O'}, {'Medical': 'O'}, {'College': 'O'}, {'Beijing,': 'O'}, {'China.Academy': 'O'}, {'of': 'O'}, {'Medical': 'O'}, {'Science': 'O'}, {'&': 'O'}, {'Peking': 'O'}, {'Union': 'O'}, {'Medical': 'O'}, {'College': 'O'}, {'Beijing,': 'O'}, {'China.Academy': 'O'}, {'of': 'O'}, {'Medical': 'O'}]"
To assess this spontaneously developed ocular surface inflammation related to Sjogrens syndrome in TSP-1null mice (12 wks) was evaluated.,"[{'To': 'O'}, {'assess': 'O'}, {'this': 'O'}, {'spontaneously': 'O'}, {'developed': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'inflammation': 'I-Entity'}, {'related': 'O'}, {'to': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'TSP-1null': 'I-Entity'}, {'mice': 'O'}, {'(12': 'O'}, {'wks)': 'O'}, {'was': 'O'}, {'evaluated.': 'O'}]"
"Due to the lack of specific symptoms, diagnosis of these conditions remains a challenge.","[{'Due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'specific': 'O'}, {'symptoms,': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'these': 'O'}, {'conditions': 'O'}, {'remains': 'O'}, {'a': 'O'}, {'challenge.': 'O'}]"
"Osteomalacia is a relatively common condition, which is frequently underdiagnosed due to lack of clinical suspicion and non-specific symptoms.","[{'Osteomalacia': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'relatively': 'O'}, {'common': 'O'}, {'condition,': 'O'}, {'which': 'O'}, {'is': 'O'}, {'frequently': 'O'}, {'underdiagnosed': 'O'}, {'due': 'O'}, {'to': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'clinical': 'O'}, {'suspicion': 'O'}, {'and': 'O'}, {'non-specific': 'O'}, {'symptoms.': 'O'}]"
"There were 3,186 new cases of SS in the study cohort with crude incidence rates of SS of 30/100,000 person-years in patients without gout and 49/100,000 person-years in patients with gout.","[{'There': 'O'}, {'were': 'O'}, {'3,186': 'O'}, {'new': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'study': 'O'}, {'cohort': 'O'}, {'with': 'O'}, {'crude': 'O'}, {'incidence': 'O'}, {'rates': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'of': 'O'}, {'30/100,000': 'O'}, {'person-years': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'gout': 'I-Entity'}, {'and': 'O'}, {'49/100,000': 'O'}, {'person-years': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'gout.': 'I-Entity'}]"
"However, her symptoms progressed gradually and finally she found it difficult to walk.","[{'However,': 'O'}, {'her': 'O'}, {'symptoms': 'O'}, {'progressed': 'O'}, {'gradually': 'O'}, {'and': 'O'}, {'finally': 'O'}, {'she': 'O'}, {'found': 'O'}, {'it': 'O'}, {'difficult': 'O'}, {'to': 'O'}, {'walk.': 'O'}]"
"The purpose of this article is to illustrate that in addition to dry eye, SS can cause serious, vision-threatening extraglandular ocular manifestations.","[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'article': 'O'}, {'is': 'O'}, {'to': 'O'}, {'illustrate': 'O'}, {'that': 'O'}, {'in': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'dry': 'B-Entity'}, {'eye,': 'I-Entity'}, {'SS': 'I-Entity'}, {'can': 'O'}, {'cause': 'O'}, {'serious,': 'O'}, {'vision-threatening': 'O'}, {'extraglandular': 'O'}, {'ocular': 'I-Entity'}, {'manifestations.': 'O'}]"
"Because the most common term used in conversations considering autoimmunity is autoantibodies, it is well-expected that the indirect immunofluorescence assay, which detects antibodies directed against various antigens, is one of our most impressive techniques for investigating autoimmune diseases (AIDs).","[{'Because': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'term': 'O'}, {'used': 'O'}, {'in': 'O'}, {'conversations': 'O'}, {'considering': 'O'}, {'autoimmunity': 'I-Entity'}, {'is': 'O'}, {'autoantibodies,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'well-expected': 'O'}, {'that': 'O'}, {'the': 'O'}, {'indirect': 'O'}, {'immunofluorescence': 'O'}, {'assay,': 'O'}, {'which': 'O'}, {'detects': 'O'}, {'antibodies': 'O'}, {'directed': 'O'}, {'against': 'O'}, {'various': 'O'}, {'antigens,': 'O'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'our': 'O'}, {'most': 'O'}, {'impressive': 'O'}, {'techniques': 'O'}, {'for': 'O'}, {'investigating': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(AIDs).': 'O'}]"
Data on the two diseases occurrence order are inadequate.,"[{'Data': 'O'}, {'on': 'O'}, {'the': 'O'}, {'two': 'O'}, {'diseases': 'O'}, {'occurrence': 'O'}, {'order': 'O'}, {'are': 'O'}, {'inadequate.': 'O'}]"
"Small airway disease was the most commonly recognized pulmonary disorder among symptomatic pSS patients, followed by xerotrachea and interstitial lung disease.University of Athens, Greece.","[{'Small': 'B-Entity'}, {'airway': 'I-Entity'}, {'disease': 'I-Entity'}, {'was': 'O'}, {'the': 'O'}, {'most': 'O'}, {'commonly': 'O'}, {'recognized': 'O'}, {'pulmonary': 'B-Entity'}, {'disorder': 'I-Entity'}, {'among': 'O'}, {'symptomatic': 'O'}, {'pSS': 'O'}, {'patients,': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'xerotrachea': 'I-Entity'}, {'and': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease.University': 'I-Entity'}, {'of': 'O'}, {'Athens,': 'O'}, {'Greece.': 'O'}]"
Participants described disease and symptom severity and satisfaction with current pSS treatments.,"[{'Participants': 'O'}, {'described': 'O'}, {'disease': 'O'}, {'and': 'O'}, {'symptom': 'O'}, {'severity': 'O'}, {'and': 'O'}, {'satisfaction': 'O'}, {'with': 'O'}, {'current': 'O'}, {'pSS': 'I-Entity'}, {'treatments.': 'O'}]"
The advantages of combination therapy are that the doses of the individual drugs may be lowered so reducing adverse reactions.,"[{'The': 'O'}, {'advantages': 'O'}, {'of': 'O'}, {'combination': 'O'}, {'therapy': 'O'}, {'are': 'O'}, {'that': 'O'}, {'the': 'O'}, {'doses': 'O'}, {'of': 'O'}, {'the': 'O'}, {'individual': 'O'}, {'drugs': 'O'}, {'may': 'O'}, {'be': 'O'}, {'lowered': 'O'}, {'so': 'O'}, {'reducing': 'O'}, {'adverse': 'O'}, {'reactions.': 'O'}]"
B cell activating factor (BAFF)) resulting in decreased B cell activity.,"[{'B': 'O'}, {'cell': 'O'}, {'activating': 'O'}, {'factor': 'O'}, {'(BAFF))': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'decreased': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activity.': 'O'}]"
All consecutive adult patients hospitalized in a Department of Internal Medicine over a 10-year period for acute pericarditis with pericardial effusion were retrospectively reviewed.,"[{'All': 'O'}, {'consecutive': 'O'}, {'adult': 'O'}, {'patients': 'O'}, {'hospitalized': 'O'}, {'in': 'O'}, {'a': 'O'}, {'Department': 'O'}, {'of': 'O'}, {'Internal': 'O'}, {'Medicine': 'O'}, {'over': 'O'}, {'a': 'O'}, {'10-year': 'O'}, {'period': 'O'}, {'for': 'O'}, {'acute': 'O'}, {'pericarditis': 'I-Entity'}, {'with': 'O'}, {'pericardial': 'B-Entity'}, {'effusion': 'I-Entity'}, {'were': 'O'}, {'retrospectively': 'O'}, {'reviewed.': 'O'}]"
"This study aims to investigate the positive detection rate and predictive value of autoantibodies, including anti-double stranded deoxyribonucleic acid (anti-dsDNA) antibodies, anti-histone antibodies (AHAs), anti-ribosomal (anti-Rib) P antibodies, anti-Smith (anti-Sm) antibodies, anti-U1 ribonucleoprotein (anti-U1RNP) antibodies, anti-Sjogrens syndrome type A antibodies and anti-Sjogrens syndrome type B antibodies, on organ damage in patients with systemic lupus erythematous (SLE).","[{'This': 'O'}, {'study': 'O'}, {'aims': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'positive': 'O'}, {'detection': 'O'}, {'rate': 'O'}, {'and': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'of': 'O'}, {'autoantibodies,': 'O'}, {'including': 'O'}, {'anti-double': 'O'}, {'stranded': 'I-Entity'}, {'deoxyribonucleic': 'I-Entity'}, {'acid': 'I-Entity'}, {'(anti-dsDNA)': 'O'}, {'antibodies,': 'O'}, {'anti-histone': 'O'}, {'antibodies': 'O'}, {'(AHAs),': 'O'}, {'anti-ribosomal': 'O'}, {'(anti-Rib)': 'O'}]"
"However, except for systemic sclerosis and mixed connective tissue disease, the impact of mean pulmonary arterial pressure (MPAP) on survival in CTD-ILD has not been sufficiently elucidated.","[{'However,': 'O'}, {'except': 'O'}, {'for': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'and': 'O'}, {'mixed': 'B-Entity'}, {'connective': 'I-Entity'}, {'tissue': 'I-Entity'}, {'disease,': 'I-Entity'}, {'the': 'O'}, {'impact': 'O'}, {'of': 'O'}, {'mean': 'O'}, {'pulmonary': 'O'}, {'arterial': 'O'}, {'pressure': 'O'}, {'(MPAP)': 'O'}, {'on': 'O'}, {'survival': 'O'}, {'in': 'O'}, {'CTD-ILD': 'I-Entity'}, {'has': 'O'}, {'not': 'O'}, {'been': 'O'}, {'sufficiently': 'O'}, {'elucidated.': 'O'}]"
"Although the surfaces of both the skin and oral mucosa are protected by squamous epithelial cells and fall within the scope of dermatologic practice, the oral cavity contains highly specialized structures and functions distinct from other skin biology and pathologic conditions and are also the purview of clinicians who care for patients with skin and mucosal diseases.","[{'Although': 'O'}, {'the': 'O'}, {'surfaces': 'O'}, {'of': 'O'}, {'both': 'O'}, {'the': 'O'}, {'skin': 'O'}, {'and': 'O'}, {'oral': 'O'}, {'mucosa': 'O'}, {'are': 'O'}, {'protected': 'O'}, {'by': 'O'}, {'squamous': 'O'}, {'epithelial': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'fall': 'O'}, {'within': 'O'}, {'the': 'O'}, {'scope': 'O'}, {'of': 'O'}, {'dermatologic': 'O'}, {'practice,': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'cavity': 'O'}, {'contains': 'O'}, {'highly': 'O'}, {'specialized': 'O'}, {'structures': 'O'}, {'and': 'O'}, {'functions': 'O'}, {'distinct': 'O'}, {'from': 'O'}, {'other': 'O'}, {'skin': 'O'}, {'biology': 'O'}, {'and': 'O'}, {'pathologic': 'O'}, {'conditions': 'O'}, {'and': 'O'}, {'are': 'O'}, {'also': 'O'}, {'the': 'O'}, {'purview': 'O'}, {'of': 'O'}]"
"We wanted to determine the MID for the HAQ, pain, fatigue, sleep and global VAS (0-100mm) in Sjogrens syndrome (SS) using a patient-reported overall health status anchor.","[{'We': 'O'}, {'wanted': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'MID': 'O'}, {'for': 'O'}, {'the': 'O'}, {'HAQ,': 'O'}, {'pain,': 'I-Entity'}, {'fatigue,': 'I-Entity'}, {'sleep': 'O'}, {'and': 'O'}, {'global': 'O'}, {'VAS': 'O'}, {'(0-100mm)': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'using': 'O'}, {'a': 'O'}, {'patient-reported': 'O'}, {'overall': 'O'}, {'health': 'O'}, {'status': 'O'}, {'anchor.': 'O'}]"
Dexamethasone (40mg QD for 4 days) and immunoglobulin (25g QD for 2 days) were administered for intensive treatment followed by oral methylprednisolone 40mg QD as maintenance treatment.,"[{'Dexamethasone': 'I-Entity'}, {'(40mg': 'O'}, {'QD': 'O'}, {'for': 'O'}, {'4': 'O'}, {'days)': 'O'}, {'and': 'O'}, {'immunoglobulin': 'O'}, {'(25g': 'O'}, {'QD': 'O'}, {'for': 'O'}, {'2': 'O'}, {'days)': 'O'}, {'were': 'O'}, {'administered': 'O'}, {'for': 'O'}, {'intensive': 'O'}, {'treatment': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'oral': 'O'}, {'methylprednisolone': 'I-Entity'}, {'40mg': 'O'}, {'QD': 'O'}, {'as': 'O'}, {'maintenance': 'O'}, {'treatment.': 'O'}]"
"Fifty-five (32%) patients were hospitalised, representing 111 hospitalisations (28 patients had ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢1 hospital admission).","[{'Fifty-five': 'O'}, {'(32%)': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'hospitalised,': 'O'}, {'representing': 'O'}, {'111': 'O'}, {'hospitalisations': 'O'}, {'(28': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢1': 'O'}, {'hospital': 'O'}, {'admission).': 'O'}]"
We report the case of a patient with primary Sjogren who presented proximal renal tubular acidosis associated with recurrent renal colic due to renal lithiasis and nephrocalcinosis.,"[{'We': 'O'}, {'report': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'who': 'O'}, {'presented': 'O'}, {'proximal': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'recurrent': 'O'}, {'renal': 'B-Entity'}, {'colic': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'renal': 'B-Entity'}, {'lithiasis': 'I-Entity'}, {'and': 'O'}, {'nephrocalcinosis.': 'I-Entity'}]"
Patients may be prone to dental caries and often have difficulty speaking and swallowing.,"[{'Patients': 'O'}, {'may': 'O'}, {'be': 'O'}, {'prone': 'O'}, {'to': 'O'}, {'dental': 'B-Entity'}, {'caries': 'I-Entity'}, {'and': 'O'}, {'often': 'O'}, {'have': 'O'}, {'difficulty': 'B-Entity'}, {'speaking': 'O'}, {'and': 'I-Entity'}, {'swallowing.': 'O'}]"
"The patients were categorized based on background diseases or therapeutic effects, and compared with clinical features, treatment strategies, and long-term outcomes among the groups.","[{'The': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'categorized': 'O'}, {'based': 'O'}, {'on': 'O'}, {'background': 'O'}, {'diseases': 'O'}, {'or': 'O'}, {'therapeutic': 'O'}, {'effects,': 'O'}, {'and': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'clinical': 'O'}, {'features,': 'O'}, {'treatment': 'O'}, {'strategies,': 'O'}, {'and': 'O'}, {'long-term': 'O'}, {'outcomes': 'O'}, {'among': 'O'}, {'the': 'O'}, {'groups.': 'O'}]"
We linked data to the Swedish Social Insurance Agency and calculated the proportion as well as net days of work disability in 30-day intervals from 12 months before pSS diagnosis until 24 months after .,"[{'We': 'O'}, {'linked': 'O'}, {'data': 'O'}, {'to': 'O'}, {'the': 'O'}, {'Swedish': 'O'}, {'Social': 'O'}, {'Insurance': 'O'}, {'Agency': 'O'}, {'and': 'O'}, {'calculated': 'O'}, {'the': 'O'}, {'proportion': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'net': 'O'}, {'days': 'O'}, {'of': 'O'}, {'work': 'B-Entity'}, {'disability': 'I-Entity'}, {'in': 'O'}, {'30-day': 'O'}, {'intervals': 'O'}, {'from': 'O'}, {'12': 'O'}, {'months': 'O'}, {'before': 'O'}, {'pSS': 'I-Entity'}, {'diagnosis': 'O'}, {'until': 'O'}, {'24': 'O'}, {'months': 'O'}, {'after': 'O'}, {'.': 'O'}]"
We report a 42-year-old patient presenting with acute motor sensory-axonal neuropathy in the presence of SS.,"[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'42-year-old': 'O'}, {'patient': 'O'}, {'presenting': 'O'}, {'with': 'O'}, {'acute': 'O'}, {'motor': 'O'}, {'sensory-axonal': 'O'}, {'neuropathy': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'SS.': 'I-Entity'}]"
The supplementary tests revealed positive antibodies for Sjogrens syndrome.,"[{'The': 'O'}, {'supplementary': 'O'}, {'tests': 'O'}, {'revealed': 'O'}, {'positive': 'O'}, {'antibodies': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"During the clinical course, progression of the radiologic PPFE-like lesions was observed in 13 of 21 patients.","[{'During': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'course,': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'the': 'O'}, {'radiologic': 'O'}, {'PPFE-like': 'I-Entity'}, {'lesions': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'13': 'O'}, {'of': 'O'}, {'21': 'O'}, {'patients.': 'O'}]"
"TMA is an infrequent, life-threatening multisystem disorder characterized by microangiopathic hemolytic anemia and thrombocytopenia, accompanied by microvascular thrombosis that causes variable degrees of tissue ischemia and infarction.","[{'TMA': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'infrequent,': 'O'}, {'life-threatening': 'O'}, {'multisystem': 'O'}, {'disorder': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'microangiopathic': 'B-Entity'}, {'hemolytic': 'I-Entity'}, {'anemia': 'I-Entity'}, {'and': 'O'}, {'thrombocytopenia,': 'I-Entity'}, {'accompanied': 'O'}, {'by': 'O'}, {'microvascular': 'B-Entity'}, {'thrombosis': 'I-Entity'}, {'that': 'O'}, {'causes': 'O'}, {'variable': 'O'}, {'degrees': 'O'}, {'of': 'O'}, {'tissue': 'B-Entity'}, {'ischemia': 'I-Entity'}, {'and': 'O'}, {'infarction.': 'I-Entity'}]"
"Cytotoxic medicines significantly increased the frequency of erosive oesophagitis, it tended to increase under effect of NSAID and low doses of aspirin.","[{'Cytotoxic': 'I-Entity'}, {'medicines': 'O'}, {'significantly': 'O'}, {'increased': 'O'}, {'the': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'erosive': 'O'}, {'oesophagitis,': 'I-Entity'}, {'it': 'O'}, {'tended': 'O'}, {'to': 'O'}, {'increase': 'O'}, {'under': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'NSAID': 'O'}, {'and': 'O'}, {'low': 'O'}, {'doses': 'O'}, {'of': 'O'}, {'aspirin.': 'I-Entity'}]"
"In a majority of cases (90%), AGEP is drug induced and different drugs are reported as cause of AGEP.","[{'In': 'O'}, {'a': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'cases': 'O'}, {'(90%),': 'O'}, {'AGEP': 'I-Entity'}, {'is': 'O'}, {'drug': 'O'}, {'induced': 'O'}, {'and': 'O'}, {'different': 'O'}, {'drugs': 'O'}, {'are': 'O'}, {'reported': 'O'}, {'as': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'AGEP.': 'I-Entity'}]"
"We report a case of a previously healthy 55-year-old African American female who presented with shortness of breath, hemolytic anemia, renal impairment, and thrombocytopenia.","[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'previously': 'O'}, {'healthy': 'O'}, {'55-year-old': 'O'}, {'African': 'O'}, {'American': 'O'}, {'female': 'O'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'shortness': 'B-Entity'}, {'of': 'I-Entity'}, {'breath,': 'I-Entity'}, {'hemolytic': 'B-Entity'}, {'anemia,': 'I-Entity'}, {'renal': 'B-Entity'}, {'impairment,': 'I-Entity'}, {'and': 'O'}, {'thrombocytopenia.': 'I-Entity'}]"
"IL-35 may act as a potential therapeutic agent against inflammation in patients with pSS.University, Shanghai, China.University, Shanghai, China.University, Shanghai, China.University, Shanghai, China.Liberation Army, Suzhou, China.University, Shanghai, China.Sjogrens syndrome: a case report.","[{'IL-35': 'O'}, {'may': 'O'}, {'act': 'O'}, {'as': 'O'}, {'a': 'O'}, {'potential': 'O'}, {'therapeutic': 'O'}, {'agent': 'O'}, {'against': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.University,': 'I-Entity'}, {'Shanghai,': 'O'}, {'China.University,': 'O'}, {'Shanghai,': 'O'}, {'China.University,': 'O'}, {'Shanghai,': 'O'}, {'China.University,': 'O'}, {'Shanghai,': 'O'}, {'China.Liberation': 'O'}, {'Army,': 'O'}, {'Suzhou,': 'O'}, {'China.University,': 'O'}, {'Shanghai,': 'O'}, {'China.Sjogrens': 'O'}, {'syndrome:': 'I-Entity'}]"
"Of the nine patients with polyneuropathy, eight patients presented pure sensory neuropathy including small fiber neuropathy (SFN).","[{'Of': 'O'}, {'the': 'O'}, {'nine': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'polyneuropathy,': 'I-Entity'}, {'eight': 'O'}, {'patients': 'O'}, {'presented': 'O'}, {'pure': 'O'}, {'sensory': 'O'}, {'neuropathy': 'I-Entity'}, {'including': 'O'}, {'small': 'B-Entity'}, {'fiber': 'I-Entity'}, {'neuropathy': 'I-Entity'}, {'(SFN).': 'O'}]"
Frequent and varied central and peripheral nervous system complications occur in vasculitides and connective tissue diseases.,"[{'Frequent': 'O'}, {'and': 'O'}, {'varied': 'O'}, {'central': 'B-Entity'}, {'and': 'I-Entity'}, {'peripheral': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'complications': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'vasculitides': 'I-Entity'}, {'and': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"When applying salivary diagnostics in combination with instruments to rate disease activity and progression in SS, one might be able to select those SS patients who respond to a particular type of biological.","[{'When': 'O'}, {'applying': 'O'}, {'salivary': 'O'}, {'diagnostics': 'O'}, {'in': 'O'}, {'combination': 'O'}, {'with': 'O'}, {'instruments': 'O'}, {'to': 'O'}, {'rate': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'progression': 'O'}, {'in': 'O'}, {'SS,': 'I-Entity'}, {'one': 'O'}, {'might': 'O'}, {'be': 'O'}, {'able': 'O'}, {'to': 'O'}, {'select': 'O'}, {'those': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'who': 'O'}, {'respond': 'O'}, {'to': 'O'}, {'a': 'O'}, {'particular': 'O'}, {'type': 'O'}, {'of': 'O'}, {'biological.': 'O'}]"
To assess the prevalence and determine predictors of Sjogrens syndrome (SS) in patients with clinically significant aqueous-deficient dry eye.,"[{'To': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'and': 'O'}, {'determine': 'O'}, {'predictors': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'clinically': 'O'}, {'significant': 'O'}, {'aqueous-deficient': 'O'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"On the other hand, physiological aging might be considered as a risk factor for development of SS, resulting in a faster development of the syndrome.","[{'On': 'O'}, {'the': 'O'}, {'other': 'O'}, {'hand,': 'O'}, {'physiological': 'O'}, {'aging': 'O'}, {'might': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'as': 'O'}, {'a': 'O'}, {'risk': 'O'}, {'factor': 'O'}, {'for': 'O'}, {'development': 'O'}, {'of': 'O'}, {'SS,': 'I-Entity'}, {'resulting': 'O'}, {'in': 'O'}, {'a': 'O'}, {'faster': 'O'}, {'development': 'O'}, {'of': 'O'}, {'the': 'O'}, {'syndrome.': 'O'}]"
"Current work is ongoing to define disease activity levels and clinically important changes for defining significant clinical improvement with the systemic score ESSDAI, and ESSPRI.","[{'Current': 'O'}, {'work': 'O'}, {'is': 'O'}, {'ongoing': 'O'}, {'to': 'O'}, {'define': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'clinically': 'O'}, {'important': 'O'}, {'changes': 'O'}, {'for': 'O'}, {'defining': 'O'}, {'significant': 'O'}, {'clinical': 'O'}, {'improvement': 'O'}, {'with': 'O'}, {'the': 'O'}, {'systemic': 'O'}, {'score': 'O'}, {'ESSDAI,': 'O'}, {'and': 'O'}, {'ESSPRI.': 'O'}]"
Ultimately this collaboration of care by the dental and medical professionals will benefit the Sjogrens syndrome patient and lead to better patient outcomes.,"[{'Ultimately': 'O'}, {'this': 'O'}, {'collaboration': 'O'}, {'of': 'O'}, {'care': 'O'}, {'by': 'O'}, {'the': 'O'}, {'dental': 'O'}, {'and': 'O'}, {'medical': 'O'}, {'professionals': 'O'}, {'will': 'O'}, {'benefit': 'O'}, {'the': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patient': 'O'}, {'and': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'better': 'O'}, {'patient': 'O'}, {'outcomes.': 'O'}]"
A solo LSG biopsy is insufficient for the diagnosis of IgG4-RD because of its low sensitivity.,"[{'A': 'O'}, {'solo': 'O'}, {'LSG': 'O'}, {'biopsy': 'O'}, {'is': 'O'}, {'insufficient': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'IgG4-RD': 'B-Entity'}, {'because': 'O'}, {'of': 'O'}, {'its': 'O'}, {'low': 'O'}, {'sensitivity.': 'O'}]"
"Subcutaneous TCZ might be an effective therapeutic option for treating refractory SSM when SAA levels are elevated.Yokohama, Kanagawa, Japan.MALT lymphoma.","[{'Subcutaneous': 'O'}, {'TCZ': 'I-Entity'}, {'might': 'O'}, {'be': 'O'}, {'an': 'O'}, {'effective': 'O'}, {'therapeutic': 'O'}, {'option': 'O'}, {'for': 'O'}, {'treating': 'O'}, {'refractory': 'O'}, {'SSM': 'I-Entity'}, {'when': 'O'}, {'SAA': 'I-Entity'}, {'levels': 'O'}, {'are': 'O'}, {'elevated.Yokohama,': 'O'}, {'Kanagawa,': 'O'}, {'Japan.MALT': 'O'}, {'lymphoma.': 'I-Entity'}]"
"Furthermore, in some circumstances, more than one individual may have contributed to the description or discovery of a particular anatomical structure or disease, whereas in others, an eponym may have been incorrectly applied initially and propagated for years in the medical literature.","[{'Furthermore,': 'O'}, {'in': 'O'}, {'some': 'O'}, {'circumstances,': 'O'}, {'more': 'O'}, {'than': 'O'}, {'one': 'O'}, {'individual': 'O'}, {'may': 'O'}, {'have': 'O'}, {'contributed': 'O'}, {'to': 'O'}, {'the': 'O'}, {'description': 'O'}, {'or': 'O'}, {'discovery': 'O'}, {'of': 'O'}, {'a': 'O'}, {'particular': 'O'}, {'anatomical': 'O'}, {'structure': 'O'}, {'or': 'O'}, {'disease,': 'O'}, {'whereas': 'O'}, {'in': 'O'}, {'others,': 'O'}, {'an': 'O'}, {'eponym': 'O'}, {'may': 'O'}, {'have': 'O'}, {'been': 'O'}, {'incorrectly': 'O'}, {'applied': 'O'}, {'initially': 'O'}, {'and': 'O'}, {'propagated': 'O'}, {'for': 'O'}, {'years': 'O'}, {'in': 'O'}, {'the': 'O'}, {'medical': 'O'}, {'literature.': 'O'}]"
Receiver operating characteristic analysis showed an optimal cutoff value of ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢1.5 for SGUS.,"[{'Receiver': 'O'}, {'operating': 'O'}, {'characteristic': 'O'}, {'analysis': 'O'}, {'showed': 'O'}, {'an': 'O'}, {'optimal': 'O'}, {'cutoff': 'O'}, {'value': 'O'}, {'of': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢1.5': 'O'}, {'for': 'O'}, {'SGUS.': 'O'}]"
Fabry disease is a rare X-linked metabolic disorder characterized by a deficiency in the enzyme alpha-galactosidase A.,"[{'Fabry': 'B-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'X-linked': 'O'}, {'metabolic': 'B-Entity'}, {'disorder': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'a': 'O'}, {'deficiency': 'O'}, {'in': 'O'}, {'the': 'O'}, {'enzyme': 'O'}, {'alpha-galactosidase': 'O'}, {'A.': 'O'}]"
"We assessed traditional risk factors such as hypertension, diabetes, dyslipidemia, smoking, and family history of atherosclerosis.","[{'We': 'O'}, {'assessed': 'O'}, {'traditional': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'such': 'O'}, {'as': 'O'}, {'hypertension,': 'I-Entity'}, {'diabetes,': 'I-Entity'}, {'dyslipidemia,': 'I-Entity'}, {'smoking,': 'O'}, {'and': 'O'}, {'family': 'O'}, {'history': 'O'}, {'of': 'O'}, {'atherosclerosis.': 'I-Entity'}]"
"Primary Sjogrens Syndrome (pSS) is a chronic, slowly progressive inflammatory autoimmune disorder, characterised by lymphocytic infiltration of the exocrine glands, leading to decrease of glandular secretion.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic,': 'O'}, {'slowly': 'O'}, {'progressive': 'O'}, {'inflammatory': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disorder,': 'I-Entity'}, {'characterised': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'decrease': 'O'}, {'of': 'O'}, {'glandular': 'O'}, {'secretion.': 'O'}]"
"The Medical Outcomes Study 36-Item Short-Form Health Survey Physical Functioning subscore, was significantly reduced in patients with lung involvement (P = 0.03).","[{'The': 'O'}, {'Medical': 'O'}, {'Outcomes': 'O'}, {'Study': 'O'}, {'36-Item': 'O'}, {'Short-Form': 'O'}, {'Health': 'O'}, {'Survey': 'O'}, {'Physical': 'O'}, {'Functioning': 'O'}, {'subscore,': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'reduced': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'lung': 'B-Entity'}, {'involvement': 'I-Entity'}, {'(P': 'O'}, {'=': 'O'}, {'0.03).': 'O'}]"
"She also showed hypokalemia, metabolic acidosis, and nephrocalcinosis caused by distal renal tubular acidosis associated with Sjogren syndrome.","[{'She': 'O'}, {'also': 'O'}, {'showed': 'O'}, {'hypokalemia,': 'I-Entity'}, {'metabolic': 'B-Entity'}, {'acidosis,': 'I-Entity'}, {'and': 'O'}, {'nephrocalcinosis': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'distal': 'O'}, {'renal': 'O'}, {'tubular': 'O'}, {'acidosis': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Associations between dental abnormalities and selected clinical and serologic manifestations of SSc were examined.,"[{'Associations': 'O'}, {'between': 'O'}, {'dental': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'and': 'O'}, {'selected': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'serologic': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'SSc': 'I-Entity'}, {'were': 'O'}, {'examined.': 'O'}]"
"In 9-20% of cases, Sjogrens syndrome is associated with various respiratory symptoms.","[{'In': 'O'}, {'9-20%': 'O'}, {'of': 'O'}, {'cases,': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'various': 'O'}, {'respiratory': 'O'}, {'symptoms.': 'O'}]"
Both plasma midkine and pleiotrophin levels were associated with rash and anti-SSA in SLE.,"[{'Both': 'O'}, {'plasma': 'O'}, {'midkine': 'I-Entity'}, {'and': 'O'}, {'pleiotrophin': 'I-Entity'}, {'levels': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'rash': 'I-Entity'}, {'and': 'O'}, {'anti-SSA': 'O'}, {'in': 'O'}, {'SLE.': 'I-Entity'}]"
The 26-year-old patient also developed acute motor axonal neuropathy one week after autoimmune encephalitis.,"[{'The': 'O'}, {'26-year-old': 'O'}, {'patient': 'O'}, {'also': 'O'}, {'developed': 'O'}, {'acute': 'O'}, {'motor': 'O'}, {'axonal': 'O'}, {'neuropathy': 'I-Entity'}, {'one': 'O'}, {'week': 'O'}, {'after': 'O'}, {'autoimmune': 'B-Entity'}, {'encephalitis.': 'I-Entity'}]"
"In conclusion, elevated plasma midkine and pleiotrophin levels and their associations with rash, anti-SSA and IL-17 in SLE patients suggest their involvement in this disease.University, Hefei, Anhui, China.Diagnosis, Hefei, Anhui, China.University, Hefei, Anhui, China.Diagnosis, Hefei, Anhui, China.University, Hefei, Anhui, China.Diagnosis, Hefei, Anhui, China.2001 and 2014.","[{'In': 'O'}, {'conclusion,': 'O'}, {'elevated': 'O'}, {'plasma': 'O'}, {'midkine': 'O'}, {'and': 'O'}, {'pleiotrophin': 'I-Entity'}, {'levels': 'O'}, {'and': 'O'}, {'their': 'O'}, {'associations': 'O'}, {'with': 'O'}, {'rash,': 'I-Entity'}, {'anti-SSA': 'O'}, {'and': 'O'}, {'IL-17': 'O'}, {'in': 'O'}, {'SLE': 'I-Entity'}, {'patients': 'O'}, {'suggest': 'O'}, {'their': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'this': 'O'}, {'disease.University,': 'O'}, {'Hefei,': 'O'}, {'Anhui,': 'O'}, {'China.Diagnosis,': 'O'}, {'Hefei,': 'O'}, {'Anhui,': 'O'}]"
"From these data concerning a small number of patients, treatment strategies with corticosteroids in association with immunosuppressive drugs, namely mycophenolate mofetil, had positive results.","[{'From': 'O'}, {'these': 'O'}, {'data': 'O'}, {'concerning': 'O'}, {'a': 'O'}, {'small': 'O'}, {'number': 'O'}, {'of': 'O'}, {'patients,': 'O'}, {'treatment': 'O'}, {'strategies': 'O'}, {'with': 'O'}, {'corticosteroids': 'O'}, {'in': 'O'}, {'association': 'O'}, {'with': 'O'}, {'immunosuppressive': 'O'}, {'drugs,': 'O'}, {'namely': 'O'}, {'mycophenolate': 'B-Entity'}, {'mofetil,': 'I-Entity'}, {'had': 'O'}, {'positive': 'O'}, {'results.': 'O'}]"
"All the patients and controls were examined by salivary gland ultrasonography (B-mode, color and spectral Doppler, and sonoelastography), determining the following parameters: salivary gland ultrasonography (SGUS) score, resistive index (RI) of transverse facial artery, and shear wave velocity (SWV).","[{'All': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'ultrasonography': 'O'}, {'(B-mode,': 'O'}, {'color': 'O'}, {'and': 'O'}, {'spectral': 'O'}, {'Doppler,': 'O'}, {'and': 'O'}, {'sonoelastography),': 'O'}, {'determining': 'O'}, {'the': 'O'}, {'following': 'O'}, {'parameters:': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'ultrasonography': 'O'}, {'(SGUS)': 'O'}, {'score,': 'O'}, {'resistive': 'O'}, {'index': 'O'}, {'(RI)': 'O'}]"
"MPAP evaluation provides additional information on disease status and will help physicians predict mortality in CTD-ILD.Nagoya, Aichi, Japan.Nishioiwake-cho, Seto, Aichi, 489-8642, Japan.Nishioiwake-cho, Seto, Aichi, 489-8642, Japan.","[{'MPAP': 'O'}, {'evaluation': 'O'}, {'provides': 'O'}, {'additional': 'O'}, {'information': 'O'}, {'on': 'O'}, {'disease': 'O'}, {'status': 'O'}, {'and': 'O'}, {'will': 'O'}, {'help': 'O'}, {'physicians': 'O'}, {'predict': 'O'}, {'mortality': 'O'}, {'in': 'O'}, {'CTD-ILD.Nagoya,': 'I-Entity'}, {'Aichi,': 'O'}, {'Japan.Nishioiwake-cho,': 'O'}, {'Seto,': 'O'}, {'Aichi,': 'O'}, {'489-8642,': 'O'}, {'Japan.Nishioiwake-cho,': 'O'}, {'Seto,': 'O'}]"
"The diagnosis of malignant lymphoma or lymphoproliferative diseases should be made clinically, pathologically and cytogenetically to rule out other similar diseases.of Medicine, Oita, Japan.","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'malignant': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'or': 'O'}, {'lymphoproliferative': 'B-Entity'}, {'diseases': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'made': 'O'}, {'clinically,': 'O'}, {'pathologically': 'O'}, {'and': 'O'}, {'cytogenetically': 'O'}, {'to': 'O'}, {'rule': 'O'}, {'out': 'O'}, {'other': 'O'}, {'similar': 'O'}, {'diseases.of': 'O'}, {'Medicine,': 'O'}, {'Oita,': 'O'}, {'Japan.': 'O'}]"
China.10.1097/RCT.0000000000000554.with primary Sjogrens syndrome is associated with increased disease activity.,"[{'China.10.1097/RCT.0000000000000554.with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
We reviewed the literature to evaluate the role of common laboratory tests and to examine the recent progress in the laboratory diagnosis of pediatric rheumatic diseases.,"[{'We': 'O'}, {'reviewed': 'O'}, {'the': 'O'}, {'literature': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'common': 'O'}, {'laboratory': 'O'}, {'tests': 'O'}, {'and': 'O'}, {'to': 'O'}, {'examine': 'O'}, {'the': 'O'}, {'recent': 'O'}, {'progress': 'O'}, {'in': 'O'}, {'the': 'O'}, {'laboratory': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pediatric': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Therefore, we administered a second course of immunoglobulin therapy and steroid therapy, which included both pulse and oral administration.","[{'Therefore,': 'O'}, {'we': 'O'}, {'administered': 'O'}, {'a': 'O'}, {'second': 'O'}, {'course': 'O'}, {'of': 'O'}, {'immunoglobulin': 'O'}, {'therapy': 'O'}, {'and': 'O'}, {'steroid': 'I-Entity'}, {'therapy,': 'O'}, {'which': 'O'}, {'included': 'O'}, {'both': 'O'}, {'pulse': 'O'}, {'and': 'O'}, {'oral': 'O'}, {'administration.': 'O'}]"
"In rare situations, they may also be indicated in systemic lupus erythematosus (SLE), Sjogrens syndrome and neuropathies, catastrophic antiphospholipid syndrome (APS), scleroderma, antineutrophil cytoplasmic antibody (ANCA) associated vasculitis, pyoderma gangrenosum and scleromyxedema.","[{'In': 'O'}, {'rare': 'O'}, {'situations,': 'O'}, {'they': 'O'}, {'may': 'O'}, {'also': 'O'}, {'be': 'O'}, {'indicated': 'O'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'neuropathies,': 'I-Entity'}, {'catastrophic': 'O'}, {'antiphospholipid': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(APS),': 'O'}, {'scleroderma,': 'I-Entity'}, {'antineutrophil': 'B-Entity'}, {'cytoplasmic': 'I-Entity'}]"
Thermal pulsation is a therapeutic option for patients with Sjogren disease who have MGD and dry eye symptoms.,"[{'Thermal': 'O'}, {'pulsation': 'O'}, {'is': 'O'}, {'a': 'O'}, {'therapeutic': 'O'}, {'option': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'disease': 'I-Entity'}, {'who': 'O'}, {'have': 'O'}, {'MGD': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'symptoms.': 'O'}]"
"For the purpose of this review, we defined rare patterns as patterns occurring in less than 1% of patients that test positive on indirect immunofluorescence.","[{'For': 'O'}, {'the': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'review,': 'O'}, {'we': 'O'}, {'defined': 'O'}, {'rare': 'O'}, {'patterns': 'O'}, {'as': 'O'}, {'patterns': 'O'}, {'occurring': 'O'}, {'in': 'O'}, {'less': 'O'}, {'than': 'O'}, {'1%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'that': 'O'}, {'test': 'O'}, {'positive': 'O'}, {'on': 'O'}, {'indirect': 'O'}, {'immunofluorescence.': 'O'}]"
"Sjogrens syndrome is an important differential diagnosis in patients with sensory neuronopathy because immunosuppressive therapy may prevent progressive degeneration of sensory fibres, ganglions and axons.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'important': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'sensory': 'B-Entity'}, {'neuronopathy': 'I-Entity'}, {'because': 'O'}, {'immunosuppressive': 'O'}, {'therapy': 'O'}, {'may': 'O'}, {'prevent': 'O'}, {'progressive': 'O'}, {'degeneration': 'B-Entity'}, {'of': 'O'}, {'sensory': 'I-Entity'}, {'fibres,': 'O'}, {'ganglions': 'O'}, {'and': 'O'}, {'axons.': 'O'}]"
"Whereas antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) have diagnostic significance, the dense fine speckled (DFS) pattern on HEp-2 cells may be an exclusionary marker for ANA-associated rheumatic disease (AARD).","[{'Whereas': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'(ANAs)': 'O'}, {'detected': 'O'}, {'by': 'O'}, {'indirect': 'O'}, {'immunofluorescence': 'O'}, {'(IIF)': 'O'}, {'have': 'O'}, {'diagnostic': 'O'}, {'significance,': 'O'}, {'the': 'O'}, {'dense': 'O'}, {'fine': 'O'}, {'speckled': 'O'}, {'(DFS)': 'O'}, {'pattern': 'O'}, {'on': 'O'}, {'HEp-2': 'O'}, {'cells': 'O'}, {'may': 'O'}, {'be': 'O'}, {'an': 'O'}, {'exclusionary': 'O'}, {'marker': 'O'}, {'for': 'O'}, {'ANA-associated': 'O'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'(AARD).': 'O'}]"
"Diffuse (40%), focal/multifocal (36%), multiple sclerosis (MS)-like disease (20%) and isolated optic neuritis (4%) were the most common CNS clinical pictures.","[{'Diffuse': 'O'}, {'(40%),': 'O'}, {'focal/multifocal': 'O'}, {'(36%),': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(MS)-like': 'O'}, {'disease': 'I-Entity'}, {'(20%)': 'O'}, {'and': 'O'}, {'isolated': 'O'}, {'optic': 'B-Entity'}, {'neuritis': 'I-Entity'}, {'(4%)': 'O'}, {'were': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'CNS': 'O'}, {'clinical': 'O'}, {'pictures.': 'O'}]"
"Remission had been induced by the monoclonal antibody adalimumab, and maintenance therapy had continued since her diagnosis.","[{'Remission': 'O'}, {'had': 'O'}, {'been': 'O'}, {'induced': 'O'}, {'by': 'O'}, {'the': 'O'}, {'monoclonal': 'O'}, {'antibody': 'O'}, {'adalimumab,': 'I-Entity'}, {'and': 'O'}, {'maintenance': 'O'}, {'therapy': 'O'}, {'had': 'O'}, {'continued': 'O'}, {'since': 'O'}, {'her': 'O'}, {'diagnosis.': 'O'}]"
We present the case of a 37 year-old woman admitted because of generalized grade 2 muscle weakness which developed over a week.,"[{'We': 'O'}, {'present': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'37': 'O'}, {'year-old': 'O'}, {'woman': 'O'}, {'admitted': 'O'}, {'because': 'O'}, {'of': 'O'}, {'generalized': 'O'}, {'grade': 'O'}, {'2': 'O'}, {'muscle': 'B-Entity'}, {'weakness': 'I-Entity'}, {'which': 'O'}, {'developed': 'O'}, {'over': 'O'}, {'a': 'O'}, {'week.': 'O'}]"
"The lower intake of carbohydrates was due to a lower bread intake (p = 0.04), while the higher intake of fat was due to a higher intake of butter, margarine, and oil (p = 0.01).","[{'The': 'O'}, {'lower': 'O'}, {'intake': 'O'}, {'of': 'O'}, {'carbohydrates': 'I-Entity'}, {'was': 'O'}, {'due': 'O'}, {'to': 'O'}, {'a': 'O'}, {'lower': 'O'}, {'bread': 'I-Entity'}, {'intake': 'O'}, {'(p': 'O'}, {'=': 'O'}, {'0.04),': 'O'}, {'while': 'O'}, {'the': 'O'}, {'higher': 'O'}, {'intake': 'O'}, {'of': 'O'}, {'fat': 'I-Entity'}, {'was': 'O'}, {'due': 'O'}, {'to': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'intake': 'O'}, {'of': 'O'}, {'butter,': 'I-Entity'}, {'margarine,': 'I-Entity'}, {'and': 'O'}, {'oil': 'O'}, {'(p': 'O'}, {'=': 'O'}, {'0.01).': 'O'}]"
"Moreover, changing the immunization conditions to MAP-Ro60 in the abdominal area, and to lesser extend in the tailbase, also led to impaired SG function in SJL/J mice.","[{'Moreover,': 'O'}, {'changing': 'O'}, {'the': 'O'}, {'immunization': 'O'}, {'conditions': 'O'}, {'to': 'O'}, {'MAP-Ro60': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'abdominal': 'O'}, {'area,': 'O'}, {'and': 'O'}, {'to': 'O'}, {'lesser': 'O'}, {'extend': 'O'}, {'in': 'O'}, {'the': 'O'}, {'tailbase,': 'O'}, {'also': 'O'}, {'led': 'O'}, {'to': 'O'}, {'impaired': 'O'}, {'SG': 'O'}, {'function': 'O'}, {'in': 'O'}, {'SJL/J': 'O'}, {'mice.': 'O'}]"
"To identify disease-relevant triggers of the type I IFN pathway, this study sought to investigate whether endogenous virus-like genomic repeat elements, normally silent, are expressed in patients with systemic autoimmune disease, and whether these retroelements could activate an innate immune response and induce type I IFN.","[{'To': 'O'}, {'identify': 'O'}, {'disease-relevant': 'O'}, {'triggers': 'O'}, {'of': 'O'}, {'the': 'O'}, {'type': 'O'}, {'I': 'O'}, {'IFN': 'O'}, {'pathway,': 'O'}, {'this': 'O'}, {'study': 'O'}, {'sought': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'whether': 'O'}, {'endogenous': 'O'}, {'virus-like': 'O'}, {'genomic': 'O'}, {'repeat': 'O'}, {'elements,': 'O'}, {'normally': 'O'}, {'silent,': 'O'}, {'are': 'O'}, {'expressed': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease,': 'I-Entity'}, {'and': 'O'}, {'whether': 'O'}, {'these': 'O'}, {'retroelements': 'O'}, {'could': 'O'}, {'activate': 'O'}, {'an': 'O'}, {'innate': 'O'}, {'immune': 'O'}, {'response': 'O'}]"
"We performed a retrospective chart review of 12 patients treated (6 multiple sclerosis [MS], 4 neuromyelitis optica [NMO], and 2 Sjogren's syndrome myelopathy [SSM]) with HDMTX-LR after failing to improve, or exhibiting worsening following conventional immunotherapy.","[{'We': 'O'}, {'performed': 'O'}, {'a': 'O'}, {'retrospective': 'O'}, {'chart': 'O'}, {'review': 'O'}, {'of': 'O'}, {'12': 'O'}, {'patients': 'O'}, {'treated': 'O'}, {'(6': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'[MS],': 'O'}, {'4': 'O'}, {'neuromyelitis': 'B-Entity'}, {'optica': 'I-Entity'}, {'[NMO],': 'O'}, {'and': 'O'}, {'2': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'myelopathy': 'I-Entity'}, {'[SSM])': 'O'}, {'with': 'O'}, {'HDMTX-LR': 'I-Entity'}, {'after': 'O'}, {'failing': 'O'}, {'to': 'O'}, {'improve,': 'O'}, {'or': 'O'}]"
"However, increased ‚âà√≠‚Äö√¢‚Ä¢-globulin, positive antinuclear antibodies, and anti-SS-A and anti-SS-B antibodies were detected.","[{'However,': 'O'}, {'increased': 'O'}, {'‚âà√≠‚Äö√¢‚Ä¢-globulin,': 'O'}, {'positive': 'O'}, {'antinuclear': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'anti-SS-A': 'O'}, {'and': 'O'}, {'anti-SS-B': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'detected.': 'O'}]"
In vivo LIPUS exposure to MRL/lpr mice exhibited a significant increase in both salivary flow and AQP5 expression by reducing inflammation in salivary glands (p < 0.01).,"[{'In': 'O'}, {'vivo': 'O'}, {'LIPUS': 'I-Entity'}, {'exposure': 'O'}, {'to': 'O'}, {'MRL/lpr': 'O'}, {'mice': 'O'}, {'exhibited': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'both': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'and': 'O'}, {'AQP5': 'O'}, {'expression': 'O'}, {'by': 'O'}, {'reducing': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'(p': 'O'}, {'<': 'O'}, {'0.01).': 'O'}]"
"Fourteen female SS dry eye patients were exposed for 2 hours to a controlled normal condition (23 C, 45% relative humidity, and air flow 0.10 m/s) and a controlled adverse condition that simulates desiccating stress (23 C, 5% relative humidity, and air flow 0.10 m/s).","[{'Fourteen': 'O'}, {'female': 'O'}, {'SS': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients': 'O'}, {'were': 'O'}, {'exposed': 'O'}, {'for': 'O'}, {'2': 'O'}, {'hours': 'O'}, {'to': 'O'}, {'a': 'O'}, {'controlled': 'O'}, {'normal': 'O'}, {'condition': 'O'}, {'(23': 'O'}, {'C,': 'O'}, {'45%': 'O'}, {'relative': 'O'}, {'humidity,': 'O'}, {'and': 'O'}, {'air': 'O'}, {'flow': 'O'}, {'0.10': 'O'}, {'m/s)': 'O'}, {'and': 'O'}, {'a': 'O'}, {'controlled': 'O'}, {'adverse': 'O'}, {'condition': 'O'}, {'that': 'O'}, {'simulates': 'O'}, {'desiccating': 'O'}, {'stress': 'O'}, {'(23': 'O'}, {'C,': 'O'}, {'5%': 'O'}, {'relative': 'O'}, {'humidity,': 'O'}, {'and': 'O'}, {'air': 'O'}, {'flow': 'O'}, {'0.10': 'O'}]"
"To determine associations between sicca symptoms, chronic rhinosinusitis (CRS) symptoms and asthma in a community survey.","[{'To': 'O'}, {'determine': 'O'}, {'associations': 'O'}, {'between': 'O'}, {'sicca': 'B-Entity'}, {'symptoms,': 'O'}, {'chronic': 'B-Entity'}, {'rhinosinusitis': 'I-Entity'}, {'(CRS)': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'asthma': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'community': 'O'}, {'survey.': 'O'}]"
"Neuromyotonia is a rare disorder caused by the hyperexcitability of peripheral nerves, causing spontaneous and continuous muscle contraction.","[{'Neuromyotonia': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'disorder': 'O'}, {'caused': 'O'}, {'by': 'O'}, {'the': 'O'}, {'hyperexcitability': 'O'}, {'of': 'O'}, {'peripheral': 'O'}, {'nerves,': 'O'}, {'causing': 'O'}, {'spontaneous': 'O'}, {'and': 'O'}, {'continuous': 'O'}, {'muscle': 'B-Entity'}, {'contraction.': 'I-Entity'}]"
"Taken together, our results indicate that pSS should be considered in the differential diagnosis of AIHA, even in the absence of sicca symptoms.","[{'Taken': 'O'}, {'together,': 'O'}, {'our': 'O'}, {'results': 'O'}, {'indicate': 'O'}, {'that': 'O'}, {'pSS': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'in': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'AIHA,': 'I-Entity'}, {'even': 'O'}, {'in': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'sicca': 'I-Entity'}, {'symptoms.': 'O'}]"
Better diagnostic tools are needed to determine if the frequent seronegative status of these SS patients may be related to a unique disease pathogenesis.,"[{'Better': 'O'}, {'diagnostic': 'O'}, {'tools': 'O'}, {'are': 'O'}, {'needed': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'if': 'O'}, {'the': 'O'}, {'frequent': 'O'}, {'seronegative': 'O'}, {'status': 'O'}, {'of': 'O'}, {'these': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'may': 'O'}, {'be': 'O'}, {'related': 'O'}, {'to': 'O'}, {'a': 'O'}, {'unique': 'O'}, {'disease': 'O'}, {'pathogenesis.': 'O'}]"
"We recruited 31 participants with SS dry eye, 30 participants with non-SS dry eye, and 35 healthy controls without dry eye symptoms.","[{'We': 'O'}, {'recruited': 'O'}, {'31': 'O'}, {'participants': 'O'}, {'with': 'O'}, {'SS': 'O'}, {'dry': 'B-Entity'}, {'eye,': 'I-Entity'}, {'30': 'O'}, {'participants': 'O'}, {'with': 'O'}, {'non-SS': 'O'}, {'dry': 'B-Entity'}, {'eye,': 'I-Entity'}, {'and': 'O'}, {'35': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'without': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'symptoms.': 'O'}]"
Citric acid potassium citrate was then replaced with sodium bicarbonate at 15.5‚Äö√Ñ√∂‚àö√ë‚àö¬¢mEq every 6 hours which was continued for 2 years without significant improvement in her symptoms and electrolytes.,"[{'Citric': 'B-Entity'}, {'acid': 'I-Entity'}, {'potassium': 'I-Entity'}, {'citrate': 'I-Entity'}, {'was': 'O'}, {'then': 'O'}, {'replaced': 'O'}, {'with': 'O'}, {'sodium': 'B-Entity'}, {'bicarbonate': 'I-Entity'}, {'at': 'O'}, {'15.5‚Äö√Ñ√∂‚àö√ë‚àö¬¢mEq': 'O'}, {'every': 'O'}, {'6': 'O'}, {'hours': 'O'}, {'which': 'O'}, {'was': 'O'}, {'continued': 'O'}, {'for': 'O'}, {'2': 'O'}, {'years': 'O'}, {'without': 'O'}, {'significant': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'her': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'electrolytes.': 'O'}]"
"Current understanding of the pathophysiology of lung disease in pSS suggests a similar process driving the pulmonary process as those in the salivary glands, with epithelial cells playing a critical role in the initiation, maintenance, and symptomatology of the disease.","[{'Current': 'O'}, {'understanding': 'O'}, {'of': 'O'}, {'the': 'O'}, {'pathophysiology': 'O'}, {'of': 'O'}, {'lung': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'pSS': 'O'}, {'suggests': 'O'}, {'a': 'O'}, {'similar': 'O'}, {'process': 'O'}, {'driving': 'O'}, {'the': 'O'}, {'pulmonary': 'O'}, {'process': 'O'}, {'as': 'O'}, {'those': 'O'}, {'in': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'with': 'O'}, {'epithelial': 'O'}, {'cells': 'O'}, {'playing': 'O'}, {'a': 'O'}, {'critical': 'O'}, {'role': 'O'}, {'in': 'O'}, {'the': 'O'}, {'initiation,': 'O'}, {'maintenance,': 'O'}, {'and': 'O'}, {'symptomatology': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
"Thymomas, benign or malignant, may be associated with autoimmune diseases.","[{'Thymomas,': 'I-Entity'}, {'benign': 'O'}, {'or': 'O'}, {'malignant,': 'O'}, {'may': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
Smoking affects several disease processes.,"[{'Smoking': 'I-Entity'}, {'affects': 'O'}, {'several': 'O'}, {'disease': 'O'}, {'processes.': 'O'}]"
"She was diagnosed with acute limbic encephalitis complicated by Sjogrens syndrome (SjS), due to the fact that she had a past history of SjS, elevation of anti-SS-A antibody, pleuritis and pericarditis.","[{'She': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'acute': 'O'}, {'limbic': 'B-Entity'}, {'encephalitis': 'I-Entity'}, {'complicated': 'O'}, {'by': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SjS),': 'O'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'fact': 'O'}, {'that': 'O'}, {'she': 'O'}, {'had': 'O'}, {'a': 'O'}, {'past': 'O'}, {'history': 'O'}, {'of': 'O'}, {'SjS,': 'I-Entity'}, {'elevation': 'O'}, {'of': 'O'}, {'anti-SS-A': 'O'}, {'antibody,': 'O'}, {'pleuritis': 'I-Entity'}, {'and': 'O'}, {'pericarditis.': 'I-Entity'}]"
"Also, it is important to evaluate disease activity in patients with primary Sjogrens syndrome using a score index - ESSDAI (EULAR Sjogrens Syndrome Disease Activity Index).Medyczny, Lublin, e-mail: jolanta.parada@gmail.com.","[{'Also,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'important': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'using': 'O'}, {'a': 'O'}, {'score': 'O'}, {'index': 'O'}, {'-': 'O'}, {'ESSDAI': 'O'}, {'(EULAR': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index).Medyczny,': 'O'}, {'Lublin,': 'O'}, {'e-mail:': 'O'}, {'jolanta.parada@gmail.com.': 'O'}]"
Sjogrens syndrome (SS) is a chronic inflammatory disease with an autoimmune background with possible complications from peripheral (PNS) and central nervous system (CNS).,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'disease': 'I-Entity'}, {'with': 'O'}, {'an': 'O'}, {'autoimmune': 'O'}, {'background': 'O'}, {'with': 'O'}, {'possible': 'O'}, {'complications': 'O'}, {'from': 'O'}, {'peripheral': 'O'}, {'(PNS)': 'O'}, {'and': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'(CNS).': 'O'}]"
Sjogrens syndrome (SS) is one of the most common autoimmune disorders leading to exocrine gland dysfunction.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders': 'I-Entity'}, {'leading': 'O'}, {'to': 'O'}, {'exocrine': 'B-Entity'}, {'gland': 'I-Entity'}, {'dysfunction.': 'I-Entity'}]"
"The concept includes Mikulicz's disease, Riedel's thyroiditis, pulmonary fibrosis, pulmonary pseudotumor, autoimmune pancreatitis, a part of tubulointerstitial nephritis, and chronic prostatitis.","[{'The': 'O'}, {'concept': 'O'}, {'includes': 'O'}, {""Mikulicz's"": 'B-Entity'}, {'disease,': 'I-Entity'}, {""Riedel's"": 'B-Entity'}, {'thyroiditis,': 'I-Entity'}, {'pulmonary': 'B-Entity'}, {'fibrosis,': 'I-Entity'}, {'pulmonary': 'B-Entity'}, {'pseudotumor,': 'I-Entity'}, {'autoimmune': 'B-Entity'}, {'pancreatitis,': 'I-Entity'}, {'a': 'O'}, {'part': 'O'}, {'of': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis,': 'I-Entity'}, {'and': 'O'}, {'chronic': 'B-Entity'}, {'prostatitis.': 'I-Entity'}]"
"Systemic vasculitis, which can involve the brain, may be one of the causes of stroke in young adults; therefore, a test panel for systemic vasculitis is considered for some young stroke patients.","[{'Systemic': 'B-Entity'}, {'vasculitis,': 'I-Entity'}, {'which': 'O'}, {'can': 'O'}, {'involve': 'O'}, {'the': 'O'}, {'brain,': 'O'}, {'may': 'O'}, {'be': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'stroke': 'I-Entity'}, {'in': 'O'}, {'young': 'O'}, {'adults;': 'O'}, {'therefore,': 'O'}, {'a': 'O'}, {'test': 'O'}, {'panel': 'O'}, {'for': 'O'}, {'systemic': 'B-Entity'}, {'vasculitis': 'I-Entity'}, {'is': 'O'}, {'considered': 'O'}, {'for': 'O'}, {'some': 'O'}, {'young': 'O'}, {'stroke': 'I-Entity'}, {'patients.': 'O'}]"
Dryness symptoms (95%) were the most frequent complaint and anti-Ro/SS-A were present in 94% of the cases.,"[{'Dryness': 'I-Entity'}, {'symptoms': 'O'}, {'(95%)': 'O'}, {'were': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'complaint': 'O'}, {'and': 'O'}, {'anti-Ro/SS-A': 'O'}, {'were': 'O'}, {'present': 'O'}, {'in': 'O'}, {'94%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cases.': 'O'}]"
"Three had parkinsonian syndrome, two epilepsy, two motor and sensory deficits, two headache with brain magnetic resonance abnormalities, two neuromyelitis optica, two chronic progressive myelitis and one aseptic meningitis.","[{'Three': 'O'}, {'had': 'O'}, {'parkinsonian': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'two': 'O'}, {'epilepsy,': 'I-Entity'}, {'two': 'O'}, {'motor': 'B-Entity'}, {'and': 'I-Entity'}, {'sensory': 'I-Entity'}, {'deficits,': 'I-Entity'}, {'two': 'O'}, {'headache': 'I-Entity'}, {'with': 'O'}, {'brain': 'O'}, {'magnetic': 'O'}, {'resonance': 'O'}, {'abnormalities,': 'I-Entity'}, {'two': 'O'}, {'neuromyelitis': 'B-Entity'}, {'optica,': 'I-Entity'}, {'two': 'O'}, {'chronic': 'B-Entity'}, {'progressive': 'I-Entity'}, {'myelitis': 'I-Entity'}, {'and': 'O'}, {'one': 'O'}, {'aseptic': 'B-Entity'}, {'meningitis.': 'I-Entity'}]"
"Thus, elevated PCNA is an early biomarker for exocrine glandular dysfunction associated with SS-like autoimmune disease, accompanied subsequently by decreased PRDX6 antioxidant enzyme levels that could further contribute to oxidative stress, and these changes precede inflammatory cell infiltration.","[{'Thus,': 'O'}, {'elevated': 'O'}, {'PCNA': 'O'}, {'is': 'O'}, {'an': 'O'}, {'early': 'O'}, {'biomarker': 'O'}, {'for': 'O'}, {'exocrine': 'B-Entity'}, {'glandular': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'SS-like': 'I-Entity'}, {'autoimmune': 'B-Entity'}, {'disease,': 'I-Entity'}, {'accompanied': 'O'}, {'subsequently': 'O'}, {'by': 'O'}, {'decreased': 'O'}, {'PRDX6': 'O'}, {'antioxidant': 'O'}, {'enzyme': 'O'}, {'levels': 'O'}, {'that': 'O'}, {'could': 'O'}, {'further': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'oxidative': 'O'}, {'stress,': 'O'}, {'and': 'O'}, {'these': 'O'}, {'changes': 'O'}, {'precede': 'O'}]"
"At follow-up visit, patients and physicians assessed, respectively, whether symptoms and disease activity have improved or not.","[{'At': 'O'}, {'follow-up': 'O'}, {'visit,': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'physicians': 'O'}, {'assessed,': 'O'}, {'respectively,': 'O'}, {'whether': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'have': 'O'}, {'improved': 'O'}, {'or': 'O'}, {'not.': 'O'}]"
Ocular symptoms (47.7 vs. 24.4%) and oral symptoms (52.3 vs. 9.7%) were significantly more frequent in patients than in controls.,"[{'Ocular': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'(47.7': 'O'}, {'vs.': 'O'}, {'24.4%)': 'O'}, {'and': 'O'}, {'oral': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'(52.3': 'O'}, {'vs.': 'O'}, {'9.7%)': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'than': 'O'}, {'in': 'O'}, {'controls.': 'O'}]"
Sjogrens syndrome was found at a median age of 63 years and the gender distribution showed a balanced female-male ratio of 1:1.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'found': 'O'}, {'at': 'O'}, {'a': 'O'}, {'median': 'O'}, {'age': 'O'}, {'of': 'O'}, {'63': 'O'}, {'years': 'O'}, {'and': 'O'}, {'the': 'O'}, {'gender': 'O'}, {'distribution': 'O'}, {'showed': 'O'}, {'a': 'O'}, {'balanced': 'O'}, {'female-male': 'O'}, {'ratio': 'O'}, {'of': 'O'}, {'1:1.': 'O'}]"
The results suggest the use of in-solution ASEM for histology and to study vesicle secretion systems.,"[{'The': 'O'}, {'results': 'O'}, {'suggest': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'in-solution': 'O'}, {'ASEM': 'O'}, {'for': 'O'}, {'histology': 'O'}, {'and': 'O'}, {'to': 'O'}, {'study': 'O'}, {'vesicle': 'O'}, {'secretion': 'O'}, {'systems.': 'O'}]"
"Histological examination revealed enhanced inflammatory responses in the lacrimal and salivary glands of SjS chimeras, as measured by digital image analysis and blinded histopathological scoring.","[{'Histological': 'O'}, {'examination': 'O'}, {'revealed': 'O'}, {'enhanced': 'O'}, {'inflammatory': 'O'}, {'responses': 'O'}, {'in': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'of': 'O'}, {'SjS': 'O'}, {'chimeras,': 'O'}, {'as': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'digital': 'O'}, {'image': 'O'}, {'analysis': 'O'}, {'and': 'O'}, {'blinded': 'O'}, {'histopathological': 'O'}, {'scoring.': 'O'}]"
The application of AS drops led to a statistically significant increase in the mean density of aberrant HLA-DR-positive conjunctival epithelial cells (p < 0.05) and HLA-DR-positive Langerhans cells (p < 0.05) in the GvHD group.,"[{'The': 'O'}, {'application': 'O'}, {'of': 'O'}, {'AS': 'O'}, {'drops': 'O'}, {'led': 'O'}, {'to': 'O'}, {'a': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'the': 'O'}, {'mean': 'O'}, {'density': 'O'}, {'of': 'O'}, {'aberrant': 'O'}, {'HLA-DR-positive': 'O'}, {'conjunctival': 'O'}, {'epithelial': 'O'}, {'cells': 'O'}, {'(p': 'O'}, {'<': 'O'}, {'0.05)': 'O'}, {'and': 'O'}, {'HLA-DR-positive': 'O'}, {'Langerhans': 'O'}, {'cells': 'O'}, {'(p': 'O'}, {'<': 'O'}, {'0.05)': 'O'}, {'in': 'O'}, {'the': 'O'}]"
"Although the place of systemic drugs in keratoconjunctivitis sicca treatment has been discussed, the efficacy of some topical drugs has also been demonstrated; however, there are contradictory results related to topical cyclosporine A.","[{'Although': 'O'}, {'the': 'O'}, {'place': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'drugs': 'O'}, {'in': 'O'}, {'keratoconjunctivitis': 'B-Entity'}, {'sicca': 'I-Entity'}, {'treatment': 'O'}, {'has': 'O'}, {'been': 'O'}, {'discussed,': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'some': 'O'}, {'topical': 'O'}, {'drugs': 'O'}, {'has': 'O'}, {'also': 'O'}, {'been': 'O'}, {'demonstrated;': 'O'}, {'however,': 'O'}, {'there': 'O'}, {'are': 'O'}, {'contradictory': 'O'}, {'results': 'O'}, {'related': 'O'}, {'to': 'O'}, {'topical': 'O'}, {'cyclosporine': 'B-Entity'}, {'A.': 'I-Entity'}]"
To determine whether a proliferation-inducing ligand (APRIL) has a role in the survival of plasma cells infiltrating salivary glands from SS patients.,"[{'To': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'a': 'O'}, {'proliferation-inducing': 'O'}, {'ligand': 'O'}, {'(APRIL)': 'O'}, {'has': 'O'}, {'a': 'O'}, {'role': 'O'}, {'in': 'O'}, {'the': 'O'}, {'survival': 'O'}, {'of': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'infiltrating': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'from': 'O'}, {'SS': 'I-Entity'}, {'patients.': 'O'}]"
"Although a rare pathology, posterior inferior cerebellar artery compression causing facial pain, swelling and hearing loss should be considered as a differential diagnosis in similar cases.Newcastle upon Tyne NE1 4PE, UK.","[{'Although': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'pathology,': 'O'}, {'posterior': 'O'}, {'inferior': 'B-Entity'}, {'cerebellar': 'I-Entity'}, {'artery': 'I-Entity'}, {'compression': 'I-Entity'}, {'causing': 'O'}, {'facial': 'O'}, {'pain,': 'I-Entity'}, {'swelling': 'I-Entity'}, {'and': 'O'}, {'hearing': 'B-Entity'}, {'loss': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'as': 'O'}, {'a': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'in': 'O'}, {'similar': 'O'}, {'cases.Newcastle': 'O'}, {'upon': 'O'}, {'Tyne': 'O'}, {'NE1': 'O'}, {'4PE,': 'O'}, {'UK.': 'O'}]"
"The TO, Ocular Surface Disease Index, dry eye disease (DED) parameters [such as tear breakup time (TBUT) and corneal staining score] and the systemic inflammatory markers [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)] were compared.","[{'The': 'O'}, {'TO,': 'O'}, {'Ocular': 'O'}, {'Surface': 'O'}, {'Disease': 'O'}, {'Index,': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'(DED)': 'O'}, {'parameters': 'O'}, {'[such': 'O'}, {'as': 'O'}, {'tear': 'O'}, {'breakup': 'O'}, {'time': 'O'}, {'(TBUT)': 'O'}, {'and': 'O'}, {'corneal': 'O'}, {'staining': 'O'}, {'score]': 'O'}, {'and': 'O'}, {'the': 'O'}, {'systemic': 'O'}, {'inflammatory': 'O'}, {'markers': 'O'}, {'[erythrocyte': 'O'}, {'sedimentation': 'O'}, {'rate': 'O'}, {'(ESR)': 'O'}, {'and': 'O'}, {'C-reactive': 'O'}, {'protein': 'O'}, {'(CRP)]': 'O'}]"
Dysphagia can be the presenting symptom of autoimmune disease.,"[{'Dysphagia': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'the': 'O'}, {'presenting': 'O'}, {'symptom': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'disease.': 'I-Entity'}]"
Safety assessment was also performed reporting all adverse events.,"[{'Safety': 'O'}, {'assessment': 'O'}, {'was': 'O'}, {'also': 'O'}, {'performed': 'O'}, {'reporting': 'O'}, {'all': 'O'}, {'adverse': 'O'}, {'events.': 'O'}]"
"As discussed in this review, differences in study design and patient characteristics could explain the variation in results.","[{'As': 'O'}, {'discussed': 'O'}, {'in': 'O'}, {'this': 'O'}, {'review,': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'study': 'O'}, {'design': 'O'}, {'and': 'O'}, {'patient': 'O'}, {'characteristics': 'O'}, {'could': 'O'}, {'explain': 'O'}, {'the': 'O'}, {'variation': 'O'}, {'in': 'O'}, {'results.': 'O'}]"
A retrospective analysis of eleven pregnancies complicated by isolated fetal congenital complete heart block (CCHB) in anti-SSA/Ro antibody positive women was carried out at a tertiary hospital in India to study the perinatal outcome.,"[{'A': 'O'}, {'retrospective': 'O'}, {'analysis': 'O'}, {'of': 'O'}, {'eleven': 'O'}, {'pregnancies': 'O'}, {'complicated': 'O'}, {'by': 'O'}, {'isolated': 'O'}, {'fetal': 'O'}, {'congenital': 'B-Entity'}, {'complete': 'I-Entity'}, {'heart': 'I-Entity'}, {'block': 'I-Entity'}, {'(CCHB)': 'O'}, {'in': 'O'}, {'anti-SSA/Ro': 'O'}, {'antibody': 'O'}, {'positive': 'O'}, {'women': 'O'}, {'was': 'O'}, {'carried': 'O'}, {'out': 'O'}, {'at': 'O'}, {'a': 'O'}, {'tertiary': 'O'}, {'hospital': 'O'}, {'in': 'O'}, {'India': 'O'}, {'to': 'O'}, {'study': 'O'}, {'the': 'O'}, {'perinatal': 'O'}, {'outcome.': 'O'}]"
"To date, we have only limited therapeutic options for Sjogrens syndrome, a frequent systemic autoimmune disorder of unknown origin.","[{'To': 'O'}, {'date,': 'O'}, {'we': 'O'}, {'have': 'O'}, {'only': 'O'}, {'limited': 'O'}, {'therapeutic': 'O'}, {'options': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'a': 'O'}, {'frequent': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disorder': 'I-Entity'}, {'of': 'O'}, {'unknown': 'O'}, {'origin.': 'O'}]"
Asymmetric activity pattern in the parotid glands commonly observed during the early stages of the disease may be a predictor of progression.,"[{'Asymmetric': 'O'}, {'activity': 'O'}, {'pattern': 'O'}, {'in': 'O'}, {'the': 'O'}, {'parotid': 'O'}, {'glands': 'O'}, {'commonly': 'O'}, {'observed': 'O'}, {'during': 'O'}, {'the': 'O'}, {'early': 'O'}, {'stages': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'may': 'O'}, {'be': 'O'}, {'a': 'O'}, {'predictor': 'O'}, {'of': 'O'}, {'progression.': 'O'}]"
"T cell, CD4(+)-T cell, T/B cell ratio and iDC incidence was negatively, whereas B cell and MPhi incidence was positively correlated with infiltration grade and biopsy focus score.","[{'T': 'O'}, {'cell,': 'O'}, {'CD4(+)-T': 'O'}, {'cell,': 'O'}, {'T/B': 'O'}, {'cell': 'O'}, {'ratio': 'O'}, {'and': 'O'}, {'iDC': 'O'}, {'incidence': 'O'}, {'was': 'O'}, {'negatively,': 'O'}, {'whereas': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'and': 'O'}, {'MPhi': 'O'}, {'incidence': 'O'}, {'was': 'O'}, {'positively': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'infiltration': 'O'}, {'grade': 'O'}, {'and': 'O'}, {'biopsy': 'O'}, {'focus': 'O'}, {'score.': 'O'}]"
"In conclusion, testing for anti-GD1b antibodies may identify a specific group of immune-mediated neuropathies and (MF-)GBS patients with only anti-GD1b antibodies tend to recover faster.Rotterdam, The Netherlands.Netherlands.Rotterdam, The Netherlands.The Netherlands.Rotterdam, The Netherlands.The Netherlands.Rotterdam, The Netherlands.Rotterdam, The Netherlands.Rotterdam, The Netherlands.The Netherlands.12.inclusion body myositis versus known autoimmune diseases.","[{'In': 'O'}, {'conclusion,': 'O'}, {'testing': 'O'}, {'for': 'O'}, {'anti-GD1b': 'O'}, {'antibodies': 'O'}, {'may': 'O'}, {'identify': 'O'}, {'a': 'O'}, {'specific': 'O'}, {'group': 'O'}, {'of': 'O'}, {'immune-mediated': 'O'}, {'neuropathies': 'I-Entity'}, {'and': 'O'}, {'(MF-)GBS': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'only': 'O'}, {'anti-GD1b': 'O'}, {'antibodies': 'O'}, {'tend': 'O'}, {'to': 'O'}, {'recover': 'O'}, {'faster.Rotterdam,': 'O'}, {'The': 'O'}, {'Netherlands.Netherlands.Rotterdam,': 'O'}, {'The': 'O'}, {'Netherlands.The': 'O'}, {'Netherlands.Rotterdam,': 'O'}]"
"The 'TRACTISS' Study (Anti-B-Cell Therapy In Patients With Primary Sjogrens Syndrome), in UK, will include 100 patients having anti-Ro/La antibodies, reduced basal secretion but an increased salivary flow with stimulation, within 10years of diagnosis, symptomatic oral dryness, fatigue and at least one systemic feature.Rhumatologie, Centre Hospitalier Universitaire de Brest, Brest, France.","[{'The': 'O'}, {""'TRACTISS'"": 'O'}, {'Study': 'O'}, {'(Anti-B-Cell': 'O'}, {'Therapy': 'O'}, {'In': 'O'}, {'Patients': 'O'}, {'With': 'O'}, {'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'Syndrome),': 'I-Entity'}, {'in': 'O'}, {'UK,': 'O'}, {'will': 'O'}, {'include': 'O'}, {'100': 'O'}, {'patients': 'O'}, {'having': 'O'}, {'anti-Ro/La': 'O'}, {'antibodies,': 'O'}, {'reduced': 'O'}, {'basal': 'O'}, {'secretion': 'O'}, {'but': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'with': 'O'}, {'stimulation,': 'O'}, {'within': 'O'}, {'10years': 'O'}]"
There are only four patients reported to be affected by cerebellar atrophy associated with PSS.,"[{'There': 'O'}, {'are': 'O'}, {'only': 'O'}, {'four': 'O'}, {'patients': 'O'}, {'reported': 'O'}, {'to': 'O'}, {'be': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'cerebellar': 'B-Entity'}, {'atrophy': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'PSS.': 'I-Entity'}]"
The difference in pre-post treatment score for dry eyes and dry mouth at week 8 was higher in the experimental group than in the control group.,"[{'The': 'O'}, {'difference': 'O'}, {'in': 'O'}, {'pre-post': 'O'}, {'treatment': 'O'}, {'score': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'at': 'O'}, {'week': 'O'}, {'8': 'O'}, {'was': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'the': 'O'}, {'experimental': 'O'}, {'group': 'O'}, {'than': 'O'}, {'in': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group.': 'O'}]"
"Primary Sjogrens syndrome (pSS) is an autoimmune connective tissue disease affecting the exocrine glands, leading to damage of their structure and impairment of their function.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'affecting': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'damage': 'O'}, {'of': 'O'}, {'their': 'O'}, {'structure': 'O'}, {'and': 'O'}, {'impairment': 'B-Entity'}, {'of': 'O'}, {'their': 'O'}, {'function.': 'O'}]"
IgG4-related diseases mainly target two organs.,"[{'IgG4-related': 'O'}, {'diseases': 'I-Entity'}, {'mainly': 'O'}, {'target': 'O'}, {'two': 'O'}, {'organs.': 'O'}]"
"The effect of autoimmune disease on pregnancy differs according to the type of maternal disease, disease activity, severity of organ damage, antibody profile, and drug treatment.","[{'The': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'on': 'O'}, {'pregnancy': 'O'}, {'differs': 'O'}, {'according': 'O'}, {'to': 'O'}, {'the': 'O'}, {'type': 'O'}, {'of': 'O'}, {'maternal': 'O'}, {'disease,': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'severity': 'O'}, {'of': 'O'}, {'organ': 'B-Entity'}, {'damage,': 'I-Entity'}, {'antibody': 'O'}, {'profile,': 'O'}, {'and': 'O'}, {'drug': 'O'}, {'treatment.': 'O'}]"
Interstitial lung disease (ILD) can be an extraglandular complication.,"[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'can': 'O'}, {'be': 'O'}, {'an': 'O'}, {'extraglandular': 'O'}, {'complication.': 'O'}]"
A retrospective clinical study was performed in patients with dry eye caused by SS.,"[{'A': 'O'}, {'retrospective': 'O'}, {'clinical': 'O'}, {'study': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'SS.': 'I-Entity'}]"
"In conclusion, education in oral health is imperative for subjects with this pathology and more frequent check-ups may be useful in decreasing the levels of oral pathology.Center for Biomedical Research, Universidad Aut‚Äö√†√∂‚Äö√¢‚Ä¢noma de Chile Chile.Syndrome.","[{'In': 'O'}, {'conclusion,': 'O'}, {'education': 'O'}, {'in': 'O'}, {'oral': 'O'}, {'health': 'O'}, {'is': 'O'}, {'imperative': 'O'}, {'for': 'O'}, {'subjects': 'O'}, {'with': 'O'}, {'this': 'O'}, {'pathology': 'O'}, {'and': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'check-ups': 'O'}, {'may': 'O'}, {'be': 'O'}, {'useful': 'O'}, {'in': 'O'}, {'decreasing': 'O'}, {'the': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'oral': 'B-Entity'}, {'pathology.Center': 'I-Entity'}, {'for': 'O'}, {'Biomedical': 'O'}, {'Research,': 'O'}, {'Universidad': 'O'}, {'Aut‚Äö√†√∂‚Äö√¢‚Ä¢noma': 'O'}, {'de': 'O'}]"
"A 71-year-old man visited our hospital complaining of daily progressive oral dryness, thirst and blurred vision with a feeling of dry eyes for one-year duration.","[{'A': 'O'}, {'71-year-old': 'O'}, {'man': 'O'}, {'visited': 'O'}, {'our': 'O'}, {'hospital': 'O'}, {'complaining': 'O'}, {'of': 'O'}, {'daily': 'O'}, {'progressive': 'O'}, {'oral': 'B-Entity'}, {'dryness,': 'I-Entity'}, {'thirst': 'I-Entity'}, {'and': 'O'}, {'blurred': 'B-Entity'}, {'vision': 'I-Entity'}, {'with': 'O'}, {'a': 'O'}, {'feeling': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'for': 'O'}, {'one-year': 'O'}, {'duration.': 'O'}]"
Sjogren's syndrome should be regarded as a predisposing condition for the development of renal AA amyloidosis.Sjogren's syndrome and renal AA amyloidosis have been diagnosed simultaneously in some patients.A renal biopsy should be performed in patients with Sjogren's syndrome and proteinuria and/or renal failure.eCollection 2019.connective tissue diseases presented with and without mechanic hands.,"[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'regarded': 'O'}, {'as': 'O'}, {'a': 'O'}, {'predisposing': 'O'}, {'condition': 'O'}, {'for': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'renal': 'O'}, {'AA': 'B-Entity'}, {""amyloidosis.Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'renal': 'O'}, {'AA': 'B-Entity'}, {'amyloidosis': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'diagnosed': 'O'}, {'simultaneously': 'O'}, {'in': 'O'}, {'some': 'O'}, {'patients.A': 'O'}, {'renal': 'O'}, {'biopsy': 'O'}, {'should': 'O'}, {'be': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {""Sjogren's"": 'O'}]"
This review aims to address the numerous controversies that have arisen regarding inflammatory diseases of the salivary gland over the past two centuries and more specifically address the relevance of IgG4 in this setting.,"[{'This': 'O'}, {'review': 'O'}, {'aims': 'O'}, {'to': 'O'}, {'address': 'O'}, {'the': 'O'}, {'numerous': 'O'}, {'controversies': 'O'}, {'that': 'O'}, {'have': 'O'}, {'arisen': 'O'}, {'regarding': 'O'}, {'inflammatory': 'B-Entity'}, {'diseases': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'salivary': 'I-Entity'}, {'gland': 'O'}, {'over': 'O'}, {'the': 'O'}, {'past': 'O'}, {'two': 'O'}, {'centuries': 'O'}, {'and': 'O'}, {'more': 'O'}, {'specifically': 'O'}, {'address': 'O'}, {'the': 'O'}, {'relevance': 'O'}, {'of': 'O'}, {'IgG4': 'O'}, {'in': 'O'}, {'this': 'O'}, {'setting.': 'O'}]"
RTA was diagnosed in cases of hyperchloremic metabolic acidosis with urinary pH values higher than 5.5.,"[{'RTA': 'I-Entity'}, {'was': 'O'}, {'diagnosed': 'O'}, {'in': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'hyperchloremic': 'O'}, {'metabolic': 'B-Entity'}, {'acidosis': 'I-Entity'}, {'with': 'O'}, {'urinary': 'O'}, {'pH': 'O'}, {'values': 'O'}, {'higher': 'O'}, {'than': 'O'}, {'5.5.': 'O'}]"
Functional ability and participation in life situations are compromised in many primary Sjogrens syndrome (SS) patients.,"[{'Functional': 'O'}, {'ability': 'O'}, {'and': 'O'}, {'participation': 'O'}, {'in': 'O'}, {'life': 'O'}, {'situations': 'O'}, {'are': 'O'}, {'compromised': 'O'}, {'in': 'O'}, {'many': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'patients.': 'O'}]"
"Administration of caspase inhibitors ameliorated the inflammation, indicating the critical role of caspase-mediated apoptosis.","[{'Administration': 'O'}, {'of': 'O'}, {'caspase': 'O'}, {'inhibitors': 'O'}, {'ameliorated': 'O'}, {'the': 'O'}, {'inflammation,': 'I-Entity'}, {'indicating': 'O'}, {'the': 'O'}, {'critical': 'O'}, {'role': 'O'}, {'of': 'O'}, {'caspase-mediated': 'O'}, {'apoptosis.': 'O'}]"
"Multivariable-adjusted analyses showed that gout was independently associated with a higher hazard ratio of SS of 1.73 (95% CI, 1.45, 2.06).","[{'Multivariable-adjusted': 'O'}, {'analyses': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'gout': 'I-Entity'}, {'was': 'O'}, {'independently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'hazard': 'O'}, {'ratio': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'of': 'O'}, {'1.73': 'O'}, {'(95%': 'O'}, {'CI,': 'O'}, {'1.45,': 'O'}, {'2.06).': 'O'}]"
We report three cases of OP preceding the articular symptoms of the underlying connective tissue disease by 3-6 months in two cases of rheumatoid arthritis and by 36 months in one patient with primary Sjogrens syndrome.,"[{'We': 'O'}, {'report': 'O'}, {'three': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'OP': 'I-Entity'}, {'preceding': 'O'}, {'the': 'O'}, {'articular': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'by': 'O'}, {'3-6': 'O'}, {'months': 'O'}, {'in': 'O'}, {'two': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {'by': 'O'}, {'36': 'O'}, {'months': 'O'}, {'in': 'O'}, {'one': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
"Generally, a positive test result by EliA CTD Screen had a higher likelihood ratio for systemic rheumatic disease than a positive test result by indirect immunofluorescence.","[{'Generally,': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'test': 'O'}, {'result': 'O'}, {'by': 'O'}, {'EliA': 'O'}, {'CTD': 'O'}, {'Screen': 'O'}, {'had': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'likelihood': 'O'}, {'ratio': 'O'}, {'for': 'O'}, {'systemic': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'disease': 'I-Entity'}, {'than': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'test': 'O'}, {'result': 'O'}, {'by': 'O'}, {'indirect': 'O'}, {'immunofluorescence.': 'O'}]"
"Additionally, there has been increasing evidence that cancer in SSc patients is associated with RNAP.","[{'Additionally,': 'O'}, {'there': 'O'}, {'has': 'O'}, {'been': 'O'}, {'increasing': 'O'}, {'evidence': 'O'}, {'that': 'O'}, {'cancer': 'I-Entity'}, {'in': 'O'}, {'SSc': 'I-Entity'}, {'patients': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'RNAP.': 'O'}]"
Peripheral nervous system involvement occurs in 3-18% patients of systemic lupus erythematosus (SLE) cases.,"[{'Peripheral': 'O'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'involvement': 'O'}, {'occurs': 'O'}, {'in': 'O'}, {'3-18%': 'O'}, {'patients': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'cases.': 'O'}]"
"Sera were obtained from patients and evaluated by ELISA for IgG, IgA and IgM antibodies to SP1, CA6 and PSP.","[{'Sera': 'O'}, {'were': 'O'}, {'obtained': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'evaluated': 'O'}, {'by': 'O'}, {'ELISA': 'O'}, {'for': 'O'}, {'IgG,': 'O'}, {'IgA': 'O'}, {'and': 'O'}, {'IgM': 'O'}, {'antibodies': 'O'}, {'to': 'O'}, {'SP1,': 'O'}, {'CA6': 'O'}, {'and': 'O'}, {'PSP.': 'O'}]"
The feeling of dry eyes and mouth is frequently not noticed by the patients.,"[{'The': 'O'}, {'feeling': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth': 'I-Entity'}, {'is': 'O'}, {'frequently': 'O'}, {'not': 'O'}, {'noticed': 'O'}, {'by': 'O'}, {'the': 'O'}, {'patients.': 'O'}]"
"WMA were identified as vascular pathological changes in 80% of the patients, and hypertension and HDL-c levels as predictive factors for this association.Font, Institut d‚Äö√Ñ√∂‚àö√ë‚àö¬•Investigacions Biom‚Äö√†√∂¬¨√Üdiques August Pi i Sunyer (IDIBAPS), Department of Autoimmune Diseases, Hospital do Meixoeiro, Vigo, Spain.type 1 renal tubular acidosis due to Sjogrens syndrome.","[{'WMA': 'I-Entity'}, {'were': 'O'}, {'identified': 'O'}, {'as': 'O'}, {'vascular': 'O'}, {'pathological': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'80%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients,': 'O'}, {'and': 'O'}, {'hypertension': 'I-Entity'}, {'and': 'O'}, {'HDL-c': 'O'}, {'levels': 'O'}, {'as': 'O'}, {'predictive': 'O'}, {'factors': 'O'}, {'for': 'O'}, {'this': 'O'}, {'association.Font,': 'O'}, {'Institut': 'O'}, {'d‚Äö√Ñ√∂‚àö√ë‚àö¬•Investigacions': 'O'}]"
"BACKGROUND Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder of unknown etiology which can present at any age with symptoms of mucocutaneous, musculoskeletal, renal, central nervous system, and nonspecific clinical pictures making the disease a ""master of mimicry"".","[{'BACKGROUND': 'O'}, {'Systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'multisystem': 'O'}, {'autoimmune': 'B-Entity'}, {'disorder': 'I-Entity'}, {'of': 'O'}, {'unknown': 'O'}, {'etiology': 'O'}, {'which': 'O'}, {'can': 'O'}, {'present': 'O'}, {'at': 'O'}, {'any': 'O'}, {'age': 'O'}, {'with': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'mucocutaneous,': 'O'}, {'musculoskeletal,': 'I-Entity'}, {'renal,': 'I-Entity'}]"
This large clinical study has shown that discordance between symptoms and signs in DED is an indicator of self-perceived health.,"[{'This': 'O'}, {'large': 'O'}, {'clinical': 'O'}, {'study': 'O'}, {'has': 'O'}, {'shown': 'O'}, {'that': 'O'}, {'discordance': 'O'}, {'between': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'signs': 'O'}, {'in': 'O'}, {'DED': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'indicator': 'O'}, {'of': 'O'}, {'self-perceived': 'O'}, {'health.': 'O'}]"
"We present a comprehensive review of the current literature on autoimmune disorders co-existing with NMO and identified 22 autoimmune conditions (myasthenia gravis, coeliac disease, ulcerative colitis, sclerosing cholangitis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid antibody syndrome, Sjogren's syndrome, autoimmune hypothyroidism, immune thrombocytopenic purpura, pernicious anaemia, narcolepsy, pemphigus foliaceus, alopecia areata, psoriasis, scleroderma, dermatitis herpetiformis, polymyositis, chronic inflammatory demyelinating polyneuropathy, paraneoplastic disorders, insulin dependent diabetes mellitus and autoimmune encephalitis).Feb 10.Perspective.","[{'We': 'O'}, {'present': 'O'}, {'a': 'O'}, {'comprehensive': 'O'}, {'review': 'O'}, {'of': 'O'}, {'the': 'O'}, {'current': 'O'}, {'literature': 'O'}, {'on': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders': 'I-Entity'}, {'co-existing': 'O'}, {'with': 'O'}, {'NMO': 'I-Entity'}, {'and': 'O'}, {'identified': 'O'}, {'22': 'O'}, {'autoimmune': 'B-Entity'}, {'conditions': 'O'}, {'(myasthenia': 'O'}, {'gravis,': 'I-Entity'}, {'coeliac': 'B-Entity'}, {'disease,': 'I-Entity'}, {'ulcerative': 'B-Entity'}, {'colitis,': 'I-Entity'}, {'sclerosing': 'B-Entity'}, {'cholangitis,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}]"
"CNS involvement represents a rare but not negligible complication of pSS, which may occur with a bimodal temporal pattern, both at onset and later, prompting attention in the differential diagnosis of apparently isolated neurological syndromes.","[{'CNS': 'O'}, {'involvement': 'O'}, {'represents': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'but': 'O'}, {'not': 'O'}, {'negligible': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'pSS,': 'I-Entity'}, {'which': 'O'}, {'may': 'O'}, {'occur': 'O'}, {'with': 'O'}, {'a': 'O'}, {'bimodal': 'O'}, {'temporal': 'O'}, {'pattern,': 'O'}, {'both': 'O'}, {'at': 'O'}, {'onset': 'O'}, {'and': 'O'}, {'later,': 'O'}, {'prompting': 'O'}, {'attention': 'O'}, {'in': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'apparently': 'O'}, {'isolated': 'O'}, {'neurological': 'B-Entity'}, {'syndromes.': 'I-Entity'}]"
"In addition, we found no association of serum vitamin B(12) levels to neuropathy among these patients with Sjogren syndrome.","[{'In': 'O'}, {'addition,': 'O'}, {'we': 'O'}, {'found': 'O'}, {'no': 'O'}, {'association': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'vitamin': 'B-Entity'}, {'B(12)': 'I-Entity'}, {'levels': 'O'}, {'to': 'O'}, {'neuropathy': 'I-Entity'}, {'among': 'O'}, {'these': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"All the 14 patients were followed up, and 9 patients had different degrees of sequelae, including vision decline in 4 cases, numbness and weakness in 5 cases.","[{'All': 'O'}, {'the': 'O'}, {'14': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'followed': 'O'}, {'up,': 'O'}, {'and': 'O'}, {'9': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'different': 'O'}, {'degrees': 'O'}, {'of': 'O'}, {'sequelae,': 'O'}, {'including': 'O'}, {'vision': 'B-Entity'}, {'decline': 'I-Entity'}, {'in': 'O'}, {'4': 'O'}, {'cases,': 'O'}, {'numbness': 'I-Entity'}, {'and': 'O'}, {'weakness': 'I-Entity'}, {'in': 'O'}, {'5': 'O'}, {'cases.': 'O'}]"
"Primary Sjogrens syndrome (pSS) is a chronic autoimmune rheumatic disease with symptoms including dryness, fatigue, and pain.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'B-Entity'}, {'autoimmune': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'disease': 'I-Entity'}, {'with': 'O'}, {'symptoms': 'O'}, {'including': 'O'}, {'dryness,': 'I-Entity'}, {'fatigue,': 'I-Entity'}, {'and': 'O'}, {'pain.': 'I-Entity'}]"
"Among 129 consecutive patients who underwent surgical lung biopsy to diagnose diffuse lung diseases at Kanagawa Cardiovascular and Respiratory Center between 1998 and 2002, we identified 10 and 19 patients with UIP/pSS and UIP/IPF, respectively.","[{'Among': 'O'}, {'129': 'O'}, {'consecutive': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'underwent': 'O'}, {'surgical': 'O'}, {'lung': 'O'}, {'biopsy': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'diffuse': 'O'}, {'lung': 'B-Entity'}, {'diseases': 'I-Entity'}, {'at': 'O'}, {'Kanagawa': 'O'}, {'Cardiovascular': 'O'}, {'and': 'O'}, {'Respiratory': 'O'}, {'Center': 'O'}, {'between': 'O'}, {'1998': 'O'}, {'and': 'O'}, {'2002,': 'O'}, {'we': 'O'}, {'identified': 'O'}, {'10': 'O'}, {'and': 'O'}, {'19': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'UIP/pSS': 'I-Entity'}, {'and': 'O'}, {'UIP/IPF,': 'I-Entity'}, {'respectively.': 'O'}]"
Temporomandibular disorders are a generic term referred to clinical conditions involving the jaw muscles and temporomandibular joint.,"[{'Temporomandibular': 'B-Entity'}, {'disorders': 'I-Entity'}, {'are': 'O'}, {'a': 'O'}, {'generic': 'O'}, {'term': 'O'}, {'referred': 'O'}, {'to': 'O'}, {'clinical': 'O'}, {'conditions': 'O'}, {'involving': 'O'}, {'the': 'O'}, {'jaw': 'O'}, {'muscles': 'O'}, {'and': 'O'}, {'temporomandibular': 'O'}, {'joint.': 'O'}]"
Skin biopsy was consistent with telangiectasia macularis eruptiva perstans (TMEP).,"[{'Skin': 'O'}, {'biopsy': 'O'}, {'was': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'telangiectasia': 'B-Entity'}, {'macularis': 'I-Entity'}, {'eruptiva': 'I-Entity'}, {'perstans': 'I-Entity'}, {'(TMEP).': 'O'}]"
"To report our experience in patients with IS and urinary manifestations, describing clinical findings, test's results, and response to treatment.","[{'To': 'O'}, {'report': 'O'}, {'our': 'O'}, {'experience': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'IS': 'I-Entity'}, {'and': 'O'}, {'urinary': 'O'}, {'manifestations,': 'O'}, {'describing': 'O'}, {'clinical': 'O'}, {'findings,': 'O'}, {""test's"": 'O'}, {'results,': 'O'}, {'and': 'O'}, {'response': 'O'}, {'to': 'O'}, {'treatment.': 'O'}]"
"In considering these agents, the promise of efficacy must be balanced against the harmful effects associated with biologic agents.reserved.Federal de Pernambuco, Recife, Brazil.Philadelphia, Pennsylvania.University, Raleigh, North Carolina.National Institutes of Health, Bethesda, Maryland.Philadelphia, Pennsylvania.Medicine, Boston, Massachusetts.North Carolina.Odontoiatriche, Universit‚Äö√†√∂‚Äö√Ñ‚Ä† degli Studi di Milano, Milan, Italy.Philadelphia, Pennsylvania.North Carolina.","[{'In': 'O'}, {'considering': 'O'}, {'these': 'O'}, {'agents,': 'O'}, {'the': 'O'}, {'promise': 'O'}, {'of': 'O'}, {'efficacy': 'O'}, {'must': 'O'}, {'be': 'O'}, {'balanced': 'O'}, {'against': 'O'}, {'the': 'O'}, {'harmful': 'O'}, {'effects': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'biologic': 'O'}, {'agents.reserved.Federal': 'O'}, {'de': 'O'}, {'Pernambuco,': 'O'}, {'Recife,': 'O'}, {'Brazil.Philadelphia,': 'O'}, {'Pennsylvania.University,': 'O'}, {'Raleigh,': 'O'}, {'North': 'O'}, {'Carolina.National': 'O'}, {'Institutes': 'O'}, {'of': 'O'}, {'Health,': 'O'}, {'Bethesda,': 'O'}, {'Maryland.Philadelphia,': 'O'}]"
Primary Sjogren syndrome (pSS) is a progressive autoimmune disease that primarily affects exocrine glands.,"[{'Primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'progressive': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'primarily': 'O'}, {'affects': 'O'}, {'exocrine': 'O'}, {'glands.': 'O'}]"
"Sjogren syndrome (SS) has been known to manifest with neurological complications, most frequently of the peripheral nervous system, and often in advance of xerostomia and xerophthalmia.","[{'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'has': 'O'}, {'been': 'O'}, {'known': 'O'}, {'to': 'O'}, {'manifest': 'O'}, {'with': 'O'}, {'neurological': 'B-Entity'}, {'complications,': 'I-Entity'}, {'most': 'O'}, {'frequently': 'O'}, {'of': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'nervous': 'O'}, {'system,': 'O'}, {'and': 'O'}, {'often': 'O'}, {'in': 'O'}, {'advance': 'O'}, {'of': 'O'}, {'xerostomia': 'I-Entity'}, {'and': 'O'}, {'xerophthalmia.': 'I-Entity'}]"
"Serum levels of IL-33 and sST2 were significantly elevated in pSS patients, especially in patients with ILD.","[{'Serum': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'IL-33': 'O'}, {'and': 'O'}, {'sST2': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'elevated': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'especially': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'ILD.': 'I-Entity'}]"
Testing with lissamine green staining resulted in a mean value of 1.00¬¨¬®¬¨¬±0.16 in the migraine group and 0.30¬¨¬®¬¨¬±0.46 in the control group.,"[{'Testing': 'O'}, {'with': 'O'}, {'lissamine': 'B-Entity'}, {'green': 'I-Entity'}, {'staining': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'a': 'O'}, {'mean': 'O'}, {'value': 'O'}, {'of': 'O'}, {'1.00¬¨¬®¬¨¬±0.16': 'O'}, {'in': 'O'}, {'the': 'O'}, {'migraine': 'I-Entity'}, {'group': 'O'}, {'and': 'O'}, {'0.30¬¨¬®¬¨¬±0.46': 'O'}, {'in': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group.': 'O'}]"
We assessed the efficacy and tolerance of IVIG in 19 patients with primary SS-related neuropathy without any necrotizing vasculitis in a retrospective national multicentric study.,"[{'We': 'O'}, {'assessed': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'tolerance': 'O'}, {'of': 'O'}, {'IVIG': 'O'}, {'in': 'O'}, {'19': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'SS-related': 'I-Entity'}, {'neuropathy': 'I-Entity'}, {'without': 'O'}, {'any': 'O'}, {'necrotizing': 'O'}, {'vasculitis': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'retrospective': 'O'}, {'national': 'O'}, {'multicentric': 'O'}, {'study.': 'O'}]"
"182 consecutive patients with DED were evaluated under five groups: SS, graft-versus-host disease (GVHD), Graves' orbitopathy (GO), diabetes mellitus (DM), glaucoma under treatment with benzalkonium chloride medications (BAK).","[{'182': 'O'}, {'consecutive': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'DED': 'I-Entity'}, {'were': 'O'}, {'evaluated': 'O'}, {'under': 'O'}, {'five': 'O'}, {'groups:': 'O'}, {'SS,': 'O'}, {'graft-versus-host': 'B-Entity'}, {'disease': 'I-Entity'}, {'(GVHD),': 'O'}, {""Graves'"": 'B-Entity'}, {'orbitopathy': 'I-Entity'}, {'(GO),': 'O'}, {'diabetes': 'B-Entity'}, {'mellitus': 'I-Entity'}, {'(DM),': 'O'}, {'glaucoma': 'I-Entity'}, {'under': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'benzalkonium': 'B-Entity'}, {'chloride': 'I-Entity'}, {'medications': 'O'}, {'(BAK).': 'O'}]"
"The diagnosis of amyloidosis followed the SS onset (1-25 years) and in the majority of patients the presence of B cell hyperactivity traduced by hypergammaglobulinemia, positive rheumatoid factor and/or anti-Ro/SSA and anti-La/SSB antibodies were observed.","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'amyloidosis': 'I-Entity'}, {'followed': 'O'}, {'the': 'O'}, {'SS': 'O'}, {'onset': 'O'}, {'(1-25': 'O'}, {'years)': 'O'}, {'and': 'O'}, {'in': 'O'}, {'the': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'hyperactivity': 'O'}, {'traduced': 'O'}, {'by': 'O'}, {'hypergammaglobulinemia,': 'I-Entity'}, {'positive': 'O'}, {'rheumatoid': 'I-Entity'}, {'factor': 'O'}, {'and/or': 'O'}, {'anti-Ro/SSA': 'O'}]"
Primary Sjogrens syndrome (pSS) is an autoimmune disease in which the underlying cause has yet to be elucidated.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'which': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'cause': 'O'}, {'has': 'O'}, {'yet': 'O'}, {'to': 'O'}, {'be': 'O'}, {'elucidated.': 'O'}]"
"Furthermore, in patients with autoimmune or vascular diseases, including TA, systemic manifestations should be assessed with consideration of inflammatory bowel diseases including UC in the presence of gastrointestinal symptoms such as diarrhea and hematochezia.Daegu, Korea.Daegu, Korea.Daegu, Korea.Daegu, Korea.Korea.Korea.neuropsychiatric systemic lupus erythematosus (NPSLE)?","[{'Furthermore,': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'or': 'I-Entity'}, {'vascular': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'including': 'O'}, {'TA,': 'I-Entity'}, {'systemic': 'O'}, {'manifestations': 'O'}, {'should': 'O'}, {'be': 'O'}, {'assessed': 'O'}, {'with': 'O'}, {'consideration': 'O'}, {'of': 'O'}, {'inflammatory': 'B-Entity'}, {'bowel': 'I-Entity'}, {'diseases': 'I-Entity'}, {'including': 'O'}, {'UC': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'gastrointestinal': 'B-Entity'}, {'symptoms': 'O'}, {'such': 'O'}, {'as': 'O'}, {'diarrhea': 'I-Entity'}, {'and': 'O'}, {'hematochezia.Daegu,': 'I-Entity'}, {'Korea.Daegu,': 'O'}]"
The most important variant of scarring alopecia in the context of CTDs is that associated with discoid lupus erythematosus (DLE).,"[{'The': 'O'}, {'most': 'O'}, {'important': 'O'}, {'variant': 'O'}, {'of': 'O'}, {'scarring': 'O'}, {'alopecia': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'context': 'O'}, {'of': 'O'}, {'CTDs': 'I-Entity'}, {'is': 'O'}, {'that': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'discoid': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(DLE).': 'O'}]"
Sjogrens syndrome (SS) is a systemic autoimmune disease that mainly affects middle-aged women.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'mainly': 'O'}, {'affects': 'O'}, {'middle-aged': 'O'}, {'women.': 'O'}]"
Anti-Ro/SSA and anti-La/SSB antibodies were also positive in high titer.,"[{'Anti-Ro/SSA': 'O'}, {'and': 'O'}, {'anti-La/SSB': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'also': 'O'}, {'positive': 'O'}, {'in': 'O'}, {'high': 'O'}, {'titer.': 'O'}]"
"We report two cases of type 1 diabetes mellitus (T1DM) which developed after interferon (IFN) therapy for chronic hepatitis C. The patients had experienced abrupt hyperglycemia with positive anti-glutamic acid decarboxylase antibodies, resulting in initiation of insulin therapy.","[{'We': 'O'}, {'report': 'O'}, {'two': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'type': 'B-Entity'}, {'1': 'I-Entity'}, {'diabetes': 'I-Entity'}, {'mellitus': 'I-Entity'}, {'(T1DM)': 'O'}, {'which': 'O'}, {'developed': 'O'}, {'after': 'O'}, {'interferon': 'I-Entity'}, {'(IFN)': 'I-Entity'}, {'therapy': 'O'}, {'for': 'O'}, {'chronic': 'B-Entity'}, {'hepatitis': 'I-Entity'}, {'C.': 'I-Entity'}, {'The': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'experienced': 'O'}, {'abrupt': 'O'}, {'hyperglycemia': 'I-Entity'}, {'with': 'O'}, {'positive': 'O'}, {'anti-glutamic': 'O'}, {'acid': 'I-Entity'}, {'decarboxylase': 'O'}, {'antibodies,': 'O'}, {'resulting': 'O'}, {'in': 'O'}]"
"Autoimmune CHB is a severe, potentially life-threatening disorder associated with passive transfer of maternal anti-Sjogren's syndrome A/Ro and anti-Sjogren's syndrome B/La autoantibodies.","[{'Autoimmune': 'B-Entity'}, {'CHB': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'severe,': 'O'}, {'potentially': 'O'}, {'life-threatening': 'O'}, {'disorder': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'passive': 'O'}, {'transfer': 'O'}, {'of': 'O'}, {'maternal': 'O'}, {""anti-Sjogren's"": 'O'}, {'syndrome': 'I-Entity'}, {'A/Ro': 'I-Entity'}, {'and': 'O'}, {""anti-Sjogren's"": 'O'}, {'syndrome': 'I-Entity'}, {'B/La': 'I-Entity'}, {'autoantibodies.': 'O'}]"
"In about one-third of patients, a rheumatologic condition was associated with an additional inflammatory complication or malignancy.","[{'In': 'O'}, {'about': 'O'}, {'one-third': 'O'}, {'of': 'O'}, {'patients,': 'O'}, {'a': 'O'}, {'rheumatologic': 'I-Entity'}, {'condition': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'additional': 'O'}, {'inflammatory': 'O'}, {'complication': 'O'}, {'or': 'O'}, {'malignancy.': 'I-Entity'}]"
"In this study, our aim was to evaluate subclinical cognitive impairment in patients with PSS by investigating P300 potential parameters.","[{'In': 'O'}, {'this': 'O'}, {'study,': 'O'}, {'our': 'O'}, {'aim': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'subclinical': 'O'}, {'cognitive': 'B-Entity'}, {'impairment': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'PSS': 'I-Entity'}, {'by': 'O'}, {'investigating': 'O'}, {'P300': 'O'}, {'potential': 'O'}, {'parameters.': 'O'}]"
"Sensorineural hearing loss was highly prevalent in pSS patients, predominantly in very high frequencies.","[{'Sensorineural': 'B-Entity'}, {'hearing': 'I-Entity'}, {'loss': 'I-Entity'}, {'was': 'O'}, {'highly': 'O'}, {'prevalent': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'patients,': 'O'}, {'predominantly': 'O'}, {'in': 'O'}, {'very': 'O'}, {'high': 'O'}, {'frequencies.': 'O'}]"
In the current study we aimed to explore novel disease biomarkers in saliva and tears from pSS patients.,"[{'In': 'O'}, {'the': 'O'}, {'current': 'O'}, {'study': 'O'}, {'we': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'explore': 'O'}, {'novel': 'O'}, {'disease': 'O'}, {'biomarkers': 'O'}, {'in': 'O'}, {'saliva': 'O'}, {'and': 'O'}, {'tears': 'O'}, {'from': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"Based on the clinical aspect and the possible visual impairment due to secondary glaucoma, the mass lesion on the left side was removed by neurosurgical approach.","[{'Based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'aspect': 'O'}, {'and': 'O'}, {'the': 'O'}, {'possible': 'O'}, {'visual': 'B-Entity'}, {'impairment': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'secondary': 'O'}, {'glaucoma,': 'I-Entity'}, {'the': 'O'}, {'mass': 'B-Entity'}, {'lesion': 'I-Entity'}, {'on': 'O'}, {'the': 'O'}, {'left': 'O'}, {'side': 'O'}, {'was': 'O'}, {'removed': 'O'}, {'by': 'O'}, {'neurosurgical': 'O'}, {'approach.': 'O'}]"
"Sjogrens Syndrome is a complex disease, due to an autoimmune physiopathology, that strongly impacts both patients' primary needs (nutrition and speaking), and patients' relationship life related factors (psychological health and quality of life).","[{'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'complex': 'O'}, {'disease,': 'O'}, {'due': 'O'}, {'to': 'O'}, {'an': 'O'}, {'autoimmune': 'O'}, {'physiopathology,': 'O'}, {'that': 'O'}, {'strongly': 'O'}, {'impacts': 'O'}, {'both': 'O'}, {""patients'"": 'O'}, {'primary': 'O'}, {'needs': 'O'}, {'(nutrition': 'O'}, {'and': 'O'}, {'speaking),': 'O'}, {'and': 'O'}, {""patients'"": 'O'}, {'relationship': 'O'}, {'life': 'O'}, {'related': 'O'}, {'factors': 'O'}, {'(psychological': 'O'}, {'health': 'O'}, {'and': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life).': 'O'}]"
"Abatacept improved salivary secretion from 2076‚Äö√Ñ√∂‚àö√ë‚àö¬¢¬¨¬®¬¨¬±‚Äö√Ñ√∂‚àö√ë‚àö¬¢1535 at baseline to 2857‚Äö√Ñ√∂‚àö√ë‚àö¬¢¬¨¬®¬¨¬±‚Äö√Ñ√∂‚àö√ë‚àö¬¢1431‚Äö√Ñ√∂‚àö√ë‚àö¬¢mg/2‚Äö√Ñ√∂‚àö√ë‚àö¬¢min at 52 weeks (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢9, p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢.05).","[{'Abatacept': 'I-Entity'}, {'improved': 'O'}, {'salivary': 'O'}, {'secretion': 'O'}, {'from': 'O'}, {'2076‚Äö√Ñ√∂‚àö√ë‚àö¬¢¬¨¬®¬¨¬±‚Äö√Ñ√∂‚àö√ë‚àö¬¢1535': 'O'}, {'at': 'O'}, {'baseline': 'O'}, {'to': 'O'}, {'2857‚Äö√Ñ√∂‚àö√ë‚àö¬¢¬¨¬®¬¨¬±‚Äö√Ñ√∂‚àö√ë‚àö¬¢1431‚Äö√Ñ√∂‚àö√ë‚àö¬¢mg/2‚Äö√Ñ√∂‚àö√ë‚àö¬¢min': 'O'}]"
MRI scans disclosed extensive muscle atrophy as well as fatty degeneration in the thigh.,"[{'MRI': 'O'}, {'scans': 'O'}, {'disclosed': 'O'}, {'extensive': 'O'}, {'muscle': 'B-Entity'}, {'atrophy': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'fatty': 'B-Entity'}, {'degeneration': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'thigh.': 'O'}]"
For patients with PSS there is currently no effective therapy that can alter the progression of the disease.,"[{'For': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'PSS': 'I-Entity'}, {'there': 'O'}, {'is': 'O'}, {'currently': 'O'}, {'no': 'O'}, {'effective': 'O'}, {'therapy': 'O'}, {'that': 'O'}, {'can': 'O'}, {'alter': 'O'}, {'the': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
"Rituximab-included regimen produced a better therapeutic response.Beijing 100029, China.10.3760/cma.j.issn.0253-2727.2016.01.008.successfully treated with tocilizumab: A case report.","[{'Rituximab-included': 'I-Entity'}, {'regimen': 'O'}, {'produced': 'O'}, {'a': 'O'}, {'better': 'O'}, {'therapeutic': 'O'}, {'response.Beijing': 'O'}, {'100029,': 'O'}, {'China.10.3760/cma.j.issn.0253-2727.2016.01.008.successfully': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'tocilizumab:': 'I-Entity'}, {'A': 'O'}, {'case': 'O'}, {'report.': 'O'}]"
"However, there have been limited reports of peripheral neuropathy as a complication of neuromyelitis optica (NMO).","[{'However,': 'O'}, {'there': 'O'}, {'have': 'O'}, {'been': 'O'}, {'limited': 'O'}, {'reports': 'O'}, {'of': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'neuromyelitis': 'B-Entity'}, {'optica': 'I-Entity'}, {'(NMO).': 'O'}]"
"Twelve patients (46%) had peripheral system involvement (PNS), 13 (50%) patients had central nervous involvement (CNS) disorders and one (4%) patient had both PNS and CNS involvement.","[{'Twelve': 'O'}, {'patients': 'O'}, {'(46%)': 'O'}, {'had': 'O'}, {'peripheral': 'O'}, {'system': 'I-Entity'}, {'involvement': 'O'}, {'(PNS),': 'O'}, {'13': 'O'}, {'(50%)': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'central': 'B-Entity'}, {'nervous': 'I-Entity'}, {'involvement': 'I-Entity'}, {'(CNS)': 'O'}, {'disorders': 'I-Entity'}, {'and': 'O'}, {'one': 'O'}, {'(4%)': 'O'}, {'patient': 'O'}, {'had': 'O'}, {'both': 'O'}, {'PNS': 'O'}, {'and': 'O'}, {'CNS': 'O'}, {'involvement.': 'O'}]"
"INTRODUCTION AND To determine the clinical and audiological behaviour per age group in Sjogrens Syndrome (SS), considering that it is the second most frequent autoimmune rheumatic disease.","[{'INTRODUCTION': 'O'}, {'AND': 'O'}, {'To': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'audiological': 'O'}, {'behaviour': 'O'}, {'per': 'O'}, {'age': 'O'}, {'group': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'considering': 'O'}, {'that': 'O'}, {'it': 'O'}, {'is': 'O'}, {'the': 'O'}, {'second': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'autoimmune': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"Patients with SIDs were younger (P‚Äö√Ñ√∂‚àö√ë‚àö¬ß<‚Äö√Ñ√∂‚àö√ë‚àö¬ß0.001), more frequently of female sex (P‚Äö√Ñ√∂‚àö√ë‚àö¬ß=‚Äö√Ñ√∂‚àö√ë‚àö¬ß0.025), and had a higher frequency of extra-cardiac symptoms (P‚Äö√Ñ√∂‚àö√ë‚àö¬ß<‚Äö√Ñ√∂‚àö√ë‚àö¬ß0.001) including arthralgia, myalgia, Raynaud phenomenon, and skin rash, as compared with patients with idiopathic pericarditis (n‚Äö√Ñ√∂‚àö√ë‚àö¬ß=‚Äö√Ñ√∂‚àö√ë‚àö¬ß51).","[{'Patients': 'O'}, {'with': 'O'}, {'SIDs': 'I-Entity'}, {'were': 'O'}, {'younger': 'O'}, {'(P‚Äö√Ñ√∂‚àö√ë‚àö¬ß<‚Äö√Ñ√∂‚àö√ë‚àö¬ß0.001),': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'of': 'O'}, {'female': 'O'}, {'sex': 'O'}, {'(P‚Äö√Ñ√∂‚àö√ë‚àö¬ß=‚Äö√Ñ√∂‚àö√ë‚àö¬ß0.025),': 'O'}]"
The results showed seven m/z (mass-to-charge) ratio peaks with significant differences.,"[{'The': 'O'}, {'results': 'O'}, {'showed': 'O'}, {'seven': 'O'}, {'m/z': 'O'}, {'(mass-to-charge)': 'O'}, {'ratio': 'O'}, {'peaks': 'O'}, {'with': 'O'}, {'significant': 'O'}, {'differences.': 'O'}]"
PATIENT AND We report a case of a 42-year-old white woman with Sjogren syndrome and premature ovarian failure who underwent a reversal of her premature ovarian failure and restoration of normal menses using an elimination diet protocol.,"[{'PATIENT': 'O'}, {'AND': 'O'}, {'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'42-year-old': 'O'}, {'white': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'premature': 'B-Entity'}, {'ovarian': 'I-Entity'}, {'failure': 'I-Entity'}, {'who': 'O'}, {'underwent': 'O'}, {'a': 'O'}, {'reversal': 'O'}, {'of': 'O'}, {'her': 'O'}, {'premature': 'B-Entity'}, {'ovarian': 'I-Entity'}, {'failure': 'I-Entity'}, {'and': 'O'}, {'restoration': 'O'}, {'of': 'O'}, {'normal': 'O'}, {'menses': 'O'}, {'using': 'O'}, {'an': 'O'}, {'elimination': 'O'}, {'diet': 'O'}, {'protocol.': 'O'}]"
Primary Sjogrens syndrome (pSS) is characterized by mononuclear inflammatory infiltrates and IgG plasma cells in salivary and lacrimal glands which lead to irreversible destruction of the glandular tissue and is accompanied by sensation of dryness of mouth and eyes.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'mononuclear': 'O'}, {'inflammatory': 'O'}, {'infiltrates': 'O'}, {'and': 'O'}, {'IgG': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'which': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'irreversible': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'the': 'O'}, {'glandular': 'O'}, {'tissue': 'O'}, {'and': 'O'}, {'is': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'sensation': 'O'}, {'of': 'O'}, {'dryness': 'B-Entity'}, {'of': 'I-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}]"
"Due to the absence of specific clinical manifestations and biomarkers in the early stage, pSS is generally underrecognized.","[{'Due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'specific': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'and': 'O'}, {'biomarkers': 'O'}, {'in': 'O'}, {'the': 'O'}, {'early': 'O'}, {'stage,': 'O'}, {'pSS': 'I-Entity'}, {'is': 'O'}, {'generally': 'O'}, {'underrecognized.': 'O'}]"
"However, some participants with Sjogren syndrome or dry mouth showed a significant increase in the migration of melanoidin after stimulation.","[{'However,': 'O'}, {'some': 'O'}, {'participants': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'or': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'showed': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'the': 'O'}, {'migration': 'O'}, {'of': 'O'}, {'melanoidin': 'I-Entity'}, {'after': 'O'}, {'stimulation.': 'O'}]"
The patient was diagnosed with the Sjogren syndrome and demonstrated inadequate lacrimation as assessed by Schirmer testing.,"[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'the': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'demonstrated': 'O'}, {'inadequate': 'O'}, {'lacrimation': 'O'}, {'as': 'O'}, {'assessed': 'O'}, {'by': 'O'}, {'Schirmer': 'O'}, {'testing.': 'O'}]"
"To conclude, diagnosis of Sjogren's syndrome may also be considered in a patient presenting with recurrent aseptic meningitis.doi:10.5455/JPMA.295727","[{'To': 'O'}, {'conclude,': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'may': 'O'}, {'also': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'in': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'presenting': 'O'}, {'with': 'O'}, {'recurrent': 'O'}, {'aseptic': 'B-Entity'}, {'meningitis.doi:10.5455/JPMA.295727': 'I-Entity'}]"
The diagnosis of small fiber neuropathy (SFN) is a challenge for clinical neurophysiology.,"[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'small': 'B-Entity'}, {'fiber': 'I-Entity'}, {'neuropathy': 'I-Entity'}, {'(SFN)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'challenge': 'O'}, {'for': 'O'}, {'clinical': 'O'}, {'neurophysiology.': 'O'}]"
"Patients without chronic benign pain syndrome (CBP) (HR 2.13; 95% CI [0.94-4.76]; p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.061), but in particular those with cryoglobulins (HR 2.87; 95% CI [1.20-6.86]; p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.013), developed more events.","[{'Patients': 'O'}, {'without': 'O'}, {'chronic': 'B-Entity'}, {'benign': 'I-Entity'}, {'pain': 'I-Entity'}, {'syndrome': 'O'}, {'(CBP)': 'O'}, {'(HR': 'O'}, {'2.13;': 'O'}, {'95%': 'O'}, {'CI': 'O'}, {'[0.94-4.76];': 'O'}, {'p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.061),': 'O'}]"
"It has been associated with previous infectious diseases, diabetes, paraproteinemia and, more rarely, malignant neoplasms or autoimmune disorders.","[{'It': 'O'}, {'has': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'previous': 'O'}, {'infectious': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'diabetes,': 'I-Entity'}, {'paraproteinemia': 'I-Entity'}, {'and,': 'O'}, {'more': 'O'}, {'rarely,': 'O'}, {'malignant': 'B-Entity'}, {'neoplasms': 'I-Entity'}, {'or': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders.': 'I-Entity'}]"
The results of our analysis suggest that patients with SS have 30% prevalence of OLP and OLL.,"[{'The': 'O'}, {'results': 'O'}, {'of': 'O'}, {'our': 'O'}, {'analysis': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'have': 'O'}, {'30%': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'OLP': 'I-Entity'}, {'and': 'O'}, {'OLL.': 'I-Entity'}]"
"Therapy that comprised a single course of intravenous (IV) methylprednisolone (1‚Äö√Ñ√∂‚àö√ë‚àö√±g for 3 days), followed by oral prednisolone (60‚Äö√Ñ√∂‚àö√ë‚àö√±mg/day) with gradual tapering, resulted in no amelioration of her symptoms.","[{'Therapy': 'O'}, {'that': 'O'}, {'comprised': 'O'}, {'a': 'O'}, {'single': 'O'}, {'course': 'O'}, {'of': 'O'}, {'intravenous': 'O'}, {'(IV)': 'O'}, {'methylprednisolone': 'I-Entity'}, {'(1‚Äö√Ñ√∂‚àö√ë‚àö√±g': 'O'}, {'for': 'O'}, {'3': 'O'}, {'days),': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'oral': 'O'}, {'prednisolone': 'I-Entity'}, {'(60‚Äö√Ñ√∂‚àö√ë‚àö√±mg/day)': 'O'}]"
"As described in infectious disorders, the combination of otalgia, facial weakness, and 8th cranial nerve deficits suggests damage to the geniculate ganglia (ie, the sensory ganglia of the 7th cranial nerve), with contiguous involvement of other cranial nerves causing facial weakness and vertigo.","[{'As': 'O'}, {'described': 'O'}, {'in': 'O'}, {'infectious': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'the': 'O'}, {'combination': 'O'}, {'of': 'O'}, {'otalgia,': 'I-Entity'}, {'facial': 'B-Entity'}, {'weakness,': 'I-Entity'}, {'and': 'O'}, {'8th': 'B-Entity'}, {'cranial': 'B-Entity'}, {'nerve': 'I-Entity'}, {'deficits': 'I-Entity'}, {'suggests': 'O'}, {'damage': 'O'}, {'to': 'O'}, {'the': 'O'}, {'geniculate': 'O'}, {'ganglia': 'O'}, {'(ie,': 'O'}, {'the': 'O'}, {'sensory': 'O'}, {'ganglia': 'O'}, {'of': 'O'}, {'the': 'O'}, {'7th': 'O'}, {'cranial': 'O'}, {'nerve),': 'O'}, {'with': 'O'}, {'contiguous': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'other': 'O'}, {'cranial': 'O'}, {'nerves': 'O'}, {'causing': 'O'}]"
This sign has been most commonly associated with hypertensive and diabetic microvascular fragility and thrombocytopenia.,"[{'This': 'O'}, {'sign': 'O'}, {'has': 'O'}, {'been': 'O'}, {'most': 'O'}, {'commonly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'hypertensive': 'I-Entity'}, {'and': 'O'}, {'diabetic': 'B-Entity'}, {'microvascular': 'I-Entity'}, {'fragility': 'I-Entity'}, {'and': 'O'}, {'thrombocytopenia.': 'I-Entity'}]"
"Treatment may be lengthy, requiring topical and systemic antibiotics and is often complicated due to resistance.United States.eCollection 2020 Sep.","[{'Treatment': 'O'}, {'may': 'O'}, {'be': 'O'}, {'lengthy,': 'O'}, {'requiring': 'O'}, {'topical': 'O'}, {'and': 'O'}, {'systemic': 'O'}, {'antibiotics': 'O'}, {'and': 'O'}, {'is': 'O'}, {'often': 'O'}, {'complicated': 'O'}, {'due': 'O'}, {'to': 'O'}, {'resistance.United': 'O'}, {'States.eCollection': 'O'}, {'2020': 'O'}, {'Sep.': 'O'}]"
"Accordingly, we tested the hypothesis that Sjogrens syndrome (SS) is associated with increased salivary gland expression of GADD153 and increased leukocyte infiltration in association with decreased Del-1 thereby contributing to inflammation and cell death.","[{'Accordingly,': 'O'}, {'we': 'O'}, {'tested': 'O'}, {'the': 'O'}, {'hypothesis': 'O'}, {'that': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'GADD153': 'O'}, {'and': 'O'}, {'increased': 'O'}, {'leukocyte': 'O'}, {'infiltration': 'O'}, {'in': 'O'}, {'association': 'O'}, {'with': 'O'}, {'decreased': 'O'}, {'Del-1': 'O'}, {'thereby': 'O'}, {'contributing': 'O'}, {'to': 'O'}, {'inflammation': 'O'}, {'and': 'O'}, {'cell': 'O'}, {'death.': 'O'}]"
Sjogrens syndrome (SS) is a chronic inflammatory autoimmune disease characterized by lymphocyte infiltration of the exocrine glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocyte': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands.': 'O'}]"
"Primary Sjogrens syndrome (pSS) is a systemic immune-mediated disease whose main characteristic is exocrine gland inflammation and, subsequent reduction in tear and saliva production.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'immune-mediated': 'O'}, {'disease': 'O'}, {'whose': 'O'}, {'main': 'O'}, {'characteristic': 'O'}, {'is': 'O'}, {'exocrine': 'O'}, {'gland': 'O'}, {'inflammation': 'I-Entity'}, {'and,': 'O'}, {'subsequent': 'O'}, {'reduction': 'O'}, {'in': 'O'}, {'tear': 'O'}, {'and': 'O'}, {'saliva': 'O'}, {'production.': 'O'}]"
"As result, clinical features in SS can be divided into two facets: the benign subjective but disabling manifestations such as dryness, pain and fatigue, and the systemic manifestations.","[{'As': 'O'}, {'result,': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'divided': 'O'}, {'into': 'O'}, {'two': 'O'}, {'facets:': 'O'}, {'the': 'O'}, {'benign': 'O'}, {'subjective': 'O'}, {'but': 'O'}, {'disabling': 'O'}, {'manifestations': 'O'}, {'such': 'O'}, {'as': 'O'}, {'dryness,': 'I-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'fatigue,': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'systemic': 'O'}, {'manifestations.': 'O'}]"
"As result, clinical features in SS can be divided into two facets: the benign subjective but disabling manifestations such as dryness, pain and fatigue, and the systemic manifestations.","[{'As': 'O'}, {'result,': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'divided': 'O'}, {'into': 'O'}, {'two': 'O'}, {'facets:': 'O'}, {'the': 'O'}, {'benign': 'O'}, {'subjective': 'O'}, {'but': 'O'}, {'disabling': 'O'}, {'manifestations': 'O'}, {'such': 'O'}, {'as': 'O'}, {'dryness,': 'I-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'fatigue,': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'systemic': 'O'}, {'manifestations.': 'O'}]"
We aimed to determine whether patients' symptoms differed between patients with and without systemic involvement and if the disease-specific indices correlated with each other in primary SS.,"[{'We': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {""patients'"": 'O'}, {'symptoms': 'O'}, {'differed': 'O'}, {'between': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'and': 'O'}, {'without': 'O'}, {'systemic': 'O'}, {'involvement': 'O'}, {'and': 'O'}, {'if': 'O'}, {'the': 'O'}, {'disease-specific': 'O'}, {'indices': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'each': 'O'}, {'other': 'O'}, {'in': 'O'}, {'primary': 'O'}, {'SS.': 'I-Entity'}]"
"To evaluate, by musculoskeletal ultrasound (MSUS), articular involvement in primary SS (pSS) patients by analysing hand and wrist changes, and to correlate them with clinical evaluation and laboratory tests.","[{'To': 'O'}, {'evaluate,': 'O'}, {'by': 'O'}, {'musculoskeletal': 'O'}, {'ultrasound': 'O'}, {'(MSUS),': 'O'}, {'articular': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'SS': 'I-Entity'}, {'(pSS)': 'O'}, {'patients': 'O'}, {'by': 'O'}, {'analysing': 'O'}, {'hand': 'O'}, {'and': 'O'}, {'wrist': 'O'}, {'changes,': 'O'}, {'and': 'O'}, {'to': 'O'}, {'correlate': 'O'}, {'them': 'O'}, {'with': 'O'}, {'clinical': 'O'}, {'evaluation': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'tests.': 'O'}]"
Tight junction ultrastructure was examined by transmission electron microscopy.,"[{'Tight': 'O'}, {'junction': 'O'}, {'ultrastructure': 'O'}, {'was': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'transmission': 'O'}, {'electron': 'O'}, {'microscopy.': 'O'}]"
Anti-aquaporin 4 antibodies are specific markers for Devic's disease.,"[{'Anti-aquaporin': 'O'}, {'4': 'O'}, {'antibodies': 'O'}, {'are': 'O'}, {'specific': 'O'}, {'markers': 'O'}, {'for': 'O'}, {""Devic's"": 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Retrospectively identified 80 never-smoker SS patients [56 primary SS (1-SS), 24 secondary SS (2-SS)] who underwent chest CT at our institution during a 3-year period from 2004 through 2007 were included in this study.","[{'Retrospectively': 'O'}, {'identified': 'O'}, {'80': 'O'}, {'never-smoker': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'[56': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'(1-SS),': 'O'}, {'24': 'O'}, {'secondary': 'O'}, {'SS': 'I-Entity'}, {'(2-SS)]': 'O'}, {'who': 'O'}, {'underwent': 'O'}, {'chest': 'O'}, {'CT': 'O'}, {'at': 'O'}, {'our': 'O'}, {'institution': 'O'}, {'during': 'O'}, {'a': 'O'}, {'3-year': 'O'}, {'period': 'O'}, {'from': 'O'}, {'2004': 'O'}, {'through': 'O'}, {'2007': 'O'}, {'were': 'O'}, {'included': 'O'}, {'in': 'O'}, {'this': 'O'}, {'study.': 'O'}]"
"Despite the administration of high doses of prednisolone and azathioprine for active Sjogren syndrome, the frequency of crescendo transient ischemic attacks increased with the progression of stenosis and magnetic resonance imaging showed the development of subacute cerebral infarction.","[{'Despite': 'O'}, {'the': 'O'}, {'administration': 'O'}, {'of': 'O'}, {'high': 'O'}, {'doses': 'O'}, {'of': 'O'}, {'prednisolone': 'I-Entity'}, {'and': 'O'}, {'azathioprine': 'I-Entity'}, {'for': 'O'}, {'active': 'O'}, {'Sjogren': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'the': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'crescendo': 'O'}, {'transient': 'O'}, {'ischemic': 'I-Entity'}, {'attacks': 'O'}, {'increased': 'O'}, {'with': 'O'}, {'the': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'stenosis': 'I-Entity'}, {'and': 'O'}, {'magnetic': 'O'}, {'resonance': 'O'}, {'imaging': 'O'}, {'showed': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'subacute': 'O'}, {'cerebral': 'B-Entity'}, {'infarction.': 'I-Entity'}]"
"Similarly, treatment of various autoimmune/inflammatory oral conditions is often common and involves modulation or suppression of the immune response locally and/or systemically and will be therefore addressed in a common section as well as individually for each disease when unique treatment regimens are recommended.","[{'Similarly,': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'various': 'O'}, {'autoimmune/inflammatory': 'B-Entity'}, {'oral': 'I-Entity'}, {'conditions': 'I-Entity'}, {'is': 'O'}, {'often': 'O'}, {'common': 'O'}, {'and': 'O'}, {'involves': 'O'}, {'modulation': 'O'}, {'or': 'O'}, {'suppression': 'O'}, {'of': 'O'}, {'the': 'O'}, {'immune': 'O'}, {'response': 'O'}, {'locally': 'O'}, {'and/or': 'O'}, {'systemically': 'O'}, {'and': 'O'}, {'will': 'O'}, {'be': 'O'}, {'therefore': 'O'}, {'addressed': 'O'}, {'in': 'O'}, {'a': 'O'}, {'common': 'O'}, {'section': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'individually': 'O'}, {'for': 'O'}, {'each': 'O'}, {'disease': 'O'}, {'when': 'O'}, {'unique': 'O'}, {'treatment': 'O'}, {'regimens': 'O'}, {'are': 'O'}, {'recommended.': 'O'}]"
"Relationships between SG fibrosis, age, and clinical measures were evaluated using Spearman correlations.","[{'Relationships': 'O'}, {'between': 'O'}, {'SG': 'O'}, {'fibrosis,': 'I-Entity'}, {'age,': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'measures': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'using': 'O'}, {'Spearman': 'O'}, {'correlations.': 'O'}]"
There are also reports of various symptoms connected with damage to cranial nerves and the autonomic nervous system.,"[{'There': 'O'}, {'are': 'O'}, {'also': 'O'}, {'reports': 'O'}, {'of': 'O'}, {'various': 'O'}, {'symptoms': 'O'}, {'connected': 'O'}, {'with': 'O'}, {'damage': 'B-Entity'}, {'to': 'I-Entity'}, {'cranial': 'I-Entity'}, {'nerves': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'autonomic': 'O'}, {'nervous': 'I-Entity'}, {'system.': 'O'}]"
A significant difference (P<0.05) was found in the dry eye syndrome testing results between the 2 groups in this study.,"[{'A': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'(P<0.05)': 'O'}, {'was': 'O'}, {'found': 'O'}, {'in': 'O'}, {'the': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'testing': 'O'}, {'results': 'O'}, {'between': 'O'}, {'the': 'O'}, {'2': 'O'}, {'groups': 'O'}, {'in': 'O'}, {'this': 'O'}, {'study.': 'O'}]"
"To study MMP9 and TG2 expression after anti-inflammatory treatment, patients were divided into 2 subgroups, one treated with saline and the other treated with saline plus topical corticosteroid eye drops (0.5% loteprednol etabonate) 4 times daily for 15 days.","[{'To': 'O'}, {'study': 'O'}, {'MMP9': 'O'}, {'and': 'O'}, {'TG2': 'O'}, {'expression': 'O'}, {'after': 'O'}, {'anti-inflammatory': 'O'}, {'treatment,': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'divided': 'O'}, {'into': 'O'}, {'2': 'O'}, {'subgroups,': 'O'}, {'one': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'saline': 'O'}, {'and': 'O'}, {'the': 'O'}, {'other': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'saline': 'O'}, {'plus': 'O'}, {'topical': 'O'}, {'corticosteroid': 'O'}, {'eye': 'O'}, {'drops': 'O'}, {'(0.5%': 'O'}, {'loteprednol': 'B-Entity'}, {'etabonate)': 'I-Entity'}, {'4': 'O'}]"
The otolaryngologist should be able to recognize when a systemic disease may be the cause of a patient's dysphagia and guide appropriate evaluation.,"[{'The': 'O'}, {'otolaryngologist': 'O'}, {'should': 'O'}, {'be': 'O'}, {'able': 'O'}, {'to': 'O'}, {'recognize': 'O'}, {'when': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'disease': 'O'}, {'may': 'O'}, {'be': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'a': 'O'}, {""patient's"": 'O'}, {'dysphagia': 'I-Entity'}, {'and': 'O'}, {'guide': 'O'}, {'appropriate': 'O'}, {'evaluation.': 'O'}]"
Treatment with the MMP2/9 inhibitor resulted in decreased activity of MMP-2 and -9 both in vitro and in vivo.,"[{'Treatment': 'O'}, {'with': 'O'}, {'the': 'O'}, {'MMP2/9': 'O'}, {'inhibitor': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'decreased': 'O'}, {'activity': 'O'}, {'of': 'O'}, {'MMP-2': 'O'}, {'and': 'O'}, {'-9': 'O'}, {'both': 'O'}, {'in': 'O'}, {'vitro': 'O'}, {'and': 'O'}, {'in': 'O'}, {'vivo.': 'O'}]"
"Interstitial lung disease (ILD, n =¬¨¬®‚Äö√Ñ‚Ä†15), especially non-specific interstitial pneumonia (n¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†7), was present most commonly.","[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD,': 'O'}, {'n': 'O'}, {'=¬¨¬®‚Äö√Ñ‚Ä†15),': 'O'}, {'especially': 'O'}, {'non-specific': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'(n¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†7),': 'O'}]"
The authors have also reviewed available medical literature and have indicated problems that typically occur in such patients.,"[{'The': 'O'}, {'authors': 'O'}, {'have': 'O'}, {'also': 'O'}, {'reviewed': 'O'}, {'available': 'O'}, {'medical': 'O'}, {'literature': 'O'}, {'and': 'O'}, {'have': 'O'}, {'indicated': 'O'}, {'problems': 'O'}, {'that': 'O'}, {'typically': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'such': 'O'}, {'patients.': 'O'}]"
All the subjects recounted presenting with dry mouth and associated significantly the ingestion of fluids and teeth brushing to improve the sensation of dryness.,"[{'All': 'O'}, {'the': 'O'}, {'subjects': 'O'}, {'recounted': 'O'}, {'presenting': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'associated': 'O'}, {'significantly': 'O'}, {'the': 'O'}, {'ingestion': 'O'}, {'of': 'O'}, {'fluids': 'O'}, {'and': 'O'}, {'teeth': 'O'}, {'brushing': 'O'}, {'to': 'O'}, {'improve': 'O'}, {'the': 'O'}, {'sensation': 'O'}, {'of': 'O'}, {'dryness.': 'I-Entity'}]"
"Their lymphocytic infiltration leads to manifestations from other organs (e.g., kidneys, lungs, liver, or thyroid), apart from sicca symptoms (xerostomia and keratoconjunctivitis).","[{'Their': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'manifestations': 'O'}, {'from': 'O'}, {'other': 'O'}, {'organs': 'O'}, {'(e.g.,': 'O'}, {'kidneys,': 'O'}, {'lungs,': 'O'}, {'liver,': 'O'}, {'or': 'O'}, {'thyroid),': 'O'}, {'apart': 'O'}, {'from': 'O'}, {'sicca': 'I-Entity'}, {'symptoms': 'O'}, {'(xerostomia': 'O'}, {'and': 'O'}, {'keratoconjunctivitis).': 'I-Entity'}]"
"The most common extra-articular manifestations were sicca symptom (40.6%) and carpal tunnel syndrome (35.7%), followed by pulmonary involvement (6.6%), vasculitis (3.6%), and Raynaud's phenomenon (1.2%).","[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'extra-articular': 'O'}, {'manifestations': 'O'}, {'were': 'O'}, {'sicca': 'I-Entity'}, {'symptom': 'O'}, {'(40.6%)': 'O'}, {'and': 'O'}, {'carpal': 'B-Entity'}, {'tunnel': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(35.7%),': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'pulmonary': 'O'}, {'involvement': 'O'}, {'(6.6%),': 'O'}, {'vasculitis': 'I-Entity'}, {'(3.6%),': 'O'}, {'and': 'O'}, {""Raynaud's"": 'B-Entity'}]"
"TAFRO syndrome can occur with several diseases, including infection, rheumatic disease and malignancies.","[{'TAFRO': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'can': 'O'}, {'occur': 'O'}, {'with': 'O'}, {'several': 'O'}, {'diseases,': 'O'}, {'including': 'O'}, {'infection,': 'I-Entity'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'malignancies.': 'I-Entity'}]"
The systemic form of the disease is characterized by immune complex-mediated manifestations and is complicated by lymphoma as a result of a polyclonal B cell hyperactivity that is evolving into B cell malignancy.,"[{'The': 'O'}, {'systemic': 'O'}, {'form': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'immune': 'O'}, {'complex-mediated': 'O'}, {'manifestations': 'O'}, {'and': 'O'}, {'is': 'O'}, {'complicated': 'O'}, {'by': 'O'}, {'lymphoma': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'result': 'O'}, {'of': 'O'}, {'a': 'O'}, {'polyclonal': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'hyperactivity': 'O'}, {'that': 'O'}, {'is': 'O'}, {'evolving': 'O'}, {'into': 'O'}, {'B': 'B-Entity'}, {'cell': 'I-Entity'}, {'malignancy.': 'I-Entity'}]"
"Although the spectrum of adrenergic failure is variable, ranging from orthostatic hypotension to an excessive postural tachycardia, most patients do have symptoms of more generalized autonomic failure.","[{'Although': 'O'}, {'the': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'adrenergic': 'B-Entity'}, {'failure': 'I-Entity'}, {'is': 'O'}, {'variable,': 'O'}, {'ranging': 'O'}, {'from': 'O'}, {'orthostatic': 'B-Entity'}, {'hypotension': 'I-Entity'}, {'to': 'O'}, {'an': 'O'}, {'excessive': 'O'}, {'postural': 'O'}, {'tachycardia,': 'I-Entity'}, {'most': 'O'}, {'patients': 'O'}, {'do': 'O'}, {'have': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'more': 'O'}, {'generalized': 'O'}, {'autonomic': 'B-Entity'}, {'failure.': 'I-Entity'}]"
"The central nervous system (CNS) may be involved in a variety of inflammatory diseases of the blood vessels, generally known as vasculitis.","[{'The': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'(CNS)': 'O'}, {'may': 'O'}, {'be': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'a': 'O'}, {'variety': 'O'}, {'of': 'O'}, {'inflammatory': 'B-Entity'}, {'diseases': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'blood': 'I-Entity'}, {'vessels,': 'I-Entity'}, {'generally': 'O'}, {'known': 'O'}, {'as': 'O'}, {'vasculitis.': 'I-Entity'}]"
To survey ophthalmologists about current practice patterns regarding the evaluation of dry eye patients and referrals for a Sjogren syndrome (SS) workup.,"[{'To': 'O'}, {'survey': 'O'}, {'ophthalmologists': 'O'}, {'about': 'O'}, {'current': 'O'}, {'practice': 'O'}, {'patterns': 'O'}, {'regarding': 'O'}, {'the': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'referrals': 'O'}, {'for': 'O'}, {'a': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'workup.': 'O'}]"
"Accordingly, the STAT1-mediated gene responses were significantly enhanced in PBMCs from pSS patients.","[{'Accordingly,': 'O'}, {'the': 'O'}, {'STAT1-mediated': 'O'}, {'gene': 'O'}, {'responses': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'enhanced': 'O'}, {'in': 'O'}, {'PBMCs': 'O'}, {'from': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
We considered the etiology of the neural and renal dysfunction as due to the inflammatory mechanism associated with Sjogrens syndrome.,"[{'We': 'O'}, {'considered': 'O'}, {'the': 'O'}, {'etiology': 'O'}, {'of': 'O'}, {'the': 'O'}, {'neural': 'B-Entity'}, {'and': 'I-Entity'}, {'renal': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'as': 'O'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'inflammatory': 'O'}, {'mechanism': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Reasons for referral included failure of other DMARD in 54 patients, limited DMARD options in 50 (chronic liver disease in 34, sulfa allergy in 7, high alcohol consumption in 5, and planning pregnancy in 4), physician choice in 12, previous benefit from gold in 10, benefit of clinic support in 10, inappropriate for biologics in 7, patient choice in 4, and failure of biologics in 3.","[{'Reasons': 'O'}, {'for': 'O'}, {'referral': 'O'}, {'included': 'O'}, {'failure': 'O'}, {'of': 'O'}, {'other': 'O'}, {'DMARD': 'O'}, {'in': 'O'}, {'54': 'O'}, {'patients,': 'O'}, {'limited': 'O'}, {'DMARD': 'O'}, {'options': 'O'}, {'in': 'O'}, {'50': 'O'}, {'(chronic': 'O'}, {'liver': 'I-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'34,': 'O'}, {'sulfa': 'I-Entity'}, {'allergy': 'I-Entity'}, {'in': 'O'}, {'7,': 'O'}, {'high': 'O'}, {'alcohol': 'I-Entity'}, {'consumption': 'O'}, {'in': 'O'}, {'5,': 'O'}, {'and': 'O'}, {'planning': 'O'}, {'pregnancy': 'O'}, {'in': 'O'}, {'4),': 'O'}, {'physician': 'O'}, {'choice': 'O'}, {'in': 'O'}, {'12,': 'O'}, {'previous': 'O'}, {'benefit': 'O'}, {'from': 'O'}, {'gold': 'I-Entity'}, {'in': 'O'}]"
Our analyses included 10 941 SS cases and 43‚Äö√Ñ√∂‚àö√ë‚àö¬¢764 propensity score-matched controls.,"[{'Our': 'O'}, {'analyses': 'O'}, {'included': 'O'}, {'10': 'O'}, {'941': 'O'}, {'SS': 'I-Entity'}, {'cases': 'O'}, {'and': 'O'}, {'43‚Äö√Ñ√∂‚àö√ë‚àö¬¢764': 'O'}, {'propensity': 'O'}, {'score-matched': 'O'}, {'controls.': 'O'}]"
"To investigate the association between primary Sjogrens syndrome (pSS) and coronary heart disease (CHD), and the influence of medications for pSS patients on risk of CHD.","[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'association': 'O'}, {'between': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'and': 'O'}, {'coronary': 'B-Entity'}, {'heart': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CHD),': 'O'}, {'and': 'O'}, {'the': 'O'}, {'influence': 'O'}, {'of': 'O'}, {'medications': 'O'}, {'for': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'on': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'CHD.': 'I-Entity'}]"
"MATERIAL AND We therefore examined the morphology, the exocrine and endocrine functions of the pancreas in 12 healthy consecutively included levolunteers with established SS, but without known pancreatic disease, using secretin-stimulated magnetic resonance cholangiopancreatography (MRCP), a Lundh test, oral glucose tolerance test, and blood sampling.","[{'MATERIAL': 'O'}, {'AND': 'O'}, {'We': 'O'}, {'therefore': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'morphology,': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'and': 'O'}, {'endocrine': 'O'}, {'functions': 'O'}, {'of': 'O'}, {'the': 'O'}, {'pancreas': 'O'}, {'in': 'O'}, {'12': 'O'}, {'healthy': 'O'}, {'consecutively': 'O'}, {'included': 'O'}, {'levolunteers': 'O'}, {'with': 'O'}, {'established': 'O'}, {'SS,': 'I-Entity'}, {'but': 'O'}, {'without': 'O'}, {'known': 'O'}, {'pancreatic': 'B-Entity'}, {'disease,': 'I-Entity'}, {'using': 'O'}, {'secretin-stimulated': 'O'}, {'magnetic': 'O'}, {'resonance': 'O'}, {'cholangiopancreatography': 'O'}]"
"Anti-CCG-2, -4 and -7 antibodies were detected in 25¬¨¬®‚Äö√†√´5, 33¬¨¬®‚Äö√†√´2 and 37¬¨¬®‚Äö√†√´0% patients with RA, respectively, and these antibodies were very specific for RA (specificity, 98¬¨¬®‚Äö√†√´1-99¬¨¬®‚Äö√†√´7%).","[{'Anti-CCG-2,': 'O'}, {'-4': 'O'}, {'and': 'O'}, {'-7': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'25¬¨¬®‚Äö√†√´5,': 'O'}, {'33¬¨¬®‚Äö√†√´2': 'O'}, {'and': 'O'}, {'37¬¨¬®‚Äö√†√´0%': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'RA,': 'I-Entity'}]"
"Importantly, MMP2/9 inhibitor treatment of MRL/lpr mice improved aqueous tear production and resulted in reduced number and size of lymphocytic foci in diseased lacrimal glands.","[{'Importantly,': 'O'}, {'MMP2/9': 'O'}, {'inhibitor': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'MRL/lpr': 'O'}, {'mice': 'O'}, {'improved': 'O'}, {'aqueous': 'O'}, {'tear': 'O'}, {'production': 'O'}, {'and': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'reduced': 'O'}, {'number': 'O'}, {'and': 'O'}, {'size': 'O'}, {'of': 'O'}, {'lymphocytic': 'O'}, {'foci': 'O'}, {'in': 'O'}, {'diseased': 'O'}, {'lacrimal': 'O'}, {'glands.': 'O'}]"
"Given that cathepsin S activity is increased in the lacrimal glands and tears of NOD mice (a murine model of SS), the aim of this study was to explore the clinical utility of using tear cathepsin S (CTSS) activity as a biomarker for SS.","[{'Given': 'O'}, {'that': 'O'}, {'cathepsin': 'O'}, {'S': 'O'}, {'activity': 'O'}, {'is': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'and': 'O'}, {'tears': 'O'}, {'of': 'O'}, {'NOD': 'O'}, {'mice': 'O'}, {'(a': 'O'}, {'murine': 'O'}, {'model': 'O'}, {'of': 'O'}, {'SS),': 'I-Entity'}, {'the': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'explore': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'utility': 'O'}, {'of': 'O'}, {'using': 'O'}, {'tear': 'O'}, {'cathepsin': 'O'}, {'S': 'O'}, {'(CTSS)': 'O'}, {'activity': 'O'}, {'as': 'O'}, {'a': 'O'}, {'biomarker': 'O'}, {'for': 'O'}]"
"The presence of such patients reveals that pSS is an underlying cause of acute bilateral facial paralysis.Nan Street, Taiyuan, China.Nan Street, Taiyuan, China.Nan Street, Taiyuan, China.","[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'such': 'O'}, {'patients': 'O'}, {'reveals': 'O'}, {'that': 'O'}, {'pSS': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'underlying': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'acute': 'O'}, {'bilateral': 'O'}, {'facial': 'B-Entity'}, {'paralysis.Nan': 'I-Entity'}, {'Street,': 'O'}, {'Taiyuan,': 'O'}, {'China.Nan': 'O'}, {'Street,': 'O'}, {'Taiyuan,': 'O'}, {'China.Nan': 'O'}, {'Street,': 'O'}, {'Taiyuan,': 'O'}, {'China.': 'O'}]"
"IgG4-related disease (IgG4-RD) is a chronic, systemic, inflammatory condition of unknown aetiology.","[{'IgG4-related': 'B-Entity'}, {'disease': 'I-Entity'}, {'(IgG4-RD)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic,': 'O'}, {'systemic,': 'O'}, {'inflammatory': 'O'}, {'condition': 'O'}, {'of': 'O'}, {'unknown': 'O'}, {'aetiology.': 'O'}]"
Saliva is vital for the maintenance of normal oral physiology and mucosal health.,"[{'Saliva': 'O'}, {'is': 'O'}, {'vital': 'O'}, {'for': 'O'}, {'the': 'O'}, {'maintenance': 'O'}, {'of': 'O'}, {'normal': 'O'}, {'oral': 'O'}, {'physiology': 'O'}, {'and': 'O'}, {'mucosal': 'O'}, {'health.': 'O'}]"
"The observed changes in MUC7 glycosylation could be a potential diagnostic tool for saliva quality and taken into consideration for future therapies for this multifactorial syndrome.College London, Guy's Hospital, Floor 17, Tower Wing, London SE1 9RT, UK;College London, Guy's Hospital, Floor 17, Tower Wing, London SE1 9RT, UK;Gothenburg, Medicinaregatan 9A, 405 30, Gothenburg, Sweden niclas.karlsson@medkem.gu.se.College London, Guy's Hospital, Floor 17, Tower Wing, London SE1 9RT, UK;Gothenburg, Medicinaregatan 9A, 405 30, Gothenburg, Sweden.Dec 2.product.","[{'The': 'O'}, {'observed': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'MUC7': 'O'}, {'glycosylation': 'O'}, {'could': 'O'}, {'be': 'O'}, {'a': 'O'}, {'potential': 'O'}, {'diagnostic': 'O'}, {'tool': 'O'}, {'for': 'O'}, {'saliva': 'O'}, {'quality': 'O'}, {'and': 'O'}, {'taken': 'O'}, {'into': 'O'}, {'consideration': 'O'}, {'for': 'O'}, {'future': 'O'}, {'therapies': 'O'}, {'for': 'O'}, {'this': 'O'}, {'multifactorial': 'O'}, {'syndrome.College': 'O'}, {'London,': 'O'}, {""Guy's"": 'O'}, {'Hospital,': 'O'}, {'Floor': 'O'}, {'17,': 'O'}, {'Tower': 'O'}, {'Wing,': 'O'}, {'London': 'O'}, {'SE1': 'O'}, {'9RT,': 'O'}, {'UK;College': 'O'}]"
"In this study, we enrolled 2217 patients with systemic sclerosis and 6485 controls from Taiwan's Registry of Catastrophic Illness database and National Health Insurance Research Database.","[{'In': 'O'}, {'this': 'O'}, {'study,': 'O'}, {'we': 'O'}, {'enrolled': 'O'}, {'2217': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'and': 'O'}, {'6485': 'O'}, {'controls': 'O'}, {'from': 'O'}, {""Taiwan's"": 'O'}, {'Registry': 'O'}, {'of': 'O'}, {'Catastrophic': 'B-Entity'}, {'Illness': 'I-Entity'}, {'database': 'O'}, {'and': 'O'}, {'National': 'O'}, {'Health': 'O'}, {'Insurance': 'O'}, {'Research': 'O'}, {'Database.': 'O'}]"
"In nine cases, the histological findings were positive for Sjogrens syndrome.","[{'In': 'O'}, {'nine': 'O'}, {'cases,': 'O'}, {'the': 'O'}, {'histological': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
PGSS is a serious disease which we must consider when we encounter any unexplained neurological manifestations especially those associated with vasculitic lesions.cas en Afrique noire.2015 Jul 13.,"[{'PGSS': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'serious': 'O'}, {'disease': 'O'}, {'which': 'O'}, {'we': 'O'}, {'must': 'O'}, {'consider': 'O'}, {'when': 'O'}, {'we': 'O'}, {'encounter': 'O'}, {'any': 'O'}, {'unexplained': 'O'}, {'neurological': 'O'}, {'manifestations': 'O'}, {'especially': 'O'}, {'those': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'vasculitic': 'B-Entity'}, {'lesions.cas': 'I-Entity'}, {'en': 'O'}, {'Afrique': 'O'}, {'noire.2015': 'O'}, {'Jul': 'O'}, {'13.': 'O'}]"
And the FS level might be associated with disease activity and positive anti-SSA.,"[{'And': 'O'}, {'the': 'O'}, {'FS': 'O'}, {'level': 'O'}, {'might': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'positive': 'O'}, {'anti-SSA.': 'O'}]"
"CD163 positive cells and HIF-1‚âà√≠¬¨¬±were mainly expressed in acute tubulointerstitial injury of pSS, which positively correlated to N-acetyl-‚âà√≠‚Äö√¢¬ß-D-glucosaminidase and ‚âà√≠‚Äö√¢¬ß2-microglobulin.","[{'CD163': 'O'}, {'positive': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'HIF-1‚âà√≠¬¨¬±were': 'O'}, {'mainly': 'O'}, {'expressed': 'O'}, {'in': 'O'}, {'acute': 'B-Entity'}, {'tubulointerstitial': 'B-Entity'}, {'injury': 'I-Entity'}, {'of': 'O'}, {'pSS,': 'O'}, {'which': 'O'}, {'positively': 'O'}, {'correlated': 'O'}, {'to': 'O'}, {'N-acetyl-‚âà√≠‚Äö√¢¬ß-D-glucosaminidase': 'B-Entity'}]"
An 82-year-old woman presented with acute ascending flaccid paralysis and acute respiratory failure.,"[{'An': 'O'}, {'82-year-old': 'O'}, {'woman': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'acute': 'O'}, {'ascending': 'O'}, {'flaccid': 'I-Entity'}, {'paralysis': 'I-Entity'}, {'and': 'O'}, {'acute': 'B-Entity'}, {'respiratory': 'I-Entity'}, {'failure.': 'I-Entity'}]"
"Evidence provided support for a role for anti-tTG antibodies through reduced transamidating activity and reduced apoptotic cell clearance by the macrophages of pregnant NOD mice.Rep‚Äö√†√∂‚Äö√†¬¥blica, Montevideo, Uruguay; Escuela Universitaria de Tecnolog‚Äö√†√∂‚Äö√¢‚Ä†a M‚Äö√†√∂¬¨¬©dica, Facultad de Medicina, Universidad de la Rep‚Äö√†√∂‚Äö√†¬¥blica, Montevideo, Uruguay.","[{'Evidence': 'O'}, {'provided': 'O'}, {'support': 'O'}, {'for': 'O'}, {'a': 'O'}, {'role': 'O'}, {'for': 'O'}, {'anti-tTG': 'O'}, {'antibodies': 'O'}, {'through': 'O'}, {'reduced': 'O'}, {'transamidating': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'reduced': 'O'}, {'apoptotic': 'O'}, {'cell': 'O'}, {'clearance': 'O'}, {'by': 'O'}, {'the': 'O'}, {'macrophages': 'O'}, {'of': 'O'}, {'pregnant': 'O'}, {'NOD': 'O'}, {'mice.Rep‚Äö√†√∂‚Äö√†¬¥blica,': 'O'}, {'Montevideo,': 'O'}, {'Uruguay;': 'O'}, {'Escuela': 'O'}]"
The management of recurrent parotitis is challenging because conservative methods may be of limited efficacy and invasive approaches carry the risk of complications.,"[{'The': 'O'}, {'management': 'O'}, {'of': 'O'}, {'recurrent': 'O'}, {'parotitis': 'I-Entity'}, {'is': 'O'}, {'challenging': 'O'}, {'because': 'O'}, {'conservative': 'O'}, {'methods': 'O'}, {'may': 'O'}, {'be': 'O'}, {'of': 'O'}, {'limited': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'invasive': 'O'}, {'approaches': 'O'}, {'carry': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'complications.': 'O'}]"
Patients with prior cardiovascular events and a history of atherosclerosis were excluded.,"[{'Patients': 'O'}, {'with': 'O'}, {'prior': 'O'}, {'cardiovascular': 'O'}, {'events': 'O'}, {'and': 'O'}, {'a': 'O'}, {'history': 'O'}, {'of': 'O'}, {'atherosclerosis': 'I-Entity'}, {'were': 'O'}, {'excluded.': 'O'}]"
"The lower detection limit was 2.24 U/mL, and the mean recovery rate was 100.74%.","[{'The': 'O'}, {'lower': 'O'}, {'detection': 'O'}, {'limit': 'O'}, {'was': 'O'}, {'2.24': 'O'}, {'U/mL,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'mean': 'O'}, {'recovery': 'O'}, {'rate': 'O'}, {'was': 'O'}, {'100.74%.': 'O'}]"
This open-label study was undertaken to evaluate the efficacy of rituximab in primary SS and to investigate whether expression of specific genes is associated with efficacy of this treatment.,"[{'This': 'O'}, {'open-label': 'O'}, {'study': 'O'}, {'was': 'O'}, {'undertaken': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'rituximab': 'I-Entity'}, {'in': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'whether': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'specific': 'O'}, {'genes': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'this': 'O'}, {'treatment.': 'O'}]"
"Although SS and MD are both chronic inflammatory diseases affecting the lacrimal and salivary glands, their clinical features and corticosteroid responsiveness are different.","[{'Although': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'MD': 'I-Entity'}, {'are': 'O'}, {'both': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'diseases': 'I-Entity'}, {'affecting': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'their': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'and': 'O'}, {'corticosteroid': 'O'}, {'responsiveness': 'O'}, {'are': 'O'}, {'different.': 'O'}]"
"Additionally, 62% of SS patients having autoantibodies but a negative biopsy showed fatty infiltration (FI) while non-SS controls demonstrated fatty replacement in only 32% of the cases.","[{'Additionally,': 'O'}, {'62%': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'having': 'O'}, {'autoantibodies': 'O'}, {'but': 'O'}, {'a': 'O'}, {'negative': 'O'}, {'biopsy': 'O'}, {'showed': 'O'}, {'fatty': 'B-Entity'}, {'infiltration': 'I-Entity'}, {'(FI)': 'O'}, {'while': 'O'}, {'non-SS': 'O'}, {'controls': 'O'}, {'demonstrated': 'O'}, {'fatty': 'B-Entity'}, {'replacement': 'I-Entity'}, {'in': 'O'}, {'only': 'O'}, {'32%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cases.': 'O'}]"
"A negative test result by indirect immunofluorescence, however, had a lower likelihood ratio than a negative test result by EliA CTD Screen, indicating that the negative predictive value was higher for indirect immunofluorescence than for EliA CTD screen.Catholic University Leuven, Belgium.Jun 30.diseases.","[{'A': 'O'}, {'negative': 'O'}, {'test': 'O'}, {'result': 'O'}, {'by': 'O'}, {'indirect': 'O'}, {'immunofluorescence,': 'O'}, {'however,': 'O'}, {'had': 'O'}, {'a': 'O'}, {'lower': 'O'}, {'likelihood': 'O'}, {'ratio': 'O'}, {'than': 'O'}, {'a': 'O'}, {'negative': 'O'}, {'test': 'O'}, {'result': 'O'}, {'by': 'O'}, {'EliA': 'O'}, {'CTD': 'O'}, {'Screen,': 'O'}, {'indicating': 'O'}, {'that': 'O'}, {'the': 'O'}, {'negative': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'was': 'O'}, {'higher': 'O'}, {'for': 'O'}, {'indirect': 'O'}, {'immunofluorescence': 'O'}, {'than': 'O'}, {'for': 'O'}, {'EliA': 'O'}, {'CTD': 'O'}, {'screen.Catholic': 'O'}, {'University': 'O'}, {'Leuven,': 'O'}]"
This distribution of neuropathic pain may reflect mechanisms targeting the proximal-most element of the peripheral nervous system-the dorsal root ganglia (DRG).,"[{'This': 'O'}, {'distribution': 'O'}, {'of': 'O'}, {'neuropathic': 'B-Entity'}, {'pain': 'I-Entity'}, {'may': 'O'}, {'reflect': 'O'}, {'mechanisms': 'O'}, {'targeting': 'O'}, {'the': 'O'}, {'proximal-most': 'O'}, {'element': 'O'}, {'of': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'nervous': 'O'}, {'system-the': 'O'}, {'dorsal': 'O'}, {'root': 'O'}, {'ganglia': 'O'}, {'(DRG).': 'O'}]"
DILS is usually seen in uncontrolled or untreated HIV infection but can also manifest itself independently of CD4(+) T-cell counts.,"[{'DILS': 'I-Entity'}, {'is': 'O'}, {'usually': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'uncontrolled': 'O'}, {'or': 'O'}, {'untreated': 'O'}, {'HIV': 'B-Entity'}, {'infection': 'I-Entity'}, {'but': 'O'}, {'can': 'O'}, {'also': 'O'}, {'manifest': 'O'}, {'itself': 'O'}, {'independently': 'O'}, {'of': 'O'}, {'CD4(+)': 'O'}, {'T-cell': 'O'}, {'counts.': 'O'}]"
The objective of this paper is to assess overactive bladder (OAB) symptom bother (SB) and health-related quality of life (HRQL) among patients with systemic lupus erythematosus (SLE) and primary Sjogren syndrome (pSS).,"[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'this': 'O'}, {'paper': 'O'}, {'is': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'overactive': 'B-Entity'}, {'bladder': 'I-Entity'}, {'(OAB)': 'O'}, {'symptom': 'O'}, {'bother': 'O'}, {'(SB)': 'O'}, {'and': 'O'}, {'health-related': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'(HRQL)': 'O'}, {'among': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'and': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
The aim of this study is to assess the cognitive dysfunction of PSS patients via detailed neurologic tests.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'is': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'cognitive': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'of': 'O'}, {'PSS': 'I-Entity'}, {'patients': 'O'}, {'via': 'O'}, {'detailed': 'O'}, {'neurologic': 'O'}, {'tests.': 'O'}]"
"Understanding the associations between fibromyalgia, Sjogren's syndrome and depression should improve clinical outcome via a common holistic approach.Morgantown, WV, USA.Morgantown, WV, USA.KY, USA.","[{'Understanding': 'O'}, {'the': 'O'}, {'associations': 'O'}, {'between': 'O'}, {'fibromyalgia,': 'I-Entity'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'depression': 'I-Entity'}, {'should': 'O'}, {'improve': 'O'}, {'clinical': 'O'}, {'outcome': 'O'}, {'via': 'O'}, {'a': 'O'}, {'common': 'O'}, {'holistic': 'O'}, {'approach.Morgantown,': 'O'}, {'WV,': 'O'}, {'USA.Morgantown,': 'O'}, {'WV,': 'O'}, {'USA.KY,': 'O'}, {'USA.': 'O'}]"
"We found that SS patients with MRN DRG abnormalities had statistically significant, increased IENFD on skin biopsy studies, which may suggest a relationship between trophic mediators and neuropathic pain.","[{'We': 'O'}, {'found': 'O'}, {'that': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'MRN': 'O'}, {'DRG': 'O'}, {'abnormalities': 'O'}, {'had': 'O'}, {'statistically': 'O'}, {'significant,': 'O'}, {'increased': 'O'}, {'IENFD': 'O'}, {'on': 'O'}, {'skin': 'O'}, {'biopsy': 'O'}, {'studies,': 'O'}, {'which': 'O'}, {'may': 'O'}, {'suggest': 'O'}, {'a': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'trophic': 'O'}, {'mediators': 'O'}, {'and': 'O'}, {'neuropathic': 'B-Entity'}, {'pain.': 'I-Entity'}]"
"Fifty-four patients with primary Sjogren syndrome, 35 patients without primary Sjogren syndrome (patients with dry mouth and dry eye symptoms), and 52 healthy control volunteers were included in this study.","[{'Fifty-four': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'35': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'symptoms),': 'I-Entity'}, {'and': 'O'}, {'52': 'O'}, {'healthy': 'O'}, {'control': 'O'}, {'volunteers': 'O'}, {'were': 'O'}, {'included': 'O'}, {'in': 'O'}, {'this': 'O'}, {'study.': 'O'}]"
"Higher mean titers of anti-Ro52 antibodies were associated with severe scintigraphic involvement, positive salivary gland biopsy, parotid enlargement, anaemia, leukopenia and RF.","[{'Higher': 'O'}, {'mean': 'O'}, {'titers': 'O'}, {'of': 'O'}, {'anti-Ro52': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'scintigraphic': 'O'}, {'involvement,': 'O'}, {'positive': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'biopsy,': 'O'}, {'parotid': 'B-Entity'}, {'enlargement,': 'I-Entity'}, {'anaemia,': 'I-Entity'}, {'leukopenia': 'I-Entity'}, {'and': 'O'}, {'RF.': 'I-Entity'}]"
"Importantly, we report that peripheral blood mononuclear cells as well as lymphocytic infiltrates in submandibular glands from patients with pSS demonstrated significant reductions in STIM1 and STIM2 proteins.","[{'Importantly,': 'O'}, {'we': 'O'}, {'report': 'O'}, {'that': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'lymphocytic': 'O'}, {'infiltrates': 'O'}, {'in': 'O'}, {'submandibular': 'O'}, {'glands': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'demonstrated': 'O'}, {'significant': 'O'}, {'reductions': 'O'}, {'in': 'O'}, {'STIM1': 'O'}, {'and': 'O'}, {'STIM2': 'O'}, {'proteins.': 'O'}]"
"In some cases, intravenous immunoglobulin (IVIG) therapy has been associated with some benefit.","[{'In': 'O'}, {'some': 'O'}, {'cases,': 'O'}, {'intravenous': 'O'}, {'immunoglobulin': 'O'}, {'(IVIG)': 'O'}, {'therapy': 'O'}, {'has': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'some': 'O'}, {'benefit.': 'O'}]"
"Six individuals with occupational acrylamide exposure had clinical and laboratory alterations characteristic of drug-induced autoimmune disease, specifically lupus, anti-phospholipid syndrome, Sjogren's syndrome, scleroderma, and polymyositis.","[{'Six': 'O'}, {'individuals': 'O'}, {'with': 'O'}, {'occupational': 'O'}, {'acrylamide': 'I-Entity'}, {'exposure': 'O'}, {'had': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'alterations': 'O'}, {'characteristic': 'O'}, {'of': 'O'}, {'drug-induced': 'O'}, {'autoimmune': 'I-Entity'}, {'disease,': 'I-Entity'}, {'specifically': 'O'}, {'lupus,': 'I-Entity'}, {'anti-phospholipid': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'scleroderma,': 'I-Entity'}, {'and': 'O'}, {'polymyositis.': 'I-Entity'}]"
"Only one of the containers with an adapted sterilizing filter (2.1%) became contaminated with Staphylococcus epidermidis after 1 month of treatment, whereas the contamination rate among conventional containers reached 28.9% after 7 days of treatment.","[{'Only': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'containers': 'O'}, {'with': 'O'}, {'an': 'O'}, {'adapted': 'O'}, {'sterilizing': 'O'}, {'filter': 'O'}, {'(2.1%)': 'O'}, {'became': 'O'}, {'contaminated': 'O'}, {'with': 'O'}, {'Staphylococcus': 'B-Entity'}, {'epidermidis': 'I-Entity'}, {'after': 'O'}, {'1': 'O'}, {'month': 'O'}, {'of': 'O'}, {'treatment,': 'O'}, {'whereas': 'O'}, {'the': 'O'}, {'contamination': 'O'}, {'rate': 'O'}, {'among': 'O'}, {'conventional': 'O'}, {'containers': 'O'}, {'reached': 'O'}, {'28.9%': 'O'}, {'after': 'O'}, {'7': 'O'}, {'days': 'O'}, {'of': 'O'}, {'treatment.': 'O'}]"
Our aim was to investigate the importance of fatigue in relation to other symptoms experienced as well as to evaluate the effect of rituximab treatment on fatigue in pSS patients with active disease.,"[{'Our': 'O'}, {'aim': 'O'}, {'was': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'importance': 'O'}, {'of': 'O'}, {'fatigue': 'I-Entity'}, {'in': 'O'}, {'relation': 'O'}, {'to': 'O'}, {'other': 'O'}, {'symptoms': 'O'}, {'experienced': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'rituximab': 'I-Entity'}, {'treatment': 'O'}, {'on': 'O'}, {'fatigue': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'active': 'O'}, {'disease.': 'O'}]"
There are many reports that this condition may increase risk of pregnancy complications and fetal loss.,"[{'There': 'O'}, {'are': 'O'}, {'many': 'O'}, {'reports': 'O'}, {'that': 'O'}, {'this': 'O'}, {'condition': 'O'}, {'may': 'O'}, {'increase': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'pregnancy': 'B-Entity'}, {'complications': 'I-Entity'}, {'and': 'O'}, {'fetal': 'B-Entity'}, {'loss.': 'I-Entity'}]"
"We integrated our findings with a review of the literature to understand mechanisms which may account for such a ubiquitous pattern of clinical injury.Seven rheumatic disease patients (5 Sjogrens syndrome patients, 2 undifferentiated connective tissue disease patients) were referred and could be misdiagnosed as having Parkinson's disease.","[{'We': 'O'}, {'integrated': 'O'}, {'our': 'O'}, {'findings': 'O'}, {'with': 'O'}, {'a': 'O'}, {'review': 'O'}, {'of': 'O'}, {'the': 'O'}, {'literature': 'O'}, {'to': 'O'}, {'understand': 'O'}, {'mechanisms': 'O'}, {'which': 'O'}, {'may': 'O'}, {'account': 'O'}, {'for': 'O'}, {'such': 'O'}, {'a': 'O'}, {'ubiquitous': 'O'}, {'pattern': 'O'}, {'of': 'O'}, {'clinical': 'O'}, {'injury.Seven': 'I-Entity'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'patients': 'O'}, {'(5': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patients,': 'O'}, {'2': 'O'}, {'undifferentiated': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'patients)': 'O'}, {'were': 'O'}, {'referred': 'O'}, {'and': 'O'}, {'could': 'O'}, {'be': 'O'}, {'misdiagnosed': 'O'}]"
"This type is associated with a worse prognosis, with possible progression to chronic respiratory insufficiency.","[{'This': 'O'}, {'type': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'worse': 'O'}, {'prognosis,': 'O'}, {'with': 'O'}, {'possible': 'O'}, {'progression': 'O'}, {'to': 'O'}, {'chronic': 'B-Entity'}, {'respiratory': 'B-Entity'}, {'insufficiency.': 'I-Entity'}]"
"P2X7 receptor (P2X7R), trigger of acute inflammatory responses via the NLRP3 inflammasome, is hyperfunctioning in patients with Sjogrens syndrome (SS), where it stimulates IL-18 production.","[{'P2X7': 'O'}, {'receptor': 'O'}, {'(P2X7R),': 'O'}, {'trigger': 'O'}, {'of': 'O'}, {'acute': 'O'}, {'inflammatory': 'O'}, {'responses': 'O'}, {'via': 'O'}, {'the': 'O'}, {'NLRP3': 'O'}, {'inflammasome,': 'O'}, {'is': 'O'}, {'hyperfunctioning': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'where': 'O'}, {'it': 'O'}, {'stimulates': 'O'}, {'IL-18': 'O'}, {'production.': 'O'}]"
"DIAGNOSIS: However, the patient lacked stigmata of optic neuritis, instead had visual hallucinations and encephalopathy suggestive of cortical blindness, and was noted to have occipital lobe lesions on brain MRI.","[{'DIAGNOSIS:': 'O'}, {'However,': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'lacked': 'O'}, {'stigmata': 'O'}, {'of': 'O'}, {'optic': 'B-Entity'}, {'neuritis,': 'I-Entity'}, {'instead': 'O'}, {'had': 'O'}, {'visual': 'B-Entity'}, {'hallucinations': 'I-Entity'}, {'and': 'O'}, {'encephalopathy': 'I-Entity'}, {'suggestive': 'O'}, {'of': 'O'}, {'cortical': 'B-Entity'}, {'blindness,': 'I-Entity'}, {'and': 'O'}, {'was': 'O'}, {'noted': 'O'}, {'to': 'O'}, {'have': 'O'}, {'occipital': 'B-Entity'}, {'lobe': 'I-Entity'}, {'lesions': 'I-Entity'}, {'on': 'O'}, {'brain': 'O'}, {'MRI.': 'O'}]"
"At peak activity, biological domain (96%) was followed by the constitutional (72%), glandular (60%), articular (44%), cutaneous (28%), central nervous system (20%), and renal domains (16%).","[{'At': 'O'}, {'peak': 'O'}, {'activity,': 'O'}, {'biological': 'O'}, {'domain': 'O'}, {'(96%)': 'O'}, {'was': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'the': 'O'}, {'constitutional': 'O'}, {'(72%),': 'O'}, {'glandular': 'O'}, {'(60%),': 'O'}, {'articular': 'O'}, {'(44%),': 'O'}, {'cutaneous': 'O'}, {'(28%),': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'(20%),': 'O'}, {'and': 'O'}, {'renal': 'O'}, {'domains': 'O'}, {'(16%).': 'O'}]"
"During the course of the disease, progressive exhaustion of the precursor endothelial pool may be hypothesized, leading to defective vascular layer restoration and endothelial dysfunction.Society for Rheumatology.","[{'During': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease,': 'O'}, {'progressive': 'O'}, {'exhaustion': 'O'}, {'of': 'O'}, {'the': 'O'}, {'precursor': 'O'}, {'endothelial': 'O'}, {'pool': 'O'}, {'may': 'O'}, {'be': 'O'}, {'hypothesized,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'defective': 'O'}, {'vascular': 'O'}, {'layer': 'O'}, {'restoration': 'O'}, {'and': 'O'}, {'endothelial': 'B-Entity'}, {'dysfunction.Society': 'I-Entity'}, {'for': 'O'}, {'Rheumatology.': 'O'}]"
The proportion of patients ages ‚Äö√Ñ√∂‚àö¬¢¬¨√ü50 years (ratio 4.6) with increased PWV was almost 2-fold higher than those ages >50 years (ratio 2.4) with respect to controls.,"[{'The': 'O'}, {'proportion': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'ages': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢¬¨√ü50': 'O'}, {'years': 'O'}, {'(ratio': 'O'}, {'4.6)': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'PWV': 'I-Entity'}, {'was': 'O'}, {'almost': 'O'}, {'2-fold': 'O'}, {'higher': 'O'}, {'than': 'O'}, {'those': 'O'}, {'ages': 'O'}, {'>50': 'O'}, {'years': 'O'}, {'(ratio': 'O'}, {'2.4)': 'O'}, {'with': 'O'}, {'respect': 'O'}, {'to': 'O'}, {'controls.': 'O'}]"
This and other actions may underlie the potential benefits in treating OA.,"[{'This': 'O'}, {'and': 'O'}, {'other': 'O'}, {'actions': 'O'}, {'may': 'O'}, {'underlie': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'benefits': 'O'}, {'in': 'O'}, {'treating': 'O'}, {'OA.': 'I-Entity'}]"
Systemic lupus erythematosus (SLE) and Sjogrens syndrome are autoimmune disorders which are characterized by a disturbed B cell homeostasis which leads ultimately to dysfunction of various organs.,"[{'Systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'are': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders': 'I-Entity'}, {'which': 'O'}, {'are': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'a': 'O'}, {'disturbed': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'homeostasis': 'O'}, {'which': 'O'}, {'leads': 'O'}, {'ultimately': 'O'}, {'to': 'O'}, {'dysfunction': 'B-Entity'}, {'of': 'I-Entity'}, {'various': 'O'}, {'organs.': 'I-Entity'}]"
"The neonate developed neonatal lupus complicated with right ventricular thrombus assumed to be induced by maternal transmission of antiphosphatidylethanolamine and antiprothrombin antibodies, treated successfully with tissue plasminogen activator and warfarin.University, Egypt.","[{'The': 'O'}, {'neonate': 'O'}, {'developed': 'O'}, {'neonatal': 'O'}, {'lupus': 'I-Entity'}, {'complicated': 'O'}, {'with': 'O'}, {'right': 'B-Entity'}, {'ventricular': 'I-Entity'}, {'thrombus': 'I-Entity'}, {'assumed': 'O'}, {'to': 'O'}, {'be': 'O'}, {'induced': 'O'}, {'by': 'O'}, {'maternal': 'O'}, {'transmission': 'O'}, {'of': 'O'}, {'antiphosphatidylethanolamine': 'O'}, {'and': 'O'}, {'antiprothrombin': 'O'}, {'antibodies,': 'O'}, {'treated': 'O'}, {'successfully': 'O'}, {'with': 'O'}, {'tissue': 'O'}, {'plasminogen': 'O'}, {'activator': 'O'}, {'and': 'O'}, {'warfarin.University,': 'I-Entity'}]"
"For each pregnancy in a woman with pSS, we recorded pregnancy course and outcome and newborn condition.","[{'For': 'O'}, {'each': 'O'}, {'pregnancy': 'O'}, {'in': 'O'}, {'a': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'pSS,': 'I-Entity'}, {'we': 'O'}, {'recorded': 'O'}, {'pregnancy': 'O'}, {'course': 'O'}, {'and': 'O'}, {'outcome': 'O'}, {'and': 'O'}, {'newborn': 'O'}, {'condition.': 'O'}]"
"Immunoglobulin G4 (IgG4)-related Mikulicz's disease (MD) is a fibrosis-associated inflammatory disease, often accompanied by lacrimal gland swelling.","[{'Immunoglobulin': 'O'}, {'G4': 'O'}, {'(IgG4)-related': 'O'}, {""Mikulicz's"": 'B-Entity'}, {'disease': 'I-Entity'}, {'(MD)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'fibrosis-associated': 'I-Entity'}, {'inflammatory': 'B-Entity'}, {'disease,': 'I-Entity'}, {'often': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'lacrimal': 'B-Entity'}, {'gland': 'I-Entity'}, {'swelling.': 'I-Entity'}]"
"This case suggests that an altered Th17-1 cell subset by B-cell depletion therapy is critical for the improvement of tissue damage in patients with SS, and the case suggests that clinicians should consider measuring the effector memory Th-subsets to predict the disease activity in SS patients.University Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki 852-8102, Japan.","[{'This': 'O'}, {'case': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'an': 'O'}, {'altered': 'O'}, {'Th17-1': 'O'}, {'cell': 'O'}, {'subset': 'O'}, {'by': 'O'}, {'B-cell': 'O'}, {'depletion': 'O'}, {'therapy': 'O'}, {'is': 'O'}, {'critical': 'O'}, {'for': 'O'}, {'the': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'tissue': 'B-Entity'}, {'damage': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'case': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'clinicians': 'O'}, {'should': 'O'}, {'consider': 'O'}, {'measuring': 'O'}, {'the': 'O'}, {'effector': 'O'}, {'memory': 'O'}, {'Th-subsets': 'O'}, {'to': 'O'}, {'predict': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients.University': 'O'}]"
"Primary Sjogrens syndrome (pSS) is a chronic systemic autoimmune disease, of slow progression, characterized by lymphocytic infiltration of the exocrine glands, that leads to sicca symptoms, mainly xerophtalmia and xerostomia.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease,': 'I-Entity'}, {'of': 'O'}, {'slow': 'O'}, {'progression,': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'that': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'sicca': 'I-Entity'}, {'symptoms,': 'O'}, {'mainly': 'O'}, {'xerophtalmia': 'I-Entity'}, {'and': 'O'}, {'xerostomia.': 'I-Entity'}]"
"Often, primary Sjogren syndrome is subclinical, but there are various underlying risks.","[{'Often,': 'O'}, {'primary': 'O'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'subclinical,': 'O'}, {'but': 'O'}, {'there': 'O'}, {'are': 'O'}, {'various': 'O'}, {'underlying': 'O'}, {'risks.': 'O'}]"
The time of morning stiffness was about 30 minutes.,"[{'The': 'O'}, {'time': 'O'}, {'of': 'O'}, {'morning': 'B-Entity'}, {'stiffness': 'I-Entity'}, {'was': 'O'}, {'about': 'O'}, {'30': 'O'}, {'minutes.': 'O'}]"
"While on treatment, disease remission occurred in 77.3% of cases, and one death was reported in the first 6months after diagnosis.","[{'While': 'O'}, {'on': 'O'}, {'treatment,': 'O'}, {'disease': 'O'}, {'remission': 'O'}, {'occurred': 'O'}, {'in': 'O'}, {'77.3%': 'O'}, {'of': 'O'}, {'cases,': 'O'}, {'and': 'O'}, {'one': 'O'}, {'death': 'I-Entity'}, {'was': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'the': 'O'}, {'first': 'O'}, {'6months': 'O'}, {'after': 'O'}, {'diagnosis.': 'O'}]"
We will also review the methods for the detection of autoantibodies and associated challenges for clinical results reporting.,"[{'We': 'O'}, {'will': 'O'}, {'also': 'O'}, {'review': 'O'}, {'the': 'O'}, {'methods': 'O'}, {'for': 'O'}, {'the': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'autoantibodies': 'O'}, {'and': 'O'}, {'associated': 'O'}, {'challenges': 'O'}, {'for': 'O'}, {'clinical': 'O'}, {'results': 'O'}, {'reporting.': 'O'}]"
"Taken together, these results showed that the SS parotid glands were mostly hyperemic and the SS gland responses to gustatory stimulation were stronger and more prolonged than those of the healthy glands.","[{'Taken': 'O'}, {'together,': 'O'}, {'these': 'O'}, {'results': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'the': 'O'}, {'SS': 'O'}, {'parotid': 'O'}, {'glands': 'O'}, {'were': 'O'}, {'mostly': 'O'}, {'hyperemic': 'O'}, {'and': 'O'}, {'the': 'O'}, {'SS': 'O'}, {'gland': 'O'}, {'responses': 'O'}, {'to': 'O'}, {'gustatory': 'O'}, {'stimulation': 'O'}, {'were': 'O'}, {'stronger': 'O'}, {'and': 'O'}, {'more': 'O'}, {'prolonged': 'O'}, {'than': 'O'}, {'those': 'O'}, {'of': 'O'}, {'the': 'O'}, {'healthy': 'O'}, {'glands.': 'O'}]"
"In anti-SSB antibody-positive SLE patients, the incidence of cheek erythema, alopecia, serositis, secondary Sjogrens syndrome (sSS), leukocytopenia, elevated immunoglobulin (Ig)G and positive presence of anti-Sjogrens syndrome type A (SSA)60 or anti-SSA52 antibodies was higher than in the anti-SSB antibody-negative group (P<0.05).","[{'In': 'O'}, {'anti-SSB': 'O'}, {'antibody-positive': 'O'}, {'SLE': 'I-Entity'}, {'patients,': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'cheek': 'O'}, {'erythema,': 'I-Entity'}, {'alopecia,': 'I-Entity'}, {'serositis,': 'I-Entity'}, {'secondary': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(sSS),': 'O'}, {'leukocytopenia,': 'I-Entity'}, {'elevated': 'O'}, {'immunoglobulin': 'O'}, {'(Ig)G': 'O'}, {'and': 'O'}]"
"MATERIALS, METHODS AND We describe the first case of AGEP caused by HCQ in a child affected by juvenile Sjogren syndrome.","[{'MATERIALS,': 'O'}, {'METHODS': 'O'}, {'AND': 'O'}, {'We': 'O'}, {'describe': 'O'}, {'the': 'O'}, {'first': 'O'}, {'case': 'O'}, {'of': 'O'}, {'AGEP': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'HCQ': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'child': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'juvenile': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
"In 12 of 15 cases, the positive MSGB result allowed for a definitive diagnosis (80%).","[{'In': 'O'}, {'12': 'O'}, {'of': 'O'}, {'15': 'O'}, {'cases,': 'O'}, {'the': 'O'}, {'positive': 'O'}, {'MSGB': 'O'}, {'result': 'O'}, {'allowed': 'O'}, {'for': 'O'}, {'a': 'O'}, {'definitive': 'O'}, {'diagnosis': 'O'}, {'(80%).': 'O'}]"
"Primary Sjogrens syndrome (pSS) is an autoimmune inflammatory disorder characterized by lymphocytic infiltration of exocrine glands, mainly the lacrimal and salivary glands leading to a chronic sicca syndrome.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'inflammatory': 'B-Entity'}, {'disorder': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'mainly': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'sicca': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"From 1967 to 2011, seven patients with a mean age of 63¬¨¬®¬¨¬±14.7 years were identified.","[{'From': 'O'}, {'1967': 'O'}, {'to': 'O'}, {'2011,': 'O'}, {'seven': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'a': 'O'}, {'mean': 'O'}, {'age': 'O'}, {'of': 'O'}, {'63¬¨¬®¬¨¬±14.7': 'O'}, {'years': 'O'}, {'were': 'O'}, {'identified.': 'O'}]"
"The absence of anti-Ro and anti-La antibodies associated with severe bronchiolitis is a clinical presentation that is poorly characterized in this group of patients; moreover, how to treat them remains unclear.Colegio Mexicano de Reumatolog‚Äö√†√∂‚Äö√¢‚Ä†a.","[{'The': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'anti-Ro': 'O'}, {'and': 'O'}, {'anti-La': 'O'}, {'antibodies': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'bronchiolitis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'that': 'O'}, {'is': 'O'}, {'poorly': 'O'}, {'characterized': 'O'}, {'in': 'O'}, {'this': 'O'}, {'group': 'O'}, {'of': 'O'}, {'patients;': 'O'}, {'moreover,': 'O'}, {'how': 'O'}, {'to': 'O'}, {'treat': 'O'}, {'them': 'O'}, {'remains': 'O'}, {'unclear.Colegio': 'O'}, {'Mexicano': 'O'}, {'de': 'O'}, {'Reumatolog‚Äö√†√∂‚Äö√¢‚Ä†a.': 'O'}]"
"pSS is the most frequent connective tissue disease after rheumatoid arthritis, affecting 0.3-3% of the population.","[{'pSS': 'O'}, {'is': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'after': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'affecting': 'O'}, {'0.3-3%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'population.': 'O'}]"
"SGs of Sjogrens syndrome patients (SS)-patients show signs of inflammation and altered proteostasis, associated with low IRE1‚âà√≠¬¨¬±/XBP-1 pathway activity without avert increases in apoptosis.","[{'SGs': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'patients': 'O'}, {'(SS)-patients': 'O'}, {'show': 'O'}, {'signs': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'altered': 'O'}, {'proteostasis,': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'low': 'O'}, {'IRE1‚âà√≠¬¨¬±/XBP-1': 'O'}, {'pathway': 'O'}, {'activity': 'O'}, {'without': 'O'}, {'avert': 'O'}, {'increases': 'O'}, {'in': 'O'}, {'apoptosis.': 'O'}]"
The autoimmune pathology is also accompanied by a peripheral imbalance in regulatory (T(reg) ) and inflammatory Th17 effectors.,"[{'The': 'O'}, {'autoimmune': 'I-Entity'}, {'pathology': 'O'}, {'is': 'O'}, {'also': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'a': 'O'}, {'peripheral': 'O'}, {'imbalance': 'O'}, {'in': 'O'}, {'regulatory': 'O'}, {'(T(reg)': 'O'}, {')': 'O'}, {'and': 'O'}, {'inflammatory': 'O'}, {'Th17': 'O'}, {'effectors.': 'O'}]"
"PATIENTS AND Eleven consecutive patients with non-traumatic corneal perforations or deep corneal ulcers with descemetocele refractory to conventional treatments: herpetic or zoster keratitis (n = 4), Sjogrens syndrome (n = 2), rosacea (n = 1), hydrops (n = 1), mucous membrane pemphigoid (n = 1), bacterial keratitis (n = 1) and perforation after protontherapy for melanoma (n = 1).","[{'PATIENTS': 'O'}, {'AND': 'O'}, {'Eleven': 'O'}, {'consecutive': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'non-traumatic': 'O'}, {'corneal': 'B-Entity'}, {'perforations': 'I-Entity'}, {'or': 'O'}, {'deep': 'O'}, {'corneal': 'B-Entity'}, {'ulcers': 'I-Entity'}, {'with': 'O'}, {'descemetocele': 'I-Entity'}, {'refractory': 'O'}, {'to': 'O'}, {'conventional': 'O'}, {'treatments:': 'O'}, {'herpetic': 'B-Entity'}, {'or': 'I-Entity'}, {'zoster': 'I-Entity'}, {'keratitis': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'4),': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}]"
"Compared to patients diagnosed with SSc alone, systemic sclerosis patients diagnosed with SS had lower pulmonary hypertension and less diffuse lung involvement.","[{'Compared': 'O'}, {'to': 'O'}, {'patients': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'SSc': 'I-Entity'}, {'alone,': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'patients': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'had': 'O'}, {'lower': 'O'}, {'pulmonary': 'B-Entity'}, {'hypertension': 'I-Entity'}, {'and': 'O'}, {'less': 'O'}, {'diffuse': 'O'}, {'lung': 'O'}, {'involvement.': 'O'}]"
"Liquid chromatography-mass spectrometry (LC-MS) was conducted on tear fluid and stimulated whole saliva, and proteomic biomarker profiles were generated.","[{'Liquid': 'O'}, {'chromatography-mass': 'O'}, {'spectrometry': 'O'}, {'(LC-MS)': 'O'}, {'was': 'O'}, {'conducted': 'O'}, {'on': 'O'}, {'tear': 'O'}, {'fluid': 'O'}, {'and': 'O'}, {'stimulated': 'O'}, {'whole': 'O'}, {'saliva,': 'O'}, {'and': 'O'}, {'proteomic': 'O'}, {'biomarker': 'O'}, {'profiles': 'O'}, {'were': 'O'}, {'generated.': 'O'}]"
"Because early diagnosis of the cause of neurological symptoms accompanying SS and SLE is difficult, it may be necessary to combine the two lines of treatment in the early stages.","[{'Because': 'O'}, {'early': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'neurological': 'O'}, {'symptoms': 'O'}, {'accompanying': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'SLE': 'I-Entity'}, {'is': 'O'}, {'difficult,': 'O'}, {'it': 'O'}, {'may': 'O'}, {'be': 'O'}, {'necessary': 'O'}, {'to': 'O'}, {'combine': 'O'}, {'the': 'O'}, {'two': 'O'}, {'lines': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'in': 'O'}, {'the': 'O'}, {'early': 'O'}, {'stages.': 'O'}]"
Data from the MLSP revealed disparities among Manhattan residents in primary SS incidence and prevalence by sex and differences in primary SS incidence by race/ethnicity among women.,"[{'Data': 'O'}, {'from': 'O'}, {'the': 'O'}, {'MLSP': 'O'}, {'revealed': 'O'}, {'disparities': 'O'}, {'among': 'O'}, {'Manhattan': 'O'}, {'residents': 'O'}, {'in': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'incidence': 'O'}, {'and': 'O'}, {'prevalence': 'O'}, {'by': 'O'}, {'sex': 'O'}, {'and': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'incidence': 'O'}, {'by': 'O'}, {'race/ethnicity': 'O'}, {'among': 'O'}, {'women.': 'O'}]"
"In 25-92% of patients affected by Sjogrens syndrome, neurological symptoms may precede the sicca syndrome.","[{'In': 'O'}, {'25-92%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'neurological': 'O'}, {'symptoms': 'O'}, {'may': 'O'}, {'precede': 'O'}, {'the': 'O'}, {'sicca': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
The overall prevalence of sicca symptoms (dry eyes or dry mouth) was 12.4%.,"[{'The': 'O'}, {'overall': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'sicca': 'I-Entity'}, {'symptoms': 'O'}, {'(dry': 'O'}, {'eyes': 'I-Entity'}, {'or': 'O'}, {'dry': 'B-Entity'}, {'mouth)': 'I-Entity'}, {'was': 'O'}, {'12.4%.': 'O'}]"
"HTLV-1 infected subjects were significantly more likely than controls to report complaints of hand and foot numbness (OR=5.3; 95% CI: 1.8-15.3; p=0.002 and OR=4.0; 95% CI: 1.3-12; p=0.013 respectively), difficulty running (OR=4.0; 95% CI: 1.1-14.2; p=0.032), nocturia (OR=5.0; 95% CI: 1.1-22.8; p=0.038), arthralgia (OR=3.3; 95% CI: 1.4-7.7; p=0.006), and photophobia (OR=3.3; 95% CI: 1.4-7.7; p=0.006).","[{'HTLV-1': 'B-Entity'}, {'infected': 'I-Entity'}, {'subjects': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'more': 'O'}, {'likely': 'O'}, {'than': 'O'}, {'controls': 'O'}, {'to': 'O'}, {'report': 'O'}, {'complaints': 'O'}, {'of': 'O'}, {'hand': 'B-Entity'}, {'and': 'I-Entity'}, {'foot': 'I-Entity'}, {'numbness': 'I-Entity'}, {'(OR=5.3;': 'O'}, {'95%': 'O'}, {'CI:': 'O'}, {'1.8-15.3;': 'O'}, {'p=0.002': 'O'}, {'and': 'O'}, {'OR=4.0;': 'O'}, {'95%': 'O'}, {'CI:': 'O'}, {'1.3-12;': 'O'}]"
Two had either persistent cholestasis or early acute rejection.,"[{'Two': 'O'}, {'had': 'O'}, {'either': 'O'}, {'persistent': 'O'}, {'cholestasis': 'I-Entity'}, {'or': 'O'}, {'early': 'O'}, {'acute': 'O'}, {'rejection.': 'O'}]"
"After the operation, her symptoms improved and lacrimal perforation healed after the removal of the silicone tube.","[{'After': 'O'}, {'the': 'O'}, {'operation,': 'O'}, {'her': 'O'}, {'symptoms': 'O'}, {'improved': 'O'}, {'and': 'O'}, {'lacrimal': 'B-Entity'}, {'perforation': 'I-Entity'}, {'healed': 'O'}, {'after': 'O'}, {'the': 'O'}, {'removal': 'O'}, {'of': 'O'}, {'the': 'O'}, {'silicone': 'O'}, {'tube.': 'O'}]"
"After patient developed sicca syndrome with dry eyes and mouth in 2009, her rheumatoid factor titre was elevated (550 IU/mL), erythrocyte sedimentation rate, anti-Sjogrens syndrome-related antigen A (anti-Ro/SSA) and anti-SSB/La: anti-Sjogrens syndrome-related antigen B (anti-La/SSB) became positive.","[{'After': 'O'}, {'patient': 'O'}, {'developed': 'O'}, {'sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth': 'I-Entity'}, {'in': 'O'}, {'2009,': 'O'}, {'her': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'titre': 'O'}, {'was': 'O'}, {'elevated': 'O'}, {'(550': 'O'}, {'IU/mL),': 'O'}, {'erythrocyte': 'O'}, {'sedimentation': 'O'}, {'rate,': 'O'}, {'anti-Sjogrens': 'O'}, {'syndrome-related': 'I-Entity'}, {'antigen': 'O'}, {'A': 'O'}, {'(anti-Ro/SSA)': 'O'}]"
"Although not yet licensed for this use, rituximab is currently used to treat severe, refractory systemic autoimmune diseases, with the most favourable results being observed in Sjogrens syndrome, inflammatory myopathies, systemic lupus erythematosus and cryoglobulinemia.Barcelona.","[{'Although': 'O'}, {'not': 'O'}, {'yet': 'O'}, {'licensed': 'O'}, {'for': 'O'}, {'this': 'O'}, {'use,': 'O'}, {'rituximab': 'I-Entity'}, {'is': 'O'}, {'currently': 'O'}, {'used': 'O'}, {'to': 'O'}, {'treat': 'O'}, {'severe,': 'O'}, {'refractory': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'with': 'O'}, {'the': 'O'}, {'most': 'O'}, {'favourable': 'O'}, {'results': 'O'}, {'being': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'inflammatory': 'B-Entity'}, {'myopathies,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'and': 'O'}, {'cryoglobulinemia.Barcelona.': 'I-Entity'}]"
We were able to detect autoimmune sialadenitis such as Sjogrens syndrome and IgG4-related sialadenitis by ultrasonography in patients without obvious symptoms.,"[{'We': 'O'}, {'were': 'O'}, {'able': 'O'}, {'to': 'O'}, {'detect': 'O'}, {'autoimmune': 'B-Entity'}, {'sialadenitis': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'IgG4-related': 'O'}, {'sialadenitis': 'I-Entity'}, {'by': 'O'}, {'ultrasonography': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'obvious': 'O'}, {'symptoms.': 'O'}]"
"Tear supplementation and stabilization, control of inflammation of the lacrimal glands and ocular surface, and possible stimulation of tear production are treatment options that are used according to the character and severity of dry eye disease.","[{'Tear': 'O'}, {'supplementation': 'O'}, {'and': 'O'}, {'stabilization,': 'O'}, {'control': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'and': 'O'}, {'ocular': 'O'}, {'surface,': 'O'}, {'and': 'O'}, {'possible': 'O'}, {'stimulation': 'O'}, {'of': 'O'}, {'tear': 'O'}, {'production': 'O'}, {'are': 'O'}, {'treatment': 'O'}, {'options': 'O'}, {'that': 'O'}, {'are': 'O'}, {'used': 'O'}, {'according': 'O'}, {'to': 'O'}, {'the': 'O'}, {'character': 'O'}, {'and': 'O'}, {'severity': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"Septal part of the mitral annulus PW TDE showed that systolic myocardial wave (Sm), early diastolic myocardial wave (Em), late diastolic myocardial wave (Am) and Em/Am ratios are significantly lower, and myocardial isovolumetric relaxation time (IVRTm) and MPI values are significantly higher in patients with SS.","[{'Septal': 'O'}, {'part': 'O'}, {'of': 'O'}, {'the': 'O'}, {'mitral': 'O'}, {'annulus': 'O'}, {'PW': 'O'}, {'TDE': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'systolic': 'O'}, {'myocardial': 'O'}, {'wave': 'O'}, {'(Sm),': 'O'}, {'early': 'O'}, {'diastolic': 'O'}, {'myocardial': 'O'}, {'wave': 'O'}, {'(Em),': 'O'}, {'late': 'O'}, {'diastolic': 'O'}, {'myocardial': 'O'}, {'wave': 'O'}, {'(Am)': 'O'}, {'and': 'O'}, {'Em/Am': 'O'}, {'ratios': 'O'}, {'are': 'O'}, {'significantly': 'O'}]"
The aim of this study is to determine the safety of antimalarial medications used for rheumatological conditions and the incidence of retinopathy.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'is': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'antimalarial': 'O'}, {'medications': 'O'}, {'used': 'O'}, {'for': 'O'}, {'rheumatological': 'B-Entity'}, {'conditions': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'retinopathy.': 'I-Entity'}]"
"An early diagnosis and the adoption of suitable therapeutic measures are necessary to prevent sight-threatening consequences, especially in patients with juvenile SLE.","[{'An': 'O'}, {'early': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'the': 'O'}, {'adoption': 'O'}, {'of': 'O'}, {'suitable': 'O'}, {'therapeutic': 'O'}, {'measures': 'O'}, {'are': 'O'}, {'necessary': 'O'}, {'to': 'O'}, {'prevent': 'O'}, {'sight-threatening': 'O'}, {'consequences,': 'O'}, {'especially': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'juvenile': 'O'}, {'SLE.': 'I-Entity'}]"
"A total of 1,584 patients were randomized in the EMBODY 1 and EMBODY 2 trials; 113 patients were anti-SSA positive and had a diagnosis of associated SS, and 1,375 patients (86.8%) had no diagnosis of associated SS (918 patients were randomized to receive epratuzumab and 457 to receive placebo).","[{'A': 'O'}, {'total': 'O'}, {'of': 'O'}, {'1,584': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'randomized': 'O'}, {'in': 'O'}, {'the': 'O'}, {'EMBODY': 'O'}, {'1': 'O'}, {'and': 'O'}, {'EMBODY': 'O'}, {'2': 'O'}, {'trials;': 'O'}, {'113': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'anti-SSA': 'O'}, {'positive': 'O'}, {'and': 'O'}, {'had': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'associated': 'O'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'1,375': 'O'}, {'patients': 'O'}, {'(86.8%)': 'O'}, {'had': 'O'}, {'no': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'associated': 'O'}, {'SS': 'I-Entity'}, {'(918': 'O'}]"
"Based on MRI findings, the diagnosis was SSM relapse.","[{'Based': 'O'}, {'on': 'O'}, {'MRI': 'O'}, {'findings,': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'was': 'O'}, {'SSM': 'I-Entity'}, {'relapse.': 'O'}]"
"We report a case of a 66-year-old woman presenting with nail changes, parchment-like hand changes, progressive alopecia and sicca syndrome.","[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'66-year-old': 'O'}, {'woman': 'O'}, {'presenting': 'O'}, {'with': 'O'}, {'nail': 'B-Entity'}, {'changes,': 'O'}, {'parchment-like': 'O'}, {'hand': 'O'}, {'changes,': 'O'}, {'progressive': 'O'}, {'alopecia': 'I-Entity'}, {'and': 'O'}, {'sicca': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
The aim of this study was to assess changes in salivary electrolyte flow and composition and the presence of anti-Ro/SSA and anti-La/SSB serum and saliva antibodies and their implications for the non-invasive diagnosis of SS.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'electrolyte': 'O'}, {'flow': 'O'}, {'and': 'O'}, {'composition': 'O'}, {'and': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-Ro/SSA': 'O'}, {'and': 'O'}, {'anti-La/SSB': 'O'}, {'serum': 'O'}, {'and': 'O'}, {'saliva': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'their': 'O'}, {'implications': 'O'}, {'for': 'O'}, {'the': 'O'}, {'non-invasive': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS.': 'I-Entity'}]"
"Compared to controls, alcohol consumption was inversely associated with NHL, DES, and SS (odds ratio (OR) = 0.47, 95% confidence interval (CI): 0.31-0.71; OR = 0.54, 95% CI: 0.33-0.88; and OR = 0.26, 95% CI: 0.14-0.49, respectively), while a previous history of infection requiring hospitalization was positively associated with all three conditions: NHL (OR = 1.92; 95% CI: 1.23-2.99), DES (OR = 3.29; 95% CI: 1.97-5.47), and SS (OR = 4.74; 95% CI: 2.66-8.44).","[{'Compared': 'O'}, {'to': 'O'}, {'controls,': 'O'}, {'alcohol': 'I-Entity'}, {'consumption': 'O'}, {'was': 'O'}, {'inversely': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'NHL,': 'I-Entity'}, {'DES,': 'I-Entity'}, {'and': 'O'}, {'SS': 'I-Entity'}, {'(odds': 'O'}, {'ratio': 'O'}, {'(OR)': 'O'}, {'=': 'O'}, {'0.47,': 'O'}, {'95%': 'O'}, {'confidence': 'O'}, {'interval': 'O'}, {'(CI):': 'O'}, {'0.31-0.71;': 'O'}, {'OR': 'O'}, {'=': 'O'}, {'0.54,': 'O'}, {'95%': 'O'}, {'CI:': 'O'}, {'0.33-0.88;': 'O'}]"
"Subjective symptoms reported after 1-week and 1-month follow-up were complaints of burning and pricking sensation, light sensitivity and pain.","[{'Subjective': 'O'}, {'symptoms': 'O'}, {'reported': 'O'}, {'after': 'O'}, {'1-week': 'O'}, {'and': 'O'}, {'1-month': 'O'}, {'follow-up': 'O'}, {'were': 'O'}, {'complaints': 'O'}, {'of': 'O'}, {'burning': 'B-Entity'}, {'and': 'O'}, {'pricking': 'I-Entity'}, {'sensation,': 'I-Entity'}, {'light': 'O'}, {'sensitivity': 'I-Entity'}, {'and': 'O'}, {'pain.': 'I-Entity'}]"
It is a consequence of chronic metabolic acidosis and is associated with distal renal tubular acidosis.,"[{'It': 'O'}, {'is': 'O'}, {'a': 'O'}, {'consequence': 'O'}, {'of': 'O'}, {'chronic': 'O'}, {'metabolic': 'B-Entity'}, {'acidosis': 'I-Entity'}, {'and': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'distal': 'O'}, {'renal': 'O'}, {'tubular': 'O'}, {'acidosis.': 'I-Entity'}]"
"Here, we reported a case of coexisting sarcoidosis and Sjogrens syndrome, complicated with severe hypercalcemia and renal failure, in addition to a literature review.","[{'Here,': 'O'}, {'we': 'O'}, {'reported': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'coexisting': 'O'}, {'sarcoidosis': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'complicated': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'hypercalcemia': 'I-Entity'}, {'and': 'O'}, {'renal': 'B-Entity'}, {'failure,': 'I-Entity'}, {'in': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'a': 'O'}, {'literature': 'O'}, {'review.': 'O'}]"
"They are manifested by defects in the urine concentration and hydroelectrolyte alterations, mainly distal tubular acidosis and exceptionally proximal tubular acidosis.","[{'They': 'O'}, {'are': 'O'}, {'manifested': 'O'}, {'by': 'O'}, {'defects': 'O'}, {'in': 'O'}, {'the': 'O'}, {'urine': 'O'}, {'concentration': 'O'}, {'and': 'O'}, {'hydroelectrolyte': 'O'}, {'alterations,': 'O'}, {'mainly': 'O'}, {'distal': 'O'}, {'tubular': 'O'}, {'acidosis': 'I-Entity'}, {'and': 'O'}, {'exceptionally': 'O'}, {'proximal': 'O'}, {'tubular': 'O'}, {'acidosis.': 'I-Entity'}]"
Patients with primary SS (pSS) are frequently suffering from multiple enduring disorders that raise the risk of work disability and require treatment by various health-care specialists.,"[{'Patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'SS': 'I-Entity'}, {'(pSS)': 'O'}, {'are': 'O'}, {'frequently': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'multiple': 'O'}, {'enduring': 'O'}, {'disorders': 'I-Entity'}, {'that': 'O'}, {'raise': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'work': 'B-Entity'}, {'disability': 'I-Entity'}, {'and': 'O'}, {'require': 'O'}, {'treatment': 'O'}, {'by': 'O'}, {'various': 'O'}, {'health-care': 'O'}, {'specialists.': 'O'}]"
The aim of this study was to evaluate neurological manifestations of primary Sjogrens syndrome (pSS) and investigate the etiology and pathogenesis of peripheral and central nervous complications in pSS.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'neurological': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'and': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'etiology': 'O'}, {'and': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'peripheral': 'B-Entity'}, {'and': 'I-Entity'}, {'central': 'B-Entity'}, {'nervous': 'I-Entity'}, {'complications': 'I-Entity'}, {'in': 'O'}, {'pSS.': 'I-Entity'}]"
The renal histologic score of mCRP in TINU syndrome was significantly higher than that in disease controls (P < 0.05).,"[{'The': 'O'}, {'renal': 'O'}, {'histologic': 'O'}, {'score': 'O'}, {'of': 'O'}, {'mCRP': 'O'}, {'in': 'O'}, {'TINU': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'than': 'O'}, {'that': 'O'}, {'in': 'O'}, {'disease': 'O'}, {'controls': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.05).': 'O'}]"
Connective tissue disorders commonly involve multiple organ systems including the skin and eye.,"[{'Connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disorders': 'I-Entity'}, {'commonly': 'O'}, {'involve': 'O'}, {'multiple': 'O'}, {'organ': 'O'}, {'systems': 'O'}, {'including': 'O'}, {'the': 'O'}, {'skin': 'O'}, {'and': 'O'}, {'eye.': 'O'}]"
"Primary Sjogrens syndrome (pSS) primarily involves exocrine glands, and renal tubular acidosis (RTA) is seen in one-third of the cases.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'primarily': 'O'}, {'involves': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'and': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(RTA)': 'O'}, {'is': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'one-third': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cases.': 'O'}]"
She was diagnosed with Sjogrens syndrome (SS) associated with renal tubular acidosis.,"[{'She': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis.': 'I-Entity'}]"
The average fluorescein and Rose Bengal scores improved statistically after 7 days of treatment and even more after 90 days.,"[{'The': 'O'}, {'average': 'O'}, {'fluorescein': 'I-Entity'}, {'and': 'O'}, {'Rose': 'I-Entity'}, {'Bengal': 'O'}, {'scores': 'O'}, {'improved': 'O'}, {'statistically': 'O'}, {'after': 'O'}, {'7': 'O'}, {'days': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'and': 'O'}, {'even': 'O'}, {'more': 'O'}, {'after': 'O'}, {'90': 'O'}, {'days.': 'O'}]"
The complete block can occur as an isolated defect or be associated with structural anomalies of the fetal heart.,"[{'The': 'O'}, {'complete': 'O'}, {'block': 'I-Entity'}, {'can': 'O'}, {'occur': 'O'}, {'as': 'O'}, {'an': 'O'}, {'isolated': 'O'}, {'defect': 'O'}, {'or': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'structural': 'B-Entity'}, {'anomalies': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'fetal': 'O'}, {'heart.': 'I-Entity'}]"
"In this 224 pSS cohort (213 females and 11 males), the male/female ratio was 1:19.4, the mean age of onset was (53.5¬¨¬®¬¨¬±11.7) years, and median duration was 9.4 years (ranging from 0.2 to 40.0 years).The manifestations showed that up to 33% of the patients (74/224) had leukopenia, 25% (56/224) polyarthralgia, 16.5% (37/224) raynaud phenomenon, 15.6% (35/224) hepatic injury, 12.1% (27/224) pulmonary interstitial fibrosis, 11.6% (26/224) purpuras on lower extremities, 8.0% (18/224) hemogram abnormal, 5.8% (13/224) thrombopenia, and 3.6% (8/224) renal tubule acidosis.","[{'In': 'O'}, {'this': 'O'}, {'224': 'O'}, {'pSS': 'I-Entity'}, {'cohort': 'O'}, {'(213': 'O'}, {'females': 'O'}, {'and': 'O'}, {'11': 'O'}, {'males),': 'O'}, {'the': 'O'}, {'male/female': 'O'}, {'ratio': 'O'}, {'was': 'O'}, {'1:19.4,': 'O'}, {'the': 'O'}, {'mean': 'O'}, {'age': 'O'}, {'of': 'O'}, {'onset': 'O'}, {'was': 'O'}, {'(53.5¬¨¬®¬¨¬±11.7)': 'O'}, {'years,': 'O'}, {'and': 'O'}, {'median': 'O'}, {'duration': 'O'}, {'was': 'O'}, {'9.4': 'O'}, {'years': 'O'}, {'(ranging': 'O'}]"
"On the contrary, in the UV the cerebral uptake of the tracer significantly improved from the twenty-fourth month (18/22 patients).","[{'On': 'O'}, {'the': 'O'}, {'contrary,': 'O'}, {'in': 'O'}, {'the': 'O'}, {'UV': 'O'}, {'the': 'O'}, {'cerebral': 'O'}, {'uptake': 'O'}, {'of': 'O'}, {'the': 'O'}, {'tracer': 'O'}, {'significantly': 'O'}, {'improved': 'O'}, {'from': 'O'}, {'the': 'O'}, {'twenty-fourth': 'O'}, {'month': 'O'}, {'(18/22': 'O'}, {'patients).': 'O'}]"
"All patients underwent to a wide neurological, neuropsychological, psychiatric, neuroradiological and ultrasonographic evaluation.","[{'All': 'O'}, {'patients': 'O'}, {'underwent': 'O'}, {'to': 'O'}, {'a': 'O'}, {'wide': 'O'}, {'neurological,': 'O'}, {'neuropsychological,': 'O'}, {'psychiatric,': 'I-Entity'}, {'neuroradiological': 'O'}, {'and': 'O'}, {'ultrasonographic': 'O'}, {'evaluation.': 'O'}]"
Sjogrens syndrome (SS) is a female-dominant autoimmune disease characterized by androgen depletion and defective dehydroepiandrosterone (DHEA) processing enzymatic machinery in the salivary glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'female-dominant': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'androgen': 'O'}, {'depletion': 'O'}, {'and': 'O'}, {'defective': 'O'}, {'dehydroepiandrosterone': 'I-Entity'}, {'(DHEA)': 'O'}, {'processing': 'O'}, {'enzymatic': 'O'}, {'machinery': 'O'}, {'in': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands.': 'O'}]"
"Our observations suggest that the presence of T(FH) cells in LSGs at the disease onset may predict a more pronounced clinical course of pSS.Street 22, Debrecen 4032, Hungary.Street 22, Debrecen 4032, Hungary.98, Debrecen 4032, Hungary.Street 22, Debrecen 4032, Hungary.Protein, in Primary Sjogrens Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.","[{'Our': 'O'}, {'observations': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'T(FH)': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'LSGs': 'O'}, {'at': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'onset': 'O'}, {'may': 'O'}, {'predict': 'O'}, {'a': 'O'}, {'more': 'O'}, {'pronounced': 'O'}, {'clinical': 'O'}, {'course': 'O'}, {'of': 'O'}, {'pSS.Street': 'I-Entity'}, {'22,': 'O'}, {'Debrecen': 'O'}, {'4032,': 'O'}, {'Hungary.Street': 'O'}, {'22,': 'O'}, {'Debrecen': 'O'}, {'4032,': 'O'}, {'Hungary.98,': 'O'}, {'Debrecen': 'O'}]"
"In the course of pSS, inflammatory cell infiltration consists mainly of lymphocytes infiltrating exocrine glands, which leads to their impaired function.","[{'In': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'pSS,': 'I-Entity'}, {'inflammatory': 'O'}, {'cell': 'O'}, {'infiltration': 'O'}, {'consists': 'O'}, {'mainly': 'O'}, {'of': 'O'}, {'lymphocytes': 'O'}, {'infiltrating': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'which': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'their': 'O'}, {'impaired': 'O'}, {'function.': 'O'}]"
SS is an autoimmune disease characterized by salivary and lacrimal gland dysfunction leading to dry mouth (xerostomia) and dry eyes (xerophthalmia).,"[{'SS': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'I-Entity'}, {'gland': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'leading': 'O'}, {'to': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'(xerostomia)': 'O'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'(xerophthalmia).': 'O'}]"
"When tissue Doppler echocardiography (TDE) findings were compared between the two groups, it was found that myocardial systolic wave (Sm), myocardial early diastolic wave (Em) and Em/Am ratio were significantly lower, and myocardial isovolumetric relaxation time (IVRTm) and myocardial performance index (MPI) values were significantly higher in patients with SS.","[{'When': 'O'}, {'tissue': 'O'}, {'Doppler': 'O'}, {'echocardiography': 'O'}, {'(TDE)': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'compared': 'O'}, {'between': 'O'}, {'the': 'O'}, {'two': 'O'}, {'groups,': 'O'}, {'it': 'O'}, {'was': 'O'}, {'found': 'O'}, {'that': 'O'}, {'myocardial': 'O'}, {'systolic': 'O'}, {'wave': 'O'}, {'(Sm),': 'O'}, {'myocardial': 'O'}, {'early': 'O'}, {'diastolic': 'O'}, {'wave': 'O'}, {'(Em)': 'O'}, {'and': 'O'}, {'Em/Am': 'O'}, {'ratio': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'lower,': 'O'}, {'and': 'O'}, {'myocardial': 'O'}]"
"This technique facilitates a superior yield, ensures adequate sampling of appropriate glands for histopathological analysis, and minimises the complications associated with traditional techniques.Hospital,Dublin,Ireland.Hospital,Dublin,Ireland.Hospital,Dublin,Ireland.Apr 22.","[{'This': 'O'}, {'technique': 'O'}, {'facilitates': 'O'}, {'a': 'O'}, {'superior': 'O'}, {'yield,': 'O'}, {'ensures': 'O'}, {'adequate': 'O'}, {'sampling': 'O'}, {'of': 'O'}, {'appropriate': 'O'}, {'glands': 'O'}, {'for': 'O'}, {'histopathological': 'O'}, {'analysis,': 'O'}, {'and': 'O'}, {'minimises': 'O'}, {'the': 'O'}, {'complications': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'traditional': 'O'}, {'techniques.Hospital,Dublin,Ireland.Hospital,Dublin,Ireland.Hospital,Dublin,Ireland.Apr': 'O'}, {'22.': 'O'}]"
"More recently, primary Sjogrens syndrome (pSS) was also demonstrated as an independent risk factor for cardiovascular disease, emerging as a new interesting model to study atherosclerosis in autoimmune diseases.","[{'More': 'O'}, {'recently,': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'was': 'O'}, {'also': 'O'}, {'demonstrated': 'O'}, {'as': 'O'}, {'an': 'O'}, {'independent': 'O'}, {'risk': 'O'}, {'factor': 'O'}, {'for': 'O'}, {'cardiovascular': 'B-Entity'}, {'disease,': 'I-Entity'}, {'emerging': 'O'}, {'as': 'O'}, {'a': 'O'}, {'new': 'O'}, {'interesting': 'O'}, {'model': 'O'}, {'to': 'O'}, {'study': 'O'}, {'atherosclerosis': 'I-Entity'}, {'in': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
The clinical picture of celiac disease has changed considerably during the past 30 years.,"[{'The': 'O'}, {'clinical': 'O'}, {'picture': 'O'}, {'of': 'O'}, {'celiac': 'B-Entity'}, {'disease': 'I-Entity'}, {'has': 'O'}, {'changed': 'O'}, {'considerably': 'O'}, {'during': 'O'}, {'the': 'O'}, {'past': 'O'}, {'30': 'O'}, {'years.': 'O'}]"
"rheumatoid arthritis, systemic lupus erythematosus, Sjogren syndrome, systemic sclerosis, systemic vasculitides).","[{'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'Sjogren': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'vasculitides).': 'I-Entity'}]"
"A protean of other lung abnormalities including amyloidosis, granulomatous lung disease, pseudolymphoma, pulmonary hypertension, and pleural disease have been described.School of Medicine of the University of Pennsylvania Philadelphia, PA.Foundation, Cleveland, OH.2014 Mar 25.Sjogren syndrome: a case series.","[{'A': 'O'}, {'protean': 'O'}, {'of': 'O'}, {'other': 'O'}, {'lung': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'including': 'O'}, {'amyloidosis,': 'I-Entity'}, {'granulomatous': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease,': 'I-Entity'}, {'pseudolymphoma,': 'I-Entity'}, {'pulmonary': 'B-Entity'}, {'hypertension,': 'I-Entity'}, {'and': 'O'}, {'pleural': 'B-Entity'}, {'disease': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'described.School': 'O'}, {'of': 'O'}, {'Medicine': 'O'}, {'of': 'O'}, {'the': 'O'}, {'University': 'O'}, {'of': 'O'}, {'Pennsylvania': 'O'}, {'Philadelphia,': 'O'}, {'PA.Foundation,': 'O'}, {'Cleveland,': 'O'}, {'OH.2014': 'O'}]"
"A 50-year-old woman had progressive proximal muscle weakness of bilateral thighs, myalgia, tea-colored urine, and exercise intolerance for 6 months.","[{'A': 'O'}, {'50-year-old': 'O'}, {'woman': 'O'}, {'had': 'O'}, {'progressive': 'O'}, {'proximal': 'O'}, {'muscle': 'B-Entity'}, {'weakness': 'I-Entity'}, {'of': 'O'}, {'bilateral': 'O'}, {'thighs,': 'O'}, {'myalgia,': 'I-Entity'}, {'tea-colored': 'O'}, {'urine,': 'O'}, {'and': 'O'}, {'exercise': 'O'}, {'intolerance': 'O'}, {'for': 'O'}, {'6': 'O'}, {'months.': 'O'}]"
This study shows that subconjunctival administration of anti-HMGB1 attenuates clinical manifestations of dry eye.,"[{'This': 'O'}, {'study': 'O'}, {'shows': 'O'}, {'that': 'O'}, {'subconjunctival': 'O'}, {'administration': 'O'}, {'of': 'O'}, {'anti-HMGB1': 'O'}, {'attenuates': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"Of the 174 patients screened, seventy patients with pSS underwent renal function tests, urine examination, renal ultrasound, arterial blood gases, urine pH followed by urine acidification test and renal biopsy (if indicated).","[{'Of': 'O'}, {'the': 'O'}, {'174': 'O'}, {'patients': 'O'}, {'screened,': 'O'}, {'seventy': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'underwent': 'O'}, {'renal': 'O'}, {'function': 'O'}, {'tests,': 'O'}, {'urine': 'O'}, {'examination,': 'O'}, {'renal': 'O'}, {'ultrasound,': 'O'}, {'arterial': 'O'}, {'blood': 'O'}, {'gases,': 'O'}, {'urine': 'O'}, {'pH': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'urine': 'O'}, {'acidification': 'O'}, {'test': 'O'}, {'and': 'O'}, {'renal': 'O'}, {'biopsy': 'O'}, {'(if': 'O'}, {'indicated).': 'O'}]"
Subclinical atherosclerosis defined either as carotid and/or femoral plaque formation or increased intima media thickness (IMT) levels were assessed by Doppler ultrasound.,"[{'Subclinical': 'O'}, {'atherosclerosis': 'I-Entity'}, {'defined': 'O'}, {'either': 'O'}, {'as': 'O'}, {'carotid': 'O'}, {'and/or': 'O'}, {'femoral': 'O'}, {'plaque': 'I-Entity'}, {'formation': 'O'}, {'or': 'O'}, {'increased': 'O'}, {'intima': 'O'}, {'media': 'O'}, {'thickness': 'O'}, {'(IMT)': 'O'}, {'levels': 'O'}, {'were': 'O'}, {'assessed': 'O'}, {'by': 'O'}, {'Doppler': 'O'}, {'ultrasound.': 'O'}]"
"The possibility of IC in patients with SS complaining of lower urinary tract symptoms without features of infection or other identifiable causes should be given attention.Tokyo , Japan.Tokyo , Japan.Tokyo , Japan.Tokyo , Japan.Tokyo , Japan.Tokyo , Japan.Tokyo , Japan.Tokyo , Japan.11.","[{'The': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'IC': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'complaining': 'O'}, {'of': 'O'}, {'lower': 'B-Entity'}, {'urinary': 'I-Entity'}, {'tract': 'I-Entity'}, {'symptoms': 'I-Entity'}, {'without': 'O'}, {'features': 'O'}, {'of': 'O'}, {'infection': 'I-Entity'}, {'or': 'O'}, {'other': 'O'}, {'identifiable': 'O'}, {'causes': 'O'}, {'should': 'O'}, {'be': 'O'}, {'given': 'O'}, {'attention.Tokyo': 'O'}, {',': 'O'}, {'Japan.Tokyo': 'O'}, {',': 'O'}, {'Japan.Tokyo': 'O'}, {',': 'O'}, {'Japan.Tokyo': 'O'}, {',': 'O'}, {'Japan.Tokyo': 'O'}, {',': 'O'}, {'Japan.Tokyo': 'O'}, {',': 'O'}, {'Japan.Tokyo': 'O'}, {',': 'O'}, {'Japan.Tokyo': 'O'}, {',': 'O'}]"
"Such a process also activates reactive oxidative species and antioxidants, which are linked to the triggering of inflammatory responses.","[{'Such': 'O'}, {'a': 'O'}, {'process': 'O'}, {'also': 'O'}, {'activates': 'O'}, {'reactive': 'O'}, {'oxidative': 'O'}, {'species': 'O'}, {'and': 'O'}, {'antioxidants,': 'O'}, {'which': 'O'}, {'are': 'O'}, {'linked': 'O'}, {'to': 'O'}, {'the': 'O'}, {'triggering': 'O'}, {'of': 'O'}, {'inflammatory': 'O'}, {'responses.': 'O'}]"
"Therefore, this M3-receptor agonist might be a promising drug and should be evaluated for the treatment of impaired sweating in AD complicated with or without SS.Medicine, Osaka University, Osaka, Japan.","[{'Therefore,': 'O'}, {'this': 'O'}, {'M3-receptor': 'O'}, {'agonist': 'O'}, {'might': 'O'}, {'be': 'O'}, {'a': 'O'}, {'promising': 'O'}, {'drug': 'O'}, {'and': 'O'}, {'should': 'O'}, {'be': 'O'}, {'evaluated': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'impaired': 'B-Entity'}, {'sweating': 'I-Entity'}, {'in': 'O'}, {'AD': 'I-Entity'}, {'complicated': 'O'}, {'with': 'O'}, {'or': 'O'}, {'without': 'O'}, {'SS.Medicine,': 'I-Entity'}, {'Osaka': 'O'}, {'University,': 'O'}, {'Osaka,': 'O'}, {'Japan.': 'O'}]"
"One (3.6%) of the 28 NMO patients showed peripheral neuropathy at the same time of NMO relapse, although CIDP was not seen in NMO.","[{'One': 'O'}, {'(3.6%)': 'O'}, {'of': 'O'}, {'the': 'O'}, {'28': 'O'}, {'NMO': 'I-Entity'}, {'patients': 'O'}, {'showed': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'at': 'O'}, {'the': 'O'}, {'same': 'O'}, {'time': 'O'}, {'of': 'O'}, {'NMO': 'I-Entity'}, {'relapse,': 'O'}, {'although': 'O'}, {'CIDP': 'I-Entity'}, {'was': 'O'}, {'not': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'NMO.': 'I-Entity'}]"
"Although approximately 1 in 10 patients with clinically-significant aqueous deficient dry eye has underlying SS, widespread underappreciation of SS leads to significant underdiagnosis, delays in diagnosis, and consequent morbidity and mortality.","[{'Although': 'O'}, {'approximately': 'O'}, {'1': 'O'}, {'in': 'O'}, {'10': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'clinically-significant': 'O'}, {'aqueous': 'O'}, {'deficient': 'I-Entity'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'has': 'O'}, {'underlying': 'O'}, {'SS,': 'I-Entity'}, {'widespread': 'O'}, {'underappreciation': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'leads': 'O'}, {'to': 'O'}, {'significant': 'O'}, {'underdiagnosis,': 'O'}, {'delays': 'O'}, {'in': 'O'}, {'diagnosis,': 'O'}, {'and': 'O'}, {'consequent': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality.': 'O'}]"
CASE: We describe a patient with pSS who presented with intracranial hypertension as the initial symptom of the disease.,"[{'CASE:': 'O'}, {'We': 'O'}, {'describe': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'intracranial': 'B-Entity'}, {'hypertension': 'I-Entity'}, {'as': 'O'}, {'the': 'O'}, {'initial': 'O'}, {'symptom': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
Women with rheumatic diseases deal with pregnancy complications more frequently than controls.,"[{'Women': 'O'}, {'with': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'deal': 'O'}, {'with': 'O'}, {'pregnancy': 'B-Entity'}, {'complications': 'I-Entity'}, {'more': 'O'}, {'frequently': 'O'}, {'than': 'O'}, {'controls.': 'O'}]"
The diagnosis of DM was defined as at least two outpatient visits or one inpatient admission with anti-diabetic medication prescription.,"[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'DM': 'I-Entity'}, {'was': 'O'}, {'defined': 'O'}, {'as': 'O'}, {'at': 'O'}, {'least': 'O'}, {'two': 'O'}, {'outpatient': 'O'}, {'visits': 'O'}, {'or': 'O'}, {'one': 'O'}, {'inpatient': 'O'}, {'admission': 'O'}, {'with': 'O'}, {'anti-diabetic': 'O'}, {'medication': 'O'}, {'prescription.': 'O'}]"
"Although the etiology of plasma cell dyscrasia is poorly understood, there is evidence for immune dysregulation or sustained immune stimulation playing a pivotal role in the pathogenesis of these diseases, including chronic infection and autoimmune disorders.","[{'Although': 'O'}, {'the': 'O'}, {'etiology': 'O'}, {'of': 'O'}, {'plasma': 'B-Entity'}, {'cell': 'I-Entity'}, {'dyscrasia': 'I-Entity'}, {'is': 'O'}, {'poorly': 'O'}, {'understood,': 'O'}, {'there': 'O'}, {'is': 'O'}, {'evidence': 'O'}, {'for': 'O'}, {'immune': 'O'}, {'dysregulation': 'O'}, {'or': 'O'}, {'sustained': 'O'}, {'immune': 'O'}, {'stimulation': 'O'}, {'playing': 'O'}, {'a': 'O'}, {'pivotal': 'O'}, {'role': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'these': 'O'}, {'diseases,': 'O'}, {'including': 'O'}, {'chronic': 'O'}, {'infection': 'I-Entity'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders.': 'I-Entity'}]"
"Clinicians need to consider the possibility of NMOSD for acute or subacute blurred vision, nausea, vomiting, numbness and weakness of limbs or trunk and psychiatric symptoms.","[{'Clinicians': 'O'}, {'need': 'O'}, {'to': 'O'}, {'consider': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'NMOSD': 'I-Entity'}, {'for': 'O'}, {'acute': 'O'}, {'or': 'O'}, {'subacute': 'O'}, {'blurred': 'B-Entity'}, {'vision,': 'I-Entity'}, {'nausea,': 'I-Entity'}, {'vomiting,': 'I-Entity'}, {'numbness': 'B-Entity'}, {'and': 'O'}, {'weakness': 'I-Entity'}, {'of': 'O'}, {'limbs': 'O'}, {'or': 'O'}, {'trunk': 'O'}, {'and': 'O'}, {'psychiatric': 'I-Entity'}, {'symptoms.': 'O'}]"
we describe 2 cases of primary non-Hodgkin lymphoma of the liver associated with hepatitis B virus (HBV) infection.,"[{'we': 'O'}, {'describe': 'O'}, {'2': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'non-Hodgkin': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'liver': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'hepatitis': 'B-Entity'}, {'B': 'I-Entity'}, {'virus': 'I-Entity'}, {'(HBV)': 'O'}, {'infection.': 'I-Entity'}]"
"The conjunctival disease appeared to be due to inflammation and not a decrease in tear volume.National University-Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Jeonbuk, Korea 2Ocular Surface Center, Department of Ophthalmology, Cullen Eye.College of Medicine, Houston, Texas, United States.College of Medicine, Houston, Texas, United States.College of Medicine, Houston, Texas, United States.College of Medicine, Houston, Texas, United States.patients with Sjogren's syndrome].","[{'The': 'O'}, {'conjunctival': 'B-Entity'}, {'disease': 'I-Entity'}, {'appeared': 'O'}, {'to': 'O'}, {'be': 'O'}, {'due': 'O'}, {'to': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'not': 'O'}, {'a': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'tear': 'O'}, {'volume.National': 'O'}, {'University-Biomedical': 'O'}, {'Research': 'O'}, {'Institute,': 'O'}, {'Chonbuk': 'O'}, {'National': 'O'}, {'University': 'O'}, {'Hospital,': 'O'}, {'Jeonju,': 'O'}, {'Jeonbuk,': 'O'}, {'Korea': 'O'}, {'2Ocular': 'O'}, {'Surface': 'O'}, {'Center,': 'O'}, {'Department': 'O'}, {'of': 'O'}, {'Ophthalmology,': 'O'}, {'Cullen': 'O'}, {'Eye.College': 'O'}]"
"in systemic lupus erythematosus, in rheumathoid arthritis, Sjogrens syndrome, in dermatomyositis) and in inflamatory bowel diseases (Crohn disease, colitis ulcerosa).","[{'in': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'in': 'O'}, {'rheumathoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'in': 'O'}, {'dermatomyositis)': 'I-Entity'}, {'and': 'O'}, {'in': 'O'}, {'inflamatory': 'B-Entity'}, {'bowel': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(Crohn': 'O'}, {'disease,': 'I-Entity'}, {'colitis': 'B-Entity'}, {'ulcerosa).': 'I-Entity'}]"
This is a cross-sectional study to assess the prevalence and causes of anemia in the primary Sjogrens syndrome (pSS).,"[{'This': 'O'}, {'is': 'O'}, {'a': 'O'}, {'cross-sectional': 'O'}, {'study': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'and': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'anemia': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"For each patient, the medical history and the symptoms were evaluated, and diagnostic tests were performed.","[{'For': 'O'}, {'each': 'O'}, {'patient,': 'O'}, {'the': 'O'}, {'medical': 'O'}, {'history': 'O'}, {'and': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'were': 'O'}, {'evaluated,': 'O'}, {'and': 'O'}, {'diagnostic': 'O'}, {'tests': 'O'}, {'were': 'O'}, {'performed.': 'O'}]"
Clinical symptoms and results of autonomic testing prior to and following immunotherapy were assessed.,"[{'Clinical': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'results': 'O'}, {'of': 'O'}, {'autonomic': 'O'}, {'testing': 'O'}, {'prior': 'O'}, {'to': 'O'}, {'and': 'O'}, {'following': 'O'}, {'immunotherapy': 'O'}, {'were': 'O'}, {'assessed.': 'O'}]"
"In this study, the plasma activity of L-‚âà√≠¬¨¬±-fucosidase-1 (‚âà√≠¬¨¬±-L-FUCA-1) was assayed in hospitalized children and adults and its association with SS and other rheumatic disorders further evaluated.","[{'In': 'O'}, {'this': 'O'}, {'study,': 'O'}, {'the': 'O'}, {'plasma': 'O'}, {'activity': 'O'}, {'of': 'O'}, {'L-‚âà√≠¬¨¬±-fucosidase-1': 'O'}, {'(‚âà√≠¬¨¬±-L-FUCA-1)': 'O'}, {'was': 'O'}, {'assayed': 'O'}, {'in': 'O'}, {'hospitalized': 'O'}, {'children': 'O'}, {'and': 'O'}, {'adults': 'O'}, {'and': 'O'}, {'its': 'O'}, {'association': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}]"
"GEE analysis over time revealed that physical fatigue was significantly associated with absolute number of B cells, dryness and mental fatigue, but not with ESSDAI, IgG levels and IgM-RF.","[{'GEE': 'O'}, {'analysis': 'O'}, {'over': 'O'}, {'time': 'O'}, {'revealed': 'O'}, {'that': 'O'}, {'physical': 'O'}, {'fatigue': 'I-Entity'}, {'was': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'absolute': 'O'}, {'number': 'O'}, {'of': 'O'}, {'B': 'O'}, {'cells,': 'O'}, {'dryness': 'I-Entity'}, {'and': 'O'}, {'mental': 'O'}, {'fatigue,': 'I-Entity'}, {'but': 'O'}, {'not': 'O'}, {'with': 'O'}, {'ESSDAI,': 'O'}, {'IgG': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'IgM-RF.': 'O'}]"
"Antiplatelet antibodies, especially IgG isotype, decreased significantly (P < 0.05) after RTX treatment.","[{'Antiplatelet': 'O'}, {'antibodies,': 'O'}, {'especially': 'O'}, {'IgG': 'O'}, {'isotype,': 'O'}, {'decreased': 'O'}, {'significantly': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.05)': 'O'}, {'after': 'O'}, {'RTX': 'I-Entity'}, {'treatment.': 'O'}]"
Chronic parotitis in conjunction with multiple parotid calcifications is uncommon and was identified in 10% of our cohort.,"[{'Chronic': 'O'}, {'parotitis': 'I-Entity'}, {'in': 'O'}, {'conjunction': 'O'}, {'with': 'O'}, {'multiple': 'O'}, {'parotid': 'B-Entity'}, {'calcifications': 'I-Entity'}, {'is': 'O'}, {'uncommon': 'O'}, {'and': 'O'}, {'was': 'O'}, {'identified': 'O'}, {'in': 'O'}, {'10%': 'O'}, {'of': 'O'}, {'our': 'O'}, {'cohort.': 'O'}]"
"Patients with cognitive scores > 50 had more depression, fatigue, pain (effect size all > 1), and worse performance on multiple cognitive domains.","[{'Patients': 'O'}, {'with': 'O'}, {'cognitive': 'O'}, {'scores': 'O'}, {'>': 'O'}, {'50': 'O'}, {'had': 'O'}, {'more': 'O'}, {'depression,': 'I-Entity'}, {'fatigue,': 'I-Entity'}, {'pain': 'I-Entity'}, {'(effect': 'O'}, {'size': 'O'}, {'all': 'O'}, {'>': 'O'}, {'1),': 'O'}, {'and': 'O'}, {'worse': 'O'}, {'performance': 'O'}, {'on': 'O'}, {'multiple': 'O'}, {'cognitive': 'O'}, {'domains.': 'O'}]"
"These results showed that a decrease in the concentrations of ovarian hormones in the genetically predisposed mice accelerated the onset of the disease by upregulating various pro-inflammatory cytokines at different time points and promoting the formation of anti-Ro/SSA serum autoantibodies, creating an environment favorable for the initiation of SS.Florida Atlantic University, Boca Raton, FL 33431, USA.Florida Atlantic University, Boca Raton, FL 33431, USA.Florida Atlantic University, Boca Raton, FL 33431, USA.Florida Atlantic University, Boca Raton, FL 33431, USA.","[{'These': 'O'}, {'results': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'a': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'the': 'O'}, {'concentrations': 'O'}, {'of': 'O'}, {'ovarian': 'O'}, {'hormones': 'O'}, {'in': 'O'}, {'the': 'O'}, {'genetically': 'O'}, {'predisposed': 'O'}, {'mice': 'O'}, {'accelerated': 'O'}, {'the': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'by': 'O'}, {'upregulating': 'O'}, {'various': 'O'}, {'pro-inflammatory': 'O'}, {'cytokines': 'O'}, {'at': 'O'}, {'different': 'O'}, {'time': 'O'}, {'points': 'O'}, {'and': 'O'}, {'promoting': 'O'}, {'the': 'O'}, {'formation': 'O'}, {'of': 'O'}, {'anti-Ro/SSA': 'O'}, {'serum': 'O'}, {'autoantibodies,': 'O'}]"
The present review summarizes the neurological involvement in connective tissue diseases and highlights recent findings on the diagnosis of neurological manifestations and potential underlying mechanisms.,"[{'The': 'O'}, {'present': 'O'}, {'review': 'O'}, {'summarizes': 'O'}, {'the': 'O'}, {'neurological': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'and': 'O'}, {'highlights': 'O'}, {'recent': 'O'}, {'findings': 'O'}, {'on': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'neurological': 'O'}, {'manifestations': 'O'}, {'and': 'O'}, {'potential': 'O'}, {'underlying': 'O'}, {'mechanisms.': 'O'}]"
"Myelopathies are the second most common cause (17.4-25.0% in multiple sclerosis, etc.).","[{'Myelopathies': 'I-Entity'}, {'are': 'O'}, {'the': 'O'}, {'second': 'O'}, {'most': 'O'}, {'common': 'O'}, {'cause': 'O'}, {'(17.4-25.0%': 'O'}, {'in': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'etc.).': 'O'}]"
One patient died and one patient developed end stage kidney disease.,"[{'One': 'O'}, {'patient': 'O'}, {'died': 'O'}, {'and': 'O'}, {'one': 'O'}, {'patient': 'O'}, {'developed': 'O'}, {'end': 'B-Entity'}, {'stage': 'I-Entity'}, {'kidney': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"This loss of salivary function leads to oral dryness, impaired swallowing and speech, and increased infection and is associated with other autoimmune diseases and an increased risk of certain cancers.","[{'This': 'O'}, {'loss': 'B-Entity'}, {'of': 'I-Entity'}, {'salivary': 'I-Entity'}, {'function': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'oral': 'B-Entity'}, {'dryness,': 'I-Entity'}, {'impaired': 'B-Entity'}, {'swallowing': 'I-Entity'}, {'and': 'I-Entity'}, {'speech,': 'I-Entity'}, {'and': 'O'}, {'increased': 'O'}, {'infection': 'I-Entity'}, {'and': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'and': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'certain': 'O'}, {'cancers.': 'I-Entity'}]"
Only 2 of the patients with orthostatic hypotension had a significant sensory neuropathy.,"[{'Only': 'O'}, {'2': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'orthostatic': 'B-Entity'}, {'hypotension': 'I-Entity'}, {'had': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'sensory': 'B-Entity'}, {'neuropathy.': 'I-Entity'}]"
"In this review, we present a short introduction to fractals and specifically address the following topics: treatment and healing monitoring, dental materials, dental tissue, caries, osteoporosis, periodontitis, cancer, Sjogrens syndrome, diagnosis of several other conditions and a discussion on the reliability of FD determinations from dental radiographs.","[{'In': 'O'}, {'this': 'O'}, {'review,': 'O'}, {'we': 'O'}, {'present': 'O'}, {'a': 'O'}, {'short': 'O'}, {'introduction': 'O'}, {'to': 'O'}, {'fractals': 'O'}, {'and': 'O'}, {'specifically': 'O'}, {'address': 'O'}, {'the': 'O'}, {'following': 'O'}, {'topics:': 'O'}, {'treatment': 'O'}, {'and': 'O'}, {'healing': 'O'}, {'monitoring,': 'O'}, {'dental': 'O'}, {'materials,': 'O'}, {'dental': 'O'}, {'tissue,': 'O'}, {'caries,': 'I-Entity'}, {'osteoporosis,': 'I-Entity'}, {'periodontitis,': 'I-Entity'}, {'cancer,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'diagnosis': 'O'}, {'of': 'O'}, {'several': 'O'}, {'other': 'O'}, {'conditions': 'O'}, {'and': 'O'}, {'a': 'O'}, {'discussion': 'O'}, {'on': 'O'}, {'the': 'O'}]"
"A shift in sympathetic-vagal balance associated with overall symptom burden (ESSPRI) (P = 0.04, r(2) = 0.3) and EULAR sicca score (P = 0.016; r(2) = 0.3), the latter also correlated with baroreceptor effectiveness (P = 0.03; r(2) = 0.2) and diastolic blood pressure variability (P = 0.003; r(2) = 0.4).","[{'A': 'O'}, {'shift': 'O'}, {'in': 'O'}, {'sympathetic-vagal': 'O'}, {'balance': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'overall': 'O'}, {'symptom': 'O'}, {'burden': 'O'}, {'(ESSPRI)': 'O'}, {'(P': 'O'}, {'=': 'O'}, {'0.04,': 'O'}, {'r(2)': 'O'}, {'=': 'O'}, {'0.3)': 'O'}, {'and': 'O'}, {'EULAR': 'O'}, {'sicca': 'I-Entity'}, {'score': 'O'}, {'(P': 'O'}, {'=': 'O'}, {'0.016;': 'O'}, {'r(2)': 'O'}, {'=': 'O'}, {'0.3),': 'O'}]"
"In this observational study, we initially explored anti-EBV antibodies and cell-free DNA in 395 samples from a cross-sectional plasma collection of pSS patients included in ASSESS French national cohort.","[{'In': 'O'}, {'this': 'O'}, {'observational': 'O'}, {'study,': 'O'}, {'we': 'O'}, {'initially': 'O'}, {'explored': 'O'}, {'anti-EBV': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'cell-free': 'O'}, {'DNA': 'O'}, {'in': 'O'}, {'395': 'O'}, {'samples': 'O'}, {'from': 'O'}, {'a': 'O'}, {'cross-sectional': 'O'}, {'plasma': 'O'}, {'collection': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'included': 'O'}, {'in': 'O'}, {'ASSESS': 'O'}, {'French': 'O'}, {'national': 'O'}, {'cohort.': 'O'}]"
"When short-term treatment response was defined as an improvement in World Health Organization functional class at 3 months, 16 patients (53%) were short-term responders.","[{'When': 'O'}, {'short-term': 'O'}, {'treatment': 'O'}, {'response': 'O'}, {'was': 'O'}, {'defined': 'O'}, {'as': 'O'}, {'an': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'World': 'O'}, {'Health': 'O'}, {'Organization': 'O'}, {'functional': 'O'}, {'class': 'O'}, {'at': 'O'}, {'3': 'O'}, {'months,': 'O'}, {'16': 'O'}, {'patients': 'O'}, {'(53%)': 'O'}, {'were': 'O'}, {'short-term': 'O'}, {'responders.': 'O'}]"
"One year after treatment, she continued to have mild gastrointestinal symptoms, but overall condition was stable without further intervention.permissions.","[{'One': 'O'}, {'year': 'O'}, {'after': 'O'}, {'treatment,': 'O'}, {'she': 'O'}, {'continued': 'O'}, {'to': 'O'}, {'have': 'O'}, {'mild': 'O'}, {'gastrointestinal': 'B-Entity'}, {'symptoms,': 'I-Entity'}, {'but': 'O'}, {'overall': 'O'}, {'condition': 'O'}, {'was': 'O'}, {'stable': 'O'}, {'without': 'O'}, {'further': 'O'}, {'intervention.permissions.': 'O'}]"
Whether this reflects a biological effect of cigarette smoking or other mechanisms should be further investigated in future studies.Sweden.,"[{'Whether': 'O'}, {'this': 'O'}, {'reflects': 'O'}, {'a': 'O'}, {'biological': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'cigarette': 'O'}, {'smoking': 'I-Entity'}, {'or': 'O'}, {'other': 'O'}, {'mechanisms': 'O'}, {'should': 'O'}, {'be': 'O'}, {'further': 'O'}, {'investigated': 'O'}, {'in': 'O'}, {'future': 'O'}, {'studies.Sweden.': 'O'}]"
"In children presenting with unknown acute febrile encephalopathy, Sjogren syndrome should be included in the differential diagnosis, especially when sicca symptoms are present.All rights reserved.Electronic address: toshiki.take@keio.jp.23.","[{'In': 'O'}, {'children': 'O'}, {'presenting': 'O'}, {'with': 'O'}, {'unknown': 'O'}, {'acute': 'O'}, {'febrile': 'B-Entity'}, {'encephalopathy,': 'I-Entity'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'included': 'O'}, {'in': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnosis,': 'O'}, {'especially': 'O'}, {'when': 'O'}, {'sicca': 'B-Entity'}, {'symptoms': 'O'}, {'are': 'O'}, {'present.All': 'O'}, {'rights': 'O'}, {'reserved.Electronic': 'O'}, {'address:': 'O'}, {'toshiki.take@keio.jp.23.': 'O'}]"
"Treatment of salivary glands from healthy individuals with LT ‚âà√≠¬¨¬±, a cytokine linked to disease progression in SS and IL14‚âà√≠¬¨¬± mice, reduced Ca(2+) signaling.","[{'Treatment': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'from': 'O'}, {'healthy': 'O'}, {'individuals': 'O'}, {'with': 'O'}, {'LT': 'O'}, {'‚âà√≠¬¨¬±,': 'O'}, {'a': 'O'}, {'cytokine': 'O'}, {'linked': 'O'}, {'to': 'O'}, {'disease': 'O'}, {'progression': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'IL14‚âà√≠¬¨¬±': 'O'}, {'mice,': 'O'}, {'reduced': 'O'}, {'Ca(2+)': 'I-Entity'}, {'signaling.': 'O'}]"
The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown.,"[{'The': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CTD)': 'O'}, {'induced': 'O'}, {'by': 'O'}, {'immune': 'O'}, {'checkpoint': 'O'}, {'inhibitors': 'O'}, {'(CPIs)': 'O'}, {'in': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'pre-existing': 'O'}, {'autoimmunity': 'I-Entity'}, {'is': 'O'}, {'unknown.': 'O'}]"
"Severe hypokalemia (1.8 mEq/L), accompanied by normal anion gap metabolic acidosis, a positive urine anion gap and an inappropriately high urine pH pointed toward the diagnosis of dRTA.","[{'Severe': 'O'}, {'hypokalemia': 'I-Entity'}, {'(1.8': 'O'}, {'mEq/L),': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'normal': 'O'}, {'anion': 'O'}, {'gap': 'O'}, {'metabolic': 'O'}, {'acidosis,': 'I-Entity'}, {'a': 'O'}, {'positive': 'O'}, {'urine': 'O'}, {'anion': 'O'}, {'gap': 'O'}, {'and': 'O'}, {'an': 'O'}, {'inappropriately': 'O'}, {'high': 'O'}, {'urine': 'O'}, {'pH': 'O'}, {'pointed': 'O'}, {'toward': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'dRTA.': 'I-Entity'}]"
"Psychometric properties of clinESSDAI, disease activity levels and minimal clinically important improvement thresholds and its ability to detect change over time in clinical trials were very close to that of ESSDAI.","[{'Psychometric': 'O'}, {'properties': 'O'}, {'of': 'O'}, {'clinESSDAI,': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'minimal': 'O'}, {'clinically': 'O'}, {'important': 'O'}, {'improvement': 'O'}, {'thresholds': 'O'}, {'and': 'O'}, {'its': 'O'}, {'ability': 'O'}, {'to': 'O'}, {'detect': 'O'}, {'change': 'O'}, {'over': 'O'}, {'time': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'trials': 'O'}, {'were': 'O'}, {'very': 'O'}, {'close': 'O'}, {'to': 'O'}, {'that': 'O'}, {'of': 'O'}, {'ESSDAI.': 'O'}]"
"Interstitial lung diseases (ILDs) are among the most serious complications associated with systemic rheumatic diseases, and lead to significant morbidity and mortality; they may also be the first manifestation of connective tissue diseases (CTDs).","[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(ILDs)': 'O'}, {'are': 'O'}, {'among': 'O'}, {'the': 'O'}, {'most': 'O'}, {'serious': 'O'}, {'complications': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases,': 'I-Entity'}, {'and': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'significant': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality;': 'O'}, {'they': 'O'}, {'may': 'O'}, {'also': 'O'}, {'be': 'O'}, {'the': 'O'}, {'first': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(CTDs).': 'O'}]"
Uveitis is an uncommon finding associated with Sjogren syndrome.Epub 2011 May 31.syndrome patients.,"[{'Uveitis': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'uncommon': 'O'}, {'finding': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.Epub': 'I-Entity'}, {'2011': 'O'}, {'May': 'O'}, {'31.syndrome': 'O'}, {'patients.': 'O'}]"
Primary Sjogren syndrome is a chronic inflammatory autoimmune disease.,"[{'Primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease.': 'I-Entity'}]"
Primary Sjogrens syndrome is a chronic inflammatory autoimmune disease.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"She had tenderness in both her hand and finger joints, recurrent episodes of tonsillitis and pustular eruption.","[{'She': 'O'}, {'had': 'O'}, {'tenderness': 'B-Entity'}, {'in': 'O'}, {'both': 'O'}, {'her': 'O'}, {'hand': 'O'}, {'and': 'O'}, {'finger': 'O'}, {'joints,': 'O'}, {'recurrent': 'O'}, {'episodes': 'O'}, {'of': 'O'}, {'tonsillitis': 'I-Entity'}, {'and': 'O'}, {'pustular': 'B-Entity'}, {'eruption.': 'I-Entity'}]"
Median age was 68 years (73% women).,"[{'Median': 'O'}, {'age': 'O'}, {'was': 'O'}, {'68': 'O'}, {'years': 'O'}, {'(73%': 'O'}, {'women).': 'O'}]"
"Periventricular SH seem to be associated to increased platelet serotonin release in pSS patients with FETH and correlated with disease duration, without correlation to the actual ESSDAI and markers of immunoinflammation, and might be linked with chronic immunoinflammation of low-grade intensity and vasculitis in pSS.helenasarac@hi.t-com.hrTreated With Tacrolimus and Abatacept as an Alternative to Rituximab.","[{'Periventricular': 'O'}, {'SH': 'O'}, {'seem': 'O'}, {'to': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'to': 'O'}, {'increased': 'O'}, {'platelet': 'O'}, {'serotonin': 'I-Entity'}, {'release': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'FETH': 'I-Entity'}, {'and': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'duration,': 'O'}, {'without': 'O'}, {'correlation': 'O'}, {'to': 'O'}, {'the': 'O'}, {'actual': 'O'}, {'ESSDAI': 'O'}, {'and': 'O'}, {'markers': 'O'}, {'of': 'O'}, {'immunoinflammation,': 'O'}, {'and': 'O'}, {'might': 'O'}, {'be': 'O'}, {'linked': 'O'}, {'with': 'O'}, {'chronic': 'O'}, {'immunoinflammation': 'I-Entity'}]"
Neovascularization can be treated by intravitreal bevacizumab and progression of retinal ischemic areas by retinal laser photocoagulation.,"[{'Neovascularization': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'treated': 'O'}, {'by': 'O'}, {'intravitreal': 'O'}, {'bevacizumab': 'I-Entity'}, {'and': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'retinal': 'B-Entity'}, {'ischemic': 'I-Entity'}, {'areas': 'O'}, {'by': 'O'}, {'retinal': 'O'}, {'laser': 'O'}, {'photocoagulation.': 'O'}]"
The management of these manifestations may require treatment for dryness and/or inflammation of the airways.,"[{'The': 'O'}, {'management': 'O'}, {'of': 'O'}, {'these': 'O'}, {'manifestations': 'O'}, {'may': 'O'}, {'require': 'O'}, {'treatment': 'O'}, {'for': 'O'}, {'dryness': 'I-Entity'}, {'and/or': 'O'}, {'inflammation': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'airways.': 'I-Entity'}]"
"This study suggests that pSS, conversely to SLE, is more frequently associated with hand OA.Department of Radiology, Dokuz Eylul University School of Medicine, Izmir, Turkey.A.","[{'This': 'O'}, {'study': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'pSS,': 'O'}, {'conversely': 'O'}, {'to': 'O'}, {'SLE,': 'I-Entity'}, {'is': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'hand': 'B-Entity'}, {'OA.Department': 'I-Entity'}, {'of': 'O'}, {'Radiology,': 'O'}, {'Dokuz': 'O'}, {'Eylul': 'O'}, {'University': 'O'}, {'School': 'O'}, {'of': 'O'}, {'Medicine,': 'O'}, {'Izmir,': 'O'}, {'Turkey.A.': 'O'}]"
"Furthermore, our results showed that the three alternatively spliced isoforms lacked translational response to type I IFN stimulation.","[{'Furthermore,': 'O'}, {'our': 'O'}, {'results': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'the': 'O'}, {'three': 'O'}, {'alternatively': 'O'}, {'spliced': 'O'}, {'isoforms': 'O'}, {'lacked': 'O'}, {'translational': 'O'}, {'response': 'O'}, {'to': 'O'}, {'type': 'O'}, {'I': 'O'}, {'IFN': 'O'}, {'stimulation.': 'O'}]"
"Early diagnosis, facilitated by scrutiny of MRI findings, should trigger measures to reconstitute immunity in an otherwise fatal disease.Brain and Mind Centre, University of Sydney, NSW, Australia.","[{'Early': 'O'}, {'diagnosis,': 'O'}, {'facilitated': 'O'}, {'by': 'O'}, {'scrutiny': 'O'}, {'of': 'O'}, {'MRI': 'O'}, {'findings,': 'O'}, {'should': 'O'}, {'trigger': 'O'}, {'measures': 'O'}, {'to': 'O'}, {'reconstitute': 'O'}, {'immunity': 'O'}, {'in': 'O'}, {'an': 'O'}, {'otherwise': 'O'}, {'fatal': 'O'}, {'disease.Brain': 'O'}, {'and': 'O'}, {'Mind': 'O'}, {'Centre,': 'O'}, {'University': 'O'}, {'of': 'O'}, {'Sydney,': 'O'}, {'NSW,': 'O'}, {'Australia.': 'O'}]"
"According to the global evaluation by the practitioner, 9 (47%) of the 19 patients were improved, 6 patients (31%) were stable, and 4 patients (21%) worsened.","[{'According': 'O'}, {'to': 'O'}, {'the': 'O'}, {'global': 'O'}, {'evaluation': 'O'}, {'by': 'O'}, {'the': 'O'}, {'practitioner,': 'O'}, {'9': 'O'}, {'(47%)': 'O'}, {'of': 'O'}, {'the': 'O'}, {'19': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'improved,': 'O'}, {'6': 'O'}, {'patients': 'O'}, {'(31%)': 'O'}, {'were': 'O'}, {'stable,': 'O'}, {'and': 'O'}, {'4': 'O'}, {'patients': 'O'}, {'(21%)': 'O'}, {'worsened.': 'O'}]"
"To initially validate the MS results, western blotting was performed.","[{'To': 'O'}, {'initially': 'O'}, {'validate': 'O'}, {'the': 'O'}, {'MS': 'O'}, {'results,': 'O'}, {'western': 'O'}, {'blotting': 'O'}, {'was': 'O'}, {'performed.': 'O'}]"
"Next, treating HSG cells with 5-Aza was effective in inducing SSB expression.","[{'Next,': 'O'}, {'treating': 'O'}, {'HSG': 'O'}, {'cells': 'O'}, {'with': 'O'}, {'5-Aza': 'I-Entity'}, {'was': 'O'}, {'effective': 'O'}, {'in': 'O'}, {'inducing': 'O'}, {'SSB': 'O'}, {'expression.': 'O'}]"
Recurrent parotitis is a rare manifestation of Sjogren syndrome.,"[{'Recurrent': 'O'}, {'parotitis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Baseline sicca symptoms correlated with higher fatigue both at baseline and with increasing fatigue over time.,"[{'Baseline': 'O'}, {'sicca': 'I-Entity'}, {'symptoms': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'higher': 'O'}, {'fatigue': 'I-Entity'}, {'both': 'O'}, {'at': 'O'}, {'baseline': 'O'}, {'and': 'O'}, {'with': 'O'}, {'increasing': 'O'}, {'fatigue': 'I-Entity'}, {'over': 'O'}, {'time.': 'O'}]"
"In addition, immunosuppressive treatment with steroids and, in some cases, cyclophosphamide showed improvement.","[{'In': 'O'}, {'addition,': 'O'}, {'immunosuppressive': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'steroids': 'I-Entity'}, {'and,': 'O'}, {'in': 'O'}, {'some': 'O'}, {'cases,': 'O'}, {'cyclophosphamide': 'I-Entity'}, {'showed': 'O'}, {'improvement.': 'O'}]"
"Since it is well known that IgG4 is induced by Th2 cytokines such as interleukin (IL)-4 and IL-13, IgG4-DS is speculated to be a unique inflammatory disorder characterized by Th2 immune reactions.","[{'Since': 'O'}, {'it': 'O'}, {'is': 'O'}, {'well': 'O'}, {'known': 'O'}, {'that': 'O'}, {'IgG4': 'O'}, {'is': 'O'}, {'induced': 'O'}, {'by': 'O'}, {'Th2': 'O'}, {'cytokines': 'O'}, {'such': 'O'}, {'as': 'O'}, {'interleukin': 'O'}, {'(IL)-4': 'O'}, {'and': 'O'}, {'IL-13,': 'O'}, {'IgG4-DS': 'B-Entity'}, {'is': 'O'}, {'speculated': 'O'}, {'to': 'O'}, {'be': 'O'}, {'a': 'O'}, {'unique': 'O'}, {'inflammatory': 'B-Entity'}, {'disorder': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'Th2': 'O'}, {'immune': 'O'}, {'reactions.': 'O'}]"
"However, western blots demonstrated that all five subunits were significantly higher in the rabbits with IAD, although their distribution patterns were similar to those of the control rabbits, as demonstrated by immunofluorescence.","[{'However,': 'O'}, {'western': 'O'}, {'blots': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'all': 'O'}, {'five': 'O'}, {'subunits': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'the': 'O'}, {'rabbits': 'O'}, {'with': 'O'}, {'IAD,': 'I-Entity'}, {'although': 'O'}, {'their': 'O'}, {'distribution': 'O'}, {'patterns': 'O'}, {'were': 'O'}, {'similar': 'O'}, {'to': 'O'}, {'those': 'O'}, {'of': 'O'}, {'the': 'O'}, {'control': 'O'}, {'rabbits,': 'O'}, {'as': 'O'}, {'demonstrated': 'O'}, {'by': 'O'}, {'immunofluorescence.': 'O'}]"
"A higher prevalence of moderate inflammatory infiltrate was observed in biopsies from women with lichen sclerosus than in pSS and nS-SS patients (61.5% vs. 27.5%, P=0.02).","[{'A': 'O'}, {'higher': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'moderate': 'O'}, {'inflammatory': 'O'}, {'infiltrate': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'biopsies': 'O'}, {'from': 'O'}, {'women': 'O'}, {'with': 'O'}, {'lichen': 'B-Entity'}, {'sclerosus': 'I-Entity'}, {'than': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'and': 'O'}, {'nS-SS': 'O'}, {'patients': 'O'}, {'(61.5%': 'O'}, {'vs.': 'O'}, {'27.5%,': 'O'}, {'P=0.02).': 'O'}]"
These symptoms comprise a so-called sicca syndrome (xerostomia and xerophthalmia).,"[{'These': 'O'}, {'symptoms': 'O'}, {'comprise': 'O'}, {'a': 'O'}, {'so-called': 'O'}, {'sicca': 'B-Entity'}, {'syndrome': 'O'}, {'(xerostomia': 'O'}, {'and': 'O'}, {'xerophthalmia).': 'I-Entity'}]"
The patient in the study were the presence of characteristic subjective symptoms such as eye occurring for many years dry eyes and periodic feeling of sand in the eyes and dry mouth symptoms requiring frequent drinking of liquids to help swallow food.,"[{'The': 'O'}, {'patient': 'O'}, {'in': 'O'}, {'the': 'O'}, {'study': 'O'}, {'were': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'characteristic': 'O'}, {'subjective': 'O'}, {'symptoms': 'O'}, {'such': 'O'}, {'as': 'O'}, {'eye': 'O'}, {'occurring': 'O'}, {'for': 'O'}, {'many': 'O'}, {'years': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'periodic': 'O'}, {'feeling': 'O'}, {'of': 'O'}, {'sand': 'O'}, {'in': 'O'}, {'the': 'O'}, {'eyes': 'O'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'symptoms': 'O'}, {'requiring': 'O'}, {'frequent': 'O'}, {'drinking': 'O'}, {'of': 'O'}, {'liquids': 'O'}, {'to': 'O'}, {'help': 'O'}, {'swallow': 'O'}, {'food.': 'O'}]"
Cryptococci non-neoformans have been rarely associated to infections in humans.,"[{'Cryptococci': 'B-Entity'}, {'non-neoformans': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'rarely': 'O'}, {'associated': 'O'}, {'to': 'O'}, {'infections': 'I-Entity'}, {'in': 'O'}, {'humans.': 'O'}]"
"Further studies are needed to evaluate the utility of renal biopsy and its impact on disease management.rights reserved.Dialysis and Transplant Association - European Renal AssociationMar 27.non-Hodgkin's lymphoma in Sjogren's syndrome: a prospective, observational, single-centre study.","[{'Further': 'O'}, {'studies': 'O'}, {'are': 'O'}, {'needed': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'utility': 'O'}, {'of': 'O'}, {'renal': 'O'}, {'biopsy': 'O'}, {'and': 'O'}, {'its': 'O'}, {'impact': 'O'}, {'on': 'O'}, {'disease': 'O'}, {'management.rights': 'O'}, {'reserved.Dialysis': 'O'}, {'and': 'O'}, {'Transplant': 'O'}, {'Association': 'O'}, {'-': 'O'}, {'European': 'O'}, {'Renal': 'O'}, {'AssociationMar': 'O'}, {""27.non-Hodgkin's"": 'O'}, {'lymphoma': 'I-Entity'}, {'in': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome:': 'I-Entity'}, {'a': 'O'}, {'prospective,': 'O'}]"
"The pathogenesis of lesions in the peripheral nervous system associated with the autoimmune process is complex and it appears that two mechanisms, immunological and ischemic, are of greatest importance.","[{'The': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'lesions': 'O'}, {'in': 'I-Entity'}, {'the': 'I-Entity'}, {'peripheral': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'autoimmune': 'I-Entity'}, {'process': 'O'}, {'is': 'O'}, {'complex': 'O'}, {'and': 'O'}, {'it': 'O'}, {'appears': 'O'}, {'that': 'O'}, {'two': 'O'}, {'mechanisms,': 'O'}, {'immunological': 'O'}, {'and': 'O'}, {'ischemic,': 'O'}, {'are': 'O'}, {'of': 'O'}, {'greatest': 'O'}, {'importance.': 'O'}]"
"The sSS is often identified based on the symptoms of dryness in the presence of other connective tissue disease, making the diagnosis of sSS very subjective.","[{'The': 'O'}, {'sSS': 'O'}, {'is': 'O'}, {'often': 'O'}, {'identified': 'O'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'dryness': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'other': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease,': 'I-Entity'}, {'making': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'sSS': 'O'}, {'very': 'O'}, {'subjective.': 'O'}]"
"A more severe clinical course and a higher incidence of erosion, tenosynovitis, and deformities were detected in patients with anti-CCP antibody and positive RF (p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.03, p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.04, p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.01, p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.04, respectively).","[{'A': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'clinical': 'O'}, {'course': 'O'}, {'and': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'erosion,': 'I-Entity'}, {'tenosynovitis,': 'I-Entity'}, {'and': 'O'}, {'deformities': 'I-Entity'}, {'were': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'anti-CCP': 'O'}, {'antibody': 'O'}, {'and': 'O'}, {'positive': 'O'}, {'RF': 'O'}, {'(p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.03,': 'O'}]"
Primary Sjogrens syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltrates associated with destruction of salivary gland epithelial cells (SGECs) induced mainly by apoptosis.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'infiltrates': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'epithelial': 'O'}, {'cells': 'O'}, {'(SGECs)': 'O'}, {'induced': 'O'}, {'mainly': 'O'}, {'by': 'O'}, {'apoptosis.': 'O'}]"
Neonatal thrombocytopenia is a common clinical problem and may be a result of maternal and/or fetal conditions.,"[{'Neonatal': 'O'}, {'thrombocytopenia': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'clinical': 'O'}, {'problem': 'O'}, {'and': 'O'}, {'may': 'O'}, {'be': 'O'}, {'a': 'O'}, {'result': 'O'}, {'of': 'O'}, {'maternal': 'O'}, {'and/or': 'O'}, {'fetal': 'O'}, {'conditions.': 'O'}]"
"As a control, 54 patients without SS who were negative for antinuclear antibodies were also evaluated.","[{'As': 'O'}, {'a': 'O'}, {'control,': 'O'}, {'54': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'SS': 'I-Entity'}, {'who': 'O'}, {'were': 'O'}, {'negative': 'O'}, {'for': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'also': 'O'}, {'evaluated.': 'O'}]"
Other extra-glandular organs can also be affected and PSS is associated with a markedly increased risk of lymphoma.,"[{'Other': 'O'}, {'extra-glandular': 'O'}, {'organs': 'O'}, {'can': 'O'}, {'also': 'O'}, {'be': 'O'}, {'affected': 'O'}, {'and': 'O'}, {'PSS': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'markedly': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'lymphoma.': 'I-Entity'}]"
"In 60-70% of the cases, the congenital heart block results from destruction of the conduction system of the fetal heart by anti-Ro/SSA and anti-La/SSB antibodies present in maternal serum.","[{'In': 'O'}, {'60-70%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cases,': 'O'}, {'the': 'O'}, {'congenital': 'B-Entity'}, {'heart': 'I-Entity'}, {'block': 'I-Entity'}, {'results': 'O'}, {'from': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'the': 'O'}, {'conduction': 'O'}, {'system': 'O'}, {'of': 'O'}, {'the': 'O'}, {'fetal': 'O'}, {'heart': 'O'}, {'by': 'O'}, {'anti-Ro/SSA': 'O'}, {'and': 'O'}, {'anti-La/SSB': 'O'}, {'antibodies': 'O'}, {'present': 'O'}, {'in': 'O'}, {'maternal': 'O'}, {'serum.': 'O'}]"
We report a case of porphyria cutanea tarda associated with primary sjogren's syndrome.abatacept therapy in patients with Sjogrens syndrome associated with rheumatoid arthritis: Utility to evaluate and predict response to treatment.,"[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'porphyria': 'B-Entity'}, {'cutanea': 'I-Entity'}, {'tarda': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {""sjogren's"": 'I-Entity'}, {'syndrome.abatacept': 'I-Entity'}, {'therapy': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis:': 'I-Entity'}, {'Utility': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'and': 'O'}, {'predict': 'O'}, {'response': 'O'}, {'to': 'O'}, {'treatment.': 'O'}]"
"Our results demonstrate that nanomaterials based on plant viruses can be used as diagnostic reagents for SjS, and could also be developed for the diagnosis of other diseases.","[{'Our': 'O'}, {'results': 'O'}, {'demonstrate': 'O'}, {'that': 'O'}, {'nanomaterials': 'O'}, {'based': 'O'}, {'on': 'O'}, {'plant': 'O'}, {'viruses': 'O'}, {'can': 'O'}, {'be': 'O'}, {'used': 'O'}, {'as': 'O'}, {'diagnostic': 'O'}, {'reagents': 'O'}, {'for': 'O'}, {'SjS,': 'I-Entity'}, {'and': 'O'}, {'could': 'O'}, {'also': 'O'}, {'be': 'O'}, {'developed': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'other': 'O'}, {'diseases.': 'O'}]"
No correlation with disease activity was observed in either group of patients.,"[{'No': 'O'}, {'correlation': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'either': 'O'}, {'group': 'O'}, {'of': 'O'}, {'patients.': 'O'}]"
"In patients with myelitis/transverse myelopathy associated with autoimmune disorders such as Sjogren syndrome, examining the titer values of anti-AQP4 antibody is indispensable in determining the appropriate therapy.Specific Peripheral Leucocyte Populations.","[{'In': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'myelitis/transverse': 'I-Entity'}, {'myelopathy': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'examining': 'O'}, {'the': 'O'}, {'titer': 'O'}, {'values': 'O'}, {'of': 'O'}, {'anti-AQP4': 'O'}, {'antibody': 'O'}, {'is': 'O'}, {'indispensable': 'O'}, {'in': 'O'}, {'determining': 'O'}, {'the': 'O'}, {'appropriate': 'O'}, {'therapy.Specific': 'O'}, {'Peripheral': 'O'}, {'Leucocyte': 'O'}, {'Populations.': 'O'}]"
"FDG-PET/CT revealed a tendency for abnormal (18)F-FDG accumulation and swelling of both the parotid and submandibular glands in patients with IgG4-DS, particularly in the submandibular glands.","[{'FDG-PET/CT': 'I-Entity'}, {'revealed': 'O'}, {'a': 'O'}, {'tendency': 'O'}, {'for': 'O'}, {'abnormal': 'O'}, {'(18)F-FDG': 'O'}, {'accumulation': 'O'}, {'and': 'O'}, {'swelling': 'O'}, {'of': 'O'}, {'both': 'O'}, {'the': 'O'}, {'parotid': 'O'}, {'and': 'O'}, {'submandibular': 'O'}, {'glands': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'IgG4-DS,': 'O'}, {'particularly': 'O'}, {'in': 'O'}, {'the': 'O'}, {'submandibular': 'O'}, {'glands.': 'O'}]"
"It is known that some benign inflammatory diseases show an increased uptake of (18)F-fluorodeoxyglucose, particularly granulomatous lesions like tuberculosis.","[{'It': 'O'}, {'is': 'O'}, {'known': 'O'}, {'that': 'O'}, {'some': 'O'}, {'benign': 'O'}, {'inflammatory': 'B-Entity'}, {'diseases': 'I-Entity'}, {'show': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'uptake': 'O'}, {'of': 'O'}, {'(18)F-fluorodeoxyglucose,': 'O'}, {'particularly': 'O'}, {'granulomatous': 'B-Entity'}, {'lesions': 'O'}, {'like': 'O'}, {'tuberculosis.': 'I-Entity'}]"
"To compare quality of life (QoL), depression, anxiety, and fatigue in prospectively included patients with primary Sjogrens syndrome (pSS) or with sicca but no diagnosis of Sjogrens syndrome.","[{'To': 'O'}, {'compare': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'(QoL),': 'O'}, {'depression,': 'I-Entity'}, {'anxiety,': 'I-Entity'}, {'and': 'O'}, {'fatigue': 'I-Entity'}, {'in': 'O'}, {'prospectively': 'O'}, {'included': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'or': 'O'}, {'with': 'O'}, {'sicca': 'I-Entity'}, {'but': 'O'}, {'no': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Patients with Sjogrens syndrome without immunomodulatory treatment and age-matched and gender-matched healthy controls were immunised with an H1N1 influenza vaccine and monitored for serological and cellular immune responses.,"[{'Patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'without': 'O'}, {'immunomodulatory': 'O'}, {'treatment': 'O'}, {'and': 'O'}, {'age-matched': 'O'}, {'and': 'O'}, {'gender-matched': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'immunised': 'O'}, {'with': 'O'}, {'an': 'O'}, {'H1N1': 'O'}, {'influenza': 'I-Entity'}, {'vaccine': 'O'}, {'and': 'O'}, {'monitored': 'O'}, {'for': 'O'}, {'serological': 'O'}, {'and': 'O'}, {'cellular': 'O'}, {'immune': 'O'}, {'responses.': 'O'}]"
Increased Tfh2 levels were strongly associated with increased serum IgG4 levels and the IgG4:IgG ratio in IgG4-related disease.,"[{'Increased': 'O'}, {'Tfh2': 'O'}, {'levels': 'O'}, {'were': 'O'}, {'strongly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'serum': 'O'}, {'IgG4': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'the': 'O'}, {'IgG4:IgG': 'O'}, {'ratio': 'O'}, {'in': 'O'}, {'IgG4-related': 'O'}, {'disease.': 'I-Entity'}]"
"Targeted therapies may emerge as the molecular pathways of PBC-associated symptoms are unraveled.of Medicine, SacramentobDivision of Gastroenterology and Hepatology, University of California San Diego School of Medicine, San Diego, California, USA.lacrimal gland: A case report.","[{'Targeted': 'O'}, {'therapies': 'O'}, {'may': 'O'}, {'emerge': 'O'}, {'as': 'O'}, {'the': 'O'}, {'molecular': 'O'}, {'pathways': 'O'}, {'of': 'O'}, {'PBC-associated': 'I-Entity'}, {'symptoms': 'O'}, {'are': 'O'}, {'unraveled.of': 'O'}, {'Medicine,': 'O'}, {'SacramentobDivision': 'O'}, {'of': 'O'}, {'Gastroenterology': 'O'}, {'and': 'O'}, {'Hepatology,': 'O'}, {'University': 'O'}, {'of': 'O'}, {'California': 'O'}, {'San': 'O'}, {'Diego': 'O'}, {'School': 'O'}, {'of': 'O'}, {'Medicine,': 'O'}, {'San': 'O'}, {'Diego,': 'O'}, {'California,': 'O'}, {'USA.lacrimal': 'O'}, {'gland:': 'O'}, {'A': 'O'}]"
"Finally, whole saliva and EVs isolated from whole saliva of pSS patients expressed proteins vital for innate MHC class I cellular regulation (NGAL) and T cell activation (CD44).","[{'Finally,': 'O'}, {'whole': 'O'}, {'saliva': 'O'}, {'and': 'O'}, {'EVs': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {'whole': 'O'}, {'saliva': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'expressed': 'O'}, {'proteins': 'O'}, {'vital': 'O'}, {'for': 'O'}, {'innate': 'O'}, {'MHC': 'O'}, {'class': 'O'}, {'I': 'O'}, {'cellular': 'O'}, {'regulation': 'O'}, {'(NGAL)': 'O'}, {'and': 'O'}, {'T': 'O'}, {'cell': 'O'}, {'activation': 'O'}, {'(CD44).': 'O'}]"
"Differential diagnosis of IgG4-DS is necessary from other disorders, including Sjogrens syndrome, sarcoidosis, Castleman's disease, Wegener's granulomatosis, lymphoma, and cancer.","[{'Differential': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'IgG4-DS': 'B-Entity'}, {'is': 'O'}, {'necessary': 'O'}, {'from': 'O'}, {'other': 'O'}, {'disorders,': 'O'}, {'including': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'sarcoidosis,': 'I-Entity'}, {""Castleman's"": 'B-Entity'}, {'disease,': 'I-Entity'}, {""Wegener's"": 'B-Entity'}, {'granulomatosis,': 'I-Entity'}, {'lymphoma,': 'I-Entity'}, {'and': 'O'}, {'cancer.': 'I-Entity'}]"
To evaluate the effect of lid debridement-scaling (LDS) on dry eye signs and symptoms in subjects with Sjogren syndrome (SS).,"[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'lid': 'O'}, {'debridement-scaling': 'O'}, {'(LDS)': 'O'}, {'on': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'signs': 'O'}, {'and': 'O'}, {'symptoms': 'O'}, {'in': 'O'}, {'subjects': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"Serum anti-21(OH) antibodies and soluble BAFF levels were determined by a radioimmunoassay and an enzyme-linked immunosorbent assay, respectively.","[{'Serum': 'O'}, {'anti-21(OH)': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'soluble': 'O'}, {'BAFF': 'O'}, {'levels': 'O'}, {'were': 'O'}, {'determined': 'O'}, {'by': 'O'}, {'a': 'O'}, {'radioimmunoassay': 'O'}, {'and': 'O'}, {'an': 'O'}, {'enzyme-linked': 'O'}, {'immunosorbent': 'O'}, {'assay,': 'O'}, {'respectively.': 'O'}]"
CGEV is a prognostically adverse sign in HCV infected patients and caused death of 14% patients even in a short period of follow-up (1-2 years).,"[{'CGEV': 'O'}, {'is': 'O'}, {'a': 'O'}, {'prognostically': 'O'}, {'adverse': 'O'}, {'sign': 'O'}, {'in': 'O'}, {'HCV': 'B-Entity'}, {'infected': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'caused': 'O'}, {'death': 'I-Entity'}, {'of': 'O'}, {'14%': 'O'}, {'patients': 'O'}, {'even': 'O'}, {'in': 'O'}, {'a': 'O'}, {'short': 'O'}, {'period': 'O'}, {'of': 'O'}, {'follow-up': 'O'}, {'(1-2': 'O'}, {'years).': 'O'}]"
It is based on the current evidence of efficacy of different therapies and explores their link with the pathogenesis of ocular dryness associated with SS.,"[{'It': 'O'}, {'is': 'O'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'current': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'different': 'O'}, {'therapies': 'O'}, {'and': 'O'}, {'explores': 'O'}, {'their': 'O'}, {'link': 'O'}, {'with': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'dryness': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'SS.': 'I-Entity'}]"
He had newly diagnosed diabetes mellitus with hyperlipasaemia and diffuse pancreatic swelling supportive of autoimmune pancreatitis.,"[{'He': 'O'}, {'had': 'O'}, {'newly': 'O'}, {'diagnosed': 'O'}, {'diabetes': 'B-Entity'}, {'mellitus': 'I-Entity'}, {'with': 'O'}, {'hyperlipasaemia': 'I-Entity'}, {'and': 'O'}, {'diffuse': 'O'}, {'pancreatic': 'B-Entity'}, {'swelling': 'I-Entity'}, {'supportive': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'pancreatitis.': 'I-Entity'}]"
The increased frequency of autoantibodies in RA cases and non-RA controls was associated with the number of autoimmune risk alleles carried by an individual.,"[{'The': 'O'}, {'increased': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'autoantibodies': 'O'}, {'in': 'O'}, {'RA': 'I-Entity'}, {'cases': 'O'}, {'and': 'O'}, {'non-RA': 'O'}, {'controls': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'number': 'O'}, {'of': 'O'}, {'autoimmune': 'I-Entity'}, {'risk': 'O'}, {'alleles': 'O'}, {'carried': 'O'}, {'by': 'O'}, {'an': 'O'}, {'individual.': 'O'}]"
"Conversely, systemic activity level was not associated with HRQOL impairment in multivariate analyses, even in the patient subset with ESSDAI values indicating moderate-to-high systemic activity.","[{'Conversely,': 'O'}, {'systemic': 'O'}, {'activity': 'O'}, {'level': 'O'}, {'was': 'O'}, {'not': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'HRQOL': 'O'}, {'impairment': 'I-Entity'}, {'in': 'O'}, {'multivariate': 'O'}, {'analyses,': 'O'}, {'even': 'O'}, {'in': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'subset': 'O'}, {'with': 'O'}, {'ESSDAI': 'O'}, {'values': 'O'}, {'indicating': 'O'}, {'moderate-to-high': 'O'}, {'systemic': 'O'}, {'activity.': 'O'}]"
Gougerot-Sjogren syndrome (GSS) is an autoimmune disease characterized by a lymphocytic infiltration and destruction of saliva and lachrymal glands.,"[{'Gougerot-Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(GSS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'a': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'saliva': 'O'}, {'and': 'O'}, {'lachrymal': 'O'}, {'glands.': 'O'}]"
"The goal of the present study was to investigate the autonomic dysfunction in patients with SS and the associations between autonomic dysfunction, anti-gAChR antibodies, and clinical features of SS.","[{'The': 'O'}, {'goal': 'O'}, {'of': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'autonomic': 'O'}, {'dysfunction': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'associations': 'O'}, {'between': 'O'}, {'autonomic': 'B-Entity'}, {'dysfunction,': 'I-Entity'}, {'anti-gAChR': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'of': 'O'}, {'SS.': 'I-Entity'}]"
CVST could be caused by autoimmune diseases.,"[{'CVST': 'I-Entity'}, {'could': 'O'}, {'be': 'O'}, {'caused': 'O'}, {'by': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
AIRD-OP may be the most common cause of OP.,"[{'AIRD-OP': 'B-Entity'}, {'may': 'O'}, {'be': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'OP.': 'I-Entity'}]"
To present patient reported changes in oral symptoms in response to an open-label product trial conducted in patients self-identifying as having Sjogrens syndrome.,"[{'To': 'O'}, {'present': 'O'}, {'patient': 'O'}, {'reported': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'oral': 'O'}, {'symptoms': 'O'}, {'in': 'O'}, {'response': 'O'}, {'to': 'O'}, {'an': 'O'}, {'open-label': 'O'}, {'product': 'O'}, {'trial': 'O'}, {'conducted': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'self-identifying': 'O'}, {'as': 'O'}, {'having': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Sjogrens syndrome (SS) is a systemic autoimmune disease that mainly affects the exocrine glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'mainly': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands.': 'O'}]"
"Moreover, overexpression of proteins STOM, ANXA4 and ANXA1, regulating cellular innate and adaptive immunological pathways, were further identified in EVs from tear fluid of pSS patients.","[{'Moreover,': 'O'}, {'overexpression': 'O'}, {'of': 'O'}, {'proteins': 'O'}, {'STOM,': 'O'}, {'ANXA4': 'O'}, {'and': 'O'}, {'ANXA1,': 'O'}, {'regulating': 'O'}, {'cellular': 'O'}, {'innate': 'O'}, {'and': 'O'}, {'adaptive': 'O'}, {'immunological': 'O'}, {'pathways,': 'O'}, {'were': 'O'}, {'further': 'O'}, {'identified': 'O'}, {'in': 'O'}, {'EVs': 'O'}, {'from': 'O'}, {'tear': 'O'}, {'fluid': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"In this paper, we showed the characteristics and differences between peripheral neuropathy as a complication of MS and NMO.","[{'In': 'O'}, {'this': 'O'}, {'paper,': 'O'}, {'we': 'O'}, {'showed': 'O'}, {'the': 'O'}, {'characteristics': 'O'}, {'and': 'O'}, {'differences': 'O'}, {'between': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'MS': 'I-Entity'}, {'and': 'O'}, {'NMO.': 'I-Entity'}]"
"When the oral evaluations were performed, 98.0% of the patients complained dry mouth, 96.6% of them had decreased non-stimulated salivary flow rate, and 60.1% had positive parotid sialography results, which was consistent with diagnosis.","[{'When': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'evaluations': 'O'}, {'were': 'O'}, {'performed,': 'O'}, {'98.0%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'complained': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'96.6%': 'O'}, {'of': 'O'}, {'them': 'O'}, {'had': 'O'}, {'decreased': 'O'}, {'non-stimulated': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'rate,': 'O'}, {'and': 'O'}, {'60.1%': 'O'}, {'had': 'O'}, {'positive': 'O'}, {'parotid': 'O'}, {'sialography': 'O'}, {'results,': 'O'}, {'which': 'O'}, {'was': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'diagnosis.': 'O'}]"
"Indeed, numerous studies have demonstrated that the appearance of autoantibodies precedes the clinical onset of autoimmune diseases.","[{'Indeed,': 'O'}, {'numerous': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'the': 'O'}, {'appearance': 'O'}, {'of': 'O'}, {'autoantibodies': 'O'}, {'precedes': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Four out of five sIBM/SS patients treated with immune therapies had improvement in muscle strength lasting for 6-24 months, whereas only 27% of other sIBM patients improved.","[{'Four': 'O'}, {'out': 'O'}, {'of': 'O'}, {'five': 'O'}, {'sIBM/SS': 'I-Entity'}, {'patients': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'immune': 'O'}, {'therapies': 'O'}, {'had': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'muscle': 'O'}, {'strength': 'O'}, {'lasting': 'O'}, {'for': 'O'}, {'6-24': 'O'}, {'months,': 'O'}, {'whereas': 'O'}, {'only': 'O'}, {'27%': 'O'}, {'of': 'O'}, {'other': 'O'}, {'sIBM': 'I-Entity'}, {'patients': 'O'}, {'improved.': 'O'}]"
"Here, we report the case of a 50-year-old woman who had been diagnosed as suffering from rheumatoid arthritis (RA), four years ago with positive rheumatoid serology was evaluated for multiple asymptotic papulonodules eruption.","[{'Here,': 'O'}, {'we': 'O'}, {'report': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'50-year-old': 'O'}, {'woman': 'O'}, {'who': 'O'}, {'had': 'O'}, {'been': 'O'}, {'diagnosed': 'O'}, {'as': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA),': 'O'}, {'four': 'O'}, {'years': 'O'}, {'ago': 'O'}, {'with': 'O'}, {'positive': 'O'}, {'rheumatoid': 'B-Entity'}, {'serology': 'O'}, {'was': 'O'}, {'evaluated': 'O'}, {'for': 'O'}, {'multiple': 'O'}, {'asymptotic': 'O'}, {'papulonodules': 'B-Entity'}, {'eruption.': 'O'}]"
Lacrimal and/or salivary gland enlargement is a common symptom leading to referral for rheumatological evaluation.,"[{'Lacrimal': 'B-Entity'}, {'and/or': 'I-Entity'}, {'salivary': 'I-Entity'}, {'gland': 'I-Entity'}, {'enlargement': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'symptom': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'referral': 'O'}, {'for': 'O'}, {'rheumatological': 'O'}, {'evaluation.': 'O'}]"
"Lynch syndrome (LS) is an inherited colorectal cancer (CRC) syndrome accounting for about 3-5% of all cases and involves significantly higher risk of subsequent malignancies, colonic as well as extra-colonic.","[{'Lynch': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(LS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'inherited': 'O'}, {'colorectal': 'B-Entity'}, {'cancer': 'I-Entity'}, {'(CRC)': 'O'}, {'syndrome': 'O'}, {'accounting': 'O'}, {'for': 'O'}, {'about': 'O'}, {'3-5%': 'O'}, {'of': 'O'}, {'all': 'O'}, {'cases': 'O'}, {'and': 'O'}, {'involves': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'subsequent': 'O'}, {'malignancies,': 'I-Entity'}, {'colonic': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'extra-colonic.': 'O'}]"
"Anti-double-stranded DNA, anti-‚âà√≠‚Äö√¢¬ß(2) -glycoprotein I antibodies, positive Coombs' test results, autoimmune hemolytic anemia, hypocomplementemia, and leukopenia were more common in early SLE than in SLE-mimicking conditions.","[{'Anti-double-stranded': 'O'}, {'DNA,': 'I-Entity'}, {'anti-‚âà√≠‚Äö√¢¬ß(2)': 'O'}, {'-glycoprotein': 'O'}, {'I': 'O'}, {'antibodies,': 'O'}, {'positive': 'O'}, {""Coombs'"": 'O'}, {'test': 'O'}, {'results,': 'O'}, {'autoimmune': 'B-Entity'}, {'hemolytic': 'I-Entity'}, {'anemia,': 'I-Entity'}, {'hypocomplementemia,': 'I-Entity'}, {'and': 'O'}, {'leukopenia': 'B-Entity'}]"
"Antifibrotic drugs, which include nintedanib and pirfenidone, have been approved for the treatment of idiopathic pulmonary fibrosis (IPF) and due to similar pathogenesis between IPF and CTD-ILD, their use seems attractive in patients with CTD-IL.","[{'Antifibrotic': 'O'}, {'drugs,': 'O'}, {'which': 'O'}, {'include': 'O'}, {'nintedanib': 'I-Entity'}, {'and': 'O'}, {'pirfenidone,': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'approved': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'idiopathic': 'B-Entity'}, {'pulmonary': 'I-Entity'}, {'fibrosis': 'I-Entity'}, {'(IPF)': 'O'}, {'and': 'O'}, {'due': 'O'}, {'to': 'O'}, {'similar': 'O'}, {'pathogenesis': 'O'}, {'between': 'O'}, {'IPF': 'I-Entity'}, {'and': 'O'}, {'CTD-ILD,': 'B-Entity'}, {'their': 'O'}, {'use': 'O'}, {'seems': 'O'}, {'attractive': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'CTD-IL.': 'I-Entity'}]"
"This review article highlights the current role of SE and SWE modalities in diffuse and focal changes of the parotid gland.Technische Universit‚Äö√†√∂¬¨√üt M‚Äö√†√∂¬¨‚à´nchen, Munich, Germany.2017 Feb 24.syndrome dry eye.","[{'This': 'O'}, {'review': 'O'}, {'article': 'O'}, {'highlights': 'O'}, {'the': 'O'}, {'current': 'O'}, {'role': 'O'}, {'of': 'O'}, {'SE': 'O'}, {'and': 'O'}, {'SWE': 'O'}, {'modalities': 'O'}, {'in': 'O'}, {'diffuse': 'O'}, {'and': 'O'}, {'focal': 'O'}, {'changes': 'O'}, {'of': 'O'}, {'the': 'O'}, {'parotid': 'O'}, {'gland.Technische': 'O'}, {'Universit‚Äö√†√∂¬¨√üt': 'O'}, {'M‚Äö√†√∂¬¨‚à´nchen,': 'O'}]"
The more mucoadhesive artificial tears demonstrated a significantly greater effect.,"[{'The': 'O'}, {'more': 'O'}, {'mucoadhesive': 'O'}, {'artificial': 'O'}, {'tears': 'O'}, {'demonstrated': 'O'}, {'a': 'O'}, {'significantly': 'O'}, {'greater': 'O'}, {'effect.': 'O'}]"
"The CTDs that most commonly involve the respiratory system are progressive systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Sjogren syndrome, polymyositis, dermatomyositis, and mixed connective tissue disease.","[{'The': 'O'}, {'CTDs': 'I-Entity'}, {'that': 'O'}, {'most': 'O'}, {'commonly': 'O'}, {'involve': 'O'}, {'the': 'O'}, {'respiratory': 'O'}, {'system': 'O'}, {'are': 'O'}, {'progressive': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'Sjogren': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'polymyositis,': 'I-Entity'}, {'dermatomyositis,': 'I-Entity'}, {'and': 'O'}, {'mixed': 'B-Entity'}, {'connective': 'I-Entity'}, {'tissue': 'I-Entity'}, {'disease.': 'I-Entity'}]"
The actions of these drugs on T and B cells are less clear but may depend on these leucocyte-mediated actions.,"[{'The': 'O'}, {'actions': 'O'}, {'of': 'O'}, {'these': 'O'}, {'drugs': 'O'}, {'on': 'O'}, {'T': 'O'}, {'and': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'are': 'O'}, {'less': 'O'}, {'clear': 'O'}, {'but': 'O'}, {'may': 'O'}, {'depend': 'O'}, {'on': 'O'}, {'these': 'O'}, {'leucocyte-mediated': 'O'}, {'actions.': 'O'}]"
The clinical and therapeutic aspects of primary Sjogren syndrome (PSS) in patients with peripheral neuropathy were analyzed and the specifics of individual case studies are discussed.,"[{'The': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'therapeutic': 'O'}, {'aspects': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(PSS)': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'were': 'O'}, {'analyzed': 'O'}, {'and': 'O'}, {'the': 'O'}, {'specifics': 'O'}, {'of': 'O'}, {'individual': 'O'}, {'case': 'O'}, {'studies': 'O'}, {'are': 'O'}, {'discussed.': 'O'}]"
"Patients with severe systemic disease were more frequently men (p=0.001) and had a higher frequency of anaemia (p<0.001), lymphopenia (p<0.001), rheumatoid factor (p=0.021), low C3 levels (p=0.015), low C4 levels (p<0.001) and cryoglobulins (p<0.001).","[{'Patients': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'systemic': 'B-Entity'}, {'disease': 'I-Entity'}, {'were': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'men': 'O'}, {'(p=0.001)': 'O'}, {'and': 'O'}, {'had': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'anaemia': 'I-Entity'}, {'(p<0.001),': 'O'}, {'lymphopenia': 'I-Entity'}, {'(p<0.001),': 'O'}, {'rheumatoid': 'B-Entity'}, {'factor': 'I-Entity'}, {'(p=0.021),': 'O'}]"
"When not diagnosed and treated, Fabry disease causes early death.","[{'When': 'O'}, {'not': 'O'}, {'diagnosed': 'O'}, {'and': 'O'}, {'treated,': 'O'}, {'Fabry': 'B-Entity'}, {'disease': 'I-Entity'}, {'causes': 'O'}, {'early': 'O'}, {'death.': 'I-Entity'}]"
"Topics covered by the expert discussants included electrolyte and acid-base disorders, glomerular disease, ESRD/dialysis, and transplantation.","[{'Topics': 'O'}, {'covered': 'O'}, {'by': 'O'}, {'the': 'O'}, {'expert': 'O'}, {'discussants': 'O'}, {'included': 'O'}, {'electrolyte': 'O'}, {'and': 'O'}, {'acid-base': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'glomerular': 'B-Entity'}, {'disease,': 'I-Entity'}, {'ESRD/dialysis,': 'I-Entity'}, {'and': 'O'}, {'transplantation.': 'O'}]"
Epub 2011 May 20.Sjogrens syndrome-associated dry eye.,"[{'Epub': 'O'}, {'2011': 'O'}, {'May': 'O'}, {'20.Sjogrens': 'O'}, {'syndrome-associated': 'I-Entity'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"In addition, it demonstrates that corticosteroids can be an effective first line therapy in treating orbital inflammation in similar patients.","[{'In': 'O'}, {'addition,': 'O'}, {'it': 'O'}, {'demonstrates': 'O'}, {'that': 'O'}, {'corticosteroids': 'O'}, {'can': 'O'}, {'be': 'O'}, {'an': 'O'}, {'effective': 'O'}, {'first': 'O'}, {'line': 'O'}, {'therapy': 'O'}, {'in': 'O'}, {'treating': 'O'}, {'orbital': 'B-Entity'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'similar': 'O'}, {'patients.': 'O'}]"
TG treatment resulted in induction of HSG apoptosis.,"[{'TG': 'I-Entity'}, {'treatment': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'induction': 'O'}, {'of': 'O'}, {'HSG': 'O'}, {'apoptosis.': 'O'}]"
More than 90% of cases of cryoglobulinaemia have a known underlying cause; therefore treatment is focused on the cause of the disorder rather than merely symptomatic relief.,"[{'More': 'O'}, {'than': 'O'}, {'90%': 'O'}, {'of': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'cryoglobulinaemia': 'I-Entity'}, {'have': 'O'}, {'a': 'O'}, {'known': 'O'}, {'underlying': 'O'}, {'cause;': 'O'}, {'therefore': 'O'}, {'treatment': 'O'}, {'is': 'O'}, {'focused': 'O'}, {'on': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disorder': 'O'}, {'rather': 'O'}, {'than': 'O'}, {'merely': 'O'}, {'symptomatic': 'O'}, {'relief.': 'O'}]"
"Sjogrens syndrome (SS) is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration of the exocrine glands, especially the salivary and lacrimal glands.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'especially': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands.': 'O'}]"
"IgG4-related disease (IgG4-RD) is characterized by lympho-plasmacytic infiltration and fibrosis in multiple organs, accompanied by high serum IgG4 levels.","[{'IgG4-related': 'B-Entity'}, {'disease': 'I-Entity'}, {'(IgG4-RD)': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'lympho-plasmacytic': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'fibrosis': 'I-Entity'}, {'in': 'O'}, {'multiple': 'O'}, {'organs,': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'high': 'O'}, {'serum': 'O'}, {'IgG4': 'O'}, {'levels.': 'O'}]"
The derailed Th17/Treg balance may contribute to disease progression therefore could function as a prognostic marker.Published by Elsevier Inc. All rights reserved.Electronic address: szodoray@gmail.com.Aug 20.,"[{'The': 'O'}, {'derailed': 'O'}, {'Th17/Treg': 'O'}, {'balance': 'O'}, {'may': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'disease': 'O'}, {'progression': 'O'}, {'therefore': 'O'}, {'could': 'O'}, {'function': 'O'}, {'as': 'O'}, {'a': 'O'}, {'prognostic': 'O'}, {'marker.Published': 'O'}, {'by': 'O'}, {'Elsevier': 'O'}, {'Inc.': 'O'}, {'All': 'O'}, {'rights': 'O'}, {'reserved.Electronic': 'O'}, {'address:': 'O'}, {'szodoray@gmail.com.Aug': 'O'}, {'20.': 'O'}]"
"However, in both patients, chronic xerophthalmia had been considered to be idiopathic because antibodies Ro and La were negative.","[{'However,': 'O'}, {'in': 'O'}, {'both': 'O'}, {'patients,': 'O'}, {'chronic': 'O'}, {'xerophthalmia': 'I-Entity'}, {'had': 'O'}, {'been': 'O'}, {'considered': 'O'}, {'to': 'O'}, {'be': 'O'}, {'idiopathic': 'O'}, {'because': 'O'}, {'antibodies': 'O'}, {'Ro': 'I-Entity'}, {'and': 'O'}, {'La': 'I-Entity'}, {'were': 'O'}, {'negative.': 'O'}]"
"Specific disorders included: inflammatory arthritis (n = 18), Sjogren's syndrome (n = 11), SLE (n = 8), Raynaud's syndrome (n = 8), vasculitis (n = 9), MCTD (n = 3), and other (n = 5).","[{'Specific': 'O'}, {'disorders': 'O'}, {'included:': 'O'}, {'inflammatory': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'18),': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'11),': 'O'}, {'SLE': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'8),': 'O'}, {""Raynaud's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'8),': 'O'}, {'vasculitis': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'9),': 'O'}, {'MCTD': 'I-Entity'}, {'(n': 'O'}]"
"Early and close cooperation between rheumatologist and ophthalmologist can avoid long-term complications in patients with Sjogrens disease and ocular complications.Universit‚Äö√†√∂¬¨√üt Erlangen-N‚Äö√†√∂¬¨‚à´rnberg, Erlangen.correlations.","[{'Early': 'O'}, {'and': 'O'}, {'close': 'O'}, {'cooperation': 'O'}, {'between': 'O'}, {'rheumatologist': 'O'}, {'and': 'O'}, {'ophthalmologist': 'O'}, {'can': 'O'}, {'avoid': 'O'}, {'long-term': 'O'}, {'complications': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'ocular': 'B-Entity'}, {'complications.Universit‚Äö√†√∂¬¨√üt': 'I-Entity'}, {'Erlangen-N‚Äö√†√∂¬¨‚à´rnberg,': 'O'}]"
Objective measurement of the time course of HOAs may constitute a new single instrument to evaluate and manage patients with DED because it reliably reflects the completeness of the disease.rights reserved.alexandre.denoyer@gmail.comMay 15.Treatment of Sjogren Syndrome-Related Dry Eye.,"[{'Objective': 'O'}, {'measurement': 'O'}, {'of': 'O'}, {'the': 'O'}, {'time': 'O'}, {'course': 'O'}, {'of': 'O'}, {'HOAs': 'I-Entity'}, {'may': 'O'}, {'constitute': 'O'}, {'a': 'O'}, {'new': 'O'}, {'single': 'O'}, {'instrument': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'and': 'O'}, {'manage': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'DED': 'I-Entity'}, {'because': 'O'}, {'it': 'O'}, {'reliably': 'O'}, {'reflects': 'O'}, {'the': 'O'}, {'completeness': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.rights': 'O'}, {'reserved.alexandre.denoyer@gmail.comMay': 'O'}, {'15.Treatment': 'O'}, {'of': 'O'}, {'Sjogren': 'I-Entity'}]"
Prednisone treatment ever seemed to be effective and antibiotics had no effect.,"[{'Prednisone': 'I-Entity'}, {'treatment': 'O'}, {'ever': 'O'}, {'seemed': 'O'}, {'to': 'O'}, {'be': 'O'}, {'effective': 'O'}, {'and': 'O'}, {'antibiotics': 'O'}, {'had': 'O'}, {'no': 'O'}, {'effect.': 'O'}]"
"In all cases there were single or multiple pulmonary nodules, in one case associated with cysts.","[{'In': 'O'}, {'all': 'O'}, {'cases': 'O'}, {'there': 'O'}, {'were': 'O'}, {'single': 'O'}, {'or': 'O'}, {'multiple': 'O'}, {'pulmonary': 'O'}, {'nodules,': 'O'}, {'in': 'O'}, {'one': 'O'}, {'case': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'cysts.': 'I-Entity'}]"
"Patients with Sjogrens syndrome (SS) are prone to develop malignant lymphomas, and a correlation has been established between the lymphoproliferations occurring in these disorders and the presence in patients' blood of an unusual B cell population that down-regulates complement receptor 2/CD21.","[{'Patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'are': 'O'}, {'prone': 'O'}, {'to': 'O'}, {'develop': 'O'}, {'malignant': 'B-Entity'}, {'lymphomas,': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'correlation': 'O'}, {'has': 'O'}, {'been': 'O'}, {'established': 'O'}, {'between': 'O'}, {'the': 'O'}, {'lymphoproliferations': 'I-Entity'}, {'occurring': 'O'}, {'in': 'O'}, {'these': 'O'}, {'disorders': 'O'}, {'and': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'in': 'O'}, {""patients'"": 'O'}, {'blood': 'O'}, {'of': 'O'}, {'an': 'O'}, {'unusual': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'population': 'O'}, {'that': 'O'}, {'down-regulates': 'O'}, {'complement': 'O'}, {'receptor': 'O'}, {'2/CD21.': 'O'}]"
"Before and after treatment, serum estradiol (E2), testosterone (T), luteinizing hormone (LH), prolactin (PRL) by radioimmunoassay and immunoglobulin (IgG) by immunodiffusion, erythrocyte sedimentation rate (ESR) by Westergren, interferon-‚âà√≠‚Äö√¢‚Ä¢ (IFN-‚âà√≠‚Äö√¢‚Ä¢) and interleukin-4 (IL-4) by enzyme linked immunosorbent assay were determined.","[{'Before': 'O'}, {'and': 'O'}, {'after': 'O'}, {'treatment,': 'O'}, {'serum': 'O'}, {'estradiol': 'I-Entity'}, {'(E2),': 'O'}, {'testosterone': 'I-Entity'}, {'(T),': 'O'}, {'luteinizing': 'O'}, {'hormone': 'O'}, {'(LH),': 'O'}, {'prolactin': 'O'}, {'(PRL)': 'O'}, {'by': 'O'}, {'radioimmunoassay': 'O'}, {'and': 'O'}, {'immunoglobulin': 'O'}, {'(IgG)': 'O'}, {'by': 'O'}, {'immunodiffusion,': 'O'}]"
"Some neurologic complications share convergent pathophysiology, although the pathological basis of other conditions, namely cognitive impairment in pSS, is less clear.","[{'Some': 'O'}, {'neurologic': 'O'}, {'complications': 'O'}, {'share': 'O'}, {'convergent': 'O'}, {'pathophysiology,': 'O'}, {'although': 'O'}, {'the': 'O'}, {'pathological': 'O'}, {'basis': 'O'}, {'of': 'O'}, {'other': 'O'}, {'conditions,': 'O'}, {'namely': 'O'}, {'cognitive': 'B-Entity'}, {'impairment': 'I-Entity'}, {'in': 'O'}, {'pSS,': 'I-Entity'}, {'is': 'O'}, {'less': 'O'}, {'clear.': 'O'}]"
Sarcoidosis and Sjogrens syndrome (SS) are chronic multi-system inflammatory diseases of unknown origin that most commonly attack the salivary glands.,"[{'Sarcoidosis': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'are': 'O'}, {'chronic': 'O'}, {'multi-system': 'O'}, {'inflammatory': 'O'}, {'diseases': 'O'}, {'of': 'O'}, {'unknown': 'O'}, {'origin': 'O'}, {'that': 'O'}, {'most': 'O'}, {'commonly': 'O'}, {'attack': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands.': 'O'}]"
The diffuse cystic lung diseases have a broad differential diagnosis.,"[{'The': 'O'}, {'diffuse': 'O'}, {'cystic': 'B-Entity'}, {'lung': 'I-Entity'}, {'diseases': 'I-Entity'}, {'have': 'O'}, {'a': 'O'}, {'broad': 'O'}, {'differential': 'O'}, {'diagnosis.': 'O'}]"
"Here we reveal, for the first time, that bone marrow mesenchymal stem cells in SS-like NOD/Ltj mice and human patients were defective in immunoregulatory functions.","[{'Here': 'O'}, {'we': 'O'}, {'reveal,': 'O'}, {'for': 'O'}, {'the': 'O'}, {'first': 'O'}, {'time,': 'O'}, {'that': 'O'}, {'bone': 'O'}, {'marrow': 'O'}, {'mesenchymal': 'O'}, {'stem': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'SS-like': 'I-Entity'}, {'NOD/Ltj': 'O'}, {'mice': 'O'}, {'and': 'O'}, {'human': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'defective': 'O'}, {'in': 'O'}, {'immunoregulatory': 'O'}, {'functions.': 'O'}]"
"Newly diagnosed IgG4-RD patients (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢48) were enrolled, 38 untreated pSS patients and 30 healthy volunteers were recruited as disease and healthy controls.","[{'Newly': 'O'}, {'diagnosed': 'O'}, {'IgG4-RD': 'B-Entity'}, {'patients': 'O'}, {'(n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢48)': 'O'}, {'were': 'O'}, {'enrolled,': 'O'}, {'38': 'O'}, {'untreated': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'30': 'O'}]"
"In November 2010, 47 patients, including 35 subjects vaccinated annually during 2006-2010, received immunization against influenza with trivalent inactivated split vaccine, whereas 52 patients did not accept proposed vaccination in that period.","[{'In': 'O'}, {'November': 'O'}, {'2010,': 'O'}, {'47': 'O'}, {'patients,': 'O'}, {'including': 'O'}, {'35': 'O'}, {'subjects': 'O'}, {'vaccinated': 'O'}, {'annually': 'O'}, {'during': 'O'}, {'2006-2010,': 'O'}, {'received': 'O'}, {'immunization': 'O'}, {'against': 'O'}, {'influenza': 'I-Entity'}, {'with': 'O'}, {'trivalent': 'O'}, {'inactivated': 'O'}, {'split': 'O'}, {'vaccine,': 'O'}, {'whereas': 'O'}, {'52': 'O'}, {'patients': 'O'}, {'did': 'O'}, {'not': 'O'}, {'accept': 'O'}, {'proposed': 'O'}, {'vaccination': 'O'}, {'in': 'O'}, {'that': 'O'}, {'period.': 'O'}]"
"Preoperative and perioperative management of inflammation related to dry eyes may reduce dry eyes that develop after laser in situ keratomileusis, improve wound healing, and reduce flap complications.","[{'Preoperative': 'O'}, {'and': 'O'}, {'perioperative': 'O'}, {'management': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'related': 'O'}, {'to': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'may': 'O'}, {'reduce': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'that': 'O'}, {'develop': 'O'}, {'after': 'O'}, {'laser': 'O'}, {'in': 'O'}, {'situ': 'O'}, {'keratomileusis,': 'O'}, {'improve': 'O'}, {'wound': 'O'}, {'healing,': 'O'}, {'and': 'O'}, {'reduce': 'O'}, {'flap': 'O'}, {'complications.': 'O'}]"
"Examinations did not support infection, malignant tumor, pulmonary sarcoidosis, or other connective tissue diseases.","[{'Examinations': 'O'}, {'did': 'O'}, {'not': 'O'}, {'support': 'O'}, {'infection,': 'I-Entity'}, {'malignant': 'B-Entity'}, {'tumor,': 'I-Entity'}, {'pulmonary': 'B-Entity'}, {'sarcoidosis,': 'I-Entity'}, {'or': 'O'}, {'other': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"The attention, data processing speed, verbal learning, short-term verbal memory and visuo-spatial perception performances were lower in the patients with PSS when compared to the healthy controls.","[{'The': 'O'}, {'attention,': 'O'}, {'data': 'O'}, {'processing': 'O'}, {'speed,': 'O'}, {'verbal': 'O'}, {'learning,': 'O'}, {'short-term': 'O'}, {'verbal': 'O'}, {'memory': 'O'}, {'and': 'O'}, {'visuo-spatial': 'O'}, {'perception': 'I-Entity'}, {'performances': 'O'}, {'were': 'O'}, {'lower': 'O'}, {'in': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'PSS': 'I-Entity'}, {'when': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'the': 'O'}, {'healthy': 'O'}, {'controls.': 'O'}]"
"These range from local causes within the oral cavity to underlying systemic disease, including psychologic factors.","[{'These': 'O'}, {'range': 'O'}, {'from': 'O'}, {'local': 'O'}, {'causes': 'O'}, {'within': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'cavity': 'O'}, {'to': 'O'}, {'underlying': 'O'}, {'systemic': 'O'}, {'disease,': 'I-Entity'}, {'including': 'O'}, {'psychologic': 'O'}, {'factors.': 'O'}]"
"To test the a priori hypothesis that acute and chronic work exposures to the World Trade Center (WTC) site on or after September 11, 2001 were associated with risk of new-onset systemic autoimmune diseases.","[{'To': 'O'}, {'test': 'O'}, {'the': 'O'}, {'a': 'O'}, {'priori': 'O'}, {'hypothesis': 'O'}, {'that': 'O'}, {'acute': 'O'}, {'and': 'O'}, {'chronic': 'O'}, {'work': 'O'}, {'exposures': 'O'}, {'to': 'O'}, {'the': 'O'}, {'World': 'O'}, {'Trade': 'O'}, {'Center': 'O'}, {'(WTC)': 'O'}, {'site': 'O'}, {'on': 'O'}, {'or': 'O'}, {'after': 'O'}, {'September': 'O'}, {'11,': 'O'}, {'2001': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'new-onset': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"The second objective was to study if the mechanisms underlying a decrease in inflammation (focus score) was due to CFA, MSCs, or CFA+MSCs combined.","[{'The': 'O'}, {'second': 'O'}, {'objective': 'O'}, {'was': 'O'}, {'to': 'O'}, {'study': 'O'}, {'if': 'O'}, {'the': 'O'}, {'mechanisms': 'O'}, {'underlying': 'O'}, {'a': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'inflammation': 'I-Entity'}, {'(focus': 'O'}, {'score)': 'O'}, {'was': 'O'}, {'due': 'O'}, {'to': 'O'}, {'CFA,': 'O'}, {'MSCs,': 'O'}, {'or': 'O'}, {'CFA+MSCs': 'O'}, {'combined.': 'O'}]"
"We report the case of a patient who developed rapidly fulminant acute motor axonal neuropathy (AMAN) with positive anti-GM1 antibody at high titers in association with serological and pathological evidence of SS without xerostomia or xerophthalmia.Reserve University, Cleveland, Ohio 44104, USA.","[{'We': 'O'}, {'report': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'who': 'O'}, {'developed': 'O'}, {'rapidly': 'O'}, {'fulminant': 'O'}, {'acute': 'O'}, {'motor': 'O'}, {'axonal': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'(AMAN)': 'O'}, {'with': 'O'}, {'positive': 'O'}, {'anti-GM1': 'O'}, {'antibody': 'O'}, {'at': 'O'}, {'high': 'O'}, {'titers': 'O'}, {'in': 'O'}, {'association': 'O'}, {'with': 'O'}, {'serological': 'O'}, {'and': 'O'}, {'pathological': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'without': 'O'}, {'xerostomia': 'I-Entity'}, {'or': 'O'}, {'xerophthalmia.Reserve': 'I-Entity'}]"
"It should be suspected in children presenting with unexplained renal diseases, neurological abnormalities, or unexplained fever.","[{'It': 'O'}, {'should': 'O'}, {'be': 'O'}, {'suspected': 'O'}, {'in': 'O'}, {'children': 'O'}, {'presenting': 'O'}, {'with': 'O'}, {'unexplained': 'O'}, {'renal': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'neurological': 'B-Entity'}, {'abnormalities,': 'I-Entity'}, {'or': 'O'}, {'unexplained': 'O'}, {'fever.': 'I-Entity'}]"
"In primary Sjogrens syndrome (pSS), muscle pain and/or muscular weakness is relatively frequent while myositis has been reported in 3% of patients.","[{'In': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'muscle': 'B-Entity'}, {'pain': 'I-Entity'}, {'and/or': 'O'}, {'muscular': 'B-Entity'}, {'weakness': 'I-Entity'}, {'is': 'O'}, {'relatively': 'O'}, {'frequent': 'O'}, {'while': 'O'}, {'myositis': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'3%': 'O'}, {'of': 'O'}, {'patients.': 'O'}]"
"In isolated immune or non-immune CCHB, cardiac pacemakers are implanted in symptomatic patients, however, data on the natural history of CCHB in the adult life indicate that all patients, even if asymptomatic, should receive a pacemaker when first diagnosed.","[{'In': 'O'}, {'isolated': 'O'}, {'immune': 'O'}, {'or': 'O'}, {'non-immune': 'O'}, {'CCHB,': 'I-Entity'}, {'cardiac': 'O'}, {'pacemakers': 'O'}, {'are': 'O'}, {'implanted': 'O'}, {'in': 'O'}, {'symptomatic': 'O'}, {'patients,': 'O'}, {'however,': 'O'}, {'data': 'O'}, {'on': 'O'}, {'the': 'O'}, {'natural': 'O'}, {'history': 'O'}, {'of': 'O'}, {'CCHB': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'adult': 'O'}, {'life': 'O'}, {'indicate': 'O'}, {'that': 'O'}, {'all': 'O'}, {'patients,': 'O'}, {'even': 'O'}, {'if': 'O'}, {'asymptomatic,': 'O'}, {'should': 'O'}, {'receive': 'O'}, {'a': 'O'}, {'pacemaker': 'O'}, {'when': 'O'}, {'first': 'O'}, {'diagnosed.': 'O'}]"
"A comparison of patients with and without anti-Ro52/60 antibodies revealed no differences, except gamma globulin levels and more frequent steroid use in patients with anti-Ro52/60 antibodies (P < 0.05).","[{'A': 'O'}, {'comparison': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'and': 'O'}, {'without': 'O'}, {'anti-Ro52/60': 'O'}, {'antibodies': 'O'}, {'revealed': 'O'}, {'no': 'O'}, {'differences,': 'O'}, {'except': 'O'}, {'gamma': 'O'}, {'globulin': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'steroid': 'I-Entity'}, {'use': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'anti-Ro52/60': 'O'}, {'antibodies': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.05).': 'O'}]"
"We screened the sera of 199 individuals, including patients suffering from various autoimmune disorders (Group I, n=145) and non autoimmune diseases (Group II, n=44 patients) as well as healthy individuals (Group III, n=30).","[{'We': 'O'}, {'screened': 'O'}, {'the': 'O'}, {'sera': 'O'}, {'of': 'O'}, {'199': 'O'}, {'individuals,': 'O'}, {'including': 'O'}, {'patients': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'various': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders': 'I-Entity'}, {'(Group': 'O'}, {'I,': 'O'}, {'n=145)': 'O'}, {'and': 'O'}, {'non': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(Group': 'O'}, {'II,': 'O'}, {'n=44': 'O'}, {'patients)': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'healthy': 'O'}, {'individuals': 'O'}, {'(Group': 'O'}, {'III,': 'O'}, {'n=30).': 'O'}]"
Only the present case had both thyroid disease and Sjogren's syndrome.,"[{'Only': 'O'}, {'the': 'O'}, {'present': 'O'}, {'case': 'O'}, {'had': 'O'}, {'both': 'O'}, {'thyroid': 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Additionally it was aimed to determine whether NFC could be helpful in discriminating usual interstitial pneumonia (UIP) pattern from non-specific interstitial pneumonia (NSIP) pattern.,"[{'Additionally': 'O'}, {'it': 'O'}, {'was': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'NFC': 'O'}, {'could': 'O'}, {'be': 'O'}, {'helpful': 'O'}, {'in': 'O'}, {'discriminating': 'O'}, {'usual': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'(UIP)': 'O'}, {'pattern': 'O'}, {'from': 'O'}, {'non-specific': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'(NSIP)': 'O'}, {'pattern.': 'O'}]"
"In the geriatric population, connective tissue diseases are almost invariably accompanied by age-related comorbidities, and disease- and treatment-related complications, which contribute to the significant morbidity and mortality associated with these conditions, and complicate treatment decision-making.","[{'In': 'O'}, {'the': 'O'}, {'geriatric': 'O'}, {'population,': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'are': 'O'}, {'almost': 'O'}, {'invariably': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'age-related': 'O'}, {'comorbidities,': 'O'}, {'and': 'O'}, {'disease-': 'O'}, {'and': 'O'}, {'treatment-related': 'O'}, {'complications,': 'O'}, {'which': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'the': 'O'}, {'significant': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'these': 'O'}, {'conditions,': 'O'}, {'and': 'O'}, {'complicate': 'O'}, {'treatment': 'O'}, {'decision-making.': 'O'}]"
"On PSS clinical suspicion, anti Ro/ SS-A y anti La/ SS-B antibodies have a great value to achieve the diagnosis, with MSGB useful for diagnosis of seronegative patients.","[{'On': 'O'}, {'PSS': 'I-Entity'}, {'clinical': 'O'}, {'suspicion,': 'O'}, {'anti': 'O'}, {'Ro/': 'I-Entity'}, {'SS-A': 'O'}, {'y': 'O'}, {'anti': 'O'}, {'La/': 'I-Entity'}, {'SS-B': 'O'}, {'antibodies': 'O'}, {'have': 'O'}, {'a': 'O'}, {'great': 'O'}, {'value': 'O'}, {'to': 'O'}, {'achieve': 'O'}, {'the': 'O'}, {'diagnosis,': 'O'}, {'with': 'O'}, {'MSGB': 'O'}, {'useful': 'O'}, {'for': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'seronegative': 'O'}, {'patients.': 'O'}]"
"There are ways to assess degrees of oral dryness, namely-CODS (clinical oral dryness scoring) which helps to give a numerical value to the oral signs.","[{'There': 'O'}, {'are': 'O'}, {'ways': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'degrees': 'O'}, {'of': 'O'}, {'oral': 'B-Entity'}, {'dryness,': 'I-Entity'}, {'namely-CODS': 'O'}, {'(clinical': 'O'}, {'oral': 'B-Entity'}, {'dryness': 'I-Entity'}, {'scoring)': 'O'}, {'which': 'O'}, {'helps': 'O'}, {'to': 'O'}, {'give': 'O'}, {'a': 'O'}, {'numerical': 'O'}, {'value': 'O'}, {'to': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'signs.': 'O'}]"
Correct attribution of NP events is critical in determining the correct treatment and prognosis.,"[{'Correct': 'O'}, {'attribution': 'O'}, {'of': 'O'}, {'NP': 'I-Entity'}, {'events': 'O'}, {'is': 'O'}, {'critical': 'O'}, {'in': 'O'}, {'determining': 'O'}, {'the': 'O'}, {'correct': 'O'}, {'treatment': 'O'}, {'and': 'O'}, {'prognosis.': 'O'}]"
"After a single treatment, patients exhibited increased oil flow and tear break-up time with an associated decrease in corneal and conjunctival staining.University Eye Center Durham, NC.624 patients.","[{'After': 'O'}, {'a': 'O'}, {'single': 'O'}, {'treatment,': 'O'}, {'patients': 'O'}, {'exhibited': 'O'}, {'increased': 'O'}, {'oil': 'O'}, {'flow': 'O'}, {'and': 'O'}, {'tear': 'O'}, {'break-up': 'O'}, {'time': 'O'}, {'with': 'O'}, {'an': 'O'}, {'associated': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'corneal': 'B-Entity'}, {'and': 'I-Entity'}, {'conjunctival': 'I-Entity'}, {'staining.University': 'I-Entity'}, {'Eye': 'O'}, {'Center': 'O'}, {'Durham,': 'O'}, {'NC.624': 'O'}, {'patients.': 'O'}]"
"Saliva has many functions, including tissue repair, tamponage, protection, digestion, taste, antimicrobial action, maintaining tooth integrity and antioxidant defense system.","[{'Saliva': 'O'}, {'has': 'O'}, {'many': 'O'}, {'functions,': 'O'}, {'including': 'O'}, {'tissue': 'O'}, {'repair,': 'O'}, {'tamponage,': 'O'}, {'protection,': 'O'}, {'digestion,': 'O'}, {'taste,': 'O'}, {'antimicrobial': 'O'}, {'action,': 'O'}, {'maintaining': 'O'}, {'tooth': 'O'}, {'integrity': 'O'}, {'and': 'O'}, {'antioxidant': 'O'}, {'defense': 'O'}, {'system.': 'O'}]"
"Variables such as the presence of periodontal infections, decay and alterations in the oral mucosa were analyzed, and the individual's salivary flow was measured.","[{'Variables': 'O'}, {'such': 'O'}, {'as': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'periodontal': 'B-Entity'}, {'infections,': 'I-Entity'}, {'decay': 'I-Entity'}, {'and': 'O'}, {'alterations': 'B-Entity'}, {'in': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'mucosa': 'O'}, {'were': 'O'}, {'analyzed,': 'O'}, {'and': 'O'}, {'the': 'O'}, {""individual's"": 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'was': 'O'}, {'measured.': 'O'}]"
"Later during the disease evolution, the subsequent chronic activation of B cells can lead to the development of systemic manifestations or non-Hodgkin's lymphoma.","[{'Later': 'O'}, {'during': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'evolution,': 'O'}, {'the': 'O'}, {'subsequent': 'O'}, {'chronic': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'manifestations': 'O'}, {'or': 'O'}, {""non-Hodgkin's"": 'B-Entity'}, {'lymphoma.': 'I-Entity'}]"
"Scleroderma pattern were significantly associated with the development of systemic sclerosis [P = .00001, sensitivity 94%, specificity 92%, positive predictive value 52%, negative predictive value 99%, and odds ratio 163 (95% CI, 97,9-271,5)], as well as dermatomyositis (P = .0004), overlap syndrome with signs of systemic sclerosis (P = .0001), and mixed connective tissue disease (P = .007).","[{'Scleroderma': 'I-Entity'}, {'pattern': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'[P': 'O'}, {'=': 'O'}, {'.00001,': 'O'}, {'sensitivity': 'O'}, {'94%,': 'O'}, {'specificity': 'O'}, {'92%,': 'O'}, {'positive': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'52%,': 'O'}, {'negative': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'99%,': 'O'}, {'and': 'O'}, {'odds': 'O'}, {'ratio': 'O'}, {'163': 'O'}, {'(95%': 'O'}, {'CI,': 'O'}, {'97,9-271,5)],': 'O'}]"
"Approximately 80% of female wild-type non-obese diabetic (WT NOD) mice spontaneously develop diabetes, whereas B-cell-deficient (B(-/-)) NOD mice are resistant to diabetes.","[{'Approximately': 'O'}, {'80%': 'O'}, {'of': 'O'}, {'female': 'O'}, {'wild-type': 'O'}, {'non-obese': 'O'}, {'diabetic': 'I-Entity'}, {'(WT': 'O'}, {'NOD)': 'O'}, {'mice': 'O'}, {'spontaneously': 'O'}, {'develop': 'O'}, {'diabetes,': 'I-Entity'}, {'whereas': 'O'}, {'B-cell-deficient': 'O'}, {'(B(-/-))': 'O'}, {'NOD': 'O'}, {'mice': 'O'}, {'are': 'O'}, {'resistant': 'O'}, {'to': 'O'}, {'diabetes.': 'I-Entity'}]"
"In a minority of the cases, patients can develop rarer complications, such as vasculitis and, even less commonly, ischemic colitis.","[{'In': 'O'}, {'a': 'O'}, {'minority': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cases,': 'O'}, {'patients': 'O'}, {'can': 'O'}, {'develop': 'O'}, {'rarer': 'O'}, {'complications,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'vasculitis': 'I-Entity'}, {'and,': 'O'}, {'even': 'O'}, {'less': 'O'}, {'commonly,': 'O'}, {'ischemic': 'B-Entity'}, {'colitis.': 'I-Entity'}]"
Objective To evaluate the efficacy and safety of Liujin Runzao Concentrated Decoction (LRCD) for the treatment of primary Sjogrens syndrome (pSS).,"[{'Objective': 'O'}, {'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'Liujin': 'O'}, {'Runzao': 'I-Entity'}, {'Concentrated': 'O'}, {'Decoction': 'O'}, {'(LRCD)': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
The differential diagnosis expands when recurrent parotitis is encountered.,"[{'The': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'expands': 'O'}, {'when': 'O'}, {'recurrent': 'O'}, {'parotitis': 'I-Entity'}, {'is': 'O'}, {'encountered.': 'O'}]"
"No clinical neuropsychiatric manifestations could be attributed to impaired integrity of the blood-brain barrier, or to TWEAK levels in cerebrospinal fluid or serum in either patient group.","[{'No': 'O'}, {'clinical': 'O'}, {'neuropsychiatric': 'O'}, {'manifestations': 'O'}, {'could': 'O'}, {'be': 'O'}, {'attributed': 'O'}, {'to': 'O'}, {'impaired': 'O'}, {'integrity': 'O'}, {'of': 'O'}, {'the': 'O'}, {'blood-brain': 'O'}, {'barrier,': 'O'}, {'or': 'O'}, {'to': 'O'}, {'TWEAK': 'I-Entity'}, {'levels': 'O'}, {'in': 'O'}, {'cerebrospinal': 'O'}, {'fluid': 'O'}, {'or': 'O'}, {'serum': 'O'}, {'in': 'O'}, {'either': 'O'}, {'patient': 'O'}, {'group.': 'O'}]"
"In patients with early arthritis naive to disease-modifying antirheumatic drugs, we evaluated the prevalence of initial and persistent lymphopenia, underlying diagnoses, and risk of infection or malignancy.","[{'In': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'early': 'O'}, {'arthritis': 'I-Entity'}, {'naive': 'O'}, {'to': 'O'}, {'disease-modifying': 'O'}, {'antirheumatic': 'O'}, {'drugs,': 'O'}, {'we': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'initial': 'O'}, {'and': 'O'}, {'persistent': 'O'}, {'lymphopenia,': 'I-Entity'}, {'underlying': 'O'}, {'diagnoses,': 'O'}, {'and': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'infection': 'I-Entity'}, {'or': 'O'}, {'malignancy.': 'I-Entity'}]"
"The term ""mixed connective tissue disease"" (MCTD) concerns a systemic autoimmune disease typified by overlapping features between two or more systemic autoimmune diseases and the presence of antibodies against the U1 small nuclear ribonucleoprotein autoantigen (U1snRNP).","[{'The': 'O'}, {'term': 'O'}, {'""mixed': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease""': 'I-Entity'}, {'(MCTD)': 'O'}, {'concerns': 'O'}, {'a': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'typified': 'O'}, {'by': 'O'}, {'overlapping': 'O'}, {'features': 'O'}, {'between': 'O'}, {'two': 'O'}, {'or': 'O'}, {'more': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'diseases': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'antibodies': 'O'}, {'against': 'O'}, {'the': 'O'}, {'U1': 'O'}, {'small': 'O'}, {'nuclear': 'O'}, {'ribonucleoprotein': 'O'}, {'autoantigen': 'O'}, {'(U1snRNP).': 'O'}]"
"In peripheral blood, no difference was found in CD4(+)CD25(+)Foxp3(+) Treg percentages among patients with IPF, pSS-IP, or HCs.","[{'In': 'O'}, {'peripheral': 'O'}, {'blood,': 'O'}, {'no': 'O'}, {'difference': 'O'}, {'was': 'O'}, {'found': 'O'}, {'in': 'O'}, {'CD4(+)CD25(+)Foxp3(+)': 'O'}, {'Treg': 'O'}, {'percentages': 'O'}, {'among': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'IPF,': 'I-Entity'}, {'pSS-IP,': 'O'}, {'or': 'O'}, {'HCs.': 'O'}]"
"Relapsing polychondritis shows subglottic stenosis, prominent ear and saddle nose; progressive systemic sclerosis shows osteolysis of the mandible, fibrosis of the masseter muscle with calcinosis of the subcutaneous tissue and dermatomyositis/polymyositis shows condylar erosions and autoimmune thyroiditis.","[{'Relapsing': 'O'}, {'polychondritis': 'I-Entity'}, {'shows': 'O'}, {'subglottic': 'B-Entity'}, {'stenosis,': 'I-Entity'}, {'prominent': 'O'}, {'ear': 'B-Entity'}, {'and': 'O'}, {'saddle': 'B-Entity'}, {'nose;': 'I-Entity'}, {'progressive': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'shows': 'O'}, {'osteolysis': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'mandible,': 'O'}, {'fibrosis': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'masseter': 'O'}, {'muscle': 'O'}, {'with': 'O'}, {'calcinosis': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'subcutaneous': 'O'}, {'tissue': 'O'}, {'and': 'O'}, {'dermatomyositis/polymyositis': 'I-Entity'}]"
Four infusion reactions and one delayed serum sickness-like disease resulted in rituximab discontinuation.,"[{'Four': 'O'}, {'infusion': 'O'}, {'reactions': 'O'}, {'and': 'O'}, {'one': 'O'}, {'delayed': 'O'}, {'serum': 'B-Entity'}, {'sickness-like': 'I-Entity'}, {'disease': 'I-Entity'}, {'resulted': 'O'}, {'in': 'O'}, {'rituximab': 'I-Entity'}, {'discontinuation.': 'O'}]"
"Heterogeneity, abnormal diffuse fat tissue deposition, and diffuse punctate calcification are specific for Sjogrens syndrome.","[{'Heterogeneity,': 'O'}, {'abnormal': 'O'}, {'diffuse': 'O'}, {'fat': 'O'}, {'tissue': 'O'}, {'deposition,': 'O'}, {'and': 'O'}, {'diffuse': 'O'}, {'punctate': 'O'}, {'calcification': 'I-Entity'}, {'are': 'O'}, {'specific': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Sjogrens syndrome (SS) is an autoimmune disease of unknown etiology, clinically manifested by dry eyes (xerophthalmia) and dry mouth (xerostomia).","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'O'}, {'of': 'O'}, {'unknown': 'O'}, {'etiology,': 'O'}, {'clinically': 'O'}, {'manifested': 'O'}, {'by': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'(xerophthalmia)': 'O'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'(xerostomia).': 'O'}]"
We present a 44-year-old female with an initial presentation with distal renal tubular acidosis (RTA) after she presented with hypokalaemia and normal anion gap acidosis.,"[{'We': 'O'}, {'present': 'O'}, {'a': 'O'}, {'44-year-old': 'O'}, {'female': 'O'}, {'with': 'O'}, {'an': 'O'}, {'initial': 'O'}, {'presentation': 'O'}, {'with': 'O'}, {'distal': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(RTA)': 'O'}, {'after': 'O'}, {'she': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'hypokalaemia': 'I-Entity'}, {'and': 'O'}, {'normal': 'O'}, {'anion': 'O'}, {'gap': 'O'}, {'acidosis.': 'I-Entity'}]"
"Sjogrens Syndrome (SS) is a chronic autoimmune disease, leading to deficient secretion from salivary and lacrimal glands.","[{'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease,': 'I-Entity'}, {'leading': 'O'}, {'to': 'O'}, {'deficient': 'O'}, {'secretion': 'O'}, {'from': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands.': 'O'}]"
"Therefore, Raman spectroscopy may increase the diagnostic sensitivity and specificity, meanwhile prevent patients from pain caused by biopsy.361003 Fujian, PR China.8.women in the general population: a nested case-control study.","[{'Therefore,': 'O'}, {'Raman': 'O'}, {'spectroscopy': 'O'}, {'may': 'O'}, {'increase': 'O'}, {'the': 'O'}, {'diagnostic': 'O'}, {'sensitivity': 'O'}, {'and': 'O'}, {'specificity,': 'O'}, {'meanwhile': 'O'}, {'prevent': 'O'}, {'patients': 'O'}, {'from': 'O'}, {'pain': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'biopsy.361003': 'O'}, {'Fujian,': 'O'}, {'PR': 'O'}, {'China.8.women': 'O'}, {'in': 'O'}, {'the': 'O'}, {'general': 'O'}, {'population:': 'O'}, {'a': 'O'}, {'nested': 'O'}, {'case-control': 'O'}, {'study.': 'O'}]"
"We also reviewed diagnosis, clinical and laboratory features.","[{'We': 'O'}, {'also': 'O'}, {'reviewed': 'O'}, {'diagnosis,': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'features.': 'O'}]"
"Although multiple sclerosis (MS) is the most common demyelinating disorder of the central nervous system (CNS), it lacks any definitive diagnostic test.","[{'Although': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(MS)': 'O'}, {'is': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'demyelinating': 'B-Entity'}, {'disorder': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'(CNS),': 'O'}, {'it': 'O'}, {'lacks': 'O'}, {'any': 'O'}, {'definitive': 'O'}, {'diagnostic': 'O'}, {'test.': 'O'}]"
"NMO - a severe demyelinating disorder of the central nervous system - primarily affects the spinal cord and optic nerves, resulting in longitudinally extensive transverse myelitis and/or optic neuritis.","[{'NMO': 'I-Entity'}, {'-': 'O'}, {'a': 'O'}, {'severe': 'O'}, {'demyelinating': 'B-Entity'}, {'disorder': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'-': 'O'}, {'primarily': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'spinal': 'O'}, {'cord': 'O'}, {'and': 'O'}, {'optic': 'O'}, {'nerves,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'longitudinally': 'O'}, {'extensive': 'O'}, {'transverse': 'O'}, {'myelitis': 'I-Entity'}, {'and/or': 'O'}, {'optic': 'B-Entity'}, {'neuritis.': 'I-Entity'}]"
"Further item reduction will be evaluated in prospective SSc and mimicker cases.Ontario, Canada.","[{'Further': 'O'}, {'item': 'O'}, {'reduction': 'O'}, {'will': 'O'}, {'be': 'O'}, {'evaluated': 'O'}, {'in': 'O'}, {'prospective': 'O'}, {'SSc': 'I-Entity'}, {'and': 'O'}, {'mimicker': 'O'}, {'cases.Ontario,': 'O'}, {'Canada.': 'O'}]"
We performed DNA methylation analysis by methylation-sensitive restriction digestion followed by quantitative real-time polymerase chain reaction of selected genomic loci in saliva samples of 16¬¨¬®‚Äö√Ñ‚Ä†SS patients and 10¬¨¬®‚Äö√Ñ‚Ä†sicca controls with negative MSG biopsy.,"[{'We': 'O'}, {'performed': 'O'}, {'DNA': 'O'}, {'methylation': 'O'}, {'analysis': 'O'}, {'by': 'O'}, {'methylation-sensitive': 'O'}, {'restriction': 'O'}, {'digestion': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'quantitative': 'O'}, {'real-time': 'O'}, {'polymerase': 'O'}, {'chain': 'O'}, {'reaction': 'O'}, {'of': 'O'}, {'selected': 'O'}, {'genomic': 'O'}, {'loci': 'O'}, {'in': 'O'}, {'saliva': 'O'}, {'samples': 'O'}, {'of': 'O'}, {'16¬¨¬®‚Äö√Ñ‚Ä†SS': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'10¬¨¬®‚Äö√Ñ‚Ä†sicca': 'O'}]"
"Sera from 11 patients diagnosed with SS, 8 patients with dry eye disease (DED), and 8 normal age/sex-matched controls (NL) were collected for detecting antibodies against tissue KLK1, KLK11, KLK12, and KLK13 by capture enzyme-linked immunosorbent assay.","[{'Sera': 'O'}, {'from': 'O'}, {'11': 'O'}, {'patients': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'SS,': 'I-Entity'}, {'8': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease': 'I-Entity'}, {'(DED),': 'O'}, {'and': 'O'}, {'8': 'O'}, {'normal': 'O'}, {'age/sex-matched': 'O'}, {'controls': 'O'}, {'(NL)': 'O'}, {'were': 'O'}, {'collected': 'O'}, {'for': 'O'}, {'detecting': 'O'}, {'antibodies': 'O'}, {'against': 'O'}, {'tissue': 'O'}, {'KLK1,': 'O'}, {'KLK11,': 'O'}, {'KLK12,': 'O'}, {'and': 'O'}, {'KLK13': 'O'}, {'by': 'O'}, {'capture': 'O'}]"
The purpose of this review is to provide an update on the biologic agents that have been used in the treatment of diseases that affect the oral mucosa.,"[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'review': 'O'}, {'is': 'O'}, {'to': 'O'}, {'provide': 'O'}, {'an': 'O'}, {'update': 'O'}, {'on': 'O'}, {'the': 'O'}, {'biologic': 'O'}, {'agents': 'O'}, {'that': 'O'}, {'have': 'O'}, {'been': 'O'}, {'used': 'O'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'diseases': 'O'}, {'that': 'O'}, {'affect': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'mucosa.': 'O'}]"
LS findings and ophthalmological test results of patients in early stage of disease were compared with the results of those in advanced stage and with those of normal individuals.,"[{'LS': 'O'}, {'findings': 'O'}, {'and': 'O'}, {'ophthalmological': 'O'}, {'test': 'O'}, {'results': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'in': 'O'}, {'early': 'O'}, {'stage': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'were': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'the': 'O'}, {'results': 'O'}, {'of': 'O'}, {'those': 'O'}, {'in': 'O'}, {'advanced': 'O'}, {'stage': 'O'}, {'and': 'O'}, {'with': 'O'}, {'those': 'O'}, {'of': 'O'}, {'normal': 'O'}, {'individuals.': 'O'}]"
"While additional study is warranted to assess the specificity and stability of these results, DTI could provide novel insight into the pathological processes accompanying the subtle cognitive dysfunction commonly experienced by PSS patients.USA.","[{'While': 'O'}, {'additional': 'O'}, {'study': 'O'}, {'is': 'O'}, {'warranted': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'specificity': 'O'}, {'and': 'O'}, {'stability': 'O'}, {'of': 'O'}, {'these': 'O'}, {'results,': 'O'}, {'DTI': 'O'}, {'could': 'O'}, {'provide': 'O'}, {'novel': 'O'}, {'insight': 'O'}, {'into': 'O'}, {'the': 'O'}, {'pathological': 'O'}, {'processes': 'O'}, {'accompanying': 'O'}, {'the': 'O'}, {'subtle': 'O'}, {'cognitive': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'commonly': 'O'}, {'experienced': 'O'}, {'by': 'O'}, {'PSS': 'I-Entity'}, {'patients.USA.': 'O'}]"
Sjogrens syndrome (SS) is a systemic autoimmune disease characterized by chronic inflammation of the salivary and lacrimal glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'chronic': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands.': 'O'}]"
"These findings suggest that high expression levels of Bpifb1 might predict disease traits before the onset of autoimmunity.at Niigata, Chuo-ku, Niigata, Japan.Niigata, Chuo-ku, Niigata, Japan.Niigata, Chuo-ku, Niigata, Japan.Dentistry at Niigata, Chuo-ku, Niigata, Japan.Dentistry at Niigata, Chuo-ku, Niigata, Japan.","[{'These': 'O'}, {'findings': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'high': 'O'}, {'expression': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'Bpifb1': 'O'}, {'might': 'O'}, {'predict': 'O'}, {'disease': 'O'}, {'traits': 'O'}, {'before': 'O'}, {'the': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'autoimmunity.at': 'I-Entity'}, {'Niigata,': 'O'}, {'Chuo-ku,': 'O'}, {'Niigata,': 'I-Entity'}, {'Japan.Niigata,': 'O'}, {'Chuo-ku,': 'O'}, {'Niigata,': 'I-Entity'}, {'Japan.Niigata,': 'O'}]"
"To determine the prevalence of pulmonary complications in primary Sjogren syndrome (pSS), and to identify the risk factors and the prognosis associated with pulmonary involvement in pSS patients.A total of 1341 hospitalized patients (853 with pSS and 488 with secondary Sjogren syndrome [sSS]) were retrospectively reviewed.","[{'To': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'pulmonary': 'B-Entity'}, {'complications': 'I-Entity'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'and': 'O'}, {'to': 'O'}, {'identify': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'and': 'O'}, {'the': 'O'}, {'prognosis': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'pulmonary': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.A': 'O'}, {'total': 'O'}, {'of': 'O'}, {'1341': 'O'}, {'hospitalized': 'O'}, {'patients': 'O'}, {'(853': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'488': 'O'}, {'with': 'O'}, {'secondary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'[sSS])': 'O'}]"
"Moreover, the chronically created pro-inflammatory environment appears to promote glandular atrophy and irreparable architectural modifications.","[{'Moreover,': 'O'}, {'the': 'O'}, {'chronically': 'O'}, {'created': 'O'}, {'pro-inflammatory': 'O'}, {'environment': 'O'}, {'appears': 'O'}, {'to': 'O'}, {'promote': 'O'}, {'glandular': 'O'}, {'atrophy': 'I-Entity'}, {'and': 'O'}, {'irreparable': 'O'}, {'architectural': 'O'}, {'modifications.': 'O'}]"
"Here we report a 30-year-old woman diagnosed with trigeminal damage secondary to pSS who presented atypical trigeminal neuralgia of numbness of the right head and face and persistent prickling-like pain not associated with eating, talking or tooth-brushing, and had no ""trigger point"".","[{'Here': 'O'}, {'we': 'O'}, {'report': 'O'}, {'a': 'O'}, {'30-year-old': 'O'}, {'woman': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'trigeminal': 'B-Entity'}, {'damage': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {'pSS': 'I-Entity'}, {'who': 'O'}, {'presented': 'O'}, {'atypical': 'O'}, {'trigeminal': 'B-Entity'}, {'neuralgia': 'I-Entity'}, {'of': 'O'}, {'numbness': 'B-Entity'}, {'of': 'O'}, {'the': 'O'}, {'right': 'O'}, {'head': 'O'}, {'and': 'O'}, {'face': 'O'}, {'and': 'O'}, {'persistent': 'O'}, {'prickling-like': 'O'}, {'pain': 'I-Entity'}, {'not': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'eating,': 'O'}, {'talking': 'O'}, {'or': 'O'}, {'tooth-brushing,': 'O'}, {'and': 'O'}, {'had': 'O'}]"
"Among 6 patients with follow-up computed tomography and pulmonary function, the results remained stable or worsened.","[{'Among': 'O'}, {'6': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'follow-up': 'O'}, {'computed': 'O'}, {'tomography': 'O'}, {'and': 'O'}, {'pulmonary': 'O'}, {'function,': 'O'}, {'the': 'O'}, {'results': 'O'}, {'remained': 'O'}, {'stable': 'O'}, {'or': 'O'}, {'worsened.': 'O'}]"
This study was undertaken to investigate whether there is a connection between the presence of anti-NR2 antibodies and hippocampal atrophy in human diseases.,"[{'This': 'O'}, {'study': 'O'}, {'was': 'O'}, {'undertaken': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'whether': 'O'}, {'there': 'O'}, {'is': 'O'}, {'a': 'O'}, {'connection': 'O'}, {'between': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-NR2': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'hippocampal': 'B-Entity'}, {'atrophy': 'I-Entity'}, {'in': 'O'}, {'human': 'O'}, {'diseases.': 'O'}]"
"Common treatment modalities utilized in SS patients included omega-3 supplements (82%), topical cyclosporine (74%), and artificial tear solutions (64%), as compared to omega-3 supplements (80%), hot-mask therapy (77%), and artificial tear solutions (77%), in SS-negative patients.","[{'Common': 'O'}, {'treatment': 'O'}, {'modalities': 'O'}, {'utilized': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'included': 'O'}, {'omega-3': 'B-Entity'}, {'supplements': 'O'}, {'(82%),': 'O'}, {'topical': 'O'}, {'cyclosporine': 'I-Entity'}, {'(74%),': 'O'}, {'and': 'O'}, {'artificial': 'O'}, {'tear': 'O'}, {'solutions': 'O'}, {'(64%),': 'O'}, {'as': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'omega-3': 'B-Entity'}, {'supplements': 'O'}, {'(80%),': 'O'}, {'hot-mask': 'O'}]"
Visual analog scale assessment for dry eye and dry mouth symptoms was carried out.,"[{'Visual': 'O'}, {'analog': 'O'}, {'scale': 'O'}, {'assessment': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'symptoms': 'O'}, {'was': 'O'}, {'carried': 'O'}, {'out.': 'O'}]"
"Evaluation of entropy of the corneal nerve distribution observed by a laser confocal microscopy appears to quantitatively and noninvasively characterize an aspect of the SS patients in relation to the recognition of an impairment of their ocular surface, giving us for the first time a method to objectively and precisely characterize the corneal innervation status in the SS patients.Siena, Italy.Siena, Italy.24.Sjogrens syndrome.","[{'Evaluation': 'O'}, {'of': 'O'}, {'entropy': 'O'}, {'of': 'O'}, {'the': 'O'}, {'corneal': 'O'}, {'nerve': 'O'}, {'distribution': 'O'}, {'observed': 'O'}, {'by': 'O'}, {'a': 'O'}, {'laser': 'O'}, {'confocal': 'O'}, {'microscopy': 'O'}, {'appears': 'O'}, {'to': 'O'}, {'quantitatively': 'O'}, {'and': 'O'}, {'noninvasively': 'O'}, {'characterize': 'O'}, {'an': 'O'}, {'aspect': 'O'}, {'of': 'O'}, {'the': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'in': 'O'}, {'relation': 'O'}, {'to': 'O'}, {'the': 'O'}, {'recognition': 'O'}, {'of': 'O'}, {'an': 'O'}, {'impairment': 'B-Entity'}, {'of': 'I-Entity'}, {'their': 'O'}, {'ocular': 'I-Entity'}, {'surface,': 'I-Entity'}, {'giving': 'O'}, {'us': 'O'}, {'for': 'O'}, {'the': 'O'}, {'first': 'O'}, {'time': 'O'}, {'a': 'O'}, {'method': 'O'}, {'to': 'O'}]"
"The degree of inflammation varies among individuals with PD independently of the degree of bacterial infection, suggesting that alteration of the immune function may substantially contribute to its extent.","[{'The': 'O'}, {'degree': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'varies': 'O'}, {'among': 'O'}, {'individuals': 'O'}, {'with': 'O'}, {'PD': 'I-Entity'}, {'independently': 'O'}, {'of': 'O'}, {'the': 'O'}, {'degree': 'O'}, {'of': 'O'}, {'bacterial': 'O'}, {'infection,': 'I-Entity'}, {'suggesting': 'O'}, {'that': 'O'}, {'alteration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'immune': 'O'}, {'function': 'O'}, {'may': 'O'}, {'substantially': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'its': 'O'}, {'extent.': 'O'}]"
"Regulatory T cells (Tregs) are crucial in maintaining immune tolerance and immune homeostasis, but their role in idiopathic pulmonary fibrosis (IPF) is unclear.","[{'Regulatory': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'(Tregs)': 'O'}, {'are': 'O'}, {'crucial': 'O'}, {'in': 'O'}, {'maintaining': 'O'}, {'immune': 'O'}, {'tolerance': 'O'}, {'and': 'O'}, {'immune': 'O'}, {'homeostasis,': 'O'}, {'but': 'O'}, {'their': 'O'}, {'role': 'O'}, {'in': 'O'}, {'idiopathic': 'B-Entity'}, {'pulmonary': 'I-Entity'}, {'fibrosis': 'I-Entity'}, {'(IPF)': 'O'}, {'is': 'O'}, {'unclear.': 'O'}]"
"TMH should be assessed before tests that require forced eye opening.Ltd.Osaka, Japan.dysfunctional tear syndrome.","[{'TMH': 'O'}, {'should': 'O'}, {'be': 'O'}, {'assessed': 'O'}, {'before': 'O'}, {'tests': 'O'}, {'that': 'O'}, {'require': 'O'}, {'forced': 'O'}, {'eye': 'O'}, {'opening.Ltd.Osaka,': 'O'}, {'Japan.dysfunctional': 'O'}, {'tear': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
"There was higher disease activity ESSDAI in group I than in group II (Me, 3.0 vs 2.0; p‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.003).","[{'There': 'O'}, {'was': 'O'}, {'higher': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'ESSDAI': 'O'}, {'in': 'O'}, {'group': 'O'}, {'I': 'O'}, {'than': 'O'}, {'in': 'O'}, {'group': 'O'}, {'II': 'O'}, {'(Me,': 'O'}, {'3.0': 'O'}, {'vs': 'O'}, {'2.0;': 'O'}, {'p‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.003).': 'O'}]"
"We could identify both morphological changes, i.e., ductal system abnormalities or increased interstitial fibrosis, and immunological patterns associated with SS pathogenesis.","[{'We': 'O'}, {'could': 'O'}, {'identify': 'O'}, {'both': 'O'}, {'morphological': 'O'}, {'changes,': 'O'}, {'i.e.,': 'O'}, {'ductal': 'B-Entity'}, {'system': 'I-Entity'}, {'abnormalities': 'I-Entity'}, {'or': 'O'}, {'increased': 'O'}, {'interstitial': 'O'}, {'fibrosis,': 'I-Entity'}, {'and': 'O'}, {'immunological': 'O'}, {'patterns': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'pathogenesis.': 'O'}]"
ILD is a significant cause of death in Sjogrens syndrome.,"[{'ILD': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'death': 'I-Entity'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Here we report a case of a 32-year-old woman with co-existence of four auto-immune diseases, namely autoimmune hypothyroidism, Sjogrens syndrome, systemic lupus erythematosus (SLE) and celiac disease which leads to the final diagnosis of multiple autoimmune syndrome type 3 with celiac disease.","[{'Here': 'O'}, {'we': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'32-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'co-existence': 'O'}, {'of': 'O'}, {'four': 'O'}, {'auto-immune': 'O'}, {'diseases,': 'O'}, {'namely': 'O'}, {'autoimmune': 'B-Entity'}, {'hypothyroidism,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'and': 'O'}, {'celiac': 'B-Entity'}, {'disease': 'I-Entity'}, {'which': 'O'}, {'leads': 'O'}]"
In selected patients salivary gland atrophy degree was also evaluated.,"[{'In': 'O'}, {'selected': 'O'}, {'patients': 'O'}, {'salivary': 'O'}, {'gland': 'I-Entity'}, {'atrophy': 'I-Entity'}, {'degree': 'O'}, {'was': 'O'}, {'also': 'O'}, {'evaluated.': 'O'}]"
Patients were randomized (1:1) to receive hydroxychloroquine (400 mg/d) or placebo until week 24.,"[{'Patients': 'O'}, {'were': 'O'}, {'randomized': 'O'}, {'(1:1)': 'O'}, {'to': 'O'}, {'receive': 'O'}, {'hydroxychloroquine': 'I-Entity'}, {'(400': 'O'}, {'mg/d)': 'O'}, {'or': 'O'}, {'placebo': 'O'}, {'until': 'O'}, {'week': 'O'}, {'24.': 'O'}]"
"Of the activity scores, ESSPRI dryness component was higher in pSS patients who had scores above the cut-off values for Hocevar (6.1¬¨¬®¬¨¬±2.3 vs. 4.9¬¨¬®¬¨¬±2.6, p=0.026).","[{'Of': 'O'}, {'the': 'O'}, {'activity': 'O'}, {'scores,': 'O'}, {'ESSPRI': 'O'}, {'dryness': 'I-Entity'}, {'component': 'O'}, {'was': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'who': 'O'}, {'had': 'O'}, {'scores': 'O'}, {'above': 'O'}, {'the': 'O'}, {'cut-off': 'O'}, {'values': 'O'}, {'for': 'O'}, {'Hocevar': 'O'}, {'(6.1¬¨¬®¬¨¬±2.3': 'O'}, {'vs.': 'O'}, {'4.9¬¨¬®¬¨¬±2.6,': 'O'}]"
The excess incidence associated with unrecognized rheumatic diseases was 2.7¬¨¬®‚Äö√Ñ‚Ä†% (95¬¨¬®‚Äö√Ñ‚Ä†% CI‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢1.5-4) or 25¬¨¬®‚Äö√Ñ‚Ä†% (95¬¨¬®‚Äö√Ñ‚Ä†% CI‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢12.8-34.8) of all SGA cases.,"[{'The': 'O'}, {'excess': 'O'}, {'incidence': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'unrecognized': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'was': 'O'}, {'2.7¬¨¬®‚Äö√Ñ‚Ä†%': 'O'}, {'(95¬¨¬®‚Äö√Ñ‚Ä†%': 'O'}, {'CI‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢1.5-4)': 'O'}]"
"Our Case 2 had serum anti-AQP4, anti-SSA/SSB, anti-thyreoglobulin and anti-acethylcholine-receptor antibodies, as well as clinical hypothyreoidism, but no evidence of myasthenia gravis.","[{'Our': 'O'}, {'Case': 'O'}, {'2': 'O'}, {'had': 'O'}, {'serum': 'O'}, {'anti-AQP4,': 'O'}, {'anti-SSA/SSB,': 'O'}, {'anti-thyreoglobulin': 'O'}, {'and': 'O'}, {'anti-acethylcholine-receptor': 'O'}, {'antibodies,': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'clinical': 'O'}, {'hypothyreoidism,': 'I-Entity'}, {'but': 'O'}, {'no': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'myasthenia': 'B-Entity'}, {'gravis.': 'I-Entity'}]"
"Here, we formulated recommendations for the assessment and interpretation of ANA and associated antibodies.","[{'Here,': 'O'}, {'we': 'O'}, {'formulated': 'O'}, {'recommendations': 'O'}, {'for': 'O'}, {'the': 'O'}, {'assessment': 'O'}, {'and': 'O'}, {'interpretation': 'O'}, {'of': 'O'}, {'ANA': 'O'}, {'and': 'O'}, {'associated': 'O'}, {'antibodies.': 'O'}]"
"SS may be accompanied by pleural effusion when the lung is involved, but this occurrence has been reported in only 10 cases in the literature.","[{'SS': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'pleural': 'B-Entity'}, {'effusion': 'I-Entity'}, {'when': 'O'}, {'the': 'O'}, {'lung': 'O'}, {'is': 'O'}, {'involved,': 'O'}, {'but': 'O'}, {'this': 'O'}, {'occurrence': 'O'}, {'has': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'only': 'O'}, {'10': 'O'}, {'cases': 'O'}, {'in': 'O'}, {'the': 'O'}, {'literature.': 'O'}]"
"Five per cent of patients with primary Sjogren's syndrome (pSS) develop malignant non-Hodgkin's lymphoma (NHL), usually of the mucosa-associated lymphoid tissue (MALT) and most frequently located in the major salivary glands.","[{'Five': 'O'}, {'per': 'O'}, {'cent': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'develop': 'O'}, {'malignant': 'B-Entity'}, {""non-Hodgkin's"": 'I-Entity'}, {'lymphoma': 'I-Entity'}, {'(NHL),': 'O'}, {'usually': 'O'}, {'of': 'O'}, {'the': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'O'}, {'tissue': 'O'}, {'(MALT)': 'O'}, {'and': 'O'}, {'most': 'O'}, {'frequently': 'O'}, {'located': 'O'}, {'in': 'O'}, {'the': 'O'}, {'major': 'O'}, {'salivary': 'O'}]"
Such disorders are strikingly heterogeneous and lead to a wider spectrum of clinical injury than seen in Parkinson's disease.,"[{'Such': 'O'}, {'disorders': 'O'}, {'are': 'O'}, {'strikingly': 'O'}, {'heterogeneous': 'O'}, {'and': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'a': 'O'}, {'wider': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'clinical': 'O'}, {'injury': 'O'}, {'than': 'O'}, {'seen': 'O'}, {'in': 'O'}, {""Parkinson's"": 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Impaired function is associated with reduced quality of life and symptoms such as pain, fatigue, and depression, as well as disease activity, illustrating the importance of optimal management of all aspects of the disease.Newcastle University, Newcastle upon Tyne, UK.from patients under investigation for Sjogrens syndrome.","[{'Impaired': 'B-Entity'}, {'function': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'reduced': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'and': 'O'}, {'symptoms': 'O'}, {'such': 'O'}, {'as': 'O'}, {'pain,': 'I-Entity'}, {'fatigue,': 'I-Entity'}, {'and': 'O'}, {'depression,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'illustrating': 'O'}, {'the': 'O'}, {'importance': 'O'}, {'of': 'O'}, {'optimal': 'O'}, {'management': 'O'}, {'of': 'O'}, {'all': 'O'}, {'aspects': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.Newcastle': 'O'}, {'University,': 'O'}, {'Newcastle': 'O'}, {'upon': 'O'}, {'Tyne,': 'O'}, {'UK.from': 'O'}, {'patients': 'O'}, {'under': 'O'}, {'investigation': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}]"
A single course of the chimeric humanized anti-CD20 antibody rituximab was effective in reducing disease activity in pSS patients for about six to nine months.,"[{'A': 'O'}, {'single': 'O'}, {'course': 'O'}, {'of': 'O'}, {'the': 'O'}, {'chimeric': 'O'}, {'humanized': 'O'}, {'anti-CD20': 'O'}, {'antibody': 'O'}, {'rituximab': 'I-Entity'}, {'was': 'O'}, {'effective': 'O'}, {'in': 'O'}, {'reducing': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'for': 'O'}, {'about': 'O'}, {'six': 'O'}, {'to': 'O'}, {'nine': 'O'}, {'months.': 'O'}]"
"Nontuberculous mycobacterial (NTM) infection in immunocompromized patients is currently a growing health concern, and we aimed to examine the relative risk of NTM infection in patients with Sjogrens syndrome (SS) compared with that in non-SS individuals.","[{'Nontuberculous': 'B-Entity'}, {'mycobacterial': 'I-Entity'}, {'(NTM)': 'I-Entity'}, {'infection': 'I-Entity'}, {'in': 'O'}, {'immunocompromized': 'O'}, {'patients': 'O'}, {'is': 'O'}, {'currently': 'O'}, {'a': 'O'}, {'growing': 'O'}, {'health': 'O'}, {'concern,': 'O'}, {'and': 'O'}, {'we': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'examine': 'O'}, {'the': 'O'}, {'relative': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'NTM': 'I-Entity'}, {'infection': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'that': 'O'}, {'in': 'O'}, {'non-SS': 'O'}, {'individuals.': 'O'}]"
"Tubulointerstitial nephritis is the most common renal disease in SS and may lead to renal tubular acidosis (RTA), which in turn may cause osteomalacia.","[{'Tubulointerstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'is': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'renal': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'may': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(RTA),': 'O'}, {'which': 'O'}, {'in': 'O'}, {'turn': 'O'}, {'may': 'O'}, {'cause': 'O'}, {'osteomalacia.': 'I-Entity'}]"
"The present study evaluated the role of Flt3L in the CNS of patients with pSS and in two non-autoimmune conditions, fibromyalgia (FM) and Alzheimer's disease (AD).","[{'The': 'O'}, {'present': 'O'}, {'study': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'Flt3L': 'O'}, {'in': 'O'}, {'the': 'O'}, {'CNS': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'O'}, {'and': 'O'}, {'in': 'O'}, {'two': 'O'}, {'non-autoimmune': 'O'}, {'conditions,': 'O'}, {'fibromyalgia': 'I-Entity'}, {'(FM)': 'O'}, {'and': 'O'}, {""Alzheimer's"": 'B-Entity'}, {'disease': 'I-Entity'}, {'(AD).': 'O'}]"
"Although her bicarbonate deficit was 365¬¨¬®‚Äö√Ñ‚Ä†mEq, we treated her with an overdose of intravenous sodium bicarbonate, 480¬¨¬®‚Äö√Ñ‚Ä†mEq for 24¬¨¬®‚Äö√Ñ‚Ä†hours, due to the severity of her acidemia and her altered mental status.","[{'Although': 'O'}, {'her': 'O'}, {'bicarbonate': 'I-Entity'}, {'deficit': 'O'}, {'was': 'O'}, {'365¬¨¬®‚Äö√Ñ‚Ä†mEq,': 'O'}, {'we': 'O'}, {'treated': 'O'}, {'her': 'O'}, {'with': 'O'}, {'an': 'O'}, {'overdose': 'I-Entity'}, {'of': 'O'}, {'intravenous': 'O'}, {'sodium': 'B-Entity'}, {'bicarbonate,': 'I-Entity'}, {'480¬¨¬®‚Äö√Ñ‚Ä†mEq': 'O'}, {'for': 'O'}, {'24¬¨¬®‚Äö√Ñ‚Ä†hours,': 'O'}]"
This study aimed to address the association between the usage of antibiotics to treat nontuberculous mycobacteria (NTM) infection and the risk of Sjogrens syndrome (SS).,"[{'This': 'O'}, {'study': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'address': 'O'}, {'the': 'O'}, {'association': 'O'}, {'between': 'O'}, {'the': 'O'}, {'usage': 'O'}, {'of': 'O'}, {'antibiotics': 'O'}, {'to': 'O'}, {'treat': 'O'}, {'nontuberculous': 'B-Entity'}, {'mycobacteria': 'I-Entity'}, {'(NTM)': 'O'}, {'infection': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
The purpose of this study is to evaluate systemic disease activity of pediatric Sjogrens syndrome (SS) using European League Against Rheumatism (EULAR) Sjogrens syndrome disease activity index (ESSDAI).,"[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'is': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'systemic': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'of': 'O'}, {'pediatric': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'using': 'O'}, {'European': 'O'}, {'League': 'O'}, {'Against': 'O'}, {'Rheumatism': 'I-Entity'}, {'(EULAR)': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'index': 'O'}, {'(ESSDAI).': 'O'}]"
"All patients were divided into either the systemic autoimmune group or non-autoimmune group, and the systemic autoimmune group was further divided into systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogrens syndrome, systemic sclerosis (SSc), and dermatomyositis/polymyositis (DM/PM).","[{'All': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'divided': 'O'}, {'into': 'O'}, {'either': 'O'}, {'the': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'group': 'O'}, {'or': 'O'}, {'non-autoimmune': 'O'}, {'group,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'group': 'O'}, {'was': 'O'}, {'further': 'O'}, {'divided': 'O'}, {'into': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA),': 'O'}, {'Sjogrens': 'O'}]"
"Clinical, laboratory and histopathological characteristics together with traditional risk factors for atherosclerosis were documented in all enrolled patients.","[{'Clinical,': 'O'}, {'laboratory': 'O'}, {'and': 'O'}, {'histopathological': 'O'}, {'characteristics': 'O'}, {'together': 'O'}, {'with': 'O'}, {'traditional': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'for': 'O'}, {'atherosclerosis': 'I-Entity'}, {'were': 'O'}, {'documented': 'O'}, {'in': 'O'}, {'all': 'O'}, {'enrolled': 'O'}, {'patients.': 'O'}]"
"This review takes into account epidemiological studies involving migraine and systemic lupus erythematosus, antiphospholipid syndrome, Sjogren's syndrome, and other diffuse connective tissue diseases.","[{'This': 'O'}, {'review': 'O'}, {'takes': 'O'}, {'into': 'O'}, {'account': 'O'}, {'epidemiological': 'O'}, {'studies': 'O'}, {'involving': 'O'}, {'migraine': 'I-Entity'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'antiphospholipid': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'other': 'O'}, {'diffuse': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"In this patient, serial MRI studies revealed partial resolution of dorsal column lesions, associated with decreased sensory ataxia and improved nerve-conduction studies.","[{'In': 'O'}, {'this': 'O'}, {'patient,': 'O'}, {'serial': 'O'}, {'MRI': 'O'}, {'studies': 'O'}, {'revealed': 'O'}, {'partial': 'O'}, {'resolution': 'O'}, {'of': 'O'}, {'dorsal': 'B-Entity'}, {'column': 'I-Entity'}, {'lesions,': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'decreased': 'O'}, {'sensory': 'O'}, {'ataxia': 'I-Entity'}, {'and': 'O'}, {'improved': 'O'}, {'nerve-conduction': 'O'}, {'studies.': 'O'}]"
"CTD-ILD pathogenesis includes an initial inflammatory phase, followed by a fibrotic phase, in which extracellular matrix proteins are produced and fibrotic scaring tissue within the lung develops.","[{'CTD-ILD': 'I-Entity'}, {'pathogenesis': 'O'}, {'includes': 'O'}, {'an': 'O'}, {'initial': 'O'}, {'inflammatory': 'O'}, {'phase,': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'a': 'O'}, {'fibrotic': 'O'}, {'phase,': 'O'}, {'in': 'O'}, {'which': 'O'}, {'extracellular': 'O'}, {'matrix': 'O'}, {'proteins': 'O'}, {'are': 'O'}, {'produced': 'O'}, {'and': 'O'}, {'fibrotic': 'O'}, {'scaring': 'O'}, {'tissue': 'O'}, {'within': 'O'}, {'the': 'O'}, {'lung': 'O'}, {'develops.': 'O'}]"
"Multivariate analysis adjusted for anti-SSA/Ro60, anti-SSB antibodies and rheumatoid factor status confirmed that anti-Ro52 antibodies positivity is a predictive factor for ILD (p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.01).","[{'Multivariate': 'O'}, {'analysis': 'O'}, {'adjusted': 'O'}, {'for': 'O'}, {'anti-SSA/Ro60,': 'O'}, {'anti-SSB': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'status': 'O'}, {'confirmed': 'O'}, {'that': 'O'}, {'anti-Ro52': 'O'}, {'antibodies': 'O'}, {'positivity': 'O'}, {'is': 'O'}, {'a': 'O'}, {'predictive': 'O'}, {'factor': 'O'}, {'for': 'O'}, {'ILD': 'I-Entity'}, {'(p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.01).': 'O'}]"
To compare the clinical efficacy of needle-knife and hydroxychloroquine sulfate in the treatment of dry mouth and eyes symptoms of primary Sjogrens syndrome.,"[{'To': 'O'}, {'compare': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'needle-knife': 'O'}, {'and': 'O'}, {'hydroxychloroquine': 'B-Entity'}, {'sulfate': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'eyes': 'I-Entity'}, {'symptoms': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
There is an increasing awareness that autoimmune diseases can present with neuropsychiatric manifestations.,"[{'There': 'O'}, {'is': 'O'}, {'an': 'O'}, {'increasing': 'O'}, {'awareness': 'O'}, {'that': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'can': 'O'}, {'present': 'O'}, {'with': 'O'}, {'neuropsychiatric': 'O'}, {'manifestations.': 'O'}]"
"A precise history taking is crucial for the correct diagnosis, and we could have avoided a lung resection in our case.Sumiyoshi, Nakaku, Hamamatsu City, Shizuoka, 430-8558, Japan.","[{'A': 'O'}, {'precise': 'O'}, {'history': 'O'}, {'taking': 'O'}, {'is': 'O'}, {'crucial': 'O'}, {'for': 'O'}, {'the': 'O'}, {'correct': 'O'}, {'diagnosis,': 'O'}, {'and': 'O'}, {'we': 'O'}, {'could': 'O'}, {'have': 'O'}, {'avoided': 'O'}, {'a': 'O'}, {'lung': 'O'}, {'resection': 'O'}, {'in': 'O'}, {'our': 'O'}, {'case.Sumiyoshi,': 'O'}, {'Nakaku,': 'O'}, {'Hamamatsu': 'O'}, {'City,': 'O'}, {'Shizuoka,': 'O'}, {'430-8558,': 'O'}, {'Japan.': 'O'}]"
"On examination, the most striking clinical finding was severe dental erosion and caries.","[{'On': 'O'}, {'examination,': 'O'}, {'the': 'O'}, {'most': 'O'}, {'striking': 'O'}, {'clinical': 'O'}, {'finding': 'O'}, {'was': 'O'}, {'severe': 'O'}, {'dental': 'B-Entity'}, {'erosion': 'I-Entity'}, {'and': 'O'}, {'caries.': 'I-Entity'}]"
"Here, we discuss three cases of primary SS where presenting manifestation was distal renal tubular acidosis.","[{'Here,': 'O'}, {'we': 'O'}, {'discuss': 'O'}, {'three': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'where': 'O'}, {'presenting': 'O'}, {'manifestation': 'O'}, {'was': 'O'}, {'distal': 'O'}, {'renal': 'O'}, {'tubular': 'I-Entity'}, {'acidosis.': 'I-Entity'}]"
Age and disease activity are correlated with pulmonary involvement in pSS patients.sialadenitis].,"[{'Age': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'are': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'pulmonary': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.sialadenitis].': 'O'}]"
"The heterogeneous nature of the disease and its slow progression, challenge the evaluation of these patients.","[{'The': 'O'}, {'heterogeneous': 'O'}, {'nature': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'and': 'O'}, {'its': 'O'}, {'slow': 'O'}, {'progression,': 'O'}, {'challenge': 'O'}, {'the': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'these': 'O'}, {'patients.': 'O'}]"
"Whereas functional annotation of alterations associated with hyposalivation identified the IL1 system as a dominant pro-inflammatory component, changes observed in context with ectopic lymphoid organization revealed specific shifts in chemotactic profiles and altered regulation of apoptotic processes.","[{'Whereas': 'O'}, {'functional': 'O'}, {'annotation': 'O'}, {'of': 'O'}, {'alterations': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'hyposalivation': 'O'}, {'identified': 'O'}, {'the': 'O'}, {'IL1': 'O'}, {'system': 'O'}, {'as': 'O'}, {'a': 'O'}, {'dominant': 'O'}, {'pro-inflammatory': 'O'}, {'component,': 'O'}, {'changes': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'context': 'O'}, {'with': 'O'}, {'ectopic': 'O'}, {'lymphoid': 'O'}, {'organization': 'O'}, {'revealed': 'O'}, {'specific': 'O'}, {'shifts': 'O'}, {'in': 'O'}, {'chemotactic': 'O'}, {'profiles': 'O'}, {'and': 'O'}, {'altered': 'O'}, {'regulation': 'O'}, {'of': 'O'}, {'apoptotic': 'O'}, {'processes.': 'O'}]"
"In sanroque mice, circulating Tfh cells increased in proportion to their GC counterparts, making circulating Tfh cells a feasible human biomarker of this novel mechanism of breakdown in GC tolerance.","[{'In': 'O'}, {'sanroque': 'O'}, {'mice,': 'O'}, {'circulating': 'O'}, {'Tfh': 'O'}, {'cells': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'proportion': 'O'}, {'to': 'O'}, {'their': 'O'}, {'GC': 'O'}, {'counterparts,': 'O'}, {'making': 'O'}, {'circulating': 'O'}, {'Tfh': 'O'}, {'cells': 'O'}, {'a': 'O'}, {'feasible': 'O'}, {'human': 'O'}, {'biomarker': 'O'}, {'of': 'O'}, {'this': 'O'}, {'novel': 'O'}, {'mechanism': 'O'}, {'of': 'O'}, {'breakdown': 'O'}, {'in': 'O'}, {'GC': 'O'}, {'tolerance.': 'O'}]"
"Clinically, this suggests that chronic Cevimeline administration may be useful therapeutically for SS patients suffering from a decrease in saliva secretion by improving the disordered AQP-5 localization.superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases.","[{'Clinically,': 'O'}, {'this': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'chronic': 'O'}, {'Cevimeline': 'I-Entity'}, {'administration': 'O'}, {'may': 'O'}, {'be': 'O'}, {'useful': 'O'}, {'therapeutically': 'O'}, {'for': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'a': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'saliva': 'O'}, {'secretion': 'O'}, {'by': 'O'}, {'improving': 'O'}, {'the': 'O'}, {'disordered': 'O'}, {'AQP-5': 'O'}, {'localization.superficial': 'O'}, {'ulcerative': 'B-Entity'}, {'keratitis': 'I-Entity'}, {'resistant': 'O'}, {'to': 'O'}, {'conventional': 'O'}, {'therapy:': 'O'}, {'A': 'O'}, {'report': 'O'}, {'of': 'O'}, {'3': 'O'}, {'cases.': 'O'}]"
"An event was defined as lymphoma relapse, treatment failure, disease progression, histological transformation or death.","[{'An': 'O'}, {'event': 'O'}, {'was': 'O'}, {'defined': 'O'}, {'as': 'O'}, {'lymphoma': 'I-Entity'}, {'relapse,': 'O'}, {'treatment': 'O'}, {'failure,': 'O'}, {'disease': 'O'}, {'progression,': 'O'}, {'histological': 'O'}, {'transformation': 'O'}, {'or': 'O'}, {'death.': 'I-Entity'}]"
"Anti-dsDNA and anti-nucleosome antibodies were found more frequently in JSLE patients and less frequently in LSLE patients (p‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.05 and 0.005, respectively) and decreased complement levels were more common in JSLE patients and less common in LSLE patients (p‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.001, 0.001, and‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.05, respectively).","[{'Anti-dsDNA': 'O'}, {'and': 'O'}, {'anti-nucleosome': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'found': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'in': 'O'}, {'JSLE': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'less': 'O'}, {'frequently': 'O'}, {'in': 'O'}, {'LSLE': 'I-Entity'}, {'patients': 'O'}, {'(p‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.05': 'O'}]"
"He also presented skin lesions on trunk and face, without neck stiffness.","[{'He': 'O'}, {'also': 'O'}, {'presented': 'O'}, {'skin': 'B-Entity'}, {'lesions': 'I-Entity'}, {'on': 'O'}, {'trunk': 'O'}, {'and': 'O'}, {'face,': 'O'}, {'without': 'O'}, {'neck': 'B-Entity'}, {'stiffness.': 'I-Entity'}]"
CT and MRI demonstrated bilateral subdural fluid collections over the frontal regions that were consistent with either chronic subdural haematomas or haemorrhagic subdural effusions.,"[{'CT': 'O'}, {'and': 'O'}, {'MRI': 'O'}, {'demonstrated': 'O'}, {'bilateral': 'O'}, {'subdural': 'B-Entity'}, {'fluid': 'I-Entity'}, {'collections': 'O'}, {'over': 'O'}, {'the': 'O'}, {'frontal': 'O'}, {'regions': 'O'}, {'that': 'O'}, {'were': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'either': 'O'}, {'chronic': 'O'}, {'subdural': 'B-Entity'}, {'haematomas': 'I-Entity'}, {'or': 'O'}, {'haemorrhagic': 'B-Entity'}, {'subdural': 'B-Entity'}, {'effusions.': 'I-Entity'}]"
"Primary Sjogrens (pSS) syndrome is a chronic, autoimmune, and systemic disease characterized by xerostomia, xerophthalmia, muscle pain and fatigue.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'(pSS)': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'chronic,': 'O'}, {'autoimmune,': 'O'}, {'and': 'O'}, {'systemic': 'O'}, {'disease': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'xerostomia,': 'I-Entity'}, {'xerophthalmia,': 'I-Entity'}, {'muscle': 'B-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'fatigue.': 'I-Entity'}]"
This study was designed to better characterize initial clinical and neurological findings in individuals diagnosed with HTLV-1 infection.,"[{'This': 'O'}, {'study': 'O'}, {'was': 'O'}, {'designed': 'O'}, {'to': 'O'}, {'better': 'O'}, {'characterize': 'O'}, {'initial': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'neurological': 'O'}, {'findings': 'O'}, {'in': 'O'}, {'individuals': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'HTLV-1': 'B-Entity'}, {'infection.': 'I-Entity'}]"
"These results suggest that HBZ-mediated Foxp3 expression is partly associated with the pathogenesis of HTLV-I-seropositive SS.Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.","[{'These': 'O'}, {'results': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'HBZ-mediated': 'I-Entity'}, {'Foxp3': 'O'}, {'expression': 'O'}, {'is': 'O'}, {'partly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'HTLV-I-seropositive': 'B-Entity'}, {'SS.Division': 'O'}, {'of': 'O'}, {'Advanced': 'O'}, {'Preventive': 'O'}, {'Medical': 'O'}, {'Sciences,': 'O'}, {'Nagasaki': 'O'}, {'University': 'O'}, {'Graduate': 'O'}, {'School': 'O'}, {'of': 'O'}, {'Biomedical': 'O'}, {'Sciences,': 'O'}, {'Nagasaki,': 'O'}, {'Japan.': 'O'}]"
Nearly all were resolved with continuous corticosteroid and aspirin therapy before discharge.,"[{'Nearly': 'O'}, {'all': 'O'}, {'were': 'O'}, {'resolved': 'O'}, {'with': 'O'}, {'continuous': 'O'}, {'corticosteroid': 'I-Entity'}, {'and': 'O'}, {'aspirin': 'I-Entity'}, {'therapy': 'O'}, {'before': 'O'}, {'discharge.': 'O'}]"
Management options depend on the underlying pathology but are generally limited due to lack of systematic randomized controlled trials.,"[{'Management': 'O'}, {'options': 'O'}, {'depend': 'O'}, {'on': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'pathology': 'O'}, {'but': 'O'}, {'are': 'O'}, {'generally': 'O'}, {'limited': 'O'}, {'due': 'O'}, {'to': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'systematic': 'O'}, {'randomized': 'O'}, {'controlled': 'O'}, {'trials.': 'O'}]"
"Subjects will be assessed each time before interventions during the 8-week intervention, in week 8 after all interventions and in week 12, 16, 20 and 24 for follow-up with different measurements.","[{'Subjects': 'O'}, {'will': 'O'}, {'be': 'O'}, {'assessed': 'O'}, {'each': 'O'}, {'time': 'O'}, {'before': 'O'}, {'interventions': 'O'}, {'during': 'O'}, {'the': 'O'}, {'8-week': 'O'}, {'intervention,': 'O'}, {'in': 'O'}, {'week': 'O'}, {'8': 'O'}, {'after': 'O'}, {'all': 'O'}, {'interventions': 'O'}, {'and': 'O'}, {'in': 'O'}, {'week': 'O'}, {'12,': 'O'}, {'16,': 'O'}, {'20': 'O'}, {'and': 'O'}, {'24': 'O'}, {'for': 'O'}, {'follow-up': 'O'}, {'with': 'O'}, {'different': 'O'}, {'measurements.': 'O'}]"
"The included studies investigated the effectiveness of an oral lubricating device for dry mouth, acupuncture for dry mouth, lacrimal punctum plugs for dry eyes and psychodynamic group therapy for coping with symptoms.","[{'The': 'O'}, {'included': 'O'}, {'studies': 'O'}, {'investigated': 'O'}, {'the': 'O'}, {'effectiveness': 'O'}, {'of': 'O'}, {'an': 'O'}, {'oral': 'O'}, {'lubricating': 'O'}, {'device': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'acupuncture': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'lacrimal': 'O'}, {'punctum': 'O'}, {'plugs': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'psychodynamic': 'O'}, {'group': 'O'}, {'therapy': 'O'}, {'for': 'O'}, {'coping': 'O'}, {'with': 'O'}, {'symptoms.': 'O'}]"
"Proteomic analysis of these fluids shows encouraging results and in this review, we addressed four major autoimmune-rheumatological diseases investigated through proteomic techniques and provide evidence-based data on the highlights obtained in systemic sclerosis, primary and secondary Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis.Italy.Jan 17.syndrome].","[{'Proteomic': 'O'}, {'analysis': 'O'}, {'of': 'O'}, {'these': 'O'}, {'fluids': 'O'}, {'shows': 'O'}, {'encouraging': 'O'}, {'results': 'O'}, {'and': 'O'}, {'in': 'O'}, {'this': 'O'}, {'review,': 'O'}, {'we': 'O'}, {'addressed': 'O'}, {'four': 'O'}, {'major': 'O'}, {'autoimmune-rheumatological': 'B-Entity'}, {'diseases': 'I-Entity'}, {'investigated': 'O'}, {'through': 'O'}, {'proteomic': 'O'}, {'techniques': 'O'}, {'and': 'O'}, {'provide': 'O'}, {'evidence-based': 'O'}, {'data': 'O'}, {'on': 'O'}, {'the': 'O'}, {'highlights': 'O'}, {'obtained': 'O'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'primary': 'O'}, {'and': 'O'}, {'secondary': 'O'}, {""Sjogren's"": 'B-Entity'}]"
Thorough investigation of patients with LETM who are negative for NMO-IgG may lead to an alternate cause for myelopathy.,"[{'Thorough': 'O'}, {'investigation': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'LETM': 'I-Entity'}, {'who': 'O'}, {'are': 'O'}, {'negative': 'O'}, {'for': 'O'}, {'NMO-IgG': 'I-Entity'}, {'may': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'an': 'O'}, {'alternate': 'O'}, {'cause': 'O'}, {'for': 'O'}, {'myelopathy.': 'I-Entity'}]"
AA amyloidosis is a rare complication of chronic inflammatory disorders and has been associated with rheumatoid arthritis and ankylosing spondylitis.,"[{'AA': 'B-Entity'}, {'amyloidosis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'chronic': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'disorders': 'I-Entity'}, {'and': 'O'}, {'has': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {'ankylosing': 'B-Entity'}, {'spondylitis.': 'I-Entity'}]"
"In addition, we review relevant features of other CNS inflammatory disorders that may mimic MS, including Sjogrens syndrome, systemic lupus erythematosus, Beh‚Äö√†√∂‚àö√ºet's disease, and primary CNS vasculitis.AL, USA.erythematosus.","[{'In': 'O'}, {'addition,': 'O'}, {'we': 'O'}, {'review': 'O'}, {'relevant': 'O'}, {'features': 'O'}, {'of': 'O'}, {'other': 'O'}, {'CNS': 'O'}, {'inflammatory': 'B-Entity'}, {'disorders': 'I-Entity'}, {'that': 'O'}, {'may': 'O'}, {'mimic': 'O'}, {'MS,': 'I-Entity'}, {'including': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {""Beh‚Äö√†√∂‚àö√ºet's"": 'O'}, {'disease,': 'I-Entity'}, {'and': 'O'}, {'primary': 'O'}, {'CNS': 'O'}, {'vasculitis.AL,': 'I-Entity'}]"
"For patients with hemorrhagic or central nervous system manifestations, plasma exchange is the therapy of choice and is relatively safe.","[{'For': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'hemorrhagic': 'I-Entity'}, {'or': 'I-Entity'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'manifestations,': 'O'}, {'plasma': 'O'}, {'exchange': 'O'}, {'is': 'O'}, {'the': 'O'}, {'therapy': 'O'}, {'of': 'O'}, {'choice': 'O'}, {'and': 'O'}, {'is': 'O'}, {'relatively': 'O'}, {'safe.': 'O'}]"
"Accordingly, the patient was diagnosed with stage IV chronic kidney disease.","[{'Accordingly,': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'stage': 'O'}, {'IV': 'O'}, {'chronic': 'B-Entity'}, {'kidney': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"Finally, the clinical application of LSCM in the staging of sicca syndrome has to be evaluated in future studies.non-traumatic corneal perforations or deep ulcers with descemetocele.","[{'Finally,': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'application': 'O'}, {'of': 'O'}, {'LSCM': 'O'}, {'in': 'O'}, {'the': 'O'}, {'staging': 'O'}, {'of': 'O'}, {'sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'has': 'O'}, {'to': 'O'}, {'be': 'O'}, {'evaluated': 'O'}, {'in': 'O'}, {'future': 'O'}, {'studies.non-traumatic': 'O'}, {'corneal': 'B-Entity'}, {'perforations': 'I-Entity'}, {'or': 'O'}, {'deep': 'O'}, {'ulcers': 'I-Entity'}, {'with': 'O'}, {'descemetocele.': 'I-Entity'}]"
"We assessed questionnaire scores of general fatigue, depressed mood, mental wellbeing, and physical functioning, tear production (Schirmer I test), tender point counts, serum DHEAS level, haemoglobin concentration, erythrocyte sedimentation rate, and serum immunoglobulin G. As compared to healthy participants, patients had more fatigue and depressed mood, reduced well-being and functioning, more dryness and pain, lower serum DHEAS levels, and more expression of disease as reflected by laboratory assessments (p‚Äö√Ñ√∂‚àö¬¢¬¨√ü0.001).","[{'We': 'O'}, {'assessed': 'O'}, {'questionnaire': 'O'}, {'scores': 'O'}, {'of': 'O'}, {'general': 'O'}, {'fatigue,': 'I-Entity'}, {'depressed': 'B-Entity'}, {'mood,': 'I-Entity'}, {'mental': 'O'}, {'wellbeing,': 'O'}, {'and': 'O'}, {'physical': 'O'}, {'functioning,': 'O'}, {'tear': 'O'}, {'production': 'O'}, {'(Schirmer': 'O'}, {'I': 'O'}, {'test),': 'O'}, {'tender': 'O'}, {'point': 'O'}, {'counts,': 'O'}, {'serum': 'O'}, {'DHEAS': 'I-Entity'}, {'level,': 'O'}, {'haemoglobin': 'O'}, {'concentration,': 'O'}, {'erythrocyte': 'O'}, {'sedimentation': 'O'}, {'rate,': 'O'}, {'and': 'O'}, {'serum': 'O'}, {'immunoglobulin': 'O'}]"
Primary Sjogrens syndrome (pSS) is a systemic rheumatic disease in which gastrointestinal (GI) symptoms are common.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'which': 'O'}, {'gastrointestinal': 'B-Entity'}, {'(GI)': 'I-Entity'}, {'symptoms': 'I-Entity'}, {'are': 'O'}, {'common.': 'O'}]"
"Multiple etiologies have been identified including autoimmune diseases, mainly systemic lupus erythematosus and Sjogren' syndrome.","[{'Multiple': 'O'}, {'etiologies': 'O'}, {'have': 'O'}, {'been': 'O'}, {'identified': 'O'}, {'including': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'mainly': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'and': 'O'}, {""Sjogren'"": 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Depressive symptoms were determined by the Patient Health Questionnaire 9 (PHQ-9).,"[{'Depressive': 'B-Entity'}, {'symptoms': 'O'}, {'were': 'O'}, {'determined': 'O'}, {'by': 'O'}, {'the': 'O'}, {'Patient': 'O'}, {'Health': 'O'}, {'Questionnaire': 'O'}, {'9': 'O'}, {'(PHQ-9).': 'O'}]"
"During the study period (2005-2010), 110 consecutive patients with an underlying systemic autoimmune disease, excluding Sjogren's syndrome, were referred for haematological consultation and bone marrow examination, due to cytopenias without evident cause including blood loss, haemolysis, nutritional deficiencies and haemoglobin disorders.","[{'During': 'O'}, {'the': 'O'}, {'study': 'O'}, {'period': 'O'}, {'(2005-2010),': 'O'}, {'110': 'O'}, {'consecutive': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'an': 'O'}, {'underlying': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'disease,': 'I-Entity'}, {'excluding': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'were': 'O'}, {'referred': 'O'}, {'for': 'O'}, {'haematological': 'O'}, {'consultation': 'O'}, {'and': 'O'}, {'bone': 'O'}, {'marrow': 'O'}, {'examination,': 'O'}, {'due': 'O'}, {'to': 'O'}, {'cytopenias': 'I-Entity'}, {'without': 'O'}, {'evident': 'O'}, {'cause': 'O'}, {'including': 'O'}, {'blood': 'B-Entity'}, {'loss,': 'I-Entity'}, {'haemolysis,': 'I-Entity'}]"
"Despite the implications of this prevalent disease, diagnosis currently takes years, partly due to the diversity in patient presentation.","[{'Despite': 'O'}, {'the': 'O'}, {'implications': 'O'}, {'of': 'O'}, {'this': 'O'}, {'prevalent': 'O'}, {'disease,': 'O'}, {'diagnosis': 'O'}, {'currently': 'O'}, {'takes': 'O'}, {'years,': 'O'}, {'partly': 'O'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diversity': 'O'}, {'in': 'O'}, {'patient': 'O'}, {'presentation.': 'O'}]"
A 62-year-old woman was diagnosed with severe osteomalacia caused by renal tubular acidosis associated with Sjogrens syndrome.,"[{'A': 'O'}, {'62-year-old': 'O'}, {'woman': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'osteomalacia': 'I-Entity'}, {'caused': 'O'}, {'by': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"A 61-year-old man developed subacute progressive dementia, general fatigue, a tonic-clonic seizure, and a decreased level of consciousness.","[{'A': 'O'}, {'61-year-old': 'O'}, {'man': 'O'}, {'developed': 'O'}, {'subacute': 'O'}, {'progressive': 'O'}, {'dementia,': 'I-Entity'}, {'general': 'O'}, {'fatigue,': 'I-Entity'}, {'a': 'O'}, {'tonic-clonic': 'B-Entity'}, {'seizure,': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'decreased': 'B-Entity'}, {'level': 'I-Entity'}, {'of': 'I-Entity'}, {'consciousness.': 'I-Entity'}]"
The difference in clinical characteristics and laboratory findings between anti-MDM2 positive and anti-MDM2 negative pSS patients was analyzed.,"[{'The': 'O'}, {'difference': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'characteristics': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'findings': 'O'}, {'between': 'O'}, {'anti-MDM2': 'O'}, {'positive': 'O'}, {'and': 'O'}, {'anti-MDM2': 'O'}, {'negative': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'was': 'O'}, {'analyzed.': 'O'}]"
Peripheral pattern and homogenous pattern was predominantly associated with anti-dsDNA (p < 0.05).,"[{'Peripheral': 'O'}, {'pattern': 'O'}, {'and': 'O'}, {'homogenous': 'O'}, {'pattern': 'O'}, {'was': 'O'}, {'predominantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'anti-dsDNA': 'O'}, {'(p': 'O'}, {'<': 'O'}, {'0.05).': 'O'}]"
"These may be important factors affecting the stability of the tear-film layer and its contribution to cGVHD-related dry eye.Shinjuku-ku, Tokyo, Japan.May 16.the clinical features of parotid glands.","[{'These': 'O'}, {'may': 'O'}, {'be': 'O'}, {'important': 'O'}, {'factors': 'O'}, {'affecting': 'O'}, {'the': 'O'}, {'stability': 'O'}, {'of': 'O'}, {'the': 'O'}, {'tear-film': 'O'}, {'layer': 'O'}, {'and': 'O'}, {'its': 'O'}, {'contribution': 'O'}, {'to': 'O'}, {'cGVHD-related': 'O'}, {'dry': 'B-Entity'}, {'eye.Shinjuku-ku,': 'I-Entity'}, {'Tokyo,': 'O'}, {'Japan.May': 'O'}, {'16.the': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'of': 'O'}, {'parotid': 'O'}, {'glands.': 'O'}]"
Constrictive bronchiolitis (CB) is a poorly understood pulmonary manifestation of primary Sjogren syndrome (pSS).,"[{'Constrictive': 'B-Entity'}, {'bronchiolitis': 'I-Entity'}, {'(CB)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'poorly': 'O'}, {'understood': 'O'}, {'pulmonary': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
Acquired Gitelman's syndrome (GS) associated with Sjogren syndrome (SS) is rare.,"[{'Acquired': 'O'}, {""Gitelman's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(GS)': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'rare.': 'O'}]"
"ILDs associated with dermatomyositis and secondary Sjogrens syndrome was diagnosed clinically when the following criteria were satisfied: (1) development of dyspnea within 2 months of presentation, (2) pulmonary dispersion dysfunction, (3) bilateral infiltrative shadows on chest high resolution computed tomography (HRCT).","[{'ILDs': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'dermatomyositis': 'I-Entity'}, {'and': 'O'}, {'secondary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'diagnosed': 'O'}, {'clinically': 'O'}, {'when': 'O'}, {'the': 'O'}, {'following': 'O'}, {'criteria': 'O'}, {'were': 'O'}, {'satisfied:': 'O'}, {'(1)': 'O'}, {'development': 'O'}, {'of': 'O'}, {'dyspnea': 'I-Entity'}, {'within': 'O'}, {'2': 'O'}, {'months': 'O'}, {'of': 'O'}, {'presentation,': 'O'}, {'(2)': 'O'}, {'pulmonary': 'B-Entity'}, {'dispersion': 'I-Entity'}, {'dysfunction,': 'I-Entity'}, {'(3)': 'O'}, {'bilateral': 'O'}, {'infiltrative': 'B-Entity'}, {'shadows': 'I-Entity'}]"
"Immunosuppressive treatment could be a therapeutic option for UIP/pSS.rights reserved.6-16-1, Tomioka-Higashi, Kanazawa-ku, Yokohama 236-0051, Japan.","[{'Immunosuppressive': 'O'}, {'treatment': 'O'}, {'could': 'O'}, {'be': 'O'}, {'a': 'O'}, {'therapeutic': 'O'}, {'option': 'O'}, {'for': 'O'}, {'UIP/pSS.rights': 'I-Entity'}, {'reserved.6-16-1,': 'O'}, {'Tomioka-Higashi,': 'O'}, {'Kanazawa-ku,': 'O'}, {'Yokohama': 'O'}, {'236-0051,': 'O'}, {'Japan.': 'O'}]"
Neuromyelitis optica is an idiopathic inflammatory demyelinating disease of the central nervous system (CNS) that predominantly affects the optic nerves and spinal cord.,"[{'Neuromyelitis': 'B-Entity'}, {'optica': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'idiopathic': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'demyelinating': 'I-Entity'}, {'disease': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'O'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'O'}, {'(CNS)': 'O'}, {'that': 'O'}, {'predominantly': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'optic': 'O'}, {'nerves': 'O'}, {'and': 'O'}, {'spinal': 'O'}, {'cord.': 'O'}]"
"Silencing of the RKIP gene leads to significantly increased expression and release of pro-inflammatory mediators supporting that RKIP expression could be involved in the suppression of NF-‚âà√≠‚Äö√†¬¥B activation in pSS salivary gland epithelial cells.and Histology Section, Laboratory of Cell Biology, University of Bari Medical School, Bari, Italy.Autoantibodies in Patients with Non-Hodgkin's Lymphoma.","[{'Silencing': 'O'}, {'of': 'O'}, {'the': 'O'}, {'RKIP': 'O'}, {'gene': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'significantly': 'O'}, {'increased': 'O'}, {'expression': 'O'}, {'and': 'O'}, {'release': 'O'}, {'of': 'O'}, {'pro-inflammatory': 'O'}, {'mediators': 'O'}, {'supporting': 'O'}, {'that': 'O'}, {'RKIP': 'O'}, {'expression': 'O'}, {'could': 'O'}, {'be': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'the': 'O'}, {'suppression': 'O'}, {'of': 'O'}, {'NF-‚âà√≠‚Äö√†¬¥B': 'O'}, {'activation': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'epithelial': 'O'}]"
HCQ at 300 mg daily for 12 weeks has no apparent clinical benefit for dry eye and systemic inflammation in pSS (ClinicalTrials.gov.,"[{'HCQ': 'I-Entity'}, {'at': 'O'}, {'300': 'O'}, {'mg': 'O'}, {'daily': 'O'}, {'for': 'O'}, {'12': 'O'}, {'weeks': 'O'}, {'has': 'O'}, {'no': 'O'}, {'apparent': 'O'}, {'clinical': 'O'}, {'benefit': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'and': 'O'}, {'systemic': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'(ClinicalTrials.gov.': 'O'}]"
"In pSS, however, the patients' worries about the consequences of their illness was a stronger correlate of physical HRQoL than pain.","[{'In': 'O'}, {'pSS,': 'O'}, {'however,': 'O'}, {'the': 'O'}, {""patients'"": 'O'}, {'worries': 'O'}, {'about': 'O'}, {'the': 'O'}, {'consequences': 'O'}, {'of': 'O'}, {'their': 'O'}, {'illness': 'O'}, {'was': 'O'}, {'a': 'O'}, {'stronger': 'O'}, {'correlate': 'O'}, {'of': 'O'}, {'physical': 'O'}, {'HRQoL': 'O'}, {'than': 'O'}, {'pain.': 'I-Entity'}]"
"Unstimulated whole saliva were examined for levels of ‚âà√≠‚Äö√¢¬ß2MG, Na+, potassium (K+), and chloride (Cl-).","[{'Unstimulated': 'O'}, {'whole': 'O'}, {'saliva': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'for': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'‚âà√≠‚Äö√¢¬ß2MG,': 'O'}, {'Na+,': 'I-Entity'}, {'potassium': 'I-Entity'}, {'(K+),': 'O'}, {'and': 'O'}, {'chloride': 'I-Entity'}, {'(Cl-).': 'O'}]"
"Most interestingly, B cell infiltrates were identified in patients' skin infiltrates, so that their presence might be a clue to the diagnosis of primary SS.","[{'Most': 'O'}, {'interestingly,': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'infiltrates': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'in': 'O'}, {""patients'"": 'O'}, {'skin': 'O'}, {'infiltrates,': 'O'}, {'so': 'O'}, {'that': 'O'}, {'their': 'O'}, {'presence': 'O'}, {'might': 'O'}, {'be': 'O'}, {'a': 'O'}, {'clue': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'SS.': 'I-Entity'}]"
"A 64-year-old woman complained of dry mouth for 21¬¨¬®‚Äö√Ñ‚Ä†years, recurrent swelling and pain on the right parotid in 2000, and urinary irritation symptoms in the past 2¬¨¬®‚Äö√Ñ‚Ä†years.","[{'A': 'O'}, {'64-year-old': 'O'}, {'woman': 'O'}, {'complained': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'for': 'O'}, {'21¬¨¬®‚Äö√Ñ‚Ä†years,': 'O'}, {'recurrent': 'O'}, {'swelling': 'I-Entity'}, {'and': 'O'}, {'pain': 'I-Entity'}, {'on': 'O'}, {'the': 'O'}, {'right': 'O'}, {'parotid': 'O'}, {'in': 'O'}, {'2000,': 'O'}, {'and': 'O'}, {'urinary': 'B-Entity'}, {'irritation': 'I-Entity'}, {'symptoms': 'O'}, {'in': 'O'}, {'the': 'O'}, {'past': 'O'}, {'2¬¨¬®‚Äö√Ñ‚Ä†years.': 'O'}]"
Human T-lymphotropic virus type 1 (HTLV-1) is known to cause HTLV-associated myelopathy (HAM)/tropical spastic paraparesis and adult T cell leukemia.,"[{'Human': 'B-Entity'}, {'T-lymphotropic': 'I-Entity'}, {'virus': 'O'}, {'type': 'O'}, {'1': 'O'}, {'(HTLV-1)': 'O'}, {'is': 'O'}, {'known': 'O'}, {'to': 'O'}, {'cause': 'O'}, {'HTLV-associated': 'B-Entity'}, {'myelopathy': 'I-Entity'}, {'(HAM)/tropical': 'O'}, {'spastic': 'I-Entity'}, {'paraparesis': 'I-Entity'}, {'and': 'O'}, {'adult': 'B-Entity'}, {'T': 'I-Entity'}, {'cell': 'I-Entity'}, {'leukemia.': 'I-Entity'}]"
Few studies are available on the risk of ischemic stroke after a diagnosis of primary Sjogrens syndrome (PSS).,"[{'Few': 'O'}, {'studies': 'O'}, {'are': 'O'}, {'available': 'O'}, {'on': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'ischemic': 'B-Entity'}, {'stroke': 'I-Entity'}, {'after': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(PSS).': 'O'}]"
The most common impairment of lung function was small airway function abnormalities.,"[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'impairment': 'B-Entity'}, {'of': 'I-Entity'}, {'lung': 'I-Entity'}, {'function': 'I-Entity'}, {'was': 'O'}, {'small': 'B-Entity'}, {'airway': 'I-Entity'}, {'function': 'I-Entity'}, {'abnormalities.': 'I-Entity'}]"
"Unlike typical SRC, however, the larger renal arteries seemed to be unaffected.","[{'Unlike': 'O'}, {'typical': 'O'}, {'SRC,': 'O'}, {'however,': 'O'}, {'the': 'O'}, {'larger': 'O'}, {'renal': 'O'}, {'arteries': 'O'}, {'seemed': 'O'}, {'to': 'O'}, {'be': 'O'}, {'unaffected.': 'O'}]"
Median time since diagnosis was 5.5 years.,"[{'Median': 'O'}, {'time': 'O'}, {'since': 'O'}, {'diagnosis': 'O'}, {'was': 'O'}, {'5.5': 'O'}, {'years.': 'O'}]"
"Furthermore, IL-6 deficiency abrogated differentiation of Th1 and extrafollicular T helper cells, germinal center B cells, and plasma cells in the spleen and eliminated renal T cells with IL-17, interferon-‚âà√≠‚Äö√¢‚Ä¢, and IL-21 production potential.","[{'Furthermore,': 'O'}, {'IL-6': 'O'}, {'deficiency': 'O'}, {'abrogated': 'O'}, {'differentiation': 'O'}, {'of': 'O'}, {'Th1': 'O'}, {'and': 'O'}, {'extrafollicular': 'O'}, {'T': 'O'}, {'helper': 'O'}, {'cells,': 'O'}, {'germinal': 'O'}, {'center': 'O'}, {'B': 'O'}, {'cells,': 'O'}, {'and': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'the': 'O'}, {'spleen': 'O'}, {'and': 'O'}, {'eliminated': 'O'}, {'renal': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'with': 'O'}, {'IL-17,': 'O'}, {'interferon-‚âà√≠‚Äö√¢‚Ä¢,': 'O'}]"
"We therefore, examined the autoantigenicity and disease specificity of major epitopes of cN-1A in patients with sporadic IBM compared with healthy and disease controls.","[{'We': 'O'}, {'therefore,': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'autoantigenicity': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'specificity': 'O'}, {'of': 'O'}, {'major': 'O'}, {'epitopes': 'O'}, {'of': 'O'}, {'cN-1A': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'sporadic': 'O'}, {'IBM': 'I-Entity'}, {'compared': 'O'}, {'with': 'O'}, {'healthy': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'controls.': 'O'}]"
"There was no evidence of renal allograft dysfunction at censor 6.6, 1.8 and 0.8 years after RTx.","[{'There': 'O'}, {'was': 'O'}, {'no': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'renal': 'O'}, {'allograft': 'O'}, {'dysfunction': 'I-Entity'}, {'at': 'O'}, {'censor': 'O'}, {'6.6,': 'O'}, {'1.8': 'O'}, {'and': 'O'}, {'0.8': 'O'}, {'years': 'O'}, {'after': 'O'}, {'RTx.': 'O'}]"
"Vasculitis, the presence of antiphospholipid antibodies, and platelet aggregation due to corticosteroid were possible mechanisms underlying the arrhythmias/conduction disturbances.Japan.","[{'Vasculitis,': 'I-Entity'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'antiphospholipid': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'platelet': 'B-Entity'}, {'aggregation': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'corticosteroid': 'I-Entity'}, {'were': 'O'}, {'possible': 'O'}, {'mechanisms': 'O'}, {'underlying': 'O'}, {'the': 'O'}, {'arrhythmias/conduction': 'I-Entity'}, {'disturbances.Japan.': 'I-Entity'}]"
"Since one of them experienced femoral fracture due to osteomalacia secondary to renal tubular acidosis, an earlier diagnosis of pSS is important in preventing serious complications.Medical Center, Seoul, Korea.Medical Center, Seoul, Korea.Medical Center, Seoul, Korea.Hospital at Gangdong, Seoul, Korea.Hospital at Gangdong, Seoul, Korea.Hospital at Gangdong, Seoul, Korea.Medical Center, Seoul, Korea.2017 Sep 30.","[{'Since': 'O'}, {'one': 'O'}, {'of': 'O'}, {'them': 'O'}, {'experienced': 'O'}, {'femoral': 'B-Entity'}, {'fracture': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'osteomalacia': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis,': 'I-Entity'}, {'an': 'O'}, {'earlier': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS': 'O'}, {'is': 'O'}, {'important': 'O'}, {'in': 'O'}, {'preventing': 'O'}, {'serious': 'O'}, {'complications.Medical': 'O'}, {'Center,': 'O'}, {'Seoul,': 'O'}, {'Korea.Medical': 'O'}, {'Center,': 'O'}, {'Seoul,': 'O'}, {'Korea.Medical': 'O'}, {'Center,': 'O'}, {'Seoul,': 'O'}, {'Korea.Hospital': 'O'}, {'at': 'O'}, {'Gangdong,': 'O'}]"
"In addition to the various types of interstitial pneumonia and airway abnormalities, air cysts and mediastinal manifestations may help diagnose primary Sjogren syndrome.Nabeshima, Saga 849-8501, Japan (R.E., T.K., T.H., N.K., H.I.","[{'In': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'the': 'O'}, {'various': 'O'}, {'types': 'O'}, {'of': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'and': 'O'}, {'airway': 'B-Entity'}, {'abnormalities,': 'I-Entity'}, {'air': 'O'}, {'cysts': 'I-Entity'}, {'and': 'O'}, {'mediastinal': 'O'}, {'manifestations': 'O'}, {'may': 'O'}, {'help': 'O'}, {'diagnose': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome.Nabeshima,': 'I-Entity'}, {'Saga': 'O'}, {'849-8501,': 'O'}, {'Japan': 'O'}, {'(R.E.,': 'O'}, {'T.K.,': 'O'}]"
"In these patients, the differential diagnosis includes infectious as well as inflammatory, reactive, or neoplastic processes.therapy/*immunology/pathology","[{'In': 'O'}, {'these': 'O'}, {'patients,': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'includes': 'O'}, {'infectious': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'inflammatory,': 'O'}, {'reactive,': 'O'}, {'or': 'O'}, {'neoplastic': 'I-Entity'}, {'processes.therapy/*immunology/pathology': 'O'}]"
"During the follow-up period, 2 patients developed pulmonary lesions (1 patient had an enlarged original cystic lesion in basal segment of right lower lobe 2 years after surgery, while the other developed new nodules 7 years after surgery).","[{'During': 'O'}, {'the': 'O'}, {'follow-up': 'O'}, {'period,': 'O'}, {'2': 'O'}, {'patients': 'O'}, {'developed': 'O'}, {'pulmonary': 'B-Entity'}, {'lesions': 'I-Entity'}, {'(1': 'O'}, {'patient': 'O'}, {'had': 'O'}, {'an': 'O'}, {'enlarged': 'O'}, {'original': 'O'}, {'cystic': 'O'}, {'lesion': 'I-Entity'}, {'in': 'O'}, {'basal': 'O'}, {'segment': 'O'}, {'of': 'O'}, {'right': 'O'}, {'lower': 'O'}, {'lobe': 'O'}, {'2': 'O'}, {'years': 'O'}, {'after': 'O'}, {'surgery,': 'O'}, {'while': 'O'}, {'the': 'O'}, {'other': 'O'}, {'developed': 'O'}, {'new': 'O'}, {'nodules': 'O'}, {'7': 'O'}, {'years': 'O'}, {'after': 'O'}, {'surgery).': 'O'}]"
ILD seems to be associated with higher levels of Lactic Dehydrogenases and positivity for Anti-Ro52k.,"[{'ILD': 'I-Entity'}, {'seems': 'O'}, {'to': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'higher': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'Lactic': 'O'}, {'Dehydrogenases': 'O'}, {'and': 'O'}, {'positivity': 'O'}, {'for': 'O'}, {'Anti-Ro52k.': 'O'}]"
"One etiology is primary pediatric Sjogren syndrome (SS), an autoimmune condition typically associated with dryness of the eyes and mouth in adults.","[{'One': 'O'}, {'etiology': 'O'}, {'is': 'O'}, {'primary': 'O'}, {'pediatric': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'an': 'O'}, {'autoimmune': 'O'}, {'condition': 'O'}, {'typically': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'dryness': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth': 'I-Entity'}, {'in': 'O'}, {'adults.': 'O'}]"
The diagnosis of SS can be challenging due to lack of a specific test for the disease.,"[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'challenging': 'O'}, {'due': 'O'}, {'to': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'a': 'O'}, {'specific': 'O'}, {'test': 'O'}, {'for': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
"Utilization of ambulatory dental services for dental caries, pulpitis, gingivitis, stomatitis, and periodontitis were significantly greater in patients with pSS over a three-year period prior to diagnosis compared with the controls.","[{'Utilization': 'O'}, {'of': 'O'}, {'ambulatory': 'O'}, {'dental': 'O'}, {'services': 'O'}, {'for': 'O'}, {'dental': 'B-Entity'}, {'caries,': 'I-Entity'}, {'pulpitis,': 'I-Entity'}, {'gingivitis,': 'I-Entity'}, {'stomatitis,': 'I-Entity'}, {'and': 'O'}, {'periodontitis': 'I-Entity'}, {'were': 'O'}, {'significantly': 'O'}, {'greater': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'over': 'O'}, {'a': 'O'}, {'three-year': 'O'}, {'period': 'O'}, {'prior': 'O'}, {'to': 'O'}, {'diagnosis': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'the': 'O'}, {'controls.': 'O'}]"
Similar results were found in a sub-analysis of patients with reported symptom onset after inclusion in the health surveys.,"[{'Similar': 'O'}, {'results': 'O'}, {'were': 'O'}, {'found': 'O'}, {'in': 'O'}, {'a': 'O'}, {'sub-analysis': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'reported': 'O'}, {'symptom': 'O'}, {'onset': 'O'}, {'after': 'O'}, {'inclusion': 'O'}, {'in': 'O'}, {'the': 'O'}, {'health': 'O'}, {'surveys.': 'O'}]"
We herein report the case of a 64-year old woman with recurrent attacks of hypokalemic quadriparesis which resulted from distal renal tubular acidosis (dRTA) secondary to Sjogren syndrome.,"[{'We': 'O'}, {'herein': 'O'}, {'report': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'64-year': 'O'}, {'old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'recurrent': 'O'}, {'attacks': 'O'}, {'of': 'O'}, {'hypokalemic': 'I-Entity'}, {'quadriparesis': 'I-Entity'}, {'which': 'O'}, {'resulted': 'O'}, {'from': 'O'}, {'distal': 'B-Entity'}, {'renal': 'I-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(dRTA)': 'O'}, {'secondary': 'O'}, {'to': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
We report a case of PGSS in a 64-year-old Black woman as revealed by neurological manifestations in an inflammatory context.,"[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'PGSS': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'64-year-old': 'O'}, {'Black': 'O'}, {'woman': 'O'}, {'as': 'O'}, {'revealed': 'O'}, {'by': 'O'}, {'neurological': 'O'}, {'manifestations': 'O'}, {'in': 'O'}, {'an': 'O'}, {'inflammatory': 'O'}, {'context.': 'O'}]"
"We examined the baseline clinical characteristics for patients with B-cell-mediated AI disease, plotted the overall survival and lymphoma-related survival (LRS) for these groups, and compared the median survival times.","[{'We': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'baseline': 'O'}, {'clinical': 'O'}, {'characteristics': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'B-cell-mediated': 'O'}, {'AI': 'B-Entity'}, {'disease,': 'I-Entity'}, {'plotted': 'O'}, {'the': 'O'}, {'overall': 'O'}, {'survival': 'O'}, {'and': 'O'}, {'lymphoma-related': 'I-Entity'}, {'survival': 'O'}, {'(LRS)': 'O'}, {'for': 'O'}, {'these': 'O'}, {'groups,': 'O'}, {'and': 'O'}, {'compared': 'O'}, {'the': 'O'}, {'median': 'O'}, {'survival': 'O'}, {'times.': 'O'}]"
"Systemic lupus erythematosus (SLE) and primary Sjogrens syndrome (SS) can be associated with inflammatory arthritis, which is underdiagnosed by clinical examination.","[{'Systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'and': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'can': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'inflammatory': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'which': 'O'}, {'is': 'O'}, {'underdiagnosed': 'O'}, {'by': 'O'}, {'clinical': 'O'}, {'examination.': 'O'}]"
"In total 73 Hungarian hospitalized patients, 32 children (2.5-10¬¨¬®‚Äö√Ñ‚Ä†years) and 41 adults (32-68¬¨¬®‚Äö√Ñ‚Ä†years), were enrolled in the study and underwent plasma assay of ‚âà√≠¬¨¬±-L-FUCA1 activity.","[{'In': 'O'}, {'total': 'O'}, {'73': 'O'}, {'Hungarian': 'O'}, {'hospitalized': 'O'}, {'patients,': 'O'}, {'32': 'O'}, {'children': 'O'}, {'(2.5-10¬¨¬®‚Äö√Ñ‚Ä†years)': 'O'}, {'and': 'O'}, {'41': 'O'}, {'adults': 'O'}, {'(32-68¬¨¬®‚Äö√Ñ‚Ä†years),': 'O'}, {'were': 'O'}, {'enrolled': 'O'}, {'in': 'O'}, {'the': 'O'}, {'study': 'O'}, {'and': 'O'}, {'underwent': 'O'}, {'plasma': 'O'}, {'assay': 'O'}]"
SRM and ES values for patient's and physician's global disease activity (GDA) and rheumatoid factor broadly followed the pattern of those of ESSPRI and ESSDAI.,"[{'SRM': 'O'}, {'and': 'O'}, {'ES': 'O'}, {'values': 'O'}, {'for': 'O'}, {""patient's"": 'O'}, {'and': 'O'}, {""physician's"": 'O'}, {'global': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'(GDA)': 'O'}, {'and': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'broadly': 'O'}, {'followed': 'O'}, {'the': 'O'}, {'pattern': 'O'}, {'of': 'O'}, {'those': 'O'}, {'of': 'O'}, {'ESSPRI': 'O'}, {'and': 'O'}, {'ESSDAI.': 'O'}]"
MNO-IgG was present in 40/47 patients with classic Devic's disease (85.1% sensitivity) and in 13/22 (59.1%) patients with disorders related to Devic's disease.,"[{'MNO-IgG': 'O'}, {'was': 'O'}, {'present': 'O'}, {'in': 'O'}, {'40/47': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'classic': 'O'}, {""Devic's"": 'B-Entity'}, {'disease': 'I-Entity'}, {'(85.1%': 'O'}, {'sensitivity)': 'O'}, {'and': 'O'}, {'in': 'O'}, {'13/22': 'O'}, {'(59.1%)': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'disorders': 'O'}, {'related': 'O'}, {'to': 'O'}, {""Devic's"": 'B-Entity'}, {'disease.': 'I-Entity'}]"
Sjogren's syndrome is a systemic autoimmune condition characterized by ocular and oral dryness.,"[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'condition': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'oral': 'I-Entity'}, {'dryness.': 'I-Entity'}]"
A study of the time interval of the symptoms that led to SS investigation showed a mean of 116 months.,"[{'A': 'O'}, {'study': 'O'}, {'of': 'O'}, {'the': 'O'}, {'time': 'O'}, {'interval': 'O'}, {'of': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'that': 'O'}, {'led': 'O'}, {'to': 'O'}, {'SS': 'I-Entity'}, {'investigation': 'O'}, {'showed': 'O'}, {'a': 'O'}, {'mean': 'O'}, {'of': 'O'}, {'116': 'O'}, {'months.': 'O'}]"
We present the case of a 19-year-old female with recurrent episodes of aseptic meningitis.,"[{'We': 'O'}, {'present': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'19-year-old': 'O'}, {'female': 'O'}, {'with': 'O'}, {'recurrent': 'O'}, {'episodes': 'O'}, {'of': 'O'}, {'aseptic': 'B-Entity'}, {'meningitis.': 'I-Entity'}]"
"It has also been reported to effectively control the symptoms of Sj‚Äö√†√∂‚Äö√†√®gren's syndrome, as well as preventing thrombosis in phospholipid antibody (aPL) syndrome.","[{'It': 'O'}, {'has': 'O'}, {'also': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'to': 'O'}, {'effectively': 'O'}, {'control': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {""Sj‚Äö√†√∂‚Äö√†√®gren's"": 'O'}, {'syndrome,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'preventing': 'O'}, {'thrombosis': 'I-Entity'}, {'in': 'O'}, {'phospholipid': 'B-Entity'}, {'antibody': 'I-Entity'}, {'(aPL)': 'O'}, {'syndrome.': 'I-Entity'}]"
"At multivariate analysis, headache, cognitive disorders and psychiatric symptoms was significantly associated to serological markers (anti-SSA), MRS and ultrasonographic features.","[{'At': 'O'}, {'multivariate': 'O'}, {'analysis,': 'O'}, {'headache,': 'I-Entity'}, {'cognitive': 'B-Entity'}, {'disorders': 'I-Entity'}, {'and': 'O'}, {'psychiatric': 'I-Entity'}, {'symptoms': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'to': 'O'}, {'serological': 'O'}, {'markers': 'O'}, {'(anti-SSA),': 'O'}, {'MRS': 'O'}, {'and': 'O'}, {'ultrasonographic': 'O'}, {'features.': 'O'}]"
Matrix metalloproteinase 9 is an inflammatory biomarker that has been shown to be elevated in the tears of patients with dry eyes.,"[{'Matrix': 'O'}, {'metalloproteinase': 'O'}, {'9': 'O'}, {'is': 'O'}, {'an': 'O'}, {'inflammatory': 'O'}, {'biomarker': 'O'}, {'that': 'O'}, {'has': 'O'}, {'been': 'O'}, {'shown': 'O'}, {'to': 'O'}, {'be': 'O'}, {'elevated': 'O'}, {'in': 'O'}, {'the': 'O'}, {'tears': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eyes.': 'I-Entity'}]"
The objective of the present study was to evaluate the efficacy of Oral Balance saliva substitute in alleviating dry mouth symptoms in a sample of patients with secondary Sjogrens syndrome.,"[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'Oral': 'O'}, {'Balance': 'O'}, {'saliva': 'O'}, {'substitute': 'O'}, {'in': 'O'}, {'alleviating': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'symptoms': 'O'}, {'in': 'O'}, {'a': 'O'}, {'sample': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'secondary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
"Pharmacologic BTK inhibition effectively diminishes disease symptoms in mouse models of autoimmunity; conversely, transgenic BTK overexpression induces systemic autoimmunity in mice.","[{'Pharmacologic': 'O'}, {'BTK': 'O'}, {'inhibition': 'O'}, {'effectively': 'O'}, {'diminishes': 'O'}, {'disease': 'O'}, {'symptoms': 'O'}, {'in': 'O'}, {'mouse': 'O'}, {'models': 'O'}, {'of': 'O'}, {'autoimmunity;': 'I-Entity'}, {'conversely,': 'O'}, {'transgenic': 'O'}, {'BTK': 'O'}, {'overexpression': 'O'}, {'induces': 'O'}, {'systemic': 'B-Entity'}, {'autoimmunity': 'I-Entity'}, {'in': 'O'}, {'mice.': 'O'}]"
"Thus, we attempted to describe the morphological features and evaluate the cellular density within the corneal epithelial layers in patients with non-Sjogrens (NSDE) and Sjogrens syndrome dry eyes (SSDE) by in vivo confocal microscopy (IVCM).","[{'Thus,': 'O'}, {'we': 'O'}, {'attempted': 'O'}, {'to': 'O'}, {'describe': 'O'}, {'the': 'O'}, {'morphological': 'O'}, {'features': 'O'}, {'and': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'cellular': 'O'}, {'density': 'O'}, {'within': 'O'}, {'the': 'O'}, {'corneal': 'O'}, {'epithelial': 'O'}, {'layers': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'non-Sjogrens': 'B-Entity'}, {'(NSDE)': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'(SSDE)': 'O'}, {'by': 'O'}, {'in': 'O'}, {'vivo': 'O'}, {'confocal': 'O'}, {'microscopy': 'O'}, {'(IVCM).': 'O'}]"
Pro-F and ESS scores were significantly reduced across all three visits.,"[{'Pro-F': 'O'}, {'and': 'O'}, {'ESS': 'O'}, {'scores': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'reduced': 'O'}, {'across': 'O'}, {'all': 'O'}, {'three': 'O'}, {'visits.': 'O'}]"
The inner ear histology in a SS mouse model has shown degeneration of the stria vascularis (SV) and immunoglobulin G deposition on the basement membrane of SV blood vessels.,"[{'The': 'O'}, {'inner': 'O'}, {'ear': 'O'}, {'histology': 'O'}, {'in': 'O'}, {'a': 'O'}, {'SS': 'I-Entity'}, {'mouse': 'O'}, {'model': 'O'}, {'has': 'O'}, {'shown': 'O'}, {'degeneration': 'B-Entity'}, {'of': 'O'}, {'the': 'O'}, {'stria': 'I-Entity'}, {'vascularis': 'I-Entity'}, {'(SV)': 'O'}, {'and': 'O'}, {'immunoglobulin': 'O'}, {'G': 'O'}, {'deposition': 'O'}, {'on': 'O'}, {'the': 'O'}, {'basement': 'O'}, {'membrane': 'O'}, {'of': 'O'}, {'SV': 'O'}, {'blood': 'O'}, {'vessels.': 'O'}]"
This pathology is often diagnosed when the status is irreversible and is consequently associated with a high morbi-mortality.,"[{'This': 'O'}, {'pathology': 'O'}, {'is': 'O'}, {'often': 'O'}, {'diagnosed': 'O'}, {'when': 'O'}, {'the': 'O'}, {'status': 'O'}, {'is': 'O'}, {'irreversible': 'O'}, {'and': 'O'}, {'is': 'O'}, {'consequently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'high': 'O'}, {'morbi-mortality.': 'O'}]"
The aim of the present study was to evaluate plasma vitamin D (vit D) levels in patients with SS and to compare this with a control group.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'plasma': 'O'}, {'vitamin': 'B-Entity'}, {'D': 'I-Entity'}, {'(vit': 'O'}, {'D)': 'I-Entity'}, {'levels': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'to': 'O'}, {'compare': 'O'}, {'this': 'O'}, {'with': 'O'}, {'a': 'O'}, {'control': 'O'}, {'group.': 'O'}]"
The cerebrospinal fluid examination revealed a slight increase in the cell count and protein content.,"[{'The': 'O'}, {'cerebrospinal': 'O'}, {'fluid': 'O'}, {'examination': 'O'}, {'revealed': 'O'}, {'a': 'O'}, {'slight': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'the': 'O'}, {'cell': 'O'}, {'count': 'O'}, {'and': 'O'}, {'protein': 'O'}, {'content.': 'O'}]"
"Finally, we analyzed the potential occurrence of a genetic association between IL-21 or IL-21R gene polymorphisms and pSS or elevated IL-21 secretion.","[{'Finally,': 'O'}, {'we': 'O'}, {'analyzed': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'occurrence': 'O'}, {'of': 'O'}, {'a': 'O'}, {'genetic': 'O'}, {'association': 'O'}, {'between': 'O'}, {'IL-21': 'O'}, {'or': 'O'}, {'IL-21R': 'O'}, {'gene': 'O'}, {'polymorphisms': 'O'}, {'and': 'O'}, {'pSS': 'O'}, {'or': 'O'}, {'elevated': 'O'}, {'IL-21': 'O'}, {'secretion.': 'O'}]"
ELISA was used to evaluate serum inflammatory cytokines in SS mice and autoantigens in NOD mice.,"[{'ELISA': 'O'}, {'was': 'O'}, {'used': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'serum': 'O'}, {'inflammatory': 'O'}, {'cytokines': 'O'}, {'in': 'O'}, {'SS': 'O'}, {'mice': 'O'}, {'and': 'O'}, {'autoantigens': 'O'}, {'in': 'O'}, {'NOD': 'O'}, {'mice.': 'O'}]"
"Evaluation and management of hereditary thrombophilia, MTHFR gene polymorphisms, and/or autoimmune conditions may be beneficial for patients with unexplained infertility.University, Ankara, Turkey.University, Ankara, Turkey.","[{'Evaluation': 'O'}, {'and': 'O'}, {'management': 'O'}, {'of': 'O'}, {'hereditary': 'B-Entity'}, {'thrombophilia,': 'I-Entity'}, {'MTHFR': 'O'}, {'gene': 'O'}, {'polymorphisms,': 'O'}, {'and/or': 'O'}, {'autoimmune': 'B-Entity'}, {'conditions': 'O'}, {'may': 'O'}, {'be': 'O'}, {'beneficial': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'unexplained': 'O'}, {'infertility.University,': 'I-Entity'}, {'Ankara,': 'O'}, {'Turkey.University,': 'O'}, {'Ankara,': 'O'}, {'Turkey.': 'O'}]"
B and T-cell hyperactivity due to chronic antigenic stimulation and the consequent presence of acquired lymphoid tissue seems to play a key role in the pathogenesis of AI-related lymphomas.,"[{'B': 'O'}, {'and': 'O'}, {'T-cell': 'O'}, {'hyperactivity': 'O'}, {'due': 'O'}, {'to': 'O'}, {'chronic': 'O'}, {'antigenic': 'O'}, {'stimulation': 'O'}, {'and': 'O'}, {'the': 'O'}, {'consequent': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'acquired': 'O'}, {'lymphoid': 'O'}, {'tissue': 'O'}, {'seems': 'O'}, {'to': 'O'}, {'play': 'O'}, {'a': 'O'}, {'key': 'O'}, {'role': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'AI-related': 'I-Entity'}, {'lymphomas.': 'I-Entity'}]"
US is also useful for the evaluation of inflammatory process affecting salivary glands (e.g.,"[{'US': 'O'}, {'is': 'O'}, {'also': 'O'}, {'useful': 'O'}, {'for': 'O'}, {'the': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'inflammatory': 'O'}, {'process': 'O'}, {'affecting': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'(e.g.': 'O'}]"
"Sjogrens syndrome can cause not only corneal perforation but also mucosal perforation, which may lead to a lacrimal fistula.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'can': 'O'}, {'cause': 'O'}, {'not': 'O'}, {'only': 'O'}, {'corneal': 'O'}, {'perforation': 'I-Entity'}, {'but': 'O'}, {'also': 'O'}, {'mucosal': 'O'}, {'perforation,': 'I-Entity'}, {'which': 'O'}, {'may': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'a': 'O'}, {'lacrimal': 'B-Entity'}, {'fistula.': 'I-Entity'}]"
In the course of pSS the internal organs may be involved and the symptoms may concern any system.,"[{'In': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'the': 'O'}, {'internal': 'O'}, {'organs': 'O'}, {'may': 'O'}, {'be': 'O'}, {'involved': 'O'}, {'and': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'may': 'O'}, {'concern': 'O'}, {'any': 'O'}, {'system.': 'O'}]"
"Further, a significant reduction of the subjective sensation of dry mouth symptoms could be observed (p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.0001).","[{'Further,': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'reduction': 'O'}, {'of': 'O'}, {'the': 'O'}, {'subjective': 'O'}, {'sensation': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'symptoms': 'I-Entity'}, {'could': 'O'}, {'be': 'O'}, {'observed': 'O'}, {'(p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.0001).': 'O'}]"
"Most of the patients experienced a subjective clinical improvement documented by the statistically significant reductions in the postoperative mean pain VAS (group A P<.001; group B P=.004), Xerostomia Inventory (P<.001 and P=.003) and ESSPRI scores (P<.001 and P=.008).","[{'Most': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'experienced': 'O'}, {'a': 'O'}, {'subjective': 'O'}, {'clinical': 'O'}, {'improvement': 'O'}, {'documented': 'O'}, {'by': 'O'}, {'the': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'reductions': 'O'}, {'in': 'O'}, {'the': 'O'}, {'postoperative': 'O'}, {'mean': 'O'}, {'pain': 'I-Entity'}, {'VAS': 'O'}, {'(group': 'O'}, {'A': 'O'}, {'P<.001;': 'O'}, {'group': 'O'}, {'B': 'O'}, {'P=.004),': 'O'}, {'Xerostomia': 'I-Entity'}, {'Inventory': 'O'}, {'(P<.001': 'O'}, {'and': 'O'}, {'P=.003)': 'O'}]"
"The common methods to diagnose ILDs, such as clinical manifestations, pulmonary function test, and radiological examinations are not specific for ILDs and not able to diagnose ILDs at the early stage due to their low sensitivity.","[{'The': 'O'}, {'common': 'O'}, {'methods': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'ILDs,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'clinical': 'O'}, {'manifestations,': 'O'}, {'pulmonary': 'O'}, {'function': 'O'}, {'test,': 'O'}, {'and': 'O'}, {'radiological': 'O'}, {'examinations': 'O'}, {'are': 'O'}, {'not': 'O'}, {'specific': 'O'}, {'for': 'O'}, {'ILDs': 'I-Entity'}, {'and': 'O'}, {'not': 'O'}, {'able': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'ILDs': 'I-Entity'}, {'at': 'O'}, {'the': 'O'}, {'early': 'O'}, {'stage': 'O'}, {'due': 'O'}, {'to': 'O'}, {'their': 'O'}, {'low': 'O'}, {'sensitivity.': 'O'}]"
Juvenile Sjogrens Syndrome (jSS) is a rare phenomenon that may appear as primary jSS or associated with mixed connective tissue disease (MCTD) and other autoimmune diseases as secondary jSS.,"[{'Juvenile': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'(jSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'phenomenon': 'O'}, {'that': 'O'}, {'may': 'O'}, {'appear': 'O'}, {'as': 'O'}, {'primary': 'O'}, {'jSS': 'I-Entity'}, {'or': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'mixed': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'(MCTD)': 'O'}, {'and': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'as': 'O'}, {'secondary': 'O'}, {'jSS.': 'I-Entity'}]"
"As respiratory symptoms are also common in pSS patients and may have different etiologies, we wanted to evaluate the amount and impact of respiratory symptoms in out-patients with pSS and to assess if such symptoms are related to concomitant COPD.","[{'As': 'O'}, {'respiratory': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'are': 'O'}, {'also': 'O'}, {'common': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'may': 'O'}, {'have': 'O'}, {'different': 'O'}, {'etiologies,': 'O'}, {'we': 'O'}, {'wanted': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'amount': 'O'}, {'and': 'O'}, {'impact': 'O'}, {'of': 'O'}, {'respiratory': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'in': 'O'}, {'out-patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'if': 'O'}, {'such': 'O'}, {'symptoms': 'O'}, {'are': 'O'}, {'related': 'O'}, {'to': 'O'}, {'concomitant': 'O'}, {'COPD.': 'I-Entity'}]"
Dystrophic calcinosis in soft tissue occurs in damaged or devitalized tissues in the presence of normal calcium and phosphorous metabolism.,"[{'Dystrophic': 'B-Entity'}, {'calcinosis': 'I-Entity'}, {'in': 'O'}, {'soft': 'O'}, {'tissue': 'O'}, {'occurs': 'O'}, {'in': 'O'}, {'damaged': 'O'}, {'or': 'O'}, {'devitalized': 'O'}, {'tissues': 'O'}, {'in': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'normal': 'O'}, {'calcium': 'I-Entity'}, {'and': 'O'}, {'phosphorous': 'I-Entity'}, {'metabolism.': 'O'}]"
Clinical observation studies suggest a potential association between SS and IC.,"[{'Clinical': 'O'}, {'observation': 'O'}, {'studies': 'O'}, {'suggest': 'O'}, {'a': 'O'}, {'potential': 'O'}, {'association': 'O'}, {'between': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'IC.': 'I-Entity'}]"
"The pattern of beat-to-beat blood pressure associated with performance of the Valsalva maneuver, and a low plasma norepinephrine level that did not increase in response to standing, established that the orthostatic hypotension was neurogenic.","[{'The': 'O'}, {'pattern': 'O'}, {'of': 'O'}, {'beat-to-beat': 'O'}, {'blood': 'O'}, {'pressure': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'performance': 'O'}, {'of': 'O'}, {'the': 'O'}, {'Valsalva': 'O'}, {'maneuver,': 'O'}, {'and': 'O'}, {'a': 'O'}, {'low': 'O'}, {'plasma': 'O'}, {'norepinephrine': 'I-Entity'}, {'level': 'O'}, {'that': 'O'}, {'did': 'O'}, {'not': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'response': 'O'}, {'to': 'O'}, {'standing,': 'O'}, {'established': 'O'}, {'that': 'O'}, {'the': 'O'}, {'orthostatic': 'B-Entity'}, {'hypotension': 'I-Entity'}, {'was': 'O'}, {'neurogenic.': 'I-Entity'}]"
"In the IN group, 3 patients presented with chronic kidney disease (CKD), 4 with renal tubular acidosis (RTA), 2 with symptomatic hypokalaemia, 4 with renal colic and 1 with haematuria/proteinuria.","[{'In': 'O'}, {'the': 'O'}, {'IN': 'O'}, {'group,': 'O'}, {'3': 'O'}, {'patients': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'chronic': 'B-Entity'}, {'kidney': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CKD),': 'O'}, {'4': 'O'}, {'with': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'(RTA),': 'O'}, {'2': 'O'}, {'with': 'O'}, {'symptomatic': 'O'}, {'hypokalaemia,': 'I-Entity'}, {'4': 'O'}, {'with': 'O'}, {'renal': 'B-Entity'}, {'colic': 'I-Entity'}, {'and': 'O'}, {'1': 'O'}, {'with': 'O'}, {'haematuria/proteinuria.': 'I-Entity'}]"
Patients with DLBCL and AI disease were more commonly female.,"[{'Patients': 'O'}, {'with': 'O'}, {'DLBCL': 'I-Entity'}, {'and': 'O'}, {'AI': 'B-Entity'}, {'disease': 'I-Entity'}, {'were': 'O'}, {'more': 'O'}, {'commonly': 'O'}, {'female.': 'O'}]"
Sialadenitis and xerostomia are major adverse effects of (131)I therapy in thyroid cancer patients.,"[{'Sialadenitis': 'I-Entity'}, {'and': 'O'}, {'xerostomia': 'I-Entity'}, {'are': 'O'}, {'major': 'O'}, {'adverse': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'(131)I': 'O'}, {'therapy': 'O'}, {'in': 'O'}, {'thyroid': 'B-Entity'}, {'cancer': 'I-Entity'}, {'patients.': 'O'}]"
"Pain is a major factor in health quality in Sjogrens syndrome (SS), but little is known about the factors that contribute to pain severity.","[{'Pain': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'major': 'O'}, {'factor': 'O'}, {'in': 'O'}, {'health': 'O'}, {'quality': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'but': 'O'}, {'little': 'O'}, {'is': 'O'}, {'known': 'O'}, {'about': 'O'}, {'the': 'O'}, {'factors': 'O'}, {'that': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'pain': 'I-Entity'}, {'severity.': 'O'}]"
"To test the hypothesis that increased Treg cell activity in B(-/-) mice contributes to their resistance to other autoimmune diseases, WT and B(-/-) NOD mice were given anti-CD25 to transiently deplete CD4(+) CD25(+) Treg cells.","[{'To': 'O'}, {'test': 'O'}, {'the': 'O'}, {'hypothesis': 'O'}, {'that': 'O'}, {'increased': 'O'}, {'Treg': 'O'}, {'cell': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'B(-/-)': 'O'}, {'mice': 'O'}, {'contributes': 'O'}, {'to': 'O'}, {'their': 'O'}, {'resistance': 'O'}, {'to': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'WT': 'O'}, {'and': 'O'}, {'B(-/-)': 'O'}, {'NOD': 'O'}, {'mice': 'O'}, {'were': 'O'}, {'given': 'O'}, {'anti-CD25': 'O'}, {'to': 'O'}, {'transiently': 'O'}, {'deplete': 'O'}, {'CD4(+)': 'O'}, {'CD25(+)': 'O'}]"
"A diagnosis of MAS should be considered when a patient with rheumatic disease presents with prolonged high fever, peripheral cytopenia and liver failure.","[{'A': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'MAS': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'when': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'presents': 'O'}, {'with': 'O'}, {'prolonged': 'O'}, {'high': 'O'}, {'fever,': 'I-Entity'}, {'peripheral': 'O'}, {'cytopenia': 'I-Entity'}, {'and': 'O'}, {'liver': 'B-Entity'}, {'failure.': 'I-Entity'}]"
"A 65-year-old female patient with recurrent parotitis due to Sjogren syndrome was referred to us, complaining of weekly bouts of inflammation.","[{'A': 'O'}, {'65-year-old': 'O'}, {'female': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'recurrent': 'O'}, {'parotitis': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'referred': 'O'}, {'to': 'O'}, {'us,': 'O'}, {'complaining': 'O'}, {'of': 'O'}, {'weekly': 'O'}, {'bouts': 'O'}, {'of': 'O'}, {'inflammation.': 'I-Entity'}]"
SS animal model was developed from C57BL/6J mice through immunological induction (SS mice) and NOD/ShiltJNju (NOD) mice.,"[{'SS': 'I-Entity'}, {'animal': 'O'}, {'model': 'O'}, {'was': 'O'}, {'developed': 'O'}, {'from': 'O'}, {'C57BL/6J': 'O'}, {'mice': 'O'}, {'through': 'O'}, {'immunological': 'O'}, {'induction': 'O'}, {'(SS': 'O'}, {'mice)': 'O'}, {'and': 'O'}, {'NOD/ShiltJNju': 'O'}, {'(NOD)': 'O'}, {'mice.': 'O'}]"
"Clinicians should pay specific attention and carefully evaluate the possibility of primary SS in patients with PAH.of Tokyo, Tokyo, Japan.The University of Tokyo, Tokyo, Japan.of Tokyo, Tokyo, Japan.of Tokyo, Tokyo, Japan.of Tokyo, Tokyo, Japan.of Tokyo, Tokyo, Japan.of Tokyo, Tokyo, Japan.of Tokyo, Tokyo, Japan.of Tokyo, Tokyo, Japan.of Tokyo, Tokyo, Japan.of Tokyo, Tokyo, Japan.Yokohama, Japan.of Tokyo, Tokyo, Japan.and Nippon Shinyaku; and honoraria from Bayer, Pfizer, Actelion, and Nippon Shinyaku.","[{'Clinicians': 'O'}, {'should': 'O'}, {'pay': 'O'}, {'specific': 'O'}, {'attention': 'O'}, {'and': 'O'}, {'carefully': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'PAH.of': 'I-Entity'}, {'Tokyo,': 'O'}, {'Tokyo,': 'O'}, {'Japan.The': 'O'}, {'University': 'O'}, {'of': 'O'}, {'Tokyo,': 'O'}, {'Tokyo,': 'O'}, {'Japan.of': 'O'}, {'Tokyo,': 'O'}, {'Tokyo,': 'O'}, {'Japan.of': 'O'}, {'Tokyo,': 'O'}, {'Tokyo,': 'O'}, {'Japan.of': 'O'}, {'Tokyo,': 'O'}, {'Tokyo,': 'O'}, {'Japan.of': 'O'}, {'Tokyo,': 'O'}, {'Tokyo,': 'O'}]"
"The results showed that the salivary EGF levels decreased with the progression of SS, and this deterioration in saliva quality as well as hyposalivation could play a role in the pathogenesis of refractory intraoral manifestations in SS patients.","[{'The': 'O'}, {'results': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'EGF': 'O'}, {'levels': 'O'}, {'decreased': 'O'}, {'with': 'O'}, {'the': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'this': 'O'}, {'deterioration': 'O'}, {'in': 'O'}, {'saliva': 'O'}, {'quality': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'hyposalivation': 'I-Entity'}, {'could': 'O'}, {'play': 'O'}, {'a': 'O'}, {'role': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'refractory': 'O'}, {'intraoral': 'O'}, {'manifestations': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients.': 'O'}]"
We described the musculoskeletal manifestations and analyzed the differential diagnoses.,"[{'We': 'O'}, {'described': 'O'}, {'the': 'O'}, {'musculoskeletal': 'O'}, {'manifestations': 'O'}, {'and': 'O'}, {'analyzed': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnoses.': 'O'}]"
"This data could be useful for the future study of pleural effusion in SS.Traditional Chinese Medicine Jinan 250011, China.symptoms of the inflammatory disease or associated fibromyalgia?","[{'This': 'O'}, {'data': 'O'}, {'could': 'O'}, {'be': 'O'}, {'useful': 'O'}, {'for': 'O'}, {'the': 'O'}, {'future': 'O'}, {'study': 'O'}, {'of': 'O'}, {'pleural': 'B-Entity'}, {'effusion': 'I-Entity'}, {'in': 'O'}, {'SS.Traditional': 'I-Entity'}, {'Chinese': 'O'}, {'Medicine': 'O'}, {'Jinan': 'O'}, {'250011,': 'O'}, {'China.symptoms': 'O'}, {'of': 'O'}, {'the': 'O'}, {'inflammatory': 'B-Entity'}, {'disease': 'I-Entity'}, {'or': 'O'}, {'associated': 'O'}, {'fibromyalgia?': 'I-Entity'}]"
"The patient was diagnosed with primary Sjogren syndrome (pSS) based on her symptoms, positive anti-SS-A antibodies, Coombs-negative autoimmune hemolytic anemia and pure red cell aplasia associated with RBC-bound IgG and hemophagocytosis.","[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'based': 'O'}, {'on': 'O'}, {'her': 'O'}, {'symptoms,': 'O'}, {'positive': 'O'}, {'anti-SS-A': 'O'}, {'antibodies,': 'O'}, {'Coombs-negative': 'O'}, {'autoimmune': 'B-Entity'}, {'hemolytic': 'I-Entity'}, {'anemia': 'I-Entity'}, {'and': 'O'}, {'pure': 'B-Entity'}, {'red': 'B-Entity'}, {'cell': 'I-Entity'}, {'aplasia': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'RBC-bound': 'O'}, {'IgG': 'O'}, {'and': 'O'}, {'hemophagocytosis.': 'I-Entity'}]"
"To our knowledge, this is the first study performed in a large cohort of early active pSS patients for a period of 120 weeks.","[{'To': 'O'}, {'our': 'O'}, {'knowledge,': 'O'}, {'this': 'O'}, {'is': 'O'}, {'the': 'O'}, {'first': 'O'}, {'study': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'a': 'O'}, {'large': 'O'}, {'cohort': 'O'}, {'of': 'O'}, {'early': 'O'}, {'active': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'for': 'O'}, {'a': 'O'}, {'period': 'O'}, {'of': 'O'}, {'120': 'O'}, {'weeks.': 'O'}]"
Sjogrens syndrome is a systemic autoimmune disease in which lymphatic cells destroy the salivary and lacrimal glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'O'}, {'in': 'O'}, {'which': 'O'}, {'lymphatic': 'O'}, {'cells': 'O'}, {'destroy': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands.': 'O'}]"
"However, patients with pathologic SGUS had significantly more often signs and symptoms of systemic complications, higher disease activity, and more frequently markers of lymphoma development, such as salivary gland swelling, skin vasculitis, germinal center-like structures in salivary gland biopsy findings, and CD4+ T cell lymphopenia.","[{'However,': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pathologic': 'O'}, {'SGUS': 'I-Entity'}, {'had': 'O'}, {'significantly': 'O'}, {'more': 'O'}, {'often': 'O'}, {'signs': 'O'}, {'and': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'complications,': 'O'}, {'higher': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'and': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'markers': 'O'}, {'of': 'O'}, {'lymphoma': 'I-Entity'}, {'development,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'swelling,': 'I-Entity'}, {'skin': 'B-Entity'}, {'vasculitis,': 'I-Entity'}, {'germinal': 'O'}, {'center-like': 'O'}, {'structures': 'O'}, {'in': 'O'}, {'salivary': 'O'}]"
Neuromyelitis Optic (NMO) is an inflammatory disorder involving central nervous system which often co-exists with other autoimmune diseases such as Sjogrens syndrome (SS).,"[{'Neuromyelitis': 'B-Entity'}, {'Optic': 'I-Entity'}, {'(NMO)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'inflammatory': 'B-Entity'}, {'disorder': 'I-Entity'}, {'involving': 'O'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'O'}, {'which': 'O'}, {'often': 'O'}, {'co-exists': 'O'}, {'with': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
Only 1 patient with MALT who had low SS disease activity showed progression of lymphoma when left untreated.,"[{'Only': 'O'}, {'1': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'MALT': 'I-Entity'}, {'who': 'O'}, {'had': 'O'}, {'low': 'O'}, {'SS': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'showed': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'lymphoma': 'I-Entity'}, {'when': 'O'}, {'left': 'O'}, {'untreated.': 'O'}]"
"Although both IgG4-RD and Sjogrens syndrome (SS) frequently affect salivary and lacrimal glands, the clinical and pathological features of these two conditions are different.","[{'Although': 'O'}, {'both': 'O'}, {'IgG4-RD': 'B-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'frequently': 'O'}, {'affect': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands,': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'pathological': 'O'}, {'features': 'O'}, {'of': 'O'}, {'these': 'O'}, {'two': 'O'}, {'conditions': 'O'}, {'are': 'O'}, {'different.': 'O'}]"
Laboratory investigations and labial salivary gland biopsy revealed Sjogren syndrome without associated disease.,"[{'Laboratory': 'O'}, {'investigations': 'O'}, {'and': 'O'}, {'labial': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'biopsy': 'O'}, {'revealed': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'without': 'O'}, {'associated': 'O'}, {'disease.': 'O'}]"
Both of the infants was followed up and found to be clinically normal.,"[{'Both': 'O'}, {'of': 'O'}, {'the': 'O'}, {'infants': 'O'}, {'was': 'O'}, {'followed': 'O'}, {'up': 'O'}, {'and': 'O'}, {'found': 'O'}, {'to': 'O'}, {'be': 'O'}, {'clinically': 'O'}, {'normal.': 'O'}]"
"Close monitoring of eye dryness changes by special tests in patients using LEF is recommended, especially in cases with sSS-RA having very low baseline values.453 Alahram street, Alahram, Giza, Egypt, amirashahin@hotmail.com.20.sialadenitis (Mikulicz's disease) and for differentiating it from Sjogrens syndrome (SS), with an emphasis on sonography.","[{'Close': 'O'}, {'monitoring': 'O'}, {'of': 'O'}, {'eye': 'B-Entity'}, {'dryness': 'I-Entity'}, {'changes': 'O'}, {'by': 'O'}, {'special': 'O'}, {'tests': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'using': 'O'}, {'LEF': 'O'}, {'is': 'O'}, {'recommended,': 'O'}, {'especially': 'O'}, {'in': 'O'}, {'cases': 'O'}, {'with': 'O'}, {'sSS-RA': 'O'}, {'having': 'O'}, {'very': 'O'}, {'low': 'O'}, {'baseline': 'O'}, {'values.453': 'O'}, {'Alahram': 'O'}, {'street,': 'O'}, {'Alahram,': 'O'}, {'Giza,': 'O'}, {'Egypt,': 'O'}, {'amirashahin@hotmail.com.20.sialadenitis': 'O'}]"
"On immunological blood investigations, serum c-peptide was normal, rheumatoid factor was negative, antinuclear antibodies were positive, and proliferating cell nuclear antigens were positive.","[{'On': 'O'}, {'immunological': 'O'}, {'blood': 'O'}, {'investigations,': 'O'}, {'serum': 'O'}, {'c-peptide': 'O'}, {'was': 'O'}, {'normal,': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'was': 'O'}, {'negative,': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'positive,': 'O'}, {'and': 'O'}, {'proliferating': 'O'}, {'cell': 'O'}, {'nuclear': 'O'}, {'antigens': 'O'}, {'were': 'O'}, {'positive.': 'O'}]"
The possible efficacy of a sequential anti-BAFF/anti-CD20 therapy in SS was investigated.,"[{'The': 'O'}, {'possible': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'a': 'O'}, {'sequential': 'O'}, {'anti-BAFF/anti-CD20': 'O'}, {'therapy': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'was': 'O'}, {'investigated.': 'O'}]"
Xerostomia is a symptom that can be triggered by chronic diseases such as Sjogrens syndrome (SS) and lupus erythematosus (LE).,"[{'Xerostomia': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'symptom': 'O'}, {'that': 'O'}, {'can': 'O'}, {'be': 'O'}, {'triggered': 'O'}, {'by': 'O'}, {'chronic': 'O'}, {'diseases': 'O'}, {'such': 'O'}, {'as': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'lupus': 'B-Entity'}, {'erythematosus': 'I-Entity'}, {'(LE).': 'O'}]"
"Data from rabbit studies have suggested that at least two immune cell networks form in healthy lacrimal glands, one responding to environmental dryness, the other to high temperatures.","[{'Data': 'O'}, {'from': 'O'}, {'rabbit': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'suggested': 'O'}, {'that': 'O'}, {'at': 'O'}, {'least': 'O'}, {'two': 'O'}, {'immune': 'O'}, {'cell': 'O'}, {'networks': 'O'}, {'form': 'O'}, {'in': 'O'}, {'healthy': 'O'}, {'lacrimal': 'O'}, {'glands,': 'O'}, {'one': 'O'}, {'responding': 'O'}, {'to': 'O'}, {'environmental': 'O'}, {'dryness,': 'I-Entity'}, {'the': 'O'}, {'other': 'O'}, {'to': 'O'}, {'high': 'O'}, {'temperatures.': 'O'}]"
"In the elderly, the prevalence of connective tissue diseases continues to rise due to both longer life expectancy and more effective and better-tolerated treatments.","[{'In': 'O'}, {'the': 'O'}, {'elderly,': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'continues': 'O'}, {'to': 'O'}, {'rise': 'O'}, {'due': 'O'}, {'to': 'O'}, {'both': 'O'}, {'longer': 'O'}, {'life': 'O'}, {'expectancy': 'O'}, {'and': 'O'}, {'more': 'O'}, {'effective': 'O'}, {'and': 'O'}, {'better-tolerated': 'O'}, {'treatments.': 'O'}]"
"We observed the lacrimal sac and nasolacrimal duct under lacrimal micro-endoscopy; there was no bacterial concretion, obstruction, and inflammation of lacrimal mucosa.","[{'We': 'O'}, {'observed': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'sac': 'O'}, {'and': 'O'}, {'nasolacrimal': 'O'}, {'duct': 'O'}, {'under': 'O'}, {'lacrimal': 'O'}, {'micro-endoscopy;': 'O'}, {'there': 'O'}, {'was': 'O'}, {'no': 'O'}, {'bacterial': 'O'}, {'concretion,': 'O'}, {'obstruction,': 'I-Entity'}, {'and': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'lacrimal': 'O'}, {'mucosa.': 'O'}]"
"In unstimulated control and Sjogrens labial glands, AQP5 is about 90% localized in the apical plasma membrane, with only rarely associated gold particles with intracellular membrane structures.","[{'In': 'O'}, {'unstimulated': 'O'}, {'control': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'labial': 'I-Entity'}, {'glands,': 'O'}, {'AQP5': 'O'}, {'is': 'O'}, {'about': 'O'}, {'90%': 'O'}, {'localized': 'O'}, {'in': 'O'}, {'the': 'O'}, {'apical': 'O'}, {'plasma': 'O'}, {'membrane,': 'O'}, {'with': 'O'}, {'only': 'O'}, {'rarely': 'O'}, {'associated': 'O'}, {'gold': 'O'}, {'particles': 'O'}, {'with': 'O'}, {'intracellular': 'O'}, {'membrane': 'O'}, {'structures.': 'O'}]"
"Ultrasound has enabled rheumatologists to diagnose, prognosticate and monitor disease outcome.","[{'Ultrasound': 'O'}, {'has': 'O'}, {'enabled': 'O'}, {'rheumatologists': 'O'}, {'to': 'O'}, {'diagnose,': 'O'}, {'prognosticate': 'O'}, {'and': 'O'}, {'monitor': 'O'}, {'disease': 'O'}, {'outcome.': 'O'}]"
"The evolution was favorable under potassium citrate alkalinisation, the corticosteroid therapy and hormonal substitution.","[{'The': 'O'}, {'evolution': 'O'}, {'was': 'O'}, {'favorable': 'O'}, {'under': 'O'}, {'potassium': 'B-Entity'}, {'citrate': 'I-Entity'}, {'alkalinisation,': 'O'}, {'the': 'O'}, {'corticosteroid': 'O'}, {'therapy': 'O'}, {'and': 'O'}, {'hormonal': 'O'}, {'substitution.': 'O'}]"
"SS is characterized by chronic inflammation of the salivary glands leading to loss of secretory function, thereby suggesting specialized pro-resolving mediators targeting inflammation to be a viable option for treating SS.","[{'SS': 'I-Entity'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'chronic': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'loss': 'O'}, {'of': 'O'}, {'secretory': 'O'}, {'function,': 'O'}, {'thereby': 'O'}, {'suggesting': 'O'}, {'specialized': 'O'}, {'pro-resolving': 'O'}, {'mediators': 'O'}, {'targeting': 'O'}, {'inflammation': 'I-Entity'}, {'to': 'O'}, {'be': 'O'}, {'a': 'O'}, {'viable': 'O'}, {'option': 'O'}, {'for': 'O'}, {'treating': 'O'}, {'SS.': 'I-Entity'}]"
"The combination of UDCA, prednisone, and azathioprine can achieve therapeutic success but cannot prevent disease progression.","[{'The': 'O'}, {'combination': 'O'}, {'of': 'O'}, {'UDCA,': 'I-Entity'}, {'prednisone,': 'I-Entity'}, {'and': 'O'}, {'azathioprine': 'I-Entity'}, {'can': 'O'}, {'achieve': 'O'}, {'therapeutic': 'O'}, {'success': 'O'}, {'but': 'O'}, {'cannot': 'O'}, {'prevent': 'O'}, {'disease': 'O'}, {'progression.': 'O'}]"
"Sensory symptoms without substantial motor involvement are observed predominantly in sensory ataxic, painful sensory, trigeminal, and autonomic neuropathies.","[{'Sensory': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'without': 'O'}, {'substantial': 'O'}, {'motor': 'O'}, {'involvement': 'O'}, {'are': 'O'}, {'observed': 'O'}, {'predominantly': 'O'}, {'in': 'O'}, {'sensory': 'O'}, {'ataxic,': 'I-Entity'}, {'painful': 'O'}, {'sensory,': 'B-Entity'}, {'trigeminal,': 'I-Entity'}, {'and': 'I-Entity'}, {'autonomic': 'I-Entity'}, {'neuropathies.': 'I-Entity'}]"
"To evaluate the manifestation of meibomian gland dysfunction in patients with Sjogrens syndrome (SS), non-Sjogrens syndrome dry eye (non-SS) patients, and non-dry eye controls.","[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'meibomian': 'O'}, {'gland': 'O'}, {'dysfunction': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'non-Sjogrens': 'O'}, {'syndrome': 'I-Entity'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'(non-SS)': 'O'}, {'patients,': 'O'}, {'and': 'O'}, {'non-dry': 'O'}, {'eye': 'I-Entity'}, {'controls.': 'O'}]"
Narrowing of the small airways and obstructive lung disease with multiple bullae were observed and we suspected them to be related to peribronchiolar lymphocytic infiltration.,"[{'Narrowing': 'O'}, {'of': 'I-Entity'}, {'the': 'O'}, {'small': 'O'}, {'airways': 'O'}, {'and': 'O'}, {'obstructive': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'with': 'O'}, {'multiple': 'O'}, {'bullae': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'and': 'O'}, {'we': 'O'}, {'suspected': 'O'}, {'them': 'O'}, {'to': 'O'}, {'be': 'O'}, {'related': 'O'}, {'to': 'O'}, {'peribronchiolar': 'O'}, {'lymphocytic': 'O'}, {'infiltration.': 'O'}]"
"The second pattern included ""ischaemic neurological, cardiac events and peripheral obliterative arteriopathy"" and appeared to be strictly associated with extra-glandular disease activity and longer disease duration.","[{'The': 'O'}, {'second': 'O'}, {'pattern': 'O'}, {'included': 'O'}, {'""ischaemic': 'O'}, {'neurological,': 'I-Entity'}, {'cardiac': 'I-Entity'}, {'events': 'I-Entity'}, {'and': 'O'}, {'peripheral': 'B-Entity'}, {'obliterative': 'I-Entity'}, {'arteriopathy""': 'I-Entity'}, {'and': 'O'}, {'appeared': 'O'}, {'to': 'O'}, {'be': 'O'}, {'strictly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'extra-glandular': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'longer': 'O'}, {'disease': 'O'}, {'duration.': 'O'}]"
"To assess the efficacy of the anti-CD20 antibody rituximab in improving physical function and health-related quality of life (HRQoL) in patients with active primary Sjogrens syndrome (pSS), as well as the duration and sources of HRQoL improvements.","[{'To': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'the': 'O'}, {'anti-CD20': 'O'}, {'antibody': 'O'}, {'rituximab': 'I-Entity'}, {'in': 'O'}, {'improving': 'O'}, {'physical': 'O'}, {'function': 'O'}, {'and': 'O'}, {'health-related': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'(HRQoL)': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'active': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'the': 'O'}, {'duration': 'O'}, {'and': 'O'}, {'sources': 'O'}, {'of': 'O'}, {'HRQoL': 'O'}]"
Fifty-four patients were included in the study.,"[{'Fifty-four': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'included': 'O'}, {'in': 'O'}, {'the': 'O'}, {'study.': 'O'}]"
"We found that the higher the IgG4(+) expression in plasma cells, the lower the positive rates of serum anti-SSA antibodies, anti-SSB antibodies, antinuclear antibodies (ANA), and rheumatoid factor (RF).","[{'We': 'O'}, {'found': 'O'}, {'that': 'O'}, {'the': 'O'}, {'higher': 'O'}, {'the': 'O'}, {'IgG4(+)': 'O'}, {'expression': 'O'}, {'in': 'O'}, {'plasma': 'O'}, {'cells,': 'O'}, {'the': 'O'}, {'lower': 'O'}, {'the': 'O'}, {'positive': 'O'}, {'rates': 'O'}, {'of': 'O'}, {'serum': 'O'}, {'anti-SSA': 'O'}, {'antibodies,': 'O'}, {'anti-SSB': 'O'}, {'antibodies,': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'(ANA),': 'O'}, {'and': 'O'}, {'rheumatoid': 'B-Entity'}, {'factor': 'I-Entity'}, {'(RF).': 'O'}]"
"This IL-8-stimulated activity was blocked by chloroquine and NH4Cl, indicating that endosomal acidification is important for this effect.","[{'This': 'O'}, {'IL-8-stimulated': 'O'}, {'activity': 'O'}, {'was': 'O'}, {'blocked': 'O'}, {'by': 'O'}, {'chloroquine': 'I-Entity'}, {'and': 'O'}, {'NH4Cl,': 'I-Entity'}, {'indicating': 'O'}, {'that': 'O'}, {'endosomal': 'O'}, {'acidification': 'O'}, {'is': 'O'}, {'important': 'O'}, {'for': 'O'}, {'this': 'O'}, {'effect.': 'O'}]"
"Collectively, our data identify TSP-derived peptide as a novel therapeutic option to treat autoimmune diseases.cases].","[{'Collectively,': 'O'}, {'our': 'O'}, {'data': 'O'}, {'identify': 'O'}, {'TSP-derived': 'I-Entity'}, {'peptide': 'O'}, {'as': 'O'}, {'a': 'O'}, {'novel': 'O'}, {'therapeutic': 'O'}, {'option': 'O'}, {'to': 'O'}, {'treat': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.cases].': 'I-Entity'}]"
"In this Review, we discuss the mechanisms that support the increased activation of B cells in pSS, including genetic and epigenetic factors and environmental triggers that promote B cell activation via the innate immune system.","[{'In': 'O'}, {'this': 'O'}, {'Review,': 'O'}, {'we': 'O'}, {'discuss': 'O'}, {'the': 'O'}, {'mechanisms': 'O'}, {'that': 'O'}, {'support': 'O'}, {'the': 'O'}, {'increased': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'pSS,': 'O'}, {'including': 'O'}, {'genetic': 'O'}, {'and': 'O'}, {'epigenetic': 'O'}, {'factors': 'O'}, {'and': 'O'}, {'environmental': 'O'}, {'triggers': 'O'}, {'that': 'O'}, {'promote': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activation': 'O'}, {'via': 'O'}, {'the': 'O'}, {'innate': 'O'}, {'immune': 'O'}, {'system.': 'O'}]"
"Follow-up of the patient observed the normalization of peripheral blood cell count, immunity indices and neurological examinations 6 months after discharge.","[{'Follow-up': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'observed': 'O'}, {'the': 'O'}, {'normalization': 'O'}, {'of': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'cell': 'O'}, {'count,': 'O'}, {'immunity': 'O'}, {'indices': 'O'}, {'and': 'O'}, {'neurological': 'O'}, {'examinations': 'O'}, {'6': 'O'}, {'months': 'O'}, {'after': 'O'}, {'discharge.': 'O'}]"
The diagnosis of IC was confirmed by anatomical evidence of cystitis inflammation on bladder biopsy in all (n=13) patients.,"[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'IC': 'I-Entity'}, {'was': 'O'}, {'confirmed': 'O'}, {'by': 'O'}, {'anatomical': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'cystitis': 'B-Entity'}, {'inflammation': 'I-Entity'}, {'on': 'O'}, {'bladder': 'O'}, {'biopsy': 'O'}, {'in': 'O'}, {'all': 'O'}, {'(n=13)': 'O'}, {'patients.': 'O'}]"
"During the observation period, the incidence of interstitial lung disease was higher in the PBC-SS group than in the PBC-only group (P‚Äö√Ñ√∂‚àö√ë‚àö¬ß=‚Äö√Ñ√∂‚àö√ë‚àö¬ß0.005).","[{'During': 'O'}, {'the': 'O'}, {'observation': 'O'}, {'period,': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'was': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'the': 'O'}, {'PBC-SS': 'I-Entity'}, {'group': 'O'}, {'than': 'O'}, {'in': 'O'}, {'the': 'O'}, {'PBC-only': 'I-Entity'}, {'group': 'O'}, {'(P‚Äö√Ñ√∂‚àö√ë‚àö¬ß=‚Äö√Ñ√∂‚àö√ë‚àö¬ß0.005).': 'O'}]"
It is often noted in subcutaneous tissues in patients with collagen vascular diseases and may involve a relatively localized area or be widespread.,"[{'It': 'O'}, {'is': 'O'}, {'often': 'O'}, {'noted': 'O'}, {'in': 'O'}, {'subcutaneous': 'O'}, {'tissues': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'collagen': 'B-Entity'}, {'vascular': 'I-Entity'}, {'diseases': 'I-Entity'}, {'and': 'O'}, {'may': 'O'}, {'involve': 'O'}, {'a': 'O'}, {'relatively': 'O'}, {'localized': 'O'}, {'area': 'O'}, {'or': 'O'}, {'be': 'O'}, {'widespread.': 'O'}]"
Nine to 75% of patients have pulmonary involvement such as interstitial lung diseases.,"[{'Nine': 'O'}, {'to': 'O'}, {'75%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'have': 'O'}, {'pulmonary': 'O'}, {'involvement': 'O'}, {'such': 'O'}, {'as': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"Because the anti-aquaporin 4 antibody was positive and no abnormal abdominal findings that might have caused ileus were found, we diagnosed NMO presenting only paralytic ileus as a neurologic finding.","[{'Because': 'O'}, {'the': 'O'}, {'anti-aquaporin': 'O'}, {'4': 'O'}, {'antibody': 'O'}, {'was': 'O'}, {'positive': 'O'}, {'and': 'O'}, {'no': 'O'}, {'abnormal': 'O'}, {'abdominal': 'O'}, {'findings': 'O'}, {'that': 'O'}, {'might': 'O'}, {'have': 'O'}, {'caused': 'O'}, {'ileus': 'I-Entity'}, {'were': 'O'}, {'found,': 'O'}, {'we': 'O'}, {'diagnosed': 'O'}, {'NMO': 'I-Entity'}, {'presenting': 'O'}, {'only': 'O'}, {'paralytic': 'O'}, {'ileus': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'neurologic': 'O'}, {'finding.': 'O'}]"
Vasoconstriction accompanied by changes in skin color is a normal physiologic response to cold.,"[{'Vasoconstriction': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'skin': 'O'}, {'color': 'O'}, {'is': 'O'}, {'a': 'O'}, {'normal': 'O'}, {'physiologic': 'O'}, {'response': 'O'}, {'to': 'O'}, {'cold.': 'I-Entity'}]"
"Two groups were compared: 342 patients were positive for both the histopathology and for anti-Ro/SSA and/or anti-La/SSB (H-only) and 206 patients were positive for histopathology, but negative for autoantibodies (H+SSA/SSB).","[{'Two': 'O'}, {'groups': 'O'}, {'were': 'O'}, {'compared:': 'O'}, {'342': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'both': 'O'}, {'the': 'O'}, {'histopathology': 'O'}, {'and': 'O'}, {'for': 'O'}, {'anti-Ro/SSA': 'O'}, {'and/or': 'O'}, {'anti-La/SSB': 'O'}, {'(H-only)': 'O'}, {'and': 'O'}, {'206': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'histopathology,': 'O'}, {'but': 'O'}, {'negative': 'O'}, {'for': 'O'}, {'autoantibodies': 'O'}, {'(H+SSA/SSB).': 'O'}]"
"Out of the 2458 women screened, the authors identified 62 (2.5%) women with previously undiagnosed undifferentiated connective tissue disease (UCTD) and 24 (0.98%) women with previously undiagnosed definite systemic rheumatic disease.","[{'Out': 'O'}, {'of': 'O'}, {'the': 'O'}, {'2458': 'O'}, {'women': 'O'}, {'screened,': 'O'}, {'the': 'O'}, {'authors': 'O'}, {'identified': 'O'}, {'62': 'O'}, {'(2.5%)': 'O'}, {'women': 'O'}, {'with': 'O'}, {'previously': 'O'}, {'undiagnosed': 'O'}, {'undifferentiated': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'(UCTD)': 'O'}, {'and': 'O'}, {'24': 'O'}, {'(0.98%)': 'O'}, {'women': 'O'}, {'with': 'O'}, {'previously': 'O'}, {'undiagnosed': 'O'}, {'definite': 'O'}, {'systemic': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"Also, there were significant correlations between disease activity indexes and Fibromyalgia Impact Questionnaire scores for most rheumatologic patients (RA, AS, OA, and BD) (p < 0.05; respectively, r = 0.6, 0.95, 0.887, and 1).","[{'Also,': 'O'}, {'there': 'O'}, {'were': 'O'}, {'significant': 'O'}, {'correlations': 'O'}, {'between': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'indexes': 'O'}, {'and': 'O'}, {'Fibromyalgia': 'B-Entity'}, {'Impact': 'O'}, {'Questionnaire': 'O'}, {'scores': 'O'}, {'for': 'O'}, {'most': 'O'}, {'rheumatologic': 'I-Entity'}, {'patients': 'O'}, {'(RA,': 'O'}, {'AS,': 'I-Entity'}, {'OA,': 'I-Entity'}, {'and': 'O'}, {'BD)': 'I-Entity'}, {'(p': 'O'}, {'<': 'O'}, {'0.05;': 'O'}, {'respectively,': 'O'}, {'r': 'O'}, {'=': 'O'}, {'0.6,': 'O'}, {'0.95,': 'O'}]"
"Histologically it showed marked lymphoplasmacytic inflammation, large irregular lymphoid follicles with expanded germinal centers, prominent cellular interlobular fibrosis, eosinophil infiltration, and obliterative phlebitis.","[{'Histologically': 'O'}, {'it': 'O'}, {'showed': 'O'}, {'marked': 'O'}, {'lymphoplasmacytic': 'O'}, {'inflammation,': 'I-Entity'}, {'large': 'O'}, {'irregular': 'O'}, {'lymphoid': 'O'}, {'follicles': 'O'}, {'with': 'O'}, {'expanded': 'O'}, {'germinal': 'O'}, {'centers,': 'O'}, {'prominent': 'O'}, {'cellular': 'O'}, {'interlobular': 'O'}, {'fibrosis,': 'I-Entity'}, {'eosinophil': 'O'}, {'infiltration,': 'O'}, {'and': 'O'}, {'obliterative': 'O'}, {'phlebitis.': 'I-Entity'}]"
"The TMH values of the normal and dry eye groups were 0.20¬¨¬®¬¨¬±0.05 mm and 0.14¬¨¬®¬¨¬±0.03 mm, respectively, at baseline.","[{'The': 'O'}, {'TMH': 'O'}, {'values': 'O'}, {'of': 'O'}, {'the': 'O'}, {'normal': 'O'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'groups': 'O'}, {'were': 'O'}, {'0.20¬¨¬®¬¨¬±0.05': 'O'}, {'mm': 'O'}, {'and': 'O'}, {'0.14¬¨¬®¬¨¬±0.03': 'O'}, {'mm,': 'O'}, {'respectively,': 'O'}, {'at': 'O'}, {'baseline.': 'O'}]"
"Furthermore, repeated administration of poly I:C to C57BL/6 mice over an 8-day period caused leukocytic infiltration and caspase-3 activation in the LAC, antinuclear antibody production, and impaired tear secretion.","[{'Furthermore,': 'O'}, {'repeated': 'O'}, {'administration': 'O'}, {'of': 'O'}, {'poly': 'B-Entity'}, {'I:C': 'I-Entity'}, {'to': 'O'}, {'C57BL/6': 'O'}, {'mice': 'O'}, {'over': 'O'}, {'an': 'O'}, {'8-day': 'O'}, {'period': 'O'}, {'caused': 'O'}, {'leukocytic': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'caspase-3': 'O'}, {'activation': 'O'}, {'in': 'O'}, {'the': 'O'}, {'LAC,': 'O'}, {'antinuclear': 'O'}, {'antibody': 'O'}, {'production,': 'O'}, {'and': 'O'}, {'impaired': 'B-Entity'}, {'tear': 'O'}, {'secretion.': 'O'}]"
"Herein, we demonstrate two surgical cases of thymic MALT lymphoma associated with multiple lung cysts and the characterization of this rare tumor.","[{'Herein,': 'O'}, {'we': 'O'}, {'demonstrate': 'O'}, {'two': 'O'}, {'surgical': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'thymic': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'multiple': 'O'}, {'lung': 'B-Entity'}, {'cysts': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'characterization': 'O'}, {'of': 'O'}, {'this': 'O'}, {'rare': 'O'}, {'tumor.': 'I-Entity'}]"
